



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Randomised controlled clinical trial investigating benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis in primary care adult patients versus risk of antimicrobial resistance (the ACT-TB Study)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-033999
Article Type:	Protocol
Date Submitted by the Author:	01-Sep-2019
Complete List of Authors:	Divala, Titus; London School of Hygiene and Tropical Medicine, TB Centre; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative Fielding, Katherine; London School of Hygiene & Tropical Medicine, TB Centre; University of the Witwatersrand, School of Public Health Sloan, Derek; University of Saint Andrews, School of Medicine French, Neil; University of Liverpool Faculty of Health and Life Sciences, Centre for Global Vaccine Research, Institute of Infection and Global Health Nliwasa, Marriott; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; London School of Hygiene and Tropical Medicine, TB Centre MacPherson, Peter ; Liverpool School of Tropical Medicine; Malawi Liverpool Wellcome Trust Clinical Research Programme Kandulu, Chikondi; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; Malawi Liverpool Wellcome Trust Clinical Research Programme Chiume, Lingstone ; Malawi Liverpool Wellcome Trust Clinical Research Programme; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative Chilanga, Sanderson ; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; Malawi Liverpool Wellcome Trust Clinical Research Programme Ndaferankhande, Masiye; Malawi Liverpool Wellcome Trust Clinical Research Programme Corbett, Elizabeth ; London School of Hygiene and Tropical Medicine; Malawi Liverpool Wellcome Trust Clinical Research Programme
Keywords:	trial-of-antibiotics, Tuberculosis < INFECTIOUS DISEASES, TB, antimicrobial resistance, diagnostic performance, antibiotics





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

TITLE

Randomised controlled clinical trial investigating benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis in primary care adult patients versus risk of antimicrobial resistance (the ACT-TB Study)

Authors

Titus H Divala^{1,2,3}, Katherine L Fielding^{1,4}, Derek J Sloan⁵, Neil French⁶, Marriott Nliwasa^{1,2,3}, Peter MacPherson^{3,7}, Chikondi Kandulu^{2,3}, Lingstone Chiume^{2,3}, Sanderson Chilanga^{2,3}, Masiye Ndaferankhande³, Elizabeth L Corbett^{1,2,3}

Author affiliations

1. TB Centre, London School of Hygiene & Tropical Medicine, Keppel Street, Bloomsbury, London, United Kingdom
2. Helse Nord Tuberculosis Initiative, University of Malawi College of Medicine, Blantyre, Malawi
3. Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi
4. School of Public Health, University of the Witwatersrand, Johannesburg, South Africa
5. School of Medicine, University of St Andrews (Derek J Sloan PhD)
6. Institute of Infection & Global Health, University of Liverpool, Liverpool, United Kingdom
7. Liverpool School of Tropical Medicine, Liverpool, United Kingdom

Correspondence to:

Dr Titus H Divala

TB Centre, London School of Hygiene & Tropical Medicine, Keppel Street, Bloomsbury,
London WC1E 7HT

titus.divala@lshtm.ac.uk

KEY WORDS

trial-of-antibiotics, tuberculosis, TB, antimicrobial resistance, AMR, antibiotics, diagnostic performance, sensitivity, specificity, randomised controlled clinical trial, randomised, RCT

Protocol version 3.0. 19 Feb 2019

32 ABSTRACT:

33 Introduction

34 Over 40% of global tuberculosis(TB) case notifications are diagnosed clinically without
35 mycobacteriological confirmation. Standard diagnostic algorithms include “trial-of-antibiotics”
36 –empirical antibiotic treatment given to mycobacteriology-negative individuals to treat
37 infectious causes of symptoms other than tuberculosis, as a “rule-out” diagnostic test for TB.
38 Potentially 26.5 million such antibiotic courses/year are prescribed globally for the 5.3
39 million/year mycobacteriology-negative patients, making trial-of-antibiotics the most common
40 TB diagnostic, and a global-scale risk for antimicrobial resistance(AMR). Our systematic
41 review found no randomised controlled trial(RCT) to support use of trial-of-antibiotic. The
42 RCT aims to determine the diagnostic and clinical value and AMR consequences of trial-of-
43 antibiotics.


44 Methods and analysis

45 A three-arm, open-label, RCT randomising(1:1:1) Malawian adults(≥ 18 years) seeking
46 primary care for cough into: a)azithromycin 500mg once daily for 3 days, or b)amoxicillin 1g
47 three times/day for 5 days, or c)standard-of-care(no immediate antibiotic). We will perform
48 Mycobacteriology tests(microscopy, Xpert/MTB/RIF and Mycobacterium-Tuberculosis
49 culture) at baseline. We will use Audio-Computer-Assisted-Self-Interview(ACASI) to assess
50 clinical improvement at day eight. First primary outcome will be proportion of patients
51 reporting day-eight improvement out of those with negative mycobacteriology(specificity).
52 Second primary outcome will be day 29 incidence of a composite endpoint of either death or;
53 hospitalisation or; missed tuberculosis diagnosis or; HIV or tuberculosis treatment non-
54 adherence by day 29. To determine AMR impact we compare incidence of resistant
55 nasopharyngeal *Streptococcus pneumoniae* isolates on day 29. 400 mycobacteriology-
56 negative participants/arm will be required to detect a $\geq 10\%$ absolute difference in diagnostic

INTRODUCTION

The high case-fatality rate for tuberculosis, the leading global infectious cause of death in adults¹ with approximately 10 million cases and 1.6 million deaths in 2017,² in part reflects suboptimal diagnostics.³⁻⁶ To complement diagnostic gap, standard algorithms throughout the world include a “trial-of-antibiotics” (Figure 1). This is a course of broad-spectrum antibiotics, with negligible *Mycobacterium tuberculosis* activity, given to patients with symptoms such as cough in order to “rule-out” or “rule in” tuberculosis.⁷⁻⁹ In clinical practice and most national guidelines (summarised in figure 1), patients with negative sputum mycobacteriology and who have responded to antibiotic treatment are considered tuberculosis negative while those who remain symptomatic are deemed likely to have tuberculosis and undergo further evaluations leading on to receiving tuberculosis treatment.⁷⁻

⁹



*The common clinical practice is that outpatients start antibiotics at the time of submitting sputum, to avoid the need for a third clinic visit to complete the algorithm.

Figure 1: The position of trial-of-antibiotics in standard algorithms for diagnosis of tuberculosis in low and middle income countries (based on the WHO GLI model guidelines and as implemented in national guidelines from Ghana, Malawi and South Africa.)

We estimate that 26.5 million courses of antibiotics are prescribed in the diagnosis of the 5.3 million smear negative tuberculosis registrations recorded annually,¹⁰ making antibiotics the most common diagnostic for tuberculosis.¹¹ The 26.5 million is based on the common approach where for every one smear-negative TB case detected, five antibiotics courses are used: the first two courses of antibiotics are those given to patients who end up being registered as smear-negative tuberculosis, and the other three courses account for patients

104 whose symptoms resolved and tuberculosis was ruled out.^{4 12} This frequency of prescription
105 of important broad-spectrum antibiotics raises a global-scale risk for antimicrobial resistance
106 (AMR) which like tuberculosis, is a major crisis, becoming in 2016 one of only four health
107 topics ever to be discussed at the United Nations General Assembly.¹³⁻¹⁶

108

109 We performed a systematic literature review¹⁷ which demonstrated that, despite being in
110 global and national guidelines for decades, trial-of-antibiotics has limited supporting
111 evidence base with available evidence suggesting there poor diagnostic performance.¹⁸
112 None of the identified studies was an RCT and most of the observational studies were very
113 small and not primarily designed to assess the benefits and consequences of trial-of-
114 antibiotics. Pooled sensitivity and specificity of trial-of-antibiotics versus mycobacteriology
115 tests were below internationally defined minimum performance profiles for TB diagnostics.
116 To address the evidence gaps related to a) accuracy, b) antimicrobial resistance, and c)
117 impact on clinical outcomes of trial-of-antibiotics, we will conduct an RCT (ACT-TB Study)
118 recruiting adult patients with cough presenting to health centres in Blantyre, Malawi. To our
119 knowledge this is the first randomised controlled trial to rigorously address these questions.

120 METHODS AND ANALYSIS

121 Study design

122 This is a three-arm individually randomised (1:1:1), open-label controlled clinical trial (RCT)
123 investigating accuracy and broader clinical, and antimicrobial resistance impact of using trial-
124 of-antibiotics to rule-out tuberculosis among adults presenting with cough at primary care
125 centres in Malawi (Figure 2). The trial is registered with Clinicaltrials.gov (NCT03545373).




Figure 2: Flow diagram for the clinical trial in Blantyre, Malawi

127 Study setting

128 We will screen adults aged at least 18 years presenting to Limbe and Ndirande health
129 centres in Blantyre, Malawi. Blantyre has an estimated tuberculosis prevalence of 1,014 per
130 100,000 (95% CI: 486 to 1,542), and an estimated adult HIV prevalence of 12.7% (95% CI:
131 11.9 to 13.6).¹⁹

132 Eligibility criteria

133 We will offer enrolment to patients who satisfy the following inclusion and exclusion criteria.

134 *Inclusion Criteria*

- 135 • Ambulatory clinic attendees presenting with cough
- 136 • Unwell for at least 14 days
- 137 • Aged at least 18 years
- 138 • Reside in Blantyre and willing to return to the same clinic for follow up visits over the
139 entire study period.

140 *Exclusion Criteria*

- 141 • Self-reported allergy to study medications
- 142 • WHO/Malawi National tuberculosis Program (NTP) danger signs: respiratory rate >
143 30/min, temperature >39°C, Heart rate >120/minute, confused/agitated, respiratory
144 distress, systolic blood pressure <90 mmHg, inability to walk unassisted
- 145 • Treated with antibiotics other than co-trimoxazole prophylaxis within the past 14 days
- 146 • Tuberculosis treatment or isoniazid preventive therapy within the last 6 months

148 Interventions

149 We will randomise participants, in a ratio of 1:1:1, to the following arms:

- **Arm 1** (Azithromycin): Azithromycin 500mg taken once daily for 3 days from enrolment day
- **Arm 2** (Amoxicillin): Amoxicillin 500 mg taken once daily for 5 days from enrolment day.
- **Arm 3** (Standard of care): No study antibiotic prescription.

Concomitant medication and interaction with other therapies

We do not have any restrictions with respect to concomitant medications apart from those listed in the exclusion criteria.

Trial restrictions

We do not require participants to have any dietary restrictions. We will also accept co-administration with contraception. Our trial interventions can safely be used in pregnancy, so we will include pregnant women should they be eligible.

Assessment of compliance

On Day-8, we will document self-reported compliance adherence of study products.

Withdraw of interventions

The investigator may also terminate a participant from study product if indicated by an adverse reaction. If a participant stops taking study product either voluntarily or by investigator decision, they will be encouraged to remain in follow up and their data will form part of intention to treat analyses.

Timing of interventions

The standard of care in national guidelines for primary care patients presenting with cough and are otherwise well (no danger signs) is to take sputum x 2 for smear microscopy or Xpert and ask them to return for results, typically 3 days - 1 week later (Figure 1). The Malawi tuberculosis diagnostic algorithm recommends use of broad-spectrum antibiotics as trial-of-antibiotics after negative sputum tests are provided to the patient, if they remain

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

symptomatic. Therefore, the ideal population for randomisation for this study are patients on who already have negative results for smear microscopy or Xpert. However, that may have ethical challenges considering the implications of withholding antibiotics from a symptomatic patient who may benefit from them. The first visit therefore was the most ideal time for randomisation and is in line with recommendations for test interval in investigations evaluating diagnostic tests with respect to the time interval between the index test (trial of antibiotics) and the reference test (mycobacteriology sputum sample collection). The timing also conforms to common clinical practice of prescribing trial-of-antibiotics at the same time as sputum collection to reduce diagnostic delay. The design was discussed with the District Health Office and the national TB program ahead of ethics submission.

Study outcomes

The following are descriptions of study outcomes:

Primary outcome 1: Specificity of trial-of-antibiotics versus mycobacteriology

This will be specificity of trial-of-antibiotics (the index test) in each arm against mycobacteriology tests (reference test) defined as: proportion of participants classified as tuberculosis negative (defined by self-reported day 8 improvement status of baseline symptoms) out of all who tested tuberculosis negative by mycobacteriology reference standard (smear microscopy, Xpert/MTB/RIF, or MTB culture). The mycobacteriology reference standard will be defined in participants with at least one specimen with a valid result on days 1 and 8 as tuberculosis-positive if there is at least one positive of smear microscopy, Xpert/MTB/RIF, or MTB culture; and as tuberculosis-negative if none of the tests are positive. To minimise bias, the mycobacteriology will be performed by a high-quality research laboratory in the University of Malawi College of Medicine by staff with no access to participant treatment allocation information or symptom results.

On day 8, participants will be asked the following question: *on day 1, you reported that you were unwell; compared to that day, has your illness worsened, remained the same, or improved?* Clinical improvement status will then be defined based on responses as tuberculosis-positive if participants report no change or worsening of illness; and as tuberculosis-negative if they report improvement. To minimise ascertainment bias in evaluation of improvement of baseline symptoms the interview will be conducted using Audio Computer Assisted Self-Interview (ACASI), a platform that allows patients to report their health state directly into a database via an audio questionnaire administered by a tablet device. We developed, piloted, and optimised the ACASI questionnaire in the study target population. Before proceeding to the self-interview, participants will be oriented using test questions until study staff are sure that they will be able to go through the interview on their own.




Figure 3: Ascertainment of diagnostic value of trial-of-antibiotics

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Ensignment Supérieur (ABES)

213 **Primary outcome 2: Clinical impact of trial-of-antibiotics**

214 We will investigate the overall clinical impact of trial-of-antibiotics by comparing the day 29
215 risk of any of death, hospitalisation, missed tuberculosis diagnosis (untreated
216 mycobacteriological or radiological tuberculosis identified on Day 29), and non-adherence to
217 HIV or tuberculosis treatment (defined using responses to a questionnaire assessing
218 adherence in the four days leading to the study visit). All these events are potential
219 consequences of trial-of-antibiotics, grouping them as a composite endpoint appropriately
220 represents the effect of the intervention because: 1) there are similarities in the importance
221 patients would attach to each of the components, 2) the components occur with similar
222 frequencies in the patient population, and 3) the direction of effect is anticipated to be the
223 same for all.²⁰

224 **Secondary outcome 1: impact of trial-of-antibiotics on antimicrobial resistance**

225 We will assess impact of antibiotic exposure on AMR by comparing risk of acquiring resistant
226 isolates of *S. pneumonia* in the nasopharynx by day 29. An ecological niche for many
227 bacterial species, the upper respiratory tract also presents a convenient window for
228 investigating antimicrobial resistance.²¹ *S. pneumonia* is the organism of choice not only for
229 being an important cause of respiratory tract infections but also because it often colonises
230 the upper respiratory tract and has well documented laboratory investigation procedures in
231 place.²² We will exclude those with resistant isolates on both day-1 and day-29 from the
232 numerator, as they may not truly represent incident resistance. In the denominator, we will
233 include all randomised participants and perform analysis as intention to treat.

234 **Secondary outcome 2: diagnostic value of trial-of-antibiotics**

235 This will be specificity of trial-of-antibiotics (the index test assessed using ACASI) in each
236 arm against mycobacteriology tests (reference test) defined as: proportion of participants
237 classified as tuberculosis negative (defined by self-reported day 8 improvement status of
238 baseline symptoms) out of all who tested tuberculosis negative by mycobacteriology
239 reference standard (smear microscopy, Xpert/MTB/RIF, or MTB culture). Unlike in Primary

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

outcome 1, the mycobacteriology reference standard will extend to all study participants regardless of sputum sample availability. Participants unable to provide sputum samples, will be classified as mycobacteriologically negative. Microbiology diagnosis of tuberculosis is mainly based on sputum, therefore being unable to produce it, restricts diagnostic access, which effectively implies a negative test. We have opted to analyse this population because it is significant, can be as high as 13% of symptomatic individuals in the study setting.²³

Secondary outcome 3: Economic evaluation

The objective of the economic evaluation is to undertake a cost-utility analysis to estimate the incremental cost-effectiveness of trial-of-antibiotics using azithromycin and trial-of-antibiotics using amoxicillin in comparison to standard of care, and to each other. We will systematically compare costs and consequences associated with the interventions. We will perform a within trial comparison of the three treatment arms to estimate the incremental cost per quality-adjusted life year (QALY) gained for the azithromycin or amoxicillin arm in comparison to standard of care. Costs will be estimated from the Malawian Ministry of Health perspective. Health outcomes will be quantified in QALYs, estimated from participants' responses to the Chichewa version of the EQ-5D-3L, a Health quality of life (HRQoL) measure.^{24 25} We will adopt a time horizon matching the length of participant follow-up to achieve the within trial evaluation.

Exploratory outcomes

Our exploratory analyses will be comparisons between the **azithromycin** and **amoxicillin** arms for all our primary and secondary outcomes.

Planned subgroup analyses

We will perform analysis of primary outcomes stratified by HIV status and by ART status as documented on enrolment day. This is important because the study site has high prevalence of HIV and associated bacterial infections which may be amenable to antibiotics used for trial-of-antibiotics.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

Study procedures

Figure 2 and Table 1 presents the study time schedule including a summary of patient identification, baseline procedures and outcome ascertainment at day 8 and day 29 follow up visits.

Screening

Study staff will approach patients with symptoms of pulmonary tuberculosis (including cough of any duration, fever, weight loss, and night sweats) with information about the study and seek written informed consent from all patients who meet eligibility criteria. After consenting, a participant will be given a unique study identification number confirming enrolment.

Randomisation and blinding

Randomisation will be in the ratio 1:1:1 to the three arms of the trial, using block-randomisation with variable block sizes, and stratified by study site. An independent statistician will prepare the randomisation list using Ralloc command in Stata software, then print each allocation alongside a randomisation number, and seal in opaque envelopes. Upon confirming eligibility and consenting status a designated site staff will open the next available of sequentially numbered randomisation envelopes and administer the allocated study arm.

Blinding

The study will not use blinding to ensure safety of the participants and allow appropriate patient management decision-making which may be related to the trial interventions. However, all study outcome assessment will occur without reference to study treatment allocation.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Baseline procedures

At baseline, we will collect demographic data, clinical history, record vital signs, height and weight. Participants will be requested to provide two sputum samples for Xpert/MTB/RIF and two more sputum samples the following morning for smear microscopy and MTb culture. We will also collect a urine sample for lipoarabamannan antigen detection (TB LAM); and a nasopharyngeal swab for pneumococcal culture and sensitivity testing. We will offer and perform HIV testing according to the national algorithm, and link all who test positive to care. To minimise loss to follow up, we will collect contact phone numbers, a physical address and geolocation information.

Participant follow up

On day 8, the first activity (ahead of any other interaction with study staff) will be the ACASI. Other activities include providing results for day 1 tuberculosis tests and linking those who test positive to care; collection of another sputum sample for smear microscopy and *Mycobacterium tuberculosis* (MTB) culture; and management of ongoing symptoms and other illnesses. On visit day 29, the final study visit, we will document participant vital status, hospitalisations, and establish adherence to HIV and tuberculosis treatment. We will also collect nasopharyngeal swab samples from all participants, and sputum from those with tuberculosis symptoms.

Participant retention

To minimise loss to follow up, we will record geolocation information of participants' place of residence using ePAL android app, a high-resolution mapping system validated in Blantyre. We will also record up to 3 contact phone numbers of the participant and their nominated friends and relatives. We will not replace participants who discontinue study participation or study treatment regardless of reason for withdrawal or discontinuation or the time either of these occurs.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

313 ***Data management***

314 We will collect data using TeleForm (paper based system that uses optical character
315 recognition) and Open Data Kit systems (ODK, an electronic data capture system installed
316 on android devices). Data will be committed to a secure database located at Malawi-
317 Liverpool Wellcome Trust (MLW) within 2 days for TeleForm, and 7 days for ODK.

318

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

319 **Table 1:** key study procedures over the study period

	STUDY PERIOD			
	Enrolment	Follow up		
TIMEPOINT	Day-1	Day-8		Day-29
ENROLMENT:				
Eligibility screen	x			
Informed consent	x			
Allocation	x			
INTERVENTIONS:				
Azithromycin	x			
Amoxicillin	x			
Standard of care	x			
ASSESSMENTS:				
Demographics	x			
History of antibiotic use	x	x		x
History & examination ¹	x	x		x
Sputum collection ²	x	x		
Urine for TB LAM test ³	x	x		
Nasopharyngeal swab for AMR ⁴	x			x
HIV test	x			
Linking to routine care	x	x		x
ACASI ⁵		x		
Clinical events ⁶				x
Update contact & address		x		x
1. For symptomatic participants, Day-8 sputum mycobacteriology should be fast-tracked to inform care before they leave the clinic. 2. Give sputum bottles at end of Day-1 visit for submission on Day-8. Also collect sputum and perform mycobacteriology at any time of the study when clinically indicated 3. Urine Lipoarabinomannan for Tuberculosis Diagnosis (TB LAM) 4. Nasopharyngeal swab for S. pneumoniae culture and sensitivity as a way of determining risk of antimicrobial resistance (AMR) 5. Audio Computer Assisted Self-Interview (ACASI) for documenting change of symptoms on Day- 8 versus Day-1 6. Illnesses, clinic visits, radiological outcomes, new HIV diagnosis, new tuberculosis (TB) diagnosis, death, hospitalisation, missed TB diagnosis, HIV care loss to follow up, and TB care loss to follow up				

320
321

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

Sample size and power

We assume that trial-of-antibiotics (in azithromycin arm or in amoxicillin arm) will correctly classify 60% of mycobacteriology negative participants (Table 2).¹² We have determined that 400 mycobacteriologically negative (true negatives) participants per arm will provide 80% power to detect a 10% absolute difference in proportion of participants without tuberculosis (mycobacteriologically negative) correctly classified as negative by trial-of-antibiotics (amoxicillin arm or by azithromycin arm) (60%) versus standard of care arm (50%) (Table 2). To determine the target enrolment that may be required to achieve 400 mycobacteriologically negative participants per arm, we first assume that 80% of participants randomised will have negative mycobacteriology,²³ requiring 500 participants to yield the 400 per arm. Assuming that 15% will not be able to produce sputum, and that 5% will not return for Day-8 visit, the sample size is increased to 625 per arm or 1,875 for the whole study.

Table 2: Power and sample size estimation for primary outcome 1

True negatives (mycobacteriology tests negative participants) b+d	¹ proportion of tuberculosis negatives correctly classified d/(b+d)	² effect size	power
320	0.60	0.10	69%
400	0.60	0.10	80%
480	0.60	0.10	86%
¹ specificity with either azithromycin or amoxicillin trial-of-antibiotics arms			
² risk difference (azithromycin arm versus standard of care arm; OR amoxicillin arm versus standard of care arm; OR azithromycin arm combined with amoxicillin arm versus standard of care arm)			

For the clinical impact of trial-of-antibiotics outcome, with the sample size of 625 participants/arm, and a type I alpha of 5%, we will be able to detect the difference between intervention and standard of care with 80% power, if the risk in the intervention arm is 6% or lower.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For the AMR outcome, we assume that 45% of Day-29 nasopharyngeal swabs will successfully grow *S. pneumonia*, and that 10% of the isolates will have amoxicillin or azithromycin resistance (expert evidence). Therefore, a study population of 625/arm (accounting for 10% loss to follow up to Day 29), would yield 253 isolates per arm of which 25 would exhibit amoxicillin or azithromycin resistance. For the intention to treat population (the randomised 625 participants/arm) in the standard of care arm the 25 cases of resistant isolates translate into 4% (25/625) risk. With 4% risk in the standard of care group, alpha of 0.05, and using Pearson's Chi-squared test we will be able to detect the impact of the intervention with 85% power if it leads to an increase of risk of resistant isolates from 4% to 8% (RR of 2).

Statistical approach

We will summarise the processes of recruitment including non-eligibility and reasons of exclusion in a CONSORT (Consolidated Standards of Reporting Trials) flow chart. We will describe the study participants by their baseline characteristics, by arm. We will perform analyses of all our outcomes based on an intention to treat analysis (using the arm patient was randomised to), adjusting for study site. We will report measures of effect from the following comparisons:

- i) azithromycin or amoxicillin (combined) versus standard of care
- ii) azithromycin versus standard of care
- iii) amoxicillin versus standard of care

For primary outcome 1, and secondary outcome 2, we will use a generalised linear model (GLM) with identity link to estimate risks differences and the GLM with log link to estimate risk ratios for the three comparisons, adjusting for study site. For each comparison, we will report 95% confidence intervals (CIs) and p-values from the likelihood test. If the GLM model

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

does not converge, we will use logistic regression to estimate the treatment effect using an odds ratio. If outcomes are rare, we will use logistic regression to model odds and report odds ratios, their associated 95% CIs, and p-values.

We will perform data cleaning and analysis using Stata release 15 (Stata Corp, College station, Texas, USA). The statistical approach will be expanded in a detailed statistical analysis plan, which will be finalised before unblinding the study data.

Monitoring and oversight

The trial will be monitored by the Research Support Centre Clinical Trials Unit of the University of Malawi College of Medicine. An independent Data and Safety Monitoring Board (DSMB), and a Trial Steering Committee (TSC) have been set up and meet bi-annually.

Trial closure

We will consider the trial closed after completing follow up of the last enrolled participant, and upon recording all mycobacteriology laboratory reports. Antimicrobial resistance lab work will continue beyond trial closure. The trial may be terminated early by the trial steering committee upon recommendation of the DSMB. The halting rule for a trial arm is an unacceptable high level of deaths assessed using an alpha determined at the first DSMB meeting.

DISCUSSION

The ACT-TB study will investigate the benefits and consequences of “trial-of-antibiotics,” a widely promoted approach to many patients with suspected tuberculosis in low- and middle-income countries without solid evidence base. To our knowledge, ACT-TB Study is the first RCT of this kind. Results of our trial will improve efficiency in the approach for detecting tuberculosis (the leading infectious disease killer: ~1.6 million deaths/ year)² and strengthen

1
2
3 388 our fight against antimicrobial resistance (soon to be leading cause of death: ~10 million
4
5 389 deaths/year by 2050).²⁶
6
7

8 390 **Choice of study interventions**
9

10
11
12 391 We have chosen amoxicillin because it is the first line treatment for outpatient management
13
14 392 of pneumonia in Malawi and is commonly used for trial-of-antibiotics. It also provides data of
15
16 393 immediate programmatic relevance and a starting point to investigate exacerbation of pre-
17
18 394 existing AMR pressure. However, amoxicillin may not demonstrate the full benefits for trial-
19
20 395 of-antibiotics because of organisms with intrinsic (“atypicals”) or acquired (common in gram-
21
22 396 negative organisms, and *Staphylococcus aureus*) penicillin resistance.²⁷ Oral antibiotics that
23
24 397 may provide the better diagnostic discrimination for bacterial vs mycobacterial causes of
25
26 398 cough are macrolides, such as azithromycin, because of better intrinsic coverage of
27
28 399 “bacterial causes of pneumonia including “atypical” intracellular organisms such as
29
30 400 *mycoplasma* species,²⁸⁻³⁰ and low levels of acquired macrolide-resistance in bacterial
31
32 401 isolates in Malawi.²⁷
33
34

35
36 402 **ACASI for post-treatment improvement assessment**
37

38
39 403 Our systematic review¹⁸ did not identify a consistent definition of tuberculosis or no
40
41 404 tuberculosis based on trial-of-antibiotics. A definition of clinical change following antibiotic
42
43 405 treatment is necessary for the trial-of-antibiotics as it determines who get categorised as well
44
45 406 or tuberculosis positive. Approaches that ranged from self-reported improvement, to a
46
47 407 combination of clinical and radiological assessments are likely to be highly subjective and
48
49 408 prone to bias, as well as being a potentially avoidable source of heterogeneity between
50
51 409 studies. In this study, we hope to address these biases (particularly, inter-observer
52
53 410 variability, and patient/interviewer reporting or ascertainment biases) by using self-rated
54
55 411 change of illness (on day 8) recorded using a self-completed questionnaire, the ACASI
56
57 412 (described under outcomes). The ACASI questionnaire, the delivery platform, and the
58
59
60

413 resulting data management can all be replicated in future studies, creating potential for more
414 standardisation in assessment of clinical response to treatment.

415 **Potential clinical impact of antibiotics**

416 In areas with high HIV prevalence, empirical antibiotics during tuberculosis investigations
417 could be life-saving: mortality immediately before and after tuberculosis diagnosis is high,^{3 31}
418 and is often secondary to severe bacterial infections.³¹⁻³³ The leading aetiologies of infection
419 and death on tuberculosis treatment as well as among outpatients with tuberculosis-like
420 symptoms are *Streptococcus pneumoniae* and non-typhoidal salmonellae: both can present
421 with cough (primary cause) or as co-morbidities (super-infections) in patients presenting with
422 active *Mycobacterium tuberculosis* disease.³¹⁻³³ If effective treatment of this type of life-
423 threatening primary/super-infections reduces mortality during the diagnostic work-up of
424 suspected tuberculosis in people living with HIV, then empirical use of broad-spectrum
425 antibiotics would be indicated for this purpose alone, irrespective of any diagnostic
426 contribution to tuberculosis treatment decisions. In this context, azithromycin may be the
427 most effective arm, as salmonella infections are highly sensitive to azithromycin, but not to
428 amoxicillin.²⁷

429 **AMR and trial-of-antibiotics**

430 Antimicrobial resistance relating to antibiotic use during evaluation for suspected
431 tuberculosis has not been investigated before. Previous work has shown that empirical
432 antibiotics can drive rapid emergence of antimicrobial resistance.^{34 35} Co-trimoxazole
433 prophylaxis for HIV-positive patients, introduced in 2005, was followed by near-universal
434 resistance in bloodstream infections by 2010³⁶. Mass drug administration of azithromycin for
435 trachoma control initially reduces nasopharyngeal carriage of *Streptococcus pneumoniae*,
436 but with increased macrolide-resistance 6 months later.^{37 38}

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

In this study we have the opportunity to assess the extent to which brief exposure drives antimicrobial resistance during diagnostic work-up for tuberculosis. An ecological niche for many bacterial species, the upper respiratory tract also presents a convenient window for investigating antimicrobial resistance.²¹ *S. pneumonia* is the organism of choice not only for being an important cause of respiratory tract infections but also because it often colonises the upper respiratory tract and has well documented laboratory investigation procedures in place.²² As exploratory analyses, we will also assess nasopharyngeal colonization and antimicrobial resistance in relation to tuberculosis treatment and HIV status.

Important subgroups

Response to trial-of-antibiotic- in patients with bacteriologically confirmed tuberculosis (i.e. false-negatives/low sensitivity from the perspective of tuberculosis diagnosis) may relate to multiple super-infections and so this phenomenon may vary by HIV status, since multiple concurrent infections are a hallmark of advanced HIV immunosuppression, and commonly identified in patients with suspected tuberculosis in the pre-ART era.^{4 32} More recently, in Malawi, 45% of adults who presented to primary care with prolonged cough (≥2 weeks) were HIV-positive, of whom only ~20% started tuberculosis treatment on the basis of positive mycobacteriology.²³ As such, the benefits and consequences of trial-of-antibiotics may vary by HIV status and by subsequent tuberculosis treatment decisions. We will, therefore, include a pre-specified sub-analysis of trial outcomes stratified by HIV and ART status.

ETHICS AND DISSEMINATION

The study has been reviewed and approved by the University of Malawi College of Medicine Research and Ethics Committee (COMREC), the London School of Hygiene & Tropical Medicine Research Ethics Committee, and Regional Committee for Health and Research Ethics, NTNU-Midt, Norway. Regulatory approval has been granted by the Malawi Pharmacy, Medicines, and Poisons Board (PMPB). We will present any future protocol

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

modifications to these bodies before implementing. We will submit results for publication in a peer-reviewed journal. We will submit abstracts to relevant national and international conferences. This study will follow the standards set by CONSORT guidelines.

AUTHORS' CONTRIBUTIONS

THD, KF and ELC are the main contributors to the study design and conception. All authors carefully reviewed and substantially contributed to the development of the protocol. THD developed the first draft of the manuscript. All authors reviewed and contributed to the manuscript. All authors read and approved the final manuscript. THD is the guarantor for this work.

FUNDING AND SPONSORSHIP STATEMENT

The clinical trial is funded by the Commonwealth Scholarship Commission and the Helse Nord RHF grant awarded to THD. This work is part of THD's PhD work at London School of Hygiene & Tropical Medicine (LSHTM). LSHTM is the sponsor of this clinical trial (sponsor address: Keppel Street, Bloomsbury, London WC1E 7HT). ELC is funded by a Wellcome Trust Senior Research Fellowship in Clinical Science: WT200901. The funding agencies and the sponsor had no role in the preparation of the protocol or the intention to submit this manuscript for publication.

COMPETING INTERESTS STATEMENT

We have no conflicts of interest to declare.

PATIENT AND PUBLIC INVOLVEMENT

Patients were involved in the design of the study especially the audio-computer-assisted interview (ACASI) used for collecting primary outcome data. Health workers were involved in the design of study visits and patient flow.

BODY WORD COUNT: 4,034

REFERENCES

1. Raviglione M, Sulis G. Tuberculosis 2015: burden, challenges and strategy for control and elimination. *Infectious disease reports* 2016;8(2):6570. doi: 10.4081/idr.2016.6570

2. World Health Organization. Global tuberculosis report 2018: World Health Organization 2018.

3. Nliwasa M, MacPherson P, Mukaka M, et al. High mortality and prevalence of HIV and tuberculosis in adults with chronic cough in Malawi: a cohort study. *The international journal of tuberculosis and lung disease* 2016;20(2):202-10. doi: 10.5588/ijtld.15.0388

4. Getahun H, Harrington M, O'Brien R, et al. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. *The Lancet* 2007;369(9578):2042-49. doi: 10.1016/S0140-6736(07)60284-0

5. Corbett E, MacPherson P. Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality [State of the art series. Active case finding/screening. Number 5 in the series]. *The international journal of tuberculosis and lung disease* 2013;17(9):1125-38.

6. Siddiqi K, Lambert M-L, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. *The Lancet infectious diseases* 2003;3(5):288-96.

7. Ghana Health Service. Guidelines for the Clinical Management of TB and HIV Co-infection in Ghana. In: Department DCaP, ed. Accra, 2007.

8. Ministry of Health. Malawi National TB Programme Manual. . In: Programme NT, ed. 8 ed. Lilongwe, 2016.

9. National Department of Health. South Africa National Tuberculosis Management Guidelines 2014. In: Coordination TDS, ed. Pretoria, 2014.

10. World Health Organization. Global tuberculosis report 2016. 2016

11. McDowell A, Pai M. Treatment as diagnosis and diagnosis as treatment: empirical management of presumptive tuberculosis in India. *The International Journal of Tuberculosis and Lung Disease* 2016;20(4):536-43.

12. Wilkinson D, Newman W, Reid A, et al. Trial-of-antibiotic algorithm for the diagnosis of tuberculosis in a district hospital in a developing country with high HIV prevalence. *The International Journal of Tuberculosis and Lung Disease* 2000;4(6):513-18. [published Online First: 2000/06/23]

13. Holmes AH, Moore LS, Sundsfjord A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. *The Lancet* 2016;387(10014):176-87. doi: 10.1016/S0140-6736(15)00473-0

14. World Health Organization. The evolving threat of antimicrobial resistance: options for action: Geneva: World Health Organization 2012.

- 524 15. World Health Organization. Antimicrobial resistance: global report on surveillance: World
525 Health Organization 2014.
- 526 16. Laxminarayan R, Matsoso P, Pant S, et al. Access to effective antimicrobials: a
527 worldwide challenge. *The Lancet* 2016;387(10014):168-75. doi: 10.1016/S0140-
528 6736(15)00474-2
- 529 17. Divala TH, Fielding KL, Nliwasa M, et al. Sensitivity and specificity of using trial-of-
530 antibiotics versus sputum mycobacteriology for diagnosis of tuberculosis: protocol for a
531 systematic literature review. *Systematic reviews* 2018;7(1):141.
- 532 18. Divala TH, Nliwasa M, Gupta-Wrigh A, et al. Is the current practice of using response to
533 empirical broad-spectrum antibiotic treatment as an exclusion diagnostic for tuberculosis
534 supported by evidence? Systematic review and meta-analysis. 49th World Conference on
535 Lung Health of the International Union Against Tuberculosis and Lung Disease (The
536 Union): Int J Tuberc Lung Dis, 2018.
- 537 19. National Tuberculosis Control programme. Malawi Nationwide Tuberculosis Prevalence
538 Survey. 45th Union World Conference on Lung Health. Barcelona, Spain, 2014.
- 539 20. Montori VM, Permyer-Miralda G, Ferreira-González I, et al. Validity of composite end
540 points in clinical trials. *Bmj* 2005;330(7491):594-96.
- 541 21. Man WH, de Steenhuisen P, Bogaert D. The microbiota of the respiratory tract:
542 gatekeeper to respiratory health. *Nat Rev Microbiol* 2017;15(5):259-70. doi:
543 10.1038/nrmicro.2017.14
- 544 22. Satzke C, Turner P, Virolainen-Julkunen A, et al. Standard method for detecting upper
545 respiratory carriage of *Streptococcus pneumoniae*: updated recommendations from the
546 World Health Organization Pneumococcal Carriage Working Group. *Vaccine*
547 2013;32(1):165-79. doi: 10.1016/j.vaccine.2013.08.062
- 548 23. Nliwasa M, MacPherson P, Chisala P, et al. The sensitivity and specificity of Loop-
549 Mediated Isothermal Amplification (LAMP) assay for Tuberculosis diagnosis in adults with
550 chronic cough in Malawi. *PloS one* 2016;11(5):e0155101. doi:
551 10.1371/journal.pone.0155101 [published Online First: 2016/05/14]
- 552 24. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life.
553 *Health policy (Amsterdam, Netherlands)* 1990;16(3):199.
- 554 25. Maheswaran H, Petrou S, MacPherson P, et al. Cost and quality of life analysis of HIV
555 self-testing and facility-based HIV testing and counselling in Blantyre, Malawi. *BMC*
556 *medicine* 2016;14(1):34.
- 557 26. O'Neill J. Tackling drug-resistant infections globally: Final report and recommendations.
558 2016. *HM Government and Wellcome Trust: UK* 2018
- 559 27. Musicha P, Cornick JE, Bar-Zeev N, et al. Trends in antimicrobial resistance in
560 bloodstream infection isolates at a large urban hospital in Malawi (1998–2016): a
561 surveillance study. *The Lancet Infectious Diseases* 2017;17(10):1042-52. doi:
562 10.1016/s1473-3099(17)30394-8
- 563 28. Lubell Y, Turner P, Ashley EA, et al. Susceptibility of bacterial isolates from community-
564 acquired infections in sub-Saharan Africa and Asia to macrolide antibiotics

- 565 Sensibilité aux macrolides des isolats bactériens provenant des infections acquises dans la
566 communauté en Afrique subsaharienne et en Asie
567 Susceptibilidad a macrólidos de aislados bacterianos provenientes de infecciones adquiridas
568 en la comunidad. *Tropical Medicine & International Health* 2011;16(10):1192-205. doi:
569 10.1111/j.1365-3156.2011.02837.x
- 570 29. Phua J, Dean NC, Guo Q, et al. Severe community-acquired pneumonia: timely
571 management measures in the first 24 hours. *Critical Care* 2016;20(1):237. doi:
572 10.1186/s13054-016-1414-2
- 573 30. Lim W, Smith D, Wise M, et al. British Thoracic Society community acquired pneumonia
574 guideline and the NICE pneumonia guideline: how they fit together. *Thorax*
575 2015;thoraxjnl-2015-206881.
- 576 31. Cain KP, Anekthananon T, Burapat C, et al. Causes of death in HIV-infected persons
577 who have tuberculosis, Thailand. *Emerging infectious diseases* 2009;15(2):258.
- 578 32. Bedell RA, Anderson ST, Van Lettow M, et al. High prevalence of tuberculosis and
579 serious bloodstream infections in ambulatory individuals presenting for antiretroviral
580 therapy in Malawi. *PLoS One* 2012;7(6):e39347. doi: 10.1371/journal.pone.0039347
- 581 33. Schleicher G, Feldman C. Dual infection with *Streptococcus pneumoniae* and
582 *Mycobacterium tuberculosis* in HIV-seropositive patients with community acquired
583 pneumonia. *The International Journal of Tuberculosis and Lung Disease*
584 2003;7(12):1207-08.
- 585 34. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and
586 responses. *Nature medicine* 2004;10(12s):S122. doi: 10.1038/nm1145
- 587 35. Goossens H, Ferech M, Vander Stichele R, et al. Outpatient antibiotic use in Europe and
588 association with resistance: a cross-national database study. *The Lancet*
589 2005;365(9459):579-87.
- 590 36. Everett DB, Mukaka M, Denis B, et al. Ten years of surveillance for invasive
591 *Streptococcus pneumoniae* during the era of antiretroviral scale-up and cotrimoxazole
592 prophylaxis in Malawi. *PloS one* 2011;6(3):e17765. doi: 10.1371/journal.pone.0017765
- 593 37. Coles CL, Mabula K, Seidman JC, et al. Mass distribution of azithromycin for trachoma
594 control is associated with increased risk of azithromycin-resistant *Streptococcus*
595 *pneumoniae* carriage in young children 6 months after treatment. *Clinical Infectious*
596 *Diseases* 2013;56(11):1519-26.
- 597 38. Mitjà O, Houinei W, Moses P, et al. Mass treatment with single-dose azithromycin for
598 yaws. *New England Journal of Medicine* 2015;372(8):703-10. doi:
599 10.1056/NEJMoa1408586

602 **APPENDIX 1: TRIAL REGISTRATION—DATA SET**

NCT Number	NCT03545373
Title	Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis (ACT-TB Study)
Acronym	ACT-TB
Status	Recruiting
Study Results	No Results Available
Conditions	Tuberculosis Respiratory Tract Infections Pneumonia
Interventions	Drug: Azithromycin Drug: Amoxicillin
Outcome Measures	Diagnostic accuracy of trial-of-antibiotics: Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 against a mycobacteriology reference standard. Overall clinical benefit of empirical antibiotic treatment in primary care participants with chronic cough: proportion of participants experiencing adverse clinical outcomes Impact of trial-of-antibiotics on antimicrobial resistance Diagnostic accuracy of trial-of-antibiotics including participants who did not produce sputum Economic analysis of use of trial-of-antibiotics
Sponsor/Collaborators	London School of Hygiene and Tropical Medicine University of Malawi College of Medicine
Gender	All
Age	18 Years and older Å (Adult, Older Adult)
Phases	Phase 3
Enrollment	1875
Funded Bys	Other
Study Type	Interventional
Study Designs	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Outcomes Assessor) Primary Purpose: Diagnostic
Other IDs	15232
Start Date	February 25, 2019
Primary Completion Date	Jun-20
Completion Date	Jun-20
First Posted	June 4, 2018
Results First Posted	
Last Update Posted	August 15, 2019
Locations	University of Malawi College of Medicine, Blantyre, Southern, Malawi
Study Documents	
URL	https://ClinicalTrials.gov/show/NCT03545373

603
604

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

APPENDIX 2: FULL TRIAL PROTOCOL

(attached separately)

APPENDIX 3: PATIENT INFORMATION SHEET AND INFORMED CONSENT

(attached separately)

APPENDIX 4: ETHICS AND REGULATORY APPROVALS

(attached separately)

For peer review only

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

01 September 2019

The Editor in Chief

BMJ Open

BMJ Open Editorial Office

BMA House, Tavistock Square

London, WC1H 9JR, UK

Dear Editor,

RE: Randomised controlled clinical trial investigating benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis in primary care adult patients versus risk of antimicrobial resistance (the ACT-TB Study)

We are pleased to submit a clinical trial protocol bearing the above title for consideration for publication in *BMJ Open*. This clinical trial aims to address a critical, yet ignored, intersection between two major global challenges: 1) the suboptimal nature of Tuberculosis diagnostics, perhaps the key underlying driver for the high mortality in this top killer of all infectious disease; and 2) antimicrobial resistance, which currently kills 700,000 people per year and if left unchecked, it will surpass all killers with deaths from untreatable infections catapulting to 10,000,000 per year by 2050. It is therefore not surprising that Tuberculosis and antimicrobial resistance are two of only five health issues to have ever secured a United Nations High Level Meeting.

Inspired by our recently-submitted, and under-publication-consideration systematic review (*Divala TH, Fielding KL, Nliwasa M, Sloan DJ, Gupta-Wright A, Corbett EL. Sensitivity and specificity of using trial-of-antibiotics versus sputum mycobacteriology for diagnosis of tuberculosis: protocol for a systematic literature review. Systematic reviews. 2018 Dec;7(1):141.*), we describe how we will investigate benefits and consequences of the current practice using broad-spectrum antibiotics (such as amoxicillin, macrolides, and others used for treating bacterial pneumonia) as Tuberculosis diagnostics. The use of antibiotics in TB diagnostic algorithms is a practice that is grounded on limited evidence, yet results in prescriptions of approximately 26.5 million antibiotic courses.

Administration of a course of broad spectrum antibiotics as a means of ruling out tuberculosis in coughing patients with negative sputum TB tests, has been part of the TB diagnostic algorithm for over 20 years. In this practice, known as trial-of-antibiotics, response to the antibiotics is interpreted as a negative test for Tuberculosis while failure to respond increases the probability of Tuberculosis, warranting further Tuberculosis diagnostics. Getahun and colleagues (Lancet. 2007;369(9578))

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

provide what is perhaps the best description of this approach and extent of use in sub Saharan Africa, **but to our knowledge, no comprehensive assessment of diagnostic accuracy of trial-of-antibiotics exists. Despite the wide application and potential consequences, no clinical trial or systematic review has been done on the subject.**

Our review and meta-analysis has established that the current policy and practice regarding trial-of-antibiotics has weak evidence base, poor diagnostic performance, and worryingly inconsistent choice of antibiotics, number of antibiotic courses, and interpretation of test outcomes. **We believe that this manuscript is appropriate for publication in this special issue because it has potential to 1) drive research forward, 2) help optimize TB diagnostic algorithms with current and new diagnostics, and 3) to improve clinical care and treatment outcomes in the entire TB high burden world.** This work essentially cross-cuts the ideals of the *BMJ Open*.

Ethics and regulatory approvals

The protocol has been reviewed and approved by the following bodies:

- 1. University of Malawi College of Medicine Research and Ethics Committee (COMREC),
- 2. London School of Hygiene & Tropical Medicine Research Ethics Committee
- 3. Regional Committee for Health and Research Ethics, NTNU-Midt, Norway
- 4. The Malawi Pharmacy, Medicines, and Poisons Board (PMPB)
- 5. Annual approvals are granted by 1 and 2

No part of this manuscript has been published or is under consideration for publication elsewhere. We have no conflicts of interest to disclose.

Thank you for considering our manuscript.

Sincerely,



Titus H. Divala MBBS MPH MS
Commonwealth Scholar and Helse Nord RHF Fellow
Department of Infectious Disease Epidemiology,
London School of Hygiene & Tropical Medicine, Keppel St, London
AND Helse Nord Tuberculosis Initiative, Department of Pathology,
University of Malawi College of Medicine, Blantyre, Malawi

Honorary Lecturer (Epidemiology)
Department of Pathology, University of Malawi College of Medicine, Blantyre, Malawi

Mobile: +265999478376 (Malawi), +447405231847 (UK)
Whatsapp: +447405231847
Skype: tdivala
Email: titus.divala@lshtm.ac.uk (LSHTM)
tdivala@umaryland.edu (Other)
Academic Profile: <http://www.lshtm.ac.uk/aboutus/people/divala.titus>



PARTICIPANT INFORMATION SHEET

Participant information sheet

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE

What is the benefit and unintended consequences of using antibiotic treatment as a way of excluding tuberculosis disease in patients with cough?

Introduction

We would like to invite you to take part in a research study. Joining the study is entirely up to you. Before you decide, you need to understand why the research is being done and what it would involve. One of our team will go through this information sheet with you, and answer any questions you may have. Ask questions if anything you read is not clear or you would like more information. Please feel free to talk to others about the study if you wish. Take time to decide whether or not to take part.

What is the purpose of the study?

Tuberculosis (TB) is a disease that causes a long illness and cough with sputum. Although curable TB is difficult to detect. When they fail to detect TB after testing sputum, clinicians give antibiotic treatment that can cure all other causes of TB symptoms but not TB. In this approach, TB is considered ruled out if patient gets better and it is considered likely if they do not get better. The goal of this research study is to develop understanding of how well the antibiotics help distinguish TB patients from those who do not have it, whether giving antibiotics carries other health benefits, and whether it leads to development of disease causing organisms which are resistant to drugs.

We will learn about this by comparing a group of patients given antibiotics on the first day of the study to another group not given antibiotics. There will be two groups receiving antibiotics as follows: 1) Azithromycin taken as one tablet once a day for 3 days, and 2) Amoxicillin 4 capsules taken three times a day for 5 days. The group you will go into, out of the three, will be decided by chance so you can fall into any group.

What will be involved if I accept to participate in the study?

We are considering you for participation in this study because you told us that you have a cough. Any patient who has been coughing for at least 2 weeks, is at least 18 years, and lives within Blantyre, is eligible to participate in this study if they do not have signs consistent with serious illness. Apart from you, we will recruit 1,874 other individuals.

Study activities will be performed the first day, at 1 week (Day 8), and at one month (Day 29). At each of these study visits, we will ask you questions about your contact details, your health, use of medications, and any illnesses or hospitalisations you may have had in between study visits. We will also document relevant details from your health passport and other clinical documentation you may have.

On Day 1 and at 1 week, we will ask you to submit sputum and urine samples for TB tests. If you are not able to give sputum on Day 1, we will give you containers so that you can bring them the following morning. Some of the sputum TB tests results will become available after 7 days and we will pass them to health center clinicians who will make a plan for your care, the other results may take up to 4 weeks so you will get them at the 1 month visit. Urine TB test results will not be available for your clinical care.

21-May-2019

A copy of this informed consent document to be offered to the participant

Study title: Randomised controlled clinical trial of diagnostic value, clinical benefits and unintended consequences of using trial-of-antibiotics to evaluate ambulatory adults with prolonged cough for tuberculosis in Malawi


Version & Date: 3.0/28 Feb 2019

Principal Investigator: Dr Titus H Divala

Participant Information Sheet For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml> Page 1 of 4

We will also do an HIV test. If the results are confirmed to be HIV positive we will do a viral load test, and at the end of the study activities on Day 1, we will link you to HIV management team here at the health center who will start you on treatment. Should we make a diagnosis of TB or HIV at any other point during the study, we will link you with the responsible health center team for treatment services.

On day 1 and at 1-month visit, we will swab the back of the inside of your nose as shown in this picture to collect germs that live there. We will test the germs for drug resistance. Results of this test are not relevant to your care.



On 1-week visit, we will ask you to report how your health has changed in comparison to how you were on day 1. These questions will be read to you by a computer and you will answer them by choosing various options which it will display during the interview.

The 1 month visit will be the final study visit where we will also provide you with results for TB culture and ask if you have TB symptoms. If you are in HIV or TB care, we will ask how your follow up is going. The appointment with you at 1 months is very important because it will help you to know the results of the TB tests and it will also help us know the status of your health.

The number of clinic visits you will make for this study is at least three. Here we count Day 1, one visit after one week, and another visit at one month. If you have not been able to come here for any of the visits, we will remind you by phone call or we will use the permission and information you will give us to visit you at your home. The first visit will take about 60 minutes and the later visits will take about 30 minutes each.

Will there be any risks involved in this study?

This study is a low risk study. There are no risks involved in submitting sputum or urine for the study. You may feel some discomfort during swabbing of the back of the nose and during blood collection for HIV and viral load tests. Azithromycin and amoxicillin are already widely used in Malawi and rarely cause problems. Rare side effects for azithromycin include feeling nervousness, skin reactions and disturbance of heart function. Rare side-effects for amoxicillin are mental state changes, feeling light-headed, and reactions to sunlight.

The London School of Hygiene and Tropical Medicine holds insurance policies which apply to this study. If you experience harm or injury as a result of taking part in this study, you may be eligible to claim compensation.

Will there be any benefits in this study?

The key benefit of this study is that you will have access to a more detailed TB evaluation process than usual. This will help you know if you have TB and to have the opportunity to start TB treatment. The study is also beneficial to health care providers because it will address important questions about use of antibiotics during the TB diagnostic process.

Will the findings in the study be confidential?

A copy of this informed consent document to be offered to the participant

Study title: Randomised controlled clinical trial of diagnostic value, clinical benefits and unintended consequences of using trial-of-antibiotics to evaluate ambulatory adults with prolonged cough for tuberculosis in Malawi

Version & Date: 3.0/28 Feb2019

Principal Investigator: Dr Titus H Divala

Participant Information Sheet For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml> Page 2 of 4

REC ref: LSHTM 15232; COMREC P.04/18/2381



Your identity in this study will be treated as confidential. The results of the study, including laboratory or any other data, may be published for scientific purposes but will not give your name or include any identifiable references to you. Information about TB test result and HIV test results will be recorded using an identification number. However, any records or data obtained as a result of your participation in this study may be used by LSHTM who are sponsoring this study, regulators of health research (COMREC), or by members of the research team. These records will be kept in a locked space in the University of Malawi College of Medicine. Information and samples collected in this study will be retained for up to 10 years after the end of the trial, according to our institution recommendations. These collected samples and other information may also be used for future studies if you give us that consent.

Can I withdraw from the study anytime and will this affect my treatment?

You are free to choose whether or not to participate in this study. While we would like you to participate in the study to the very end, withdrawing at any point is an option that is freely available to you without any penalty or loss of any entitled benefits. You will be provided with any significant new findings developed during the course of this study that may relate to or influence your willingness to continue participation.

What are the financial benefits of participating in this study?

There will be no payment given to you for participating in the study. The study will provide at least MK8,000 as compensation for your costs of attending the study visits. We will give this money in instalments on scheduled study visits.

Is this study approved by an ethics committee?

The study has been approved by the London School of Hygiene & Tropical Medicine Research Ethics Committee, and the College of Medicine Research Ethics Committee (COMREC).

Who do you ask if you have questions regarding the study?

If you have any questions concerning participation in this study, please feel free to ask me. Alternatively, you can contact the following people by phone or post:

	Name	Telephone	Postal address
Study investigators	Dr Titus Divala	0999478376	Helse Nord Tuberculosis Initiative
	Dr Marriott	0888681948	University of Malawi College of Medicine
	Nliwasa		Private Bag 360, Chichiri, Blantyre 3, Malawi
COMREC			
	Administrative officer, COMREC Secretariat	01 877 245 01 877 291	University of Malawi College of Medicine Private Bag 360, Chichiri, Blantyre 3, Malawi

21-May-2019

A copy of this informed consent document to be offered to the participant

Study title: Randomised controlled clinical trial of diagnostic value, clinical benefits and unintended consequences of using trial-of-antibiotics to evaluate ambulatory adults with prolonged cough for tuberculosis in Malawi

Version & Date: 3.0/28 Feb 2019

Principal Investigator: Dr Titus H Divala

Participant Information Sheet For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml> Page 3 of 4

What is the benefit and unintended consequences of using antibiotics treatments as a way of excluding tuberculosis disease in patients with cough?

Patient declaration

Statement		Initial or thumbprint each box
I confirm that I have read the above information sheet for the above named study. I have had the opportunity to consider the information, ask questions and have these answered satisfactorily.		
OR		
I have had the information explained to by study personnel in a language that I understand. I have had the opportunity to consider the information, ask questions and have these answered satisfactorily.		
I understand that my participation is voluntary and that I am free to withdraw at any time without giving any reason, without my medical care or legal rights being affected.		
I understand that relevant sections of my medical notes and data collected during the study may be looked at by authorised individuals from LSHTM, University of Malawi College of Medicine, and COMREC, where it is relevant to my taking part in this research. I give permission for these individuals to have access to my records.		
I understand that data about me may be shared via a public data repository or by sharing directly with other researchers, and that I will not be identifiable from this information		
I understand that the tissue sample collected from me will be used to support other research in the future, and may be shared anonymously with other researchers, for their ethically-approved projects		
I agree to take part in the above named study		
Printed name of participant	Signature/thumb print of participant	Date
Printed name of impartial witness*	Signature of impartial witness*	Date
I attest that I have explained the study information accurately to _____, and was understood to the best of my knowledge by, the participant and that he/she has freely given their consent to participate* in the presence of the above named impartial witness (where applicable).		
Printed name of staff obtaining consent	Signature of staff obtaining consent	Date

*Impartial witness should be someone the participant trusts. The impartial witness can write the participant name but cannot sign for them. Instead, illiterate participants should use thumbprint in place of signature and the impartial witness should go ahead and sign in designated space.

A copy of this informed consent document to be offered to the participant

Study title: Randomised controlled clinical trial of diagnostic value, clinical benefits and unintended consequences of using trial-of-antibiotics to evaluate ambulatory adults with prolonged cough for tuberculosis in Malawi
Version & Date: 3.0/28 Feb2019

Principal Investigator: Dr Titus H Divala
Participant Information Sheet For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml> Page 4 of 4

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2019-033999 on 25 March 2020. Downloaded from <http://bmjopen.bmj.com/> on June 9, 2025 at Agence Bibliographique de l



PARTICIPANT INFORMATION SHEET

Chikalata chofotokozera ofuna kutenga nawo mbali

Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Chiyambi

Tikukukupemphani kuti mutenge nawo mbali mu kafukufuku. Ndi chifuniro chanu kulowa mu kafukufukuyu. Musanapange chiganizo, mukuyenera kumvetsa chifukwa chimene kafukufukuyu akuchitikira komanso zimene zitadzachitike. M'modzi mwa anthu a gulu logwira ntchito mu kafukufuku awerenga chikalatachi pamodzi ndi inu, ndipo ayankha mafunso ena aliwonse amene mungakhale nawo. Funsani mafunso ngati simukumvetsa zomwe mwawerenga kapena ngati mukufuna uthenga owonjezera. Muli omasuka kulankhula ndi ena zokhudza kafukufukuyu ngati mukufuna. Ganizani mofatsa musanavomereze kutenga nawo mbali kapena ayi.

Kodi cholinga cha kafukufukuyu ndi chiyani?

Chifuwa chachikulu (TB) ndi matenda amene munthu amkhala chidwalire kwa nthawi yaitali. Odwalayo, amapanga makhololo. Ngakhale chili chochizika, chifuwa chachikulu ndi chovuta kuchipeza. Pamene njira zoyeza makholoro zalephera kupeza chifuwa chachikulu, achipatala amapereka mankhwala opha tizirombo toyambitsa matenda amene angathane ndi zonse zimene zimayambitsa zizindikiro za matenda ofanana ndi chifuwa chachikulu. Ngati odwala apeza bwino ndi njira imeneyi amaganiziridwa kuti alibe matenda a chifuwa chachikulu koma ngati sanapeze bwino amaganiziridwa kuti ali ndi chifuwa chachikulu. Cholinga cha kafukufuku ameneyu ndi kufuna kumvetsa za m'mene mankhwala amenewa amathandizira kusiyantsa odwala matenda a chifuwa chachikulu ndi amene alibe matendawa, ngati mankhwalawa ali ndi phindu lina kwa odwala, komanso ngati kupereka mankhwalawa kukubweretsa tizirombo tosamva makhwala.

Tiphunzira zimenezi pakusiyantsa gulu la anthu odwala amene apatsidwa mankhwala opha tizirombo toyambitsa matenda patsiku loyamba la kafukufukuyu ndi gulu lina limene silinapatsidwe mankhwalawa. Pakhala magulu awiri olandira mankhwala opha tizirombo motere: 1) Azithromycin omwedwa pilisi imodzi kamodzi patsiku kwa masiku atatu, komanso 2) Amoxicillin makapusolo anayi omwedwa katatu patsiku kwa masiku asanu. Gulu limene mulowe, mwa magulu atatuwa, lisankhidwa mwa mayere choncho mukhoza kupezeka mu gulu lina lirilonse.

Kodi chidzachitike ndi chiyani ngati ndingavomereze kutenga nawo mbali mu kafukufukuyu?

Tikukupemphani kuti mutenge nawo mbali mu kafukufukuyu chifukwa mwatiuza kuti muli ndi chifuwa. Odwala wina aliyense amene wakhala akukhosomola kwa masabata osachepera awiri, ali ndi zaka zosachepera 18, ndipo amakhala mu Blantyre muno, atha kutenga nawo mbali mu kafukufukuyu ngati alibe zizindikiro zosonyeza kudwalika kwambiri. Kupatula inu, tilemba anthu ena okwanira 1,874.

Zochitika za kafukufukuyu zidzapangidwa patsiku loyamba, pa sabata imodzi (Tsiku 8), ndi pamwezi umodzi (Tsiku 29). Pa masiku a kafukufuku onsewa, tidzakufunsani mafunso okhudzana ndi m'mene tingalumikizirane nanu, thanzi lanu, kagwiritsidwe ntchito ka mankhwala, ndi matenda ena aliwonse kapena kugonekedwa mu chipatala komwe kungakuchitikireni. Tidzalembanso zinthu zofunika

Mpateni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Version & Date: 3.0/28 Feb 2019

Mkulu wakafukufuku: Dr Titus H Divala

Chikalata chofotokozera ofuna kutenga nawo mbali

REC ref: LSHTM 152321, COMREC P.04/18/2381

Page 1 of 5




kuchokera mu bukhu lanu la kuchipatala komanso zolembedwa zina za chipatala zimene mungakhale nazo.

Patsiku loyamba ndi pakutha pasabata yoyamba, tidzakufunsani kuti mupereke makhololo komanso mkodzo pofuna kuyeza matenda a chifuwa chachikulu. Ngati simungakwanitse kupereka makhololo patsiku loyamba, tidzakupatsani mabotolo kuti mudzawabweretse m'mawa wa tsiku lotsatira. Zotsatira zina za makhololo zidzatuluka pakutha pa masiku asanu ndi awiri ndipo tidzazipereka kwa matodolo a chipatala chino kuti akuthandizeni, zotsatira zina zidzatenga pafupi-fupi masabata anayi choncho mudzazilandira pa ulendo wa pamwezi umodzi. Zotsatira zanu zoyesa mikodzo ku matenda a chifuwa chachikulu sizidzakhalapo ku nkhani ya chisamaliro chanu cha kuchipatala.

Tidzayezanso kachiroombo ka HIV. Ngati zotsatirazi zasonyeza kuti muli ndi kachiroombo ka HIV tidzayeza kuchuluka kwa tizirombo ta HIV, komanso kukutumizani kolandilira chithandizo chamatendawa. Ngati tingakupenzi kuti muli ndi matenda a chifuwa chachikulu kapena kachiroombo ka HIV panthawi ina iliyonse mkati mwa kafukufukuyu, tidzakutumizani kolandilira zithandizo zamatendawa pompano pachipatala.

Patsiku loyamba komanso pa ulendo wa mwezi woyamba, tidzapukuta kumbuyo kwa mkati mwa mphuno mwanu ngati m'mene zikuonekera pachithunzichi kuti titenge tizirombo timene timakhala m'menemo. Tidzayeza tizirombo timeneti kuti tione ngati tikumva mankhwala. Zotsatira zimenezi sizidzagwiritsidwa ntchito kuchisamaliro chanu chaku chipatala.



Pa ulendo wa sabata yoyamba, tidzakupemphani kuti mutiuze m'mene thanzi lanu lasinthira kuyerekeza ndi m'mene munaliri patsiku loyamba. Mafunso amenewa adzawerengedwa kwa inu kudzera pa makina a kompyuta ndipo mudzawayankha pakusankha mayankho angapo amene makinawa adzawonetse panthawi yomwe azidzafunsa.

Ulendo wa pa mwezi umodzi udzakhala wotsiriza umene tidzakupatseninsu zotsatira za zoyesa za matenda a chifuwa chachikulu komanso tidzakufunsani ngati muli ndi zizindikiro za matenda a chifuwa chachikulu. Ngati panthawiyi mudzakhale kuti mukulandira Thandizo la HIV kapena TB, tidzakufuna kudziwa kuti zikuyenda bwanji. Kukumana ndi inu patatha mwezi umodzi ndikofunikira kwambiri chifukwa zidzakuthandizirani kuti mudziwe zotsatira za zoyeza za matenda a chifuwa chachikulu ndipo zidzatithandiziranso kudziwa zam'mene thanzi lanu liliri.

Maulendo a kuchipatala amene mudzayende a kafukufukuyu ndiwosachepera atatu. Pamenepa tikuwerenga tsiku loyamba, ulendo umodzi pakutha pa sabata imodzi, ndi ulendo umodzi pa mwezi umodzi. Ngati simunakwanitse kubwera kuno pa ulendo wina uliwonse tidzakukumbutsani pokuyimbirani lamya kapena tidzagwiritsa ntchito chilorezo ndi uthenga umene mudzatipitse kuti tikuyendereni kunyumba kwanu. Patsiku loyamba tidzakhala nanu kwa mphindi makumi asanu ndi imodzi, pamene paasiku ena onse, tidzakhala nanu kwa mphindi makumi atatu.

Kodi padzakhala ziopsezo zina zilizonse zochitika mu kafukufukuyu?

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Version & Date: 3.0/28 Feb 2019

Mkulu wakafukufuku: Dr Titus H Divala

Chikalata chofotokozera ofuna kutenga nawo mbali

REC ref: LSHTM 15232; COMREC P.04/18/2381

Page 2 of 5



Kupanga nawo kafukufukuyu sikuika moyo wanu pa chiopsyeyo chochuluka. Palibe chiopsezo pa kupereka makhololo kapena mikozo mu kafukufukuyu. Mukhoza kusamva bwino panthawi yopukuta kumbuyo kwa mphuno komanso panthawi yotenga magazi oyeza za kachiroombo ka HIV ndi kuchuluka kwa tizirombo toyambitsa matendawa. Azithromycin ndi amoxicillin ndi mankhwala oti akhala akugwiritsidwa ntchito kwa nthawi yayitali m'Malawi ndipo sikweni-kweni kuyambitsa mavuto. Patali-patali azithromycin amapangitsa kumva nthumazi, ziwengo, komanso kusokonekera kwa kagwiridwe ntchito ka mtima. Patali-patali amoxicillin amapangitsa kusakhazikika mmanganizo, kumva chizungulire, komanso kutuluka ziwengo munthu akakhala padzuwa.

A London School of Hygiene ndi Tropical Medicine ali ndi thumba landalama zachipukuta misozi lokhudzana ndi kafukufukuyu. Ngati mwapweteka kapena kuvulala chifukwa chotenga nawo mbali mu kafukufukuyu, mudzakhale omasuka kupempha chipukuta misonzi.

Kodi padzakhala zopindula zina zilizonse mu kafukufukuyu?

Chopindulitsa chodziwika cha kafukufukuyu ndi chakuti mudzakhala ndi mwayi oyezedwa matenda a chifuwa chachikulu mozama kuposa m'mene zimakhallira nthawi zonse. Zimenezi zidzakuthandizirani kudziwa ngati muli ndi matenda a chifuwa chachikulu komanso kukhala ndi mwayi oyamba kulandira thandizo la mankhwala a chifuwa chachikulu. Kafukufukuyu ndi opindindulitsanso kwa opereka chisamaliro cha kuchipatala chifukwa adzayankha mafunso ofunikira okhudzana ndi kagwiritsidwe ntchito ka mankhwala opha tizirombo toyambitsa matenda panthawi ya ndondomeko yoyeza matenda a chifuwa chachikulu.

Kodi zotsatira za mukafukufukuyu zidzakhala za chinsinsi?

Chizindikiritso chanu mu kafukufukuyu chidzatengedwa kukhala cha chinsinsi. Zotsatira za kafukufukuyu, zikhoza kudzasindikizidwa ndi cholinga cha sayansi koma dzina lanu kapena chizindikiritso chilichonse chokhudzana ndi inu chidzabisidwa. Uthenga okhudza zotsatira zoyesa matenda achifuwa chachikulu kapena HIV zidzalembedwa pogwiritsa ntchito nambala yanu yakafukufuku. Komabe, zina zomwe mungatifotokozere zitha kudzagwiritsidwa ntchito ndi amene ali oyang'anira za kafukufuku wa zaumoyo (COMREC) komanso LSHTM. kapena ndi mamembala a gulu la kafukufukuyu. Zolembedwazi zidasungidwa mumalo otsekedwa bwino ku sukulu ya ukachenjede ya Malawi College of Medicine. Uthenga ndi zoyesa zotengedwa mu kafukufukuyu zidzassungidwa kwa zaka pafupi-fupi khumi (10) pakutha pakuyesaku, malingana ndi ndondomeko ya bungwe lathu. Zoyesa zotengedwazi ndi mauthenga ena zikhoza kugwiritsidwanso ntchito pa kafukufuku wamtsogolo ngati mutatipatsa chilolezo chimenecho.

Kodi ndikhoza kusiya kafukufukuyu nthawi ina iliyonse ndipo zimenezi zingadzakhudze thandizo langa la mankhwala?

Muli ndi ufulu kusankha kutenga nawo mbali kapena kusatenga nawo mbali mu kafukufukuyu. Ngakhale tingakonde kuti mutenge nawo mbali mu kafukufukuyu mpaka ku mapeto, kutuluka nthawi iliyonse mukafukufuku ndi chisankho chanu popanda chilango chilli chonse kapena kuluza kulandira thandizo lililonse lomwe mukuyenera kulandira. Munthawi yakafukufukuyu, tidzakudziwitsani patati

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Version & Date: 3.0/28 Feb 2019

Mkulu wakafukufuku: Dr Titus H Divala

Chikalata chofotokozera ofuna kutenga nawo mbali

REC ref: LSHTM 15232; COMREC P.04/18/2381

Page 3 of 5



patuluka mauthenga ena a sayansi ofotokoza zinthu zimene zingakupangitseni kuti mulingalirenso zachisamkho chanu chotenga nawo mbali.

Kodi pali phindu la ndalama lotani pakutenga nawo mbali mu kafukufukuyu?

Sipadzakhala kupatsidwa malipiro chifukwa chotenga nawo mbali mukafukufukuyu. Ndalama yomwe tidzakupatseni ndi yokwana MK8,000. Ndalamayi tizikupatsani pangonopango pamasiku anu akafukufuku..

Kodi kafukufukuyu ndiwovomerezeka ndi komiti yowona za ufulu wa anthu mukafukufuku?

Kafukufukuyu wavomerezedwa ndi London School of Hygiene & Tropical Medicine Research Ethics Committee, ndi College of Medicine Research Ethics Committee (COMREC).

Kodi mungafunse ndani ngati muli ndi mafunso okhudzana ndi kafukufukuyu?

Ngati muli ndi mafunso ena aliwonse okhudza kutenga nawo mbali mukafukufukuyu, chonde khalani omasuka kundifunsa. Munjira ina, mukhoza kulumikizana ndi anthu otsatirawa pa lanya kapena polemba kalata kumakeyala awa:

	Name Dzina	Telephone Lamya	Postal address Adilesi
Study investigators Akulu-akulu akafukufuku	Dr Titus Divala	0999478376	Helse Nord Tuberculosis Initiative University of Malawi College of Medicine
	Dr Marriott Nliwasa	0888681948	Private Bag 360, Chichiri, Blantyre 3, Malawi
COMREC	Administrative officer, COMREC Secretariat	01 877 245 01 877 291	University of Malawi College of Medicine Private Bag 360, Chichiri, Blantyre 3, Malawi

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake
Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Mkulu wakafukufuku: Dr Titus H Divala
Chikalata chofotokozera ofuna kutenga nawo mbali

Version & Date: 3.0/28 Feb 2019

REC ref: LSHTM 15232; COMREC P.04/18/2381



Kodi pali phindu lotani komanso zotsatira zosayembekezereka zotani pogwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ngati njira yothana ndi matenda a chifuwa chachikulu mu anthu amene ali ndi chifuwa?

Chitsimikizo cha odwala

Lembani mubokosi liri kumanjali mawu oyamba adzina lanu kapena dindani ndi chala ngati mukuvomereza

Mfundo yachitsimikizo	
Ndikutsimikiza kuti ndawerenga chikalata cha uthenga wa kafukufuku amene watchulidwa m'mwambamu. Ndakhala ndi mwayi woganizira za uthengawu, kufunsa mafunso komanso ndayankhidwa mokhutira.	
KAPENA	
Ndafotokozeredwa uthengawu ndi akafukufuku mu chilankhulo chimene ndikuchimvetsa. Ndakhala ndi mwayi woganizira za uthengawu, kufunsa mafunso komanso ndayankhidwa mokhutira.	
Ndikumvetsa kuti kutenga nawo mbali kwanga ndikosakakamizidwa ndipo ndili ndi ufulu kusiya panthawi ina iliyonse popanda kupereka chifukwa china chilichonse, popanda kukhudza chisamaliro cha kuchipatala kapena ufulu wanga.	
Ndikumvetsa kuti magawo ofunikira a zolembedwa zanga za ku chipatala komanso mu kafukufukuyu kuwonedwa ndi anthu ovomerezeka aku LSHTM, University of Malawi College of Medicine komanso COMREC, pamene kuli kofunika kutenga nawo mbali mukafukufukuyu.	
Ndikupereka chilolezo kwa anthu amenewa kuti athe kuwona za zolembedwa zanga.	
Ndikumvetsa kuti zomwe atolere akafukufuku zokhudza ine zikhoza kugawilidwa kwa anthu ena opanga kakafukufuku, ndipo kuti sipadzakhala chizindikiro chilichonse chosonyeza kuti zinachokera kwa ine.	
Ndikumvetsa kuti zoyeza za mthupi mwanga zimene zidzatengedwe kwa ine zidzagwiritsidwa ntchito kuthandizira kafukufuku wina mtsogolo, ndipo zikhoza kudzagawidwa mwachinsinsi ndi akafukufuku ena, pa ntchito yawo yovomerezeka ndi malamulo aowona zakafukufuku.	
Ndikuvomereza kutenga nawo mbali mu kafukufuku amene watchulidwa pamwambayu.	

Dzina la wotenga nawo mbali **Sayini/chidindo cha chala cha wotenga mbali** **Tsiku**

Dzina la mboni yopanda mbali* **Sayini ya mboni yopanda mbali** **Tsiku**

Ndikutsimikiza kuti ndafotokoza za uthenga wa kafukufukuyu molondola kwa _____, ndipo zinamveka monga mwakudziwa kwanga ndi, wotenga nawo mbali komanso kuti apereka chilolezo chawo kuti atenge nawo mbali* pamaso pa mboni yopanda mbali imene yatchulidwa pamwambapa (ngati kuli koyenera).

Dzina la wotenga chilolezo **Sayini ya wotenga chilolezo** **Tsiku**

*Mboni yopanda mbali ikuyenekera kukhala yokhulupiridwa ndi munthu ofuna kutenga nawo mukafukufukuyo. Mboni ikhoza kulemba dzina la munthu ofuna kutenga nawo mukafukufukuyo koma siingasayine mmalo mwake. Munthu ofuna kutenga nawo mukafukufuku, ngati samatha kuwerenga ndi kulemba, asayine ndi chidindo cha chala chake ndipo mboni isayine dzina ndi sayini, pamalo ambone.

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?



CERTIFICATE OF ETHICS APPROVAL

This is to certify that the College of Medicine Research and Ethics Committee (COMREC) has reviewed and approved a study entitled:

P.04/18/2381 - Accuracy and Consequences of using Trial-of-antibiotics for TB diagnosis (ACT-TB Study) by Titus H Divala

On 03-Jul-18

As you proceed with the implementation of your study, we would like you to adhere to international ethical guidelines, national guidelines and all requirements by COMREC as indicated on the next page

03-Jul-18

Dr. YB. Mlombe - Chairperson (COMREC)

Date

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

REQUIREMENTS FOR ALL COMREC APPROVED RESEARCH PROTOCOLS

1. Pay the research overhead fees as required by the College of Medicine for all approved studies.
2. You should note that the COMREC Sub-Committee on Research Participants' Safety will monitor the conduct of the approved protocol and any deviation from the approved protocol may result in your study being stopped.
3. You will provide an interim report in the course of the study and an end of study report.
4. All COMREC approvals of new applications and progress reports are valid for one year only. Therefore all approved studies running for more than one year are subject to continuing review annually. You are required to submit a progress report to COMREC within 90-30 days before the expiration date. Your current expiration date is 03-Jul-19. Studies shall be considered lapsed and inactive if continuing review application is not received one month after the expiry of the previous approval. In that case, all study related operations should cease immediately except those that are necessary for the welfare of subjects.
5. All investigators who are Medical Practitioners must be fully registered with the Medical Council of Malawi.



PHARMACY, MEDICINES & POISONS BOARD

Mission: To promote and improve the health of the population of Malawi through the regulation of Pharmacy Personnel, Pharmacy Businesses, Medicines and Allied Substances

ALL CORRESPONDENCE SHOULD BE ADDRESSED TO THE REGISTRAR

Head Office:

Off Paul Kagame/
Chilambula Road
P.O.Box 30241
Capital City

LILONGWE 3, MALAWI

Phone: (+265) 01 755 165

Fax : (+265) 01 755 204

Email: info@pmpb.mw

Web: www.pmpb.mw

PMPB/CTRC/III/14062018102

DATE: 4th July, 2018

Department of Infectious Disease Epidemiology
London School of Hygiene and Tropical Medicine
Keppel St
London

Attn.: Dr. Titus Divala

RE: ACCURACY AND CONSEQUENCES OF USING TRIAL-OF-ANTIBIOTICS FOR TB DIAGNOSIS (ACT-TB STUDY).

Refer to your application to register the above mentioned clinical trial with the Pharmacy, Medicines and Poisons Board (PMPB).

The Clinical Trial Review Committee (CTRC), at its meeting held on 22nd June, 2018, issued a **No Objection** to the implementation of the trial after members agreed that the nature of the trial was seen to be outside the scope of trials that should be regulated by PMPB through the CTCR.

Please contact the undersigned if there are any issues that need further clarification.

Yours faithfully,

M. Kawaye
ACTING REGISTRAR





Region:	Saksbehandler:	Telefon:	Vår dato:	Vår referanse:
REK nord			06.11.2018	2018/1964/REK nord
			Deres dato:	Deres referanse:
			25.09.2018	
			Vår referanse må oppgis ved alle henvendelser	

Jon Øyvind Odland
Institutt for samfunnsmedisin

2018/1964 En kontrollert klinisk studie for å undersøke responsen til bredspekret antibiotika som en eksklusjonsdiagnose i allmen praksis mot risiko for antibiotika resistens

Forskningsansvarlig institusjon: UiT Norges arktiske universitet

Prosjektleder: Jon Øyvind Odland

Vi viser til søknad om forhåndsgodkjenning av ovennevnte forskningsprosjekt. Søknaden ble behandlet av Regional komité for medisinsk og helsefaglig forskningsetikk (REK nord) i møtet 25.10.2018. Vurderingen er gjort med hjemmel i helseforskningsloven (hforsknl) § 10.

Prosjektleders prosjekttale

Det skal undersøkes, ved hjelp av en randomisert, kontrollert studie om respons til bredspekret antibiotika kan brukes som eksklusjonsdiagnose for tuberkulose. Dette skal vurderes opp mot risiko for resistensutvikling knyttet til behandlingen. Tre grupper (625 per gruppe) individuelt randomisert (1:1:1), med åpen informasjon undersøkes med standard diagnostisk tilnærming. Kun voksne deltakere, med full brukermidvirkning og informert samtykke. Studien kan forenkle diagnostikk og klinikk for en utsatt gruppe mennesker. Studien skal i sin helhet foregå i Malawi. Alle etiske godkjenninger fra Malawi og London er vedlagt.

Komiteen vurderte at Hanne Husom Haukland var inhabil og hun fratrådte møtet da saken ble behandlet, jf. fvl. § 6.

Om prosjektet

Prosjektet er en del av en PhD. Studenten skal avlegge sin PhD i London.

Dette er et samarbeidsprosjekt mellom Universitetet i Malawi, London School of Hygiene and Tropical Medicine, og Universitetet i Tromsø.

Prosjektet skal gjennomføres i Malawi og er et «Tuberkulose initiativ» fra Helse Nord.

Det foreligger godkjenning fra London School of Hygiene and Tropical Medicine, og University of Malawi.

Data

Det skal hentes data fra pasientjournal og fra lokale poliklinikker. Data er standard medisinske opplysninger knyttet til infeksjoner og sykehistorie.

Nye helseopplysninger er respons på behandling av infeksjoner.

Data aidentifiseres med koblingsnøkkel. Database oppbevares i 5 år i Malawi.

Deltakere/rekruttering

Voksne deltakere fordeles i tre grupper voksne deltakere (625 per gruppe), individuelt randomisert. Deltakere rekrutteres gjennom behandling på poliklinikkene.

REK har ingen innvendinger til prosjektet

Vedtak

REK har gjort en helhetlig forskningsetisk vurdering av alle prosjektets sider og godkjenner det med hjemmel i helseforskningsloven § 10. REK forutsetter at prosjektet også har godkjenning fra Malawi.

Sluttmelding og søknad om prosjektendring

Prosjektleder skal sende sluttmelding til REK nord på eget skjema senest 21.03.2022, jf. hfl. § 12. Prosjektleder skal sende søknad om prosjektendring til REK nord dersom det skal gjøres vesentlige endringer i forhold til de opplysninger som er gitt i søknaden, jf. hfl. § 11.

Klageadgang

Du kan klage på komiteens vedtak, jf. forvaltningsloven § 28 flg. Klagen sendes til REK nord. Klagefristen er tre uker fra du mottar dette brevet. Dersom vedtaket opprettholdes av REK nord, sendes klagen videre til Den nasjonale forskningsetiske komité for medisin og helsefag for endelig vurdering.

Med vennlig hilsen

May Britt Rossvoll
sekretariatsleder

Kopi til: jon.oyvind.odland@uit.no

London School of Hygiene & Tropical Medicine

Keppel Street, London WC1E 7HT
 United Kingdom
 Switchboard: +44 (0)20 7636 8636
www.lshtm.ac.uk

LONDON
 SCHOOL of
 HYGIENE
 & TROPICAL
 MEDICINE

**Observational / Interventions Research Ethics Committee**

Dr Titus Divala
 LSHTM

9 May 2018

Dear Titus,

Study Title: RCT investigating if benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis in primary care adult patients outweigh the risk of antimicrobial resistance

LSHTM ethics ref: 15232

Thank you for your application for the above research, which has now been considered by the Interventions Committee.

Confirmation of ethical opinion

On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation, subject to the conditions specified below.

Conditions of the favourable opinion

Approval is dependent on local ethical approval having been received, where relevant.

Approved documents

The final list of documents reviewed and approved by the Committee is as follows:

Document Type	File Name	Date	Version
Safety Information	ACT_PackageInsertAzithromycin	14/03/2013	JUNE 2013
Safety Information	ACT_PackageInsertAmoxicillin	21/12/2015	DEC 2015
Sponsor Letter	2018-KEP-077_Sponsor Confirmation_13.03.18	13/03/2018	1
Other	GCP Cert_LSHTM_TDivala_21.03.18	21/03/2018	1
Investigator CV	ACT-CV1_TitusDivala	30/03/2018	1
Investigator CV	ACT-CV2_KatherineFielding	30/03/2018	1
Investigator CV	ACT-CV3_LizCorbett	30/03/2018	1
Information Sheet	ACT-20180330InformedConsentEnglish	30/03/2018	1.0
Information Sheet	ACT-20180330InformedConsentChichewa	30/03/2018	1.0
Protocol / Proposal	ACT-20180330Protocol	30/03/2018	1.0

After ethical review

The Chief Investigator (CI) or delegate is responsible for informing the ethics committee of any subsequent changes to the application. These must be submitted to the Committee for review using an Amendment form. Amendments must not be initiated before receipt of written favourable opinion from the committee.

The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reactions (SUSARs) which occur during the project by submitting a Serious Adverse Event form.

An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study.

At the end of the study, the CI or delegate must notify the committee using an End of Study form.

All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at: <http://leo.lshtm.ac.uk>

Additional information is available at: www.lshtm.ac.uk/ethics

Yours sincerely,

1 ethics@lshtm.ac.uk
2 <http://www.lshtm.ac.uk/ethics/>
3
4
5

6 **Improving health worldwide**
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

London School of Hygiene & Tropical Medicine

Keppel Street, London WC1E 7HT
 United Kingdom
 Switchboard: +44 (0)20 7636 8636
www.lshtm.ac.uk

LONDON
 SCHOOL of
 HYGIENE
 & TROPICAL
 MEDICINE

**Observational / Interventions Research Ethics Committee**

Dr Titus Divala
 LSHTM

12/04/2019

Dear Titus,

Project Title: RCT investigating if benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis in primary care adult patients outweigh the risk of antimicrobial resistance

Project ID: 15232

Thank you for your annual report application for the continuation of your research dated 09/04/2019 12:01 , which has now been considered by the Chair on behalf of the Ethics Committee.

Confirmation of ethical opinion

This application is approved by the committee for a further year.

Conditions of the favourable opinion

Approval is dependent on local ethical approval having been received, where relevant.

After ethical review

Any changes to the application must be submitted to the committee via an Amendment form.

The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reaction (SUSARs) which occur during the project by submitting a SUSAR and Protocol Violation form.

An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study.

At the end of the study, the CI or delegate must notify the committee using an End of Study form.

All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at <http://leo.lshtm.ac.uk>.

Additional information is available at: www.lshtm.ac.uk/ethics.

Yours sincerely,

Professor John DH Porter
 Chair

ethics@lshtm.ac.uk
<http://www.lshtm.ac.uk/ethics/>

Improving health worldwide

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200-207

Reporting Item		Page Number
Administrative information		
Title	#1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1

1	Trial registration	#2a	Trial identifier and registry name. If not yet	3
2			registered, name of intended registry	
3				
4				
5				
6	Trial registration:	#2b	All items from the World Health Organization Trial	27
7				
8	data set		Registration Data Set	
9				
10				
11				
12	Protocol version	#3	Date and version identifier	1
13				
14				
15	Funding	#4	Sources and types of financial, material, and other	23
16			support	
17				
18				
19				
20	Roles and	#5a	Names, affiliations, and roles of protocol	23
21				
22	responsibilities:		contributors	
23				
24	contributorship			
25				
26				
27				
28	Roles and	#5b	Name and contact information for the trial sponsor	23
29				
30	responsibilities:			
31				
32	sponsor contact			
33				
34	information			
35				
36				
37				
38	Roles and	#5c	Role of study sponsor and funders, if any, in study	23
39				
40	responsibilities:		design; collection, management, analysis, and	
41				
42	sponsor and funder		interpretation of data; writing of the report; and the	
43				
44			decision to submit the report for publication,	
45				
46			including whether they will have ultimate authority	
47				
48			over any of these activities	
49				
50				
51				
52	Roles and	#5d	Composition, roles, and responsibilities of the	19
53				
54	responsibilities:		coordinating centre, steering committee, endpoint	
55				
56	committees		adjudication committee, data management team,	
57				
58				
59				
60				

1			and other individuals or groups overseeing the
2			trial, if applicable (see Item 21a for data
3			monitoring committee)
4			
5			
6			
7			
8	Introduction		
9			
10			
11	Background and	#6a	Description of research question and justification
12			
13	rationale		for undertaking the trial, including summary of
14			relevant studies (published and unpublished)
15			examining benefits and harms for each
16			intervention
17			
18			
19			
20			
21			
22			
23	Background and	#6b	Explanation for choice of comparators
24			
25	rationale: choice of		
26			
27	comparators		
28			
29			
30			
31	Objectives	#7	Specific objectives or hypotheses
32			
33			
34	Trial design	#8	Description of trial design including type of trial
35			(eg, parallel group, crossover, factorial, single
36			group), allocation ratio, and framework (eg,
37			superiority, equivalence, non-inferiority,
38			exploratory)
39			
40			
41			
42			
43			
44			
45			
46	Methods:		
47			
48	Participants,		
49			
50	interventions, and		
51			
52	outcomes		
53			
54			
55			
56	Study setting	#9	Description of study settings (eg, community
57			
58			
59			
60			

		clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
Interventions: description	#11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
Interventions: modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)
Interventions: adherence	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)
Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event),

1		method of aggregation (eg, median, proportion),	
2			
3		and time point for each outcome. Explanation of	
4			
5		the clinical relevance of chosen efficacy and harm	
6			
7		outcomes is strongly recommended	
8			
9			
10	Participant timeline	#13	Time schedule of enrolment, interventions
11			
12			(including any run-ins and washouts),
13			
14			assessments, and visits for participants. A
15			
16			schematic diagram is highly recommended (see
17			
18			Figure)
19			
20			
21			
22	Sample size	#14	Estimated number of participants needed to
23			
24			achieve study objectives and how it was
25			
26			determined, including clinical and statistical
27			
28			assumptions supporting any sample size
29			
30			calculations
31			
32			
33			
34	Recruitment	#15	Strategies for achieving adequate participant
35			
36			enrolment to reach target sample size
37			
38			
39			
40	Methods:		
41			
42	Assignment of		
43			
44	interventions (for		
45			
46	controlled trials)		
47			
48			
49			
50	Allocation:	#16a	Method of generating the allocation sequence (eg,
51			
52	sequence		computer-generated random numbers), and list of
53			
54	generation		any factors for stratification. To reduce
55			
56			predictability of a random sequence, details of any
57			
58			
59			
60			

planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions

- Allocation [#16b](#) Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned
- Allocation: [#16c](#) Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions
- Blinding (masking) [#17a](#) Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how
- Blinding (masking): [#17b](#) If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial

Methods: Data collection, management, and analysis

- Data collection plan [#18a](#) Plans for assessment and collection of outcome, baseline, and other trial data, including any

1		related processes to promote data quality (eg,	
2		duplicate measurements, training of assessors)	
3			
4		and a description of study instruments (eg,	
5		questionnaires, laboratory tests) along with their	
6		reliability and validity, if known. Reference to	
7		where data collection forms can be found, if not in	
8		the protocol	
9			
10			
11			
12			
13			
14			
15			
16			
17	Data collection plan:	#18b	Plans to promote participant retention and
18	retention		complete follow-up, including list of any outcome
19			data to be collected for participants who
20			discontinue or deviate from intervention protocols
21			
22			
23			
24			
25			
26			
27	Data management	#19	Plans for data entry, coding, security, and
28			storage, including any related processes to
29			promote data quality (eg, double data entry; range
30			checks for data values). Reference to where
31			details of data management procedures can be
32			found, if not in the protocol
33			
34			
35			
36			
37			
38			
39			
40			
41	Statistics: outcomes	#20a	Statistical methods for analysing primary and
42			secondary outcomes. Reference to where other
43			details of the statistical analysis plan can be
44			found, if not in the protocol
45			
46			
47			
48			
49			
50			
51	Statistics: additional	#20b	Methods for any additional analyses (eg,
52	analyses		subgroup and adjusted analyses)
53			
54			
55			
56			
57	Statistics: analysis	#20c	Definition of analysis population relating to
58			
59			
60			

population and protocol non-adherence (eg, as randomised
missing data analysis), and any statistical methods to handle
missing data (eg, multiple imputation)

Methods:

Monitoring

Data monitoring: [#21a](#) Composition of data monitoring committee (DMC);
formal committee summary of its role and reporting structure;
statement of whether it is independent from the
sponsor and competing interests; and reference
to where further details about its charter can be
found, if not in the protocol. Alternatively, an
explanation of why a DMC is not needed

Data monitoring: [#21b](#) Description of any interim analyses and stopping
interim analysis guidelines, including who will have access to
these interim results and make the final decision
to terminate the trial

Harms [#22](#) Plans for collecting, assessing, reporting, and
managing solicited and spontaneously reported
adverse events and other unintended effects of
trial interventions or trial conduct

Auditing [#23](#) Frequency and procedures for auditing trial
conduct, if any, and whether the process will be
independent from investigators and the sponsor

Ethics and

p28, appendix

(protocol)

p28, appendix

(protocol)

p28, appendix

(protocol)

1	dissemination			
2				
3				
4	Research ethics	#24	Plans for seeking research ethics committee /	22
5				
6	approval		institutional review board (REC / IRB) approval	
7				
8				
9	Protocol	#25	Plans for communicating important protocol	22
10				
11	amendments		modifications (eg, changes to eligibility criteria,	
12			outcomes, analyses) to relevant parties (eg,	
13			investigators, REC / IRBs, trial participants, trial	
14			registries, journals, regulators)	
15				
16				
17				
18				
19				
20				
21	Consent or assent	#26a	Who will obtain informed consent or assent from	p28 appendix
22			potential trial participants or authorised	(consent)
23			surrogates, and how (see Item 32)	
24				
25				
26				
27				
28				
29	Consent or assent:	#26b	Additional consent provisions for collection and	p28 appendix
30			use of participant data and biological specimens	(consent)
31	ancillary studies		in ancillary studies, if applicable	
32				
33				
34				
35				
36	Confidentiality	#27	How personal information about potential and	p28 appendix
37			enrolled participants will be collected, shared, and	(consent)
38			maintained in order to protect confidentiality	
39			before, during, and after the trial	
40				
41				
42				
43				
44				
45				
46	Declaration of	#28	Financial and other competing interests for	23
47			principal investigators for the overall trial and each	
48	interests		study site	
49				
50				
51				
52				
53				
54	Data access	#29	Statement of who will have access to the final trial	p28, appendix
55			dataset, and disclosure of contractual agreements	(protocol)
56				
57				
58				
59				
60				

		that limit such access for investigators	
Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	p28, appendix (protocol)
Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	
Dissemination policy: authorship	#31b	Authorship eligibility guidelines and any intended use of professional writers	p28, appendix (protocol)
Dissemination policy: reproducible research	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	p28, appendix (protocol)
Appendices			
Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	p28 appendix (consent)
Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for	p28 appendix (consent/protocol)

future use in ancillary studies, if applicable

Notes:

- The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist was completed on 01. September 2019 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

For peer review only

BMJ Open

Accuracy and Consequences of using Trial-of-antibiotics for TB diagnosis (ACT-TB Study): protocol for a randomised controlled clinical trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-033999.R1
Article Type:	Protocol
Date Submitted by the Author:	15-Jan-2020
Complete List of Authors:	Divala, Titus; London School of Hygiene and Tropical Medicine, TB Centre; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative Fielding, Katherine; London School of Hygiene & Tropical Medicine, TB Centre; University of the Witwatersrand, School of Public Health Sloan, Derek; University of Saint Andrews, School of Medicine French, Neil; University of Liverpool Faculty of Health and Life Sciences, Centre for Global Vaccine Research, Institute of Infection and Global Health Nliwasa, Marriott; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; London School of Hygiene and Tropical Medicine, TB Centre MacPherson, Peter ; Liverpool School of Tropical Medicine; Malawi Liverpool Wellcome Trust Clinical Research Programme Kandulu, Chikondi; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; Malawi Liverpool Wellcome Trust Clinical Research Programme Chiume, Lingstone ; Malawi Liverpool Wellcome Trust Clinical Research Programme; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative Chilanga, Sanderson ; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; Malawi Liverpool Wellcome Trust Clinical Research Programme Ndaferankhande, Masiye; Malawi Liverpool Wellcome Trust Clinical Research Programme Corbett, Elizabeth ; London School of Hygiene and Tropical Medicine; Malawi Liverpool Wellcome Trust Clinical Research Programme
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	Diagnostics, Epidemiology, Evidence based practice, General practice / Family practice, HIV/AIDS
Keywords:	trial-of-antibiotics, Tuberculosis < INFECTIOUS DISEASES, TB, antimicrobial resistance, diagnostic performance, antibiotics



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

TITLE

Accuracy and Consequences of using *Trial-of-antibiotics* for TB diagnosis (ACT-TB Study): protocol for a randomised controlled clinical trial

Authors

Titus H Divala^{1,2,3}, Katherine L Fielding^{1,4}, Derek J Sloan⁵, Neil French⁶, Marriott Nliwasa^{1,2,3}, Peter MacPherson^{3,7}, Chikondi Kandulu^{2,3}, Lingstone Chiume^{2,3}, Sanderson Chilanga^{2,3}, Masiye Ndaferankhande³, Elizabeth L Corbett^{1,2,3}

Author affiliations

1. TB Centre, London School of Hygiene & Tropical Medicine, Keppel Street, Bloomsbury, London, United Kingdom
2. Helse Nord Tuberculosis Initiative, University of Malawi College of Medicine, Blantyre, Malawi
3. Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi
4. School of Public Health, University of the Witwatersrand, Johannesburg, South Africa
5. School of Medicine, University of St Andrews (Derek J Sloan PhD)
6. Institute of Infection & Global Health, University of Liverpool, Liverpool, United Kingdom
7. Liverpool School of Tropical Medicine, Liverpool, United Kingdom

Correspondence to:

Dr Titus H Divala
TB Centre, London School of Hygiene & Tropical Medicine, Keppel Street, Bloomsbury, London WC1E 7HT
titus.divala@lshtm.ac.uk

KEY WORDS

trial-of-antibiotics, tuberculosis, TB, antimicrobial resistance, AMR, antibiotics, diagnostic performance, sensitivity, specificity, randomised controlled clinical trial, randomised, RCT

Protocol version 3.0, 19 Feb 2019

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

31 ABSTRACT:

32 Introduction

33 Over 40% of global tuberculosis case notifications are diagnosed clinically without
34 mycobacteriological confirmation. Standard diagnostic algorithms include “trial-of-antibiotics”
35 –empirical antibiotic treatment given to mycobacteriology-negative individuals to treat
36 infectious causes of symptoms other than tuberculosis, as a “rule-out” diagnostic test for
37 tuberculosis. Potentially 26.5 million such antibiotic courses/year are prescribed globally for
38 the 5.3 million/year mycobacteriology-negative patients, making trial-of-antibiotics the most
39 common tuberculosis diagnostic, and a global-scale risk for antimicrobial resistance (AMR).
40 Our systematic review found no randomised controlled trial (RCT) to support use of trial-of-
41 antibiotic. The RCT aims to determine the diagnostic and clinical value and AMR
42 consequences of trial-of-antibiotics.

43 Methods and analysis

44 A three-arm, open-label, RCT randomising (1:1:1) Malawian adults (≥ 18 years) seeking
45 primary care for cough into: a) azithromycin 500mg once daily for 3 days, or b) amoxicillin 1g
46 three times/day for 5 days, or c) standard-of-care (no immediate antibiotic). We will perform
47 Mycobacteriology tests (microscopy, Xpert/MTB/RIF and Mycobacterium-Tuberculosis
48 culture) at baseline. We will use Audio-Computer-Assisted-Self-Interview (ACASI) to assess
49 clinical improvement at day eight. First primary outcome will be proportion of patients
50 reporting day-eight improvement out of those with negative mycobacteriology (specificity).
51 Second primary outcome will be day 29 incidence of a composite endpoint of either death or;
52 hospitalisation or; missed tuberculosis diagnosis. To determine AMR impact we compare
53 proportion of resistant nasopharyngeal *Streptococcus pneumoniae* isolates on day 29. 400
54 mycobacteriology-negative participants/arm will be required to detect a $\geq 10\%$ absolute

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

55 difference in diagnostic specificity with 80% power. We will estimate measures of effect by
56 comparing outcomes in antibiotic arms (combined and individually) to standard-of-care.

57 **Ethics and dissemination**

58 The study has been reviewed and approved by Malawi College of Medicine Research and
59 Ethics Committee, London School of Hygiene & Tropical Medicine (LSHTM) Research Ethics
60 Committee, and Regional Committee for Health and Research Ethics –Norway, and Malawi
61 Pharmacy, Medicines, and Poisons Board (Appendix 1). We will present abstracts at
62 relevant conferences, and prepare a manuscript for publication in a peer-reviewed journal.

63 **Registration**

64 Clinicaltrials.gov, NCT03545373

65 **Strengths and limitations**

- 66 • To our knowledge this is the first randomised controlled trial to address benefits and
67 consequences of using antibiotics as an exclusion diagnostic for tuberculosis, a
68 widely used practice that results in millions of antibiotic prescriptions/year.
- 69 • We will also contribute evidence on AMR affecting common antimicrobials used for
70 managing respiratory infections.
- 71 • The use of ACASI for assessing clinical response and adherence to antibiotic
72 treatment which can be used in future studies.
- 73 • Acknowledged weaknesses include limited power to evaluate safety of deferred
74 antibiotic treatment; conduct subgroup analysis by HIV status; and the possibility that
75 participants randomised to the standard-of-care arm may find alternative access to
76 antibiotics therefore misclassifying exposure/intervention status.

79 INTRODUCTION

80 The high case-fatality rate for tuberculosis, the leading global infectious cause of death in
81 adults¹ with approximately 10 million cases and 1.6 million deaths in 2017,² in part reflects
82 suboptimal diagnostics.³⁻⁶ To complement this diagnostic gap, standard algorithms
83 throughout the world include a “trial-of-antibiotics” (Figure 1). This is a course of broad-
84 spectrum antibiotics, with negligible *Mycobacterium tuberculosis* activity, given to patients
85 with symptoms such as cough in order to “rule-out” or “rule in” tuberculosis.⁷⁻⁹ In clinical
86 practice and most national guidelines (summarised in figure 1), patients who have negative
87 sputum mycobacteriology and have responded to antibiotic treatment are considered
88 tuberculosis-negative while those who remain symptomatic are deemed likely to have
89 tuberculosis and undergo further evaluations potentially leading on to receiving tuberculosis
90 treatment.⁷⁻⁹

91
92
93 We estimate that 26.5 million courses of antibiotics are prescribed in the diagnosis of the 5.3
94 million smear negative tuberculosis registrations recorded annually,¹⁰ making antibiotics the
95 most common diagnostic for tuberculosis.¹¹ Our 26.5 million estimate assumes that for every
96 one smear-negative tuberculosis case detected, five antibiotics courses are used: the first
97 two courses being given to patients are ultimately registered as smear-negative tuberculosis,
98 while the other three courses represent patients whose symptoms resolved without starting
99 anti-tuberculosis treatment.^{4 12} This high frequency of prescription of important broad-
100 spectrum antibiotics raises a global-scale risk for antimicrobial resistance (AMR) which like
101 tuberculosis, is a major crisis, becoming in 2016 one of only four health topics ever to be
102 discussed at the United Nations General Assembly.¹³⁻¹⁶

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

104 We performed a systematic literature review¹⁷ which demonstrated that, despite being in
105 global and national guidelines for decades, trial-of-antibiotics has a limited supporting
106 evidence base but with the available evidence suggesting poor diagnostic performance.¹⁸
107 None of the identified studies was an RCT and most of the observational studies were very
108 small and not primarily designed to assess the benefits and consequences of trial-of-
109 antibiotics. Pooled sensitivity and specificity of trial-of-antibiotics versus mycobacteriology
110 tests were below internationally defined minimum performance profiles for tuberculosis
111 diagnostics.¹⁹
112 We hypothesise that use of antibiotics in the course of evaluating patients for tuberculosis
113 has both benefits and risks that need to be weighed carefully to optimise patient and public
114 health outcomes. We will address evidence gaps related to a) accuracy, b) antimicrobial
115 resistance, and c) impact on clinical outcomes of trial-of-antibiotics by conducting an RCT
116 (ACT-TB Study) recruiting adult patients with cough presenting to health centres in Blantyre,
117 Malawi. To our knowledge this is the first randomised controlled trial to rigorously address
118 these questions.
119

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

METHODS AND ANALYSIS

Study design

This is a three-arm individually randomised (1:1:1), open-label controlled clinical trial (RCT) investigating accuracy and broader clinical, and antimicrobial resistance impact of using trial-of-antibiotics to rule-out tuberculosis among adults presenting with cough at primary care centres in Malawi (Figure 2). The trial is registered with Clinicaltrials.gov (NCT03545373) (Appendix 2). The full trial protocol is provided as Appendix 3.

Study setting

We will screen adults aged at least 18 years presenting to Limbe and Ndirande health centres in Blantyre, Malawi. Blantyre has an estimated tuberculosis prevalence of 1,014 per 100,000 (95% CI: 486 to 1,542), and an estimated adult HIV prevalence of 12.7% (95% CI: 11.9 to 13.6).²⁰

Eligibility criteria

We will offer enrolment to patients who satisfy the following inclusion and exclusion criteria.

Inclusion Criteria

- Ambulatory clinic attendees presenting with cough
- Unwell for at least 14 days
- Aged at least 18 years
- Reside in Blantyre and willing to return to the same clinic for follow up visits over the entire study period.

Exclusion Criteria

- Self-reported allergy to study medications

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 142 • WHO/Malawi National tuberculosis Program (NTP) danger signs: respiratory rate >
143 30/min, temperature >39°C, Heart rate >120/minute, confused/agitated, respiratory
144 distress, systolic blood pressure <90 mmHg, inability to walk unassisted
- 145 • Treated with antibiotics other than co-trimoxazole prophylaxis within the past 14 days
- 146 • Tuberculosis treatment or isoniazid preventive therapy within the last 6 months

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES).

Interventions

We will randomise participants, in a ratio of 1:1:1, to the following arms:

- **Arm 1** (Azithromycin): Azithromycin 500mg taken once daily for 3 days from enrolment day
- **Arm 2** (Amoxicillin): Amoxicillin 1g taken three times daily for 5 days from enrolment day.
- **Arm 3** (Standard of care): No study antibiotic prescription.

Rationale for interventions

Amoxicillin was chosen because it is the standard antibiotic used as first line treatment and for trial-of-antibiotics in Malawi. However, amoxicillin may not demonstrate the best performance for trial-of-antibiotics because of increasing resistance, and a narrow coverage for aetiology of community acquired pneumonia and “atypical” organisms. We chose azithromycin to represent the optimal biological specificity of an oral regimen due to more complete coverage of atypical organisms that cause community acquired pneumonia (e.g mycoplasma and chlamydia), and also the low resistance rates in Malawi where macrolides are rarely used. The dose for Azithromycin is as recommended in the British National Formulary (BNF) as treatment for community acquired pneumonia.²¹ The dose for amoxicillin is the BNF recommendation for severe infections but it is the recommended first line established by the Department of Medicine at Queen Elizabeth Central Hospital (Blantyre, Malawi) based on local microbiology.

Timing of interventions

The standard of care in Malawi defined by National Tuberculosis Programme guidelines for primary care patients presenting with cough who are otherwise well (no danger signs) is to take two sputum specimens for smear microscopy or Xpert and ask patients to return for

results, typically 3 days - 1 week later (Figure 1). The Malawi tuberculosis diagnostic algorithm recommends use of broad-spectrum antibiotics as trial-of-antibiotics after negative sputum tests are provided to patients who remain symptomatic. Therefore, the ideal population for randomisation for this study are patients on who already have negative results for smear microscopy or Xpert. However, that may have ethical challenges considering the implications of withholding treatment (if randomised to reference arm) from a symptomatic patient who, according to guidelines, should be given antibiotics. The first visit therefore was the most ideal time for randomisation and is in line with recommendations for test interval in investigations evaluating diagnostic tests with respect to the time interval between the index test (trial-of-antibiotics) and the reference test (mycobacteriology sputum sample collection). The timing also conforms to common clinical practice of prescribing trial-of-antibiotics at the same time as sputum collection to reduce diagnostic delay. The design was discussed with the District Health Office and the national tuberculosis programme ahead of ethics submission.

Known drug reactions

Azithromycin and amoxicillin have a long registration history, have been widely used globally and are well tolerated. Rare side effects for azithromycin include nervousness, dermatologic reactions including Stevens–Johnson syndrome, anaphylaxis and prolonged QT interval. Rare side-effects for amoxicillin are mental state changes, light-headedness, photosensitivity and severe allergic reactions.

Concomitant medication and interaction with other therapies

We do not have any restrictions with respect to concomitant medications apart from those listed in the exclusion criteria. We expect some participants to be on HIV antiretroviral drugs and some to subsequently start tuberculosis therapy. Important interactions therefore would be those those between the product and HIV antiretroviral drugs. There is no moderate or

198 major interaction between either azithromycin or amoxicillin with the classes of HIV
199 antiretroviral drugs currently used in Malawi.

200 **Trial restrictions**

201 We do not require participants to have any dietary restrictions. We will also accept co-
202 administration with contraception. Azithromycin and amoxicillin are both considered safe in
203 pregnancy, so we will include pregnant women should they be eligible.

204 **Assessment of compliance**

205 On Day-8, we will document self-reported compliance adherence of study products.

206 **Withdraw of interventions**

207 The investigator may also terminate a participant from study product if indicated by an
208 adverse reaction. If a participant stops taking study product either voluntarily or by
209 investigator decision, they will be encouraged to remain in follow up and their data will form
210 part of intention to treat analyses.

211 **Study outcomes**

212 The clinical trial has two separately powered, and distinctly assessed primary outcomes, one
213 for diagnostic evaluation (Primary outcome 1: Day 8) and the other for clinical impact
214 (Primary outcome 2: Day 29) of the intervention. The following are descriptions of all study
215 outcomes:

216 ***Primary outcome 1: Specificity of day 8 symptom change versus mycobacteriology***

217 The investigational test is change in symptoms at Day 8 categorised as: improved or not
218 improved (no change or worsened) in response to the question: *on day 1, you reported that*
219 *you were unwell; compared to that day, has your illness worsened, remained the same, or*
220 *improved?*

221 As with all self-rated outcomes, social desirability bias (tendency of participants to answer
222 questions in a manner that will be viewed favourably by healthcare worker), and interviewer
223 bias (interviewers' subconscious or conscious influencing subject response) may affect the
224 outcome. To minimise these biases in evaluation of improvement of baseline symptoms the
225 interview will be conducted using Audio Computer Assisted Self-Interview (ACASI), a
226 platform that allows patients to report their health state in private and directly into a database
227 via an audio questionnaire administered by a tablet. The lack of human-to-human interaction
228 will minimize interviewer, ascertainment, and social desirability biases. Another concern with
229 open-label design is placebo-effect favouring those randomised to antibiotics over the
230 standard of care arm that is however not addressed in our design.

231 We developed, piloted, and optimised the ACASI questionnaire in the study target population
232 and arrived at the question: *on day 1, you reported that you were unwell; compared to that*
233 *day, has your illness worsened, remained the same, or improved?* Before proceeding to the
234 self-interview, participants will be oriented using test questions until study staff are sure that
235 they will be able to go through the interview on their own. We will term ACASI interview
236 outcome as **ACASI-test-negative** if the participant reports improvement or **ACASI-test-**
237 **positive** if the participant reports no change or worsening.

238 The mycobacteriology reference standard will be defined in participants with at least one
239 valid sputum test result on days 1 and 8 as **sputum-test-positive** if there is at least one
240 positive of smear microscopy, Xpert/MTB/RIF, or MTB culture; and as **sputum-test-**
241 **negative** if none of the tests is positive. To minimise bias, the sputum tests will be performed
242 by a high-quality research laboratory in the University of Malawi College of Medicine by staff
243 with no access to participant treatment allocation information or symptom results.

244 The specificity of day 8 symptom change (the index test measured using ACASI) against
245 mycobacteriology tests (reference test) is defined as: **proportion of sputum-test-negative**
246 **who are ACASI-test-negative.**

247

Primary outcome 2: Clinical impact of trial-of-antibiotics

We will investigate the overall clinical impact of trial-of-antibiotics by comparing the day 29 risk of any of death, hospitalisation, and “missed tuberculosis” (untreated mycobacteriological or radiological tuberculosis). All these events can lead to mortality and are potential consequences of trial-of-antibiotics; therefore, grouping them as a composite endpoint appropriately represents the effect of the intervention because: 1) there are similarities in the importance of each of the components, 2) the components occur with similar frequencies in the patient population, and 3) the direction of effect is anticipated to be the same for all.²²

The connection between trial-of-antibiotics and risk of hospitalisation and death assumes a protective effect of antibiotics. In patients presenting with chronic cough at primary care in high HIV prevalence settings, frequencies of mortality and hospitalization over a two months period are similar, ranging from 2 to 6%.²³

We have included missed tuberculosis diagnosis in our composite clinical outcome because this too can lead to death. We are defining “missed tuberculosis” as participants who meet standard mycobacteriological and radiological tuberculosis definitions but are incorrectly classified as tuberculosis-negative and not yet on tuberculosis treatment by Day 29. Clinical, radiological, and microbiological evaluation for tuberculosis will be done at Day 8, Day 29, as well as day between these two for patients who report worsening symptoms.

Secondary outcome 1: impact of trial-of-antibiotics on antimicrobial resistance

We will use *Streptococcus pneumoniae* isolated from swabs of the nasopharynx as the indicator pathogen for AMR evaluation. An ecological niche for many bacterial species, the upper respiratory tract also presents a convenient window for investigating antimicrobial resistance. *Streptococcus pneumoniae* is the organism of choice not only for being an important cause of respiratory tract infections but also because it often colonises the upper

respiratory tract, acquires resistance readily, and has well documented laboratory investigation procedures in place.²⁴

We will define **AMR positive** as having nasopharyngeal isolates of *Streptococcus pneumoniae* that are resistant to any of the following commonly used antibiotics: ceftriaxone, amoxycillin, cefoxitin, azithromycin, and erythromycin as determined using disc diffusion technique; and **AMR negative** as either (1) not isolating any *Streptococcus pneumoniae* or (2) isolating any *Streptococcus pneumoniae* that is not resistant to any of the assessed antibiotics. For each arm, and at both baseline and day 29, we will report proportion of AMR positive participants. The study outcome will be the proportion of AMR positive participants at day 29.

Secondary outcome 2: diagnostic value of trial-of-antibiotics in all patients including those without a valid sputum result

The investigational test is as described for primary outcome 1. The mycobacteriology reference standard will be defined as sputum test positive if at least one positive of smear microscopy, Xpert/MTB/RIF, or MTB culture from samples collected on days 1 and 8. The reference test will be sputum-test-negative if none of the tests is positive and where there is no valid sputum test result available. The most likely reason for not having a valid sputum result will be inability to produce sputum, but other explanations will be: lost sample before laboratory analysis, an invalid laboratory reading, or contamination. We have opted to analyse this population because in symptomatic adults of the study setting, failure to produce sputum can be as high as 13%.²³

Secondary outcome 3: Economic evaluation

The objective of the economic evaluation is to undertake a cost-utility analysis to estimate the incremental cost-effectiveness of trial-of-antibiotics using azithromycin and trial-of-antibiotics using amoxicillin in comparison to standard of care, and to each other. We will systematically compare costs and consequences associated with the interventions. We will perform a within trial comparison of the three treatment arms to estimate the incremental

cost per quality-adjusted life year (QALY) gained for the azithromycin or amoxicillin arm in comparison to standard of care. Costs will be estimated from the Malawian Ministry of Health perspective. Health outcomes will be quantified in QALYs, estimated from participants' responses to the Chichewa version of the EQ-5D-3L, a Health quality of life (HRQoL) measure.^{25 26} We will adopt a time horizon matching the length of participant follow-up to achieve the within trial evaluation.

Exploratory outcomes

Our exploratory analyses will be comparisons between the **azithromycin** and **amoxicillin** arms for all our primary and secondary outcomes.

Planned subgroup analyses

We will perform analysis of primary outcomes stratified by HIV status and by ART status as documented on enrolment day. This is important because the study site has high prevalence of HIV and associated bacterial infections which may be amenable to antibiotics used for trial-of-antibiotics.

Study procedures

Figure 2 and Table 1 presents the study time schedule including a summary of patient identification, baseline procedures and outcome ascertainment at day 8 and day 29 follow up visits.

Screening

Study staff will approach patients with symptoms of pulmonary tuberculosis (including cough of any duration, fever, weight loss, and night sweats) with information about the study and seek written informed consent (Appendix 4) from all patients who meet eligibility criteria. After consenting, a participant will be given a unique study identification number confirming enrolment.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Randomisation

Randomisation will be in the ratio 1:1:1 to the three arms of the trial, using block-randomisation with variable block sizes, and stratified by study site. An independent statistician will prepare the randomisation list using Ralloc command in Stata software, then print each allocation alongside a randomisation number, and seal in opaque envelopes. Upon confirming eligibility and consenting status a designated site staff will open the next available of sequentially numbered randomisation envelopes and administer the allocated study arm.

Blinding

The study is not placebo controlled because of funding limitations, and so will not use blinding due to the nature of the study design. However, study team masking will be maintained with all study outcome assessment occurring without reference to randomisation arm.

Baseline procedures

At baseline, we will collect demographic data, clinical history, record vital signs, height and weight. Participants will be requested to provide two sputum samples for Xpert/MTB/RIF and two more sputum samples the following morning for smear microscopy and MTB culture. We will also collect a urine sample for lipoarabamannan antigen detection (TB LAM); and a nasopharyngeal swab for pneumococcal culture and sensitivity testing. We will offer and perform HIV testing according to the national algorithm, and link all who test positive to care. To minimise loss to follow up, we will collect contact phone numbers, a physical address and geolocation information.

Participant follow up

On day 8, the first activity (ahead of any other interaction with study staff) will be the ACASI. Other activities include providing results for day 1 tuberculosis tests and linking those who test positive to care; collection of another sputum sample for smear microscopy and

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

350 *Mycobacterium tuberculosis* (MTB) culture; and management of ongoing symptoms and
351 other illnesses. On visit day 29, the final study visit, we will document participant vital status,
352 hospitalisations, and establish adherence to HIV and tuberculosis treatment. We will also
353 collect nasopharyngeal swab samples from all participants, and sputum from those with
354 tuberculosis symptoms.

355 **Participant retention**

356 To minimise loss to follow up, we will record geolocation information of participants' place of
357 residence using ePAL android app, a high-resolution mapping system validated in Blantyre.
358 We will also record up to 3 contact phone numbers of the participant and their nominated
359 friends and relatives. We will not replace participants who discontinue study participation or
360 study treatment regardless of reason for withdrawal or discontinuation or the time either of
361 these occurs.

362 **Data management**

363 We will collect data using TeleForm (paper based system that uses optical character
364 recognition) and Open Data Kit systems (ODK, an electronic data capture system installed
365 on android devices). Data will be committed to a secure database located at Malawi-
366 Liverpool Wellcome Trust (MLW) within 2 days for TeleForm, and 7 days for ODK.

367

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

368 **Table 1:** key study procedures over the study period

	STUDY PERIOD			
	Enrolment	Follow up		
TIMEPOINT	Day-1	Day-8		Day-29
ENROLMENT:				
Eligibility screen	x			
Informed consent	x			
Allocation	x			
INTERVENTIONS:				
Azithromycin	x			
Amoxicillin	x			
Standard of care	x			
ASSESSMENTS:				
Demographics	x			
History of antibiotic use	x	x		x
History & examination ¹	x	x		x
Sputum collection ²	x	x		
Urine for TB LAM test ³	x	x		
Nasopharyngeal swab for AMR ⁴	x			x
HIV test	x			
Linking to routine care	x	x		x
ACASI ⁵		x		
Clinical events ⁶				x
Update contact & address		x		x
1. For symptomatic participants, Day-8 sputum mycobacteriology should be fast-tracked to inform care before they leave the clinic. 2. Give sputum bottles at end of Day-1 visit for submission on Day-8. Also collect sputum and perform mycobacteriology at any time of the study when clinically indicated 3. Urine Lipoarabinomannan for Tuberculosis Diagnosis (TB LAM) 4. Nasopharyngeal swab for Streptococcus pneumoniae culture and sensitivity as a way of determining risk of antimicrobial resistance (AMR) 5. Audio Computer Assisted Self-Interview (ACASI) for documenting change of symptoms on Day- 8 versus Day-1 6. Illnesses, clinic visits, radiological outcomes, new HIV diagnosis, new tuberculosis diagnosis, death, hospitalisation, missed tuberculosis diagnosis, HIV care loss to follow up, and tuberculosis care loss to follow up				

369

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

370 Statistical approach

371 We will summarise the processes of recruitment including non-eligibility and reasons of
372 exclusion in a CONSORT (Consolidated Standards of Reporting Trials) flow chart. We will
373 describe the study participants by their baseline characteristics, by arm. We will perform
374 analyses of all our outcomes based on an intention to treat analysis (using the arm patient
375 was randomised to). Analysis for primary outcome 1 will be restricted to participants with a
376 valid sputum test result. We will report measures of effect from the following comparisons:

- 377 i) Azithromycin or amoxicillin (combined) versus standard of care
- 378 ii) azithromycin versus standard of care
- 379 iii) amoxicillin versus standard of care

380 We will use a generalised linear model (GLM) with identity link to estimate risks differences
381 and the GLM with log link to estimate risk ratios for the three comparisons, adjusting for
382 study site. For each comparison, we will report 95% confidence intervals (CIs) and p-values
383 from the likelihood test. If outcomes are rare, or the GLM model does not converge, we will
384 use logistic regression to estimate the treatment effect using an odds ratio. We will report the
385 odds ratios with their associated 95% CIs and p-values.

386 We will perform data cleaning and analysis using Stata release 15 (Stata Corp, College
387 station, Texas, USA). The statistical approach will be expanded in a detailed statistical
388 analysis plan, which will be finalised before unblinding the study data.

389 Sample size and power

390 We performed power and sample size estimations for the diagnostic impact, clinical impact,
391 and AMR impact outcomes as described below. Our sample size estimations are based on
392 planned analysis that will use Chi-squared test for comparing two independent proportions.
393 We applied a normal-approximation correction for continuity.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Diagnostic impact outcome

We assume that at Day 8, change in well-being from baseline state in trial-of-antibiotics (azithromycin or amoxicillin) arms will correctly classify 60% of all mycobacteriology negative participants (i.e 60%specificity of day 8 symptom change in trial-of-antibiotics arms).¹² We wanted to estimate a sample size that would provide a discriminatory power of 80% at a two-sided significance level of 5%, to detect at least 10% difference in specificity (i.e ≤50% specificity of day 8 symptom change in standard of care arm). The sample sizes will differ by the number of arms being compared, we have therefore provided two separate estimates in line with type of comparisons specified under section 7.

Sample size for a combination of 2 antibiotic arms against standard of care arm

The sample size estimates along with assumptions for this comparison are shown in the Table 2A. To achieve the desired 80% discriminatory power, we will need to recruit at least 305 sputum-test-negative participants per arm. Accounting for TB prevalence, ability to produce and submit sputum, and loss-to-follow up increases the sample to 472 per arm or 1,416 for the whole study.

Table 2A: Sample size estimation for the *diagnostic impact outcome* comparing a combination of two antibiotic arms to standard of care arm

POWER (X2 difference between independent proportions)	Effect size (50% SoC vs 60% amoxycillin or azithromycin)	Effective sample per arm (Sputum negative participants needed)
0.70	0.10	325
0.75	0.10	363
0.80	0.10	400
0.85	0.10	463
0.90	0.10	538
Target power and respective sample size estimates based on knowledge of TB risk, ability to produce and submit sputum, and loss-to-follow up.		

Sample size for one antibiotic arm against standard of care arm

The sample size estimates along with assumptions for this comparison are shown in the Table 2B. To achieve the desired 80% discriminatory power, we will need to recruit at least 400 sputum-test-negative participants per arm. Accounting for TB prevalence, ability to produce and submit sputum, and loss-to-follow up increases the sample to 625 per arm or 1,875 for the whole study.

Table 2B: Sample size estimation for the *diagnostic impact outcome* one antibiotic arm to standard of care arm

POWER (X2 difference between independent proportions)	Effect size (50% SoC vs 60% amoxycillin or azithromycin)	Effective sample per arm (Sputum negative participants needed)
0.70	0.10	243
0.75	0.10	271
0.85	0.10	347
0.90	0.10	403
Target power and respective sample size estimates based on knowledge of TB risk, ability to produce and submit sputum, and loss-to-follow up.		

Power for clinical impact outcome

For the clinical impact of trial-of-antibiotics outcome, we assume a 4% baseline risk of composite outcome, and a loss to follow up of 10% by Day 29. Using the sample size of 625 participants per arm (obtained in Table 2B), and a type I alpha of 5%, we will be able to detect the difference between arms with 80% power, if the risk in the intervention arm is twice that of the standard of care arm. This estimate is applicable to all comparisons shown in section 3.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Power for AMR outcome

Study arms will be compared based proportion of participants with resistant *Streptococcus pneumoniae* on day 29. We assume that 45% of Day-29 nasopharyngeal swabs will successfully grow *Streptococcus pneumoniae*, and that 10% of the isolates will meet the definition of resistance (described earlier under outcomes), and that 10% will be lost to follow up by Day 29. Therefore, on day 29, the standard of care arm (of 625 participants) will have 253 *Streptococcus pneumoniae* isolates, 25 of which would meet the definition of resistance. This translates into a 4% (25/625) risk of AMR positive cases in the standard of care arm. To detect a twofold change in odds of day 29 AMR risk with at least 80% power, using Pearson's Chi-squared test, at 0.05 alpha, we will need at least 431 and 553 participants per arm for the 2:1 and pairwise comparisons respectively.

Monitoring and oversight

The trial will be monitored by the Research Support Centre Clinical Trials Unit of the University of Malawi College of Medicine. An independent Data and Safety Monitoring Board (DSMB), and a Trial Steering Committee (TSC) have been set up and meet bi-annually.

Trial closure

We will consider the trial closed after completing follow up of the last enrolled participant, and upon recording all mycobacteriology laboratory reports. Antimicrobial resistance lab work will continue beyond trial closure. The trial may be terminated early by the trial steering committee upon recommendation of the DSMB. The halting rule for a trial arm is an unacceptable high level of deaths assessed using an alpha determined at the first DSMB meeting.

PATIENT AND PUBLIC INVOLVEMENT

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

451 Patients were involved in the design of the study especially the audio-computer-assisted
452 interview (ACASI) used for collecting primary outcome data. Health workers were involved in
453 the design of study visits and patient flow.

454 DISCUSSION

455 The ACT-TB study will investigate the benefits and consequences of “trial-of-antibiotics,” a
456 widely promoted approach to many patients with suspected tuberculosis in low- and middle-
457 income countries without solid evidence base. To our knowledge, ACT-TB Study is the first
458 RCT of this kind. Results of our trial will add to the evidence-base regarding routine
459 diagnosis of tuberculosis in low and middle-income countries and strengthen our fight
460 against AMR. Both tuberculosis and AMR are diseases of major importance globally, with
461 tuberculosis causing an estimated 1.6 million deaths in 2017 and AMR projected to cause
462 10 million deaths per year by 2050.^{2 27}

463 Choice of study interventions

464 We have chosen amoxicillin because it is the first line treatment for outpatient management
465 of pneumonia in Malawi and is commonly used for trial-of-antibiotics. It also provides data of
466 immediate programmatic relevance and a starting point to investigate exacerbation of pre-
467 existing AMR pressure. However, amoxicillin may not demonstrate the full benefits for trial-
468 of-antibiotics because of organisms with intrinsic (“atypicals”) or acquired (common in gram-
469 negative organisms, and *Staphylococcus aureus*) penicillin resistance.²⁸ Oral antibiotics that
470 may provide the better diagnostic discrimination for bacterial versus mycobacterial causes of
471 cough are macrolides, such as azithromycin, because of better intrinsic coverage of
472 “atypical” intracellular organisms such as *mycoplasma* species that cause community
473 acquired pneumonia,²⁹⁻³¹ and low levels of acquired macrolide-resistance in bacterial isolates
474 in Malawi.²⁸

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACASI for post-treatment improvement assessment

Our systematic review¹⁸ did not identify a consistent definition of tuberculosis or no tuberculosis based on trial-of-antibiotics. A definition of clinical change following antibiotic treatment is necessary for the trial-of-antibiotics as this determines who get categorised as well or tuberculosis-positive. Approaches that ranged from self-reported improvement to a combination of clinical and radiological assessments are likely to be highly subjective and prone to bias, as well as being a potentially avoidable source of heterogeneity between studies. In this study, we hope to address these biases (particularly, inter-observer variability, and patient/interviewer reporting or ascertainment biases) by using self-rated change of illness (on day 8) recorded using a self-completed questionnaire, the ACASI (described under outcomes). The ACASI questionnaire, the delivery platform, and the resulting data management can all be replicated in future studies, creating potential for more standardisation in assessment of clinical response to treatment.

Potential clinical impact of antibiotics

In areas with high HIV prevalence, empirical antibiotics during tuberculosis investigations could be life-saving: mortality immediately before and after tuberculosis diagnosis is high,^{3 32} and is often secondary to severe bacterial infections.³²⁻³⁴ The leading aetiologies of infection and death on tuberculosis treatment as well as among outpatients with tuberculosis-like symptoms are *Streptococcus pneumoniae* and non-typhoidal salmonellae: both can present with cough (primary cause) or as co-morbidities (super-infections) in patients presenting with active *Mycobacterium tuberculosis* disease.³²⁻³⁴ If effective treatment of this type of life-threatening primary/super-infections reduces mortality during the diagnostic work-up of suspected tuberculosis in people living with HIV, then empirical use of broad-spectrum antibiotics would be indicated for this purpose alone, irrespective of any diagnostic contribution to tuberculosis treatment decisions. In this context, azithromycin may be the

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

most effective arm, as salmonella infections are highly sensitive to azithromycin, but not to amoxicillin.²⁸

AMR and trial-of-antibiotics

Antimicrobial resistance relating to antibiotic use during evaluation for suspected tuberculosis has not been investigated before. Previous work has shown that empirical antibiotics can drive rapid emergence of antimicrobial resistance.^{35 36} Co-trimoxazole prophylaxis for HIV-positive patients, introduced in 2005, was followed by near-universal resistance in bloodstream infections by 2010³⁷. Mass drug administration of azithromycin for trachoma control initially reduces nasopharyngeal carriage of *Streptococcus pneumoniae*, but with increased macrolide-resistance 6 months later.^{38 39}

In this study we have the opportunity to assess the extent to which brief exposure drives antimicrobial resistance during diagnostic work-up for tuberculosis. An ecological niche for many bacterial species, the upper respiratory tract also presents a convenient sampling opportunity for investigating antimicrobial resistance.⁴⁰ *Streptococcus pneumoniae* is the organism of choice not only for being an important cause of respiratory tract infections but also because it often colonises the upper respiratory tract, acquires resistance readily, and has well documented laboratory investigation procedures in place.²⁴ As exploratory analyses, we will also assess nasopharyngeal colonization and antimicrobial resistance in relation to tuberculosis treatment and HIV status.

Important subgroups

Clinical response to trial-of-antibiotics is possible and indeed well-described in patients with bacteriologically confirmed tuberculosis (i.e. false-negatives/low sensitivity from the perspective of tuberculosis diagnosis) may relate to multiple super-infections.^{4 33} As such, this phenomenon may vary by HIV status, since multiple concurrent infections are a hallmark of advanced HIV immunosuppression, and are most commonly reported in patients with

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

suspected tuberculosis in the pre-ART era. In 2015, in Malawi, 45% of adults who presented to primary care with prolonged cough (≥ 2 weeks) were HIV-positive, of whom only ~20% started tuberculosis treatment on the basis of positive mycobacteriology.²³ As such, the benefits and consequences of trial-of-antibiotics may vary by HIV status and ART coverage, and by subsequent tuberculosis treatment decisions. We will, therefore, include a pre-specified sub-analysis of trial outcomes stratified by HIV and ART status.

Limitations

The study has several limitations. Firstly, we did not use a placebo-control arm. Secondly, the study is not adequately powered to evaluate safety of deferred antibiotic treatment or conduct subgroup analyses of outcomes by HIV status, both which are important evidence gaps. Other limitations include the possibility that participants randomised to the standard-of-care arm may find alternative access to antibiotics therefore misclassifying exposure/intervention status. There is also a possibility of misclassifying active tuberculosis status because of the suboptimal nature of the available tests.

ETHICS AND DISSEMINATION

The study has been reviewed and approved by the University of Malawi College of Medicine Research and Ethics Committee (COMREC; registration number P.04/18/2381), the London School of Hygiene & Tropical Medicine Research Ethics Committee (LSHTM EC; registration number 15232), and Regional Committee for Health and Research Ethics, NTNU-Midt, Norway (REK nord; registration number 208/1964). Regulatory approval has been granted by the Malawi Pharmacy, Medicines, and Poisons Board (PMPB; registration number CTRC/III/14062018102). We will present any future protocol modifications to these bodies before implementing. We will submit results for publication in a peer-reviewed journal. We will submit abstracts to relevant national and international conferences. This work will also

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

form part of a PhD thesis for TD, which he will submit to the LSHTM. This study will follow the standards set by CONSORT guidelines.

AUTHORS' CONTRIBUTIONS

THD, KF and ELC are the main contributors to the conception, and design of the study. DS, MN and PM contributed to the general study planning and clinical design. NF contributed to the general study planning and antimicrobial resistance design. CK, LC, SC, and MF contributed to the design, piloting, and refining of study and clinical procedures. THD developed the first draft of the manuscript. All authors carefully reviewed and substantially contributed to the development of the trial protocol and this manuscript. All authors read and approved the final manuscript. THD is the guarantor for this work.

FUNDING AND SPONSORSHIP STATEMENT

The clinical trial is funded by the Commonwealth Scholarship Commission and the Helse Nord RHF grant awarded to THD. This work is part of THD's PhD work at London School of Hygiene & Tropical Medicine (LSHTM). LSHTM is the sponsor of this clinical trial (sponsor address: Keppel Street, Bloomsbury, London WC1E 7HT). ELC is funded by a Wellcome Trust Senior Research Fellowship in Clinical Science: WT200901. The funding agencies and the sponsor had no role in the preparation of the protocol or the intention to submit this manuscript for publication.

COMPETING INTERESTS STATEMENT

We have no conflicts of interest to declare.

BODY WORD COUNT: 4,034

REFERENCES

1
2
3 571 1. Raviglione M, Sulis G. Tuberculosis 2015: burden, challenges and strategy for control and
4 572 elimination. *Infectious disease reports* 2016;8(2):6570. doi: 10.4081/idr.2016.6570
5
6 573 2. World Health Organization. Global tuberculosis report 2018: World Health Organization
7 574 2018.
8
9 575 3. Nliwasa M, MacPherson P, Mukaka M, et al. High mortality and prevalence of HIV and
10 576 tuberculosis in adults with chronic cough in Malawi: a cohort study. *The international*
11 577 *journal of tuberculosis and lung disease* 2016;20(2):202-10. doi: 10.5588/ijtld.15.0388
12
13 578 4. Getahun H, Harrington M, O'Brien R, et al. Diagnosis of smear-negative pulmonary
14 579 tuberculosis in people with HIV infection or AIDS in resource-constrained settings:
15 580 informing urgent policy changes. *The Lancet* 2007;369(9578):2042-49. doi:
16 581 10.1016/S0140-6736(07)60284-0
17
18 582 5. Corbett E, MacPherson P. Tuberculosis screening in high human immunodeficiency virus
19 583 prevalence settings: turning promise into reality [State of the art series. Active case
20 584 finding/screening. Number 5 in the series]. *The international journal of tuberculosis and*
21 585 *lung disease* 2013;17(9):1125-38.
22
23 586 6. Siddiqi K, Lambert M-L, Walley J. Clinical diagnosis of smear-negative pulmonary
24 587 tuberculosis in low-income countries: the current evidence. *The Lancet infectious*
25 588 *diseases* 2003;3(5):288-96.
26
27 589 7. Ghana Health Service. Guidelines for the Clinical Management of TB and HIV Co-
28 590 infection in Ghana. In: Department DCaP, ed. Accra, 2007.
29
30 591 8. Ministry of Health. Malawi National TB Programme Manual. . In: Programme NT, ed. 8 ed.
31 592 Lilongwe, 2016.
32
33 593 9. National Department of Health. South Africa National Tuberculosis Management
34 594 Guidelines 2014. In: Coordination TDS, ed. Pretoria, 2014.
35
36 595 10. World Health Organization. Global tuberculosis report 2016. 2016
37
38 596 11. McDowell A, Pai M. Treatment as diagnosis and diagnosis as treatment: empirical
39 597 management of presumptive tuberculosis in India. *The International Journal of*
40 598 *Tuberculosis and Lung Disease* 2016;20(4):536-43.
41
42 599 12. Wilkinson D, Newman W, Reid A, et al. Trial-of-antibiotic algorithm for the diagnosis of
43 600 tuberculosis in a district hospital in a developing country with high HIV prevalence. *The*
44 601 *International Journal of Tuberculosis and Lung Disease* 2000;4(6):513-18. [published
45 602 Online First: 2000/06/23]
46
47 603 13. Holmes AH, Moore LS, Sundsfjord A, et al. Understanding the mechanisms and drivers
48 604 of antimicrobial resistance. *The Lancet* 2016;387(10014):176-87. doi: 10.1016/S0140-
49 605 6736(15)00473-0
50
51 606 14. World Health Organization. The evolving threat of antimicrobial resistance: options for
52 607 action: Geneva: World Health Organization 2012.
53
54 608 15. World Health Organization. Antimicrobial resistance: global report on surveillance: World
55 609 Health Organization 2014.
56
57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

- 610 16. Laxminarayan R, Matsoso P, Pant S, et al. Access to effective antimicrobials: a
611 worldwide challenge. *The Lancet* 2016;387(10014):168-75. doi: 10.1016/S0140-
612 6736(15)00474-2
- 613 17. Divala TH, Fielding KL, Nliwasa M, et al. Sensitivity and specificity of using trial-of-
614 antibiotics versus sputum mycobacteriology for diagnosis of tuberculosis: protocol for a
615 systematic literature review. *Systematic reviews* 2018;7(1):141.
- 616 18. Divala TH, Nliwasa M, Gupta-Wright A, et al. Is the current practice of using response to
617 empirical broad-spectrum antibiotic treatment as an exclusion diagnostic for tuberculosis
618 supported by evidence? Systematic review and meta-analysis. 49th World Conference on
619 Lung Health of the International Union Against Tuberculosis and Lung Disease (The
620 Union): Int J Tuberc Lung Dis, 2018.
- 621 19. World Health Organization. High priority target product profiles for new tuberculosis
622 diagnostics: report of a consensus meeting, 28-29 April 2014, Geneva, Switzerland:
623 World Health Organization, 2014.
- 624 20. National Tuberculosis Control programme. Malawi Nationwide Tuberculosis Prevalence
625 Survey. 45th Union World Conference on Lung Health. Barcelona, Spain, 2014.
- 626 21. Joint Formulary Committee. British national formulary (BNF) 78: Pharmaceutical Press
627 2019.
- 628 22. Montori VM, Permyer-Miranda G, Ferreira-González I, et al. Validity of composite end
629 points in clinical trials. *Bmj* 2005;330(7491):594-96.
- 630 23. Nliwasa M, MacPherson P, Chisala P, et al. The sensitivity and specificity of Loop-
631 Mediated Isothermal Amplification (LAMP) assay for Tuberculosis diagnosis in adults with
632 chronic cough in Malawi. *PloS one* 2016;11(5):e0155101. doi:
633 10.1371/journal.pone.0155101 [published Online First: 2016/05/14]
- 634 24. Satzke C, Turner P, Virolainen-Julkunen A, et al. Standard method for detecting upper
635 respiratory carriage of *Streptococcus pneumoniae*: updated recommendations from the
636 World Health Organization Pneumococcal Carriage Working Group. *Vaccine*
637 2013;32(1):165-79. doi: 10.1016/j.vaccine.2013.08.062
- 638 25. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life.
639 *Health policy (Amsterdam, Netherlands)* 1990;16(3):199.
- 640 26. Maheswaran H, Petrou S, MacPherson P, et al. Cost and quality of life analysis of HIV
641 self-testing and facility-based HIV testing and counselling in Blantyre, Malawi. *BMC*
642 *medicine* 2016;14(1):34.
- 643 27. O'Neill J. Tackling drug-resistant infections globally: Final report and recommendations.
644 2016. *HM Government and Wellcome Trust: UK* 2018
- 645 28. Musicha P, Cornick JE, Bar-Zeev N, et al. Trends in antimicrobial resistance in
646 bloodstream infection isolates at a large urban hospital in Malawi (1998–2016): a
647 surveillance study. *The Lancet Infectious Diseases* 2017;17(10):1042-52. doi:
648 10.1016/s1473-3099(17)30394-8
- 649 29. Lubell Y, Turner P, Ashley EA, et al. Susceptibility of bacterial isolates from community-
650 acquired infections in sub-Saharan Africa and Asia to macrolide antibiotics

1
2
3 651 Sensibilité aux macrolides des isolats bactériens provenant des infections acquises dans la
4 652 communauté en Afrique subsaharienne et en Asie
5 653 Susceptibilidad a macrólidos de aislados bacterianos provenientes de infecciones adquiridas
6 654 en la comunidad. *Tropical Medicine & International Health* 2011;16(10):1192-205. doi:
7 655 10.1111/j.1365-3156.2011.02837.x
8
9 656 30. Phua J, Dean NC, Guo Q, et al. Severe community-acquired pneumonia: timely
10 657 management measures in the first 24 hours. *Critical Care* 2016;20(1):237. doi:
11 658 10.1186/s13054-016-1414-2
12
13 659 31. Lim W, Smith D, Wise M, et al. British Thoracic Society community acquired pneumonia
14 660 guideline and the NICE pneumonia guideline: how they fit together. *Thorax*
15 661 2015:thoraxjnl-2015-206881.
16
17 662 32. Cain KP, Anekthananon T, Burapat C, et al. Causes of death in HIV-infected persons
18 663 who have tuberculosis, Thailand. *Emerging infectious diseases* 2009;15(2):258.
19
20 664 33. Bedell RA, Anderson ST, Van Lettow M, et al. High prevalence of tuberculosis and
21 665 serious bloodstream infections in ambulatory individuals presenting for antiretroviral
22 666 therapy in Malawi. *PLoS One* 2012;7(6):e39347. doi: 10.1371/journal.pone.0039347
23
24 667 34. Schleicher G, Feldman C. Dual infection with *Streptococcus pneumoniae* and
25 668 *Mycobacterium tuberculosis* in HIV-seropositive patients with community acquired
26 669 pneumonia. *The International Journal of Tuberculosis and Lung Disease*
27 670 2003;7(12):1207-08.
28
29 671 35. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and
30 672 responses. *Nature medicine* 2004;10(12s):S122. doi: 10.1038/nm1145
31
32 673 36. Goossens H, Ferech M, Vander Stichele R, et al. Outpatient antibiotic use in Europe and
33 674 association with resistance: a cross-national database study. *The Lancet*
34 675 2005;365(9459):579-87.
35
36 676 37. Everett DB, Mukaka M, Denis B, et al. Ten years of surveillance for invasive
37 677 *Streptococcus pneumoniae* during the era of antiretroviral scale-up and cotrimoxazole
38 678 prophylaxis in Malawi. *PloS one* 2011;6(3):e17765. doi: 10.1371/journal.pone.0017765
39
40 679 38. Coles CL, Mabula K, Seidman JC, et al. Mass distribution of azithromycin for trachoma
41 680 control is associated with increased risk of azithromycin-resistant *Streptococcus*
42 681 *pneumoniae* carriage in young children 6 months after treatment. *Clinical Infectious*
43 682 *Diseases* 2013;56(11):1519-26.
44
45 683 39. Mitjà O, Houinei W, Moses P, et al. Mass treatment with single-dose azithromycin for
46 684 yaws. *New England Journal of Medicine* 2015;372(8):703-10. doi:
47 685 10.1056/NEJMoa1408586
48
49 686 40. Man WH, de Steenhuijsen P, Bogaert D. The microbiota of the respiratory tract:
50 687 gatekeeper to respiratory health. *Nat Rev Microbiol* 2017;15(5):259-70. doi:
51 688 10.1038/nrmicro.2017.14
52
53 689
54 690
55 691
56
57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

LEGENDS FOR FIGURES

1. Legend for figure 1

*The common clinical practice is that outpatients start antibiotics at the time of submitting sputum, to avoid the need for a third clinic visit to complete the algorithm.

Figure 1: The position of trial-of-antibiotics in standard algorithms for diagnosis of tuberculosis in low and middle income countries (based on the 2018 WHO GLI model guidelines and as implemented in national guidelines e.g Ghana, Malawi and South Africa.)

2. Legend for figure 2

ART = antiretroviral treatment for HIV

NTP = Malawi National Tuberculosis Program

TB LAM = Urine Lipoarabinomannan for Tuberculosis Diagnosis

VL = HIV Viral load

Figure 2: Flow diagram for the clinical trial in Blantyre, Malawi

3. Legend for figure 3

Figure 3: Assessing the diagnostic value of a change in symptoms from baseline to day 8

APPENDIX 1: ETHICS AND REGULATORY APPROVALS

(attached separately)

APPENDIX 2: TRIAL REGISTRATION—DATA SET

(attached separately)


APPENDIX 3: FULL TRIAL PROTOCOL

1
2
3 716 (attached separately)
4 717
5
6 718
7
8 719
9
10 720 (attached separately)
11 721
12 722
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

**APPENDIX 4: PATIENT INFORMATION SHEET AND INFORMED
CONSENT**


For peer review only

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.



*The common clinical practice is that outpatients start antibiotics at the time of submitting sputum, to avoid the need for a third clinic visit to complete the algorithm.

Figure 1: The position of trial-of-antibiotics in standard algorithms for diagnosis of tuberculosis in low and middle income countries (based on the 2018 WHO GLI model guidelines and as implemented in national guidelines e.g Ghana, Malawi and South Africa.)



ART = antiretroviral treatment for HIV
 NTP = Malawi National Tuberculosis Program
 TB LAM = Urine Lipoarabinomannan for Tuberculosis Diagnosis
 VL = HIV Viral load

Figure 2: Flow diagram for the clinical trial in Blantyre, Malawi

Reference Result: any positive smear microscopy, Xpert/MTB/RIF, or MTB Culture from sputum samples collected on Day 1 and Day 8 visit defines tuberculosis-test-positive

	Sputum-test-positive	Sputum-test-negative
ACASI* Response on Day 8 <i>ACASI test is defined by response to the following question asked using ACASI on Day 8: on day 1, you reported that you were unwell; compared to that day, has your illness <u>worsened</u>, <u>remained the same</u>, or <u>improved</u>?</i>	ACASI-test-positive (worse or no change) a	b
	ACASI-test negative (Improved) c	d

Primary outcome: specificity, calculated by $d / (b+d)$

*Audio Computer Assisted Self-Interview (ACASI) in which the participant, after a how-to-use test session, responds to the prescribed question on a database-linked android tablet, without any human interaction, and in private.

Figure 3: Assessing the diagnostic value of a change in symptoms from baseline to day 8

366x222mm (96 x 96 DPI)



CERTIFICATE OF ETHICS APPROVAL

This is to certify that the College of Medicine Research and Ethics Committee (COMREC) has reviewed and approved a study entitled:

P.04/18/2381 - Accuracy and Consequences of using Trial-of-antibiotics for TB diagnosis (ACT-TB Study) by Titus H Divala

On 03-Jul-18

As you proceed with the implementation of your study, we would like you to adhere to international ethical guidelines, national guidelines and all requirements by COMREC as indicated on the next page

03-Jul-18

Dr. YB. Mlombe - Chairperson (COMREC)

Date

REQUIREMENTS FOR ALL COMREC APPROVED RESEARCH PROTOCOLS

1. Pay the research overhead fees as required by the College of Medicine for all approved studies.
2. You should note that the COMREC Sub-Committee on Research Participants' Safety will monitor the conduct of the approved protocol and any deviation from the approved protocol may result in your study being stopped.
3. You will provide an interim report in the course of the study and an end of study report.
4. All COMREC approvals of new applications and progress reports are valid for one year only. Therefore all approved studies running for more than one year are subject to continuing review annually. You are required to submit a progress report to COMREC within 90-30 days before the expiration date. Your current expiration date is 03-Jul-19. Studies shall be considered lapsed and inactive if continuing review application is not received one month after the expiry of the previous approval. In that case, all study related operations should cease immediately except those that are necessary for the welfare of subjects.
5. All investigators who are Medical Practitioners must be fully registered with the Medical Council of Malawi.



PHARMACY, MEDICINES & POISONS BOARD

Mission: To promote and improve the health of the population of Malawi through the regulation of Pharmacy Personnel, Pharmacy Businesses, Medicines and Allied Substances

ALL CORRESPONDENCE SHOULD BE ADDRESSED TO THE REGISTRAR

Head Office:

Off Paul Kagame/
Chilambula Road
P.O.Box 30241
Capital City
LILONGWE 3, MALAWI

Phone: (+265) 01 755 165
Fax : (+265) 01 755 204
Email: info@pmpb.mw
Web: www.pmpb.mw

PMPB/CTRC/III/14062018102
DATE: 4th July, 2018

Department of Infectious Disease Epidemiology
London School of Hygiene and Tropical Medicine
Keppel St
London

Attn.: Dr. Titus Divala

RE: ACCURACY AND CONSEQUENCES OF USING TRIAL-OF-ANTIBIOTICS FOR TB DIAGNOSIS (ACT-TB STUDY).

Refer to your application to register the above mentioned clinical trial with the Pharmacy, Medicines and Poisons Board (PMPB).

The Clinical Trial Review Committee (CTRC), at its meeting held on 22nd June, 2018, issued a **No Objection** to the implementation of the trial after members agreed that the nature of the trial was seen to be outside the scope of trials that should be regulated by PMPB through the CTCR.

Please contact the undersigned if there are any issues that need further clarification.

Yours faithfully,

M. Kawaye
ACTING REGISTRAR





Region:	Saksbehandler:	Telefon:	Vår dato:	Vår referanse:
REK nord			06.11.2018	2018/1964/REK nord
			Deres dato:	Deres referanse:
			25.09.2018	
			Vår referanse må oppgis ved alle henvendelser	

Jon Øyvind Odland
Institutt for samfunnsmedisin

2018/1964 En kontrollert klinisk studie for å undersøke responsen til bredspekret antibiotika som en eksklusjonsdiagnose i allmenpraksis mot risiko for antibiotika resistens

Forskningsansvarlig institusjon: UiT Norges arktiske universitet

Prosjektleder: Jon Øyvind Odland

Vi viser til søknad om forhåndsgodkjenning av ovennevnte forskningsprosjekt. Søknaden ble behandlet av Regional komité for medisinsk og helsefaglig forskningsetikk (REK nord) i møtet 25.10.2018. Vurderingen er gjort med hjemmel i helseforskningsloven (hforsknl) § 10.

Prosjektleders prosjekttale

Det skal undersøkes, ved hjelp av en randomisert, kontrollert studie om respons til bredspekret antibiotika kan brukes som eksklusjonsdiagnose for tuberkulose. Dette skal vurderes opp mot risiko for resistensutvikling knyttet til behandlingen. Tre grupper (625 per gruppe) individuelt randomisert (1:1:1), med åpen informasjon undersøkes med standard diagnostisk tilnærming. Kun voksne deltakere, med full brukermedvirkning og informert samtykke. Studien kan forenkle diagnostikk og klinikk for en utsatt gruppe mennesker. Studien skal i sin helhet foregå i Malawi. Alle etiske godkjenninger fra Malawi og London er vedlagt.

Komiteen vurderte at Hanne Husom Haukland var inhabil og hun fratrådte møtet da saken ble behandlet, jf. fvl. § 6.

Om prosjektet

Prosjektet er en del av en PhD. Studenten skal avlegge sin PhD i London.

Dette er et samarbeidsprosjekt mellom Universitetet i Malawi, London School of Hygiene and Tropical Medicine, og Universitetet i Tromsø.

Prosjektet skal gjennomføres i Malawi og er et «Tuberkulose initiativ» fra Helse Nord.

Det foreligger godkjenning fra London School of Hygiene and Tropical Medicine, og University of Malawi.

Data

Det skal hentes data fra pasientjournal og fra lokale poliklinikker. Data er standard medisinske opplysninger knyttet til infeksjoner og sykehistorie.

Nye helseopplysninger er respons på behandling av infeksjoner.

Data aidentifiseres med koblingsnøkkel. Database oppbevares i 5 år i Malawi.

Deltakere/rekruttering

Voksne deltakere fordeles i tre grupper voksne deltakere (625 per gruppe), individuelt randomisert. Deltakere rekrutteres gjennom behandling på poliklinikkene.

REK har ingen innvendinger til prosjektet

Vedtak

REK har gjort en helhetlig forskningsetisk vurdering av alle prosjektets sider og godkjenner det med hjemmel i helseforskningsloven § 10. REK forutsetter at prosjektet også har godkjenning fra Malawi.

Sluttmelding og søknad om prosjektendring

Prosjektleder skal sende sluttmelding til REK nord på eget skjema senest 21.03.2022, jf. hfl. § 12. Prosjektleder skal sende søknad om prosjektendring til REK nord dersom det skal gjøres vesentlige endringer i forhold til de opplysninger som er gitt i søknaden, jf. hfl. § 11.

Klageadgang

Du kan klage på komiteens vedtak, jf. forvaltningsloven § 28 flg. Klagen sendes til REK nord. Klagefristen er tre uker fra du mottar dette brevet. Dersom vedtaket opprettholdes av REK nord, sendes klagen videre til Den nasjonale forskningsetiske komité for medisin og helsefag for endelig vurdering.

Med vennlig hilsen

May Britt Rossvoll
sekretariatsleder

Kopi til: jon.oyvind.odland@uit.no

London School of Hygiene & Tropical Medicine

Keppel Street, London WC1E 7HT
 United Kingdom
 Switchboard: +44 (0)20 7636 8636
www.lshtm.ac.uk

LONDON
 SCHOOL of
 HYGIENE
 & TROPICAL
 MEDICINE

**Observational / Interventions Research Ethics Committee**

Dr Titus Divala
 LSHTM

9 May 2018

Dear Titus,

Study Title: RCT investigating if benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis in primary care adult patients outweigh the risk of antimicrobial resistance

LSHTM ethics ref: 15232

Thank you for your application for the above research, which has now been considered by the Interventions Committee.

Confirmation of ethical opinion

On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation, subject to the conditions specified below.

Conditions of the favourable opinion

Approval is dependent on local ethical approval having been received, where relevant.

Approved documents

The final list of documents reviewed and approved by the Committee is as follows:

Document Type	File Name	Date	Version
Safety Information	ACT_PackageInsertAzithromycin	14/03/2013	JUNE 2013
Safety Information	ACT_PackageInsertAmoxicillin	21/12/2015	DEC 2015
Sponsor Letter	2018-KEP-077_Sponsor Confirmation_13.03.18	13/03/2018	1
Other	GCP Cert_LSHTM_TDivala_21.03.18	21/03/2018	1
Investigator CV	ACT-CV1_TitusDivala	30/03/2018	1
Investigator CV	ACT-CV2_KatherineFielding	30/03/2018	1
Investigator CV	ACT-CV3_LizCorbett	30/03/2018	1
Information Sheet	ACT-20180330InformedConsentEnglish	30/03/2018	1.0
Information Sheet	ACT-20180330InformedConsentChichewa	30/03/2018	1.0
Protocol / Proposal	ACT-20180330Protocol	30/03/2018	1.0

After ethical review

The Chief Investigator (CI) or delegate is responsible for informing the ethics committee of any subsequent changes to the application. These must be submitted to the Committee for review using an Amendment form. Amendments must not be initiated before receipt of written favourable opinion from the committee.

The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reactions (SUSARs) which occur during the project by submitting a Serious Adverse Event form.

An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study.

At the end of the study, the CI or delegate must notify the committee using an End of Study form.

All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at: <http://leo.lshtm.ac.uk>

Additional information is available at: www.lshtm.ac.uk/ethics

Yours sincerely,

1 ethics@lshtm.ac.uk
2 <http://www.lshtm.ac.uk/ethics/>
3
4
5

6 **Improving health worldwide**
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

London School of Hygiene & Tropical Medicine

Keppel Street, London WC1E 7HT
 United Kingdom
 Switchboard: +44 (0)20 7636 8636
www.lshtm.ac.uk

LONDON
 SCHOOL of
 HYGIENE
 & TROPICAL
 MEDICINE

**Observational / Interventions Research Ethics Committee**

Dr Titus Divala
 LSHTM

12/04/2019

Dear Titus,

Project Title: RCT investigating if benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis in primary care adult patients outweigh the risk of antimicrobial resistance

Project ID: 15232

Thank you for your annual report application for the continuation of your research dated 09/04/2019 12:01 , which has now been considered by the Chair on behalf of the Ethics Committee.

Confirmation of ethical opinion

This application is approved by the committee for a further year.

Conditions of the favourable opinion

Approval is dependent on local ethical approval having been received, where relevant.

After ethical review

Any changes to the application must be submitted to the committee via an Amendment form.

The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reaction (SUSARs) which occur during the project by submitting a SUSAR and Protocol Violation form.

An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study.

At the end of the study, the CI or delegate must notify the committee using an End of Study form.

All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at <http://leo.lshtm.ac.uk>.

Additional information is available at: www.lshtm.ac.uk/ethics.

Yours sincerely,


Professor John DH Porter
 Chair

ethics@lshtm.ac.uk
<http://www.lshtm.ac.uk/ethics/>

Improving health worldwide

APPENDIX 1: TRIAL REGISTRATION—DATA SET

NCT Number	NCT03545373
Title	Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis (ACT-TB Study)
Acronym	ACT-TB
Status	Recruiting
Study Results	No Results Available
Conditions	Tuberculosis Respiratory Tract Infections Pneumonia
Interventions	Drug: Azithromycin Drug: Amoxicillin
Outcome Measures	Diagnostic accuracy of trial-of-antibiotics: Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 against a mycobacteriology reference standard. Overall clinical benefit of empirical antibiotic treatment in primary care participants with chronic cough: proportion of participants experiencing adverse clinical outcomes Impact of trial-of-antibiotics on antimicrobial resistance Diagnostic accuracy of trial-of-antibiotics including participants who did not produce sputum Economic analysis of use of trial-of-antibiotics
Sponsor/Collaborators	London School of Hygiene and Tropical Medicine University of Malawi College of Medicine
Gender	All
Age	18 Years and older Å (Adult, Older Adult)
Phases	Phase 3
Enrollment	1875
Funded Bys	Other
Study Type	Interventional
Study Designs	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Outcomes Assessor) Primary Purpose: Diagnostic
Other IDs	15232
Start Date	February 25, 2019
Primary Completion Date	Jun-20
Completion Date	Jun-20
First Posted	June 4, 2018
Results First Posted	
Last Update Posted	August 15, 2019
Locations	University of Malawi College of Medicine, Blantyre, Southern, Malawi
Study Documents	
URL	https://ClinicalTrials.gov/show/NCT03545373



Randomised controlled clinical trial investigating benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis (TB) in primary care adult patients versus risk of antimicrobial resistance (AMR)

Short title: Accuracy and Consequences of using Trial-of-antibiotics for TB diagnosis

Acronym: ACT-TB Study

Trial registration:

Protocol version: 3.0, 19 Feb 2019

Chief Investigator: Titus H Divala
London School of Hygiene & Tropical Medicine
Keppel Street, London WC1E 7HT
Tel: +44 740 523 1847
Email: titus.divala@lshtm.ac.uk

Co-Investigators: Katherine L Fielding, Neil French, Derek J Sloan, Elizabeth L Corbett

Collaborators: Marriott Nliwasa, Augustine Choko, Ankur Gupta-Wright, Jennifer Cornic, Jon Øyvind Odland, Chisomo Msefula, Hendramoorthy Maheswaran

Sponsor: London School of Hygiene & Tropical Medicine is the main research sponsor for this study. For further information regarding the sponsorship conditions, please contact the Research Governance and Integrity Office:
London School of Hygiene & Tropical Medicine
Keppel Street, London WC1E 7HT
Tel: +44 207 927 2626
Email: RGIO@lshtm.ac.uk

Funding: Helse Nord RHF
Tromsø, Norway; Tel: +47 97065144
Email: Hanne.Husom.Haukland@helse-nord.no

Study Coordination Centre: University of Malawi College of Medicine
Private Bag 360
Chichiri, Blantyre, Malawi
Tel: +2651871911
Email: rscdirector@medcol.mw

This trial will adhere to the principles outlined in the International Council for Harmonisation Good Clinical Practice (ICH GCP) guidelines, protocol and all applicable local regulations.

Table of contents	
1	Abbreviations 6
2	Study Summary 8
3	Introduction 11
3.1	Background..... 11
3.2	Systematic literature review 13
3.3	Planned study 15
3.4	Rationale for current study 16
3.4.1	Accuracy of trial-of-antibiotics 16
3.4.2	Antimicrobial resistance and trial-of-antibiotics 16
3.4.3	Potential benefits of antibiotics 17
3.4.4	Important subgroups..... 18
3.5	Choice of study interventions..... 19
3.6	Nasopharyngeal pneumococcus for AMR 20
3.7	Objectives and outcomes 20
4	Study design, participants, and statistical approach 23
4.1	Study design 23
4.2	Study setting..... 23
4.3	Standard of care 23
4.4	Eligibility criteria..... 25
4.4.1	Inclusion Criteria 25
4.4.2	Exclusion Criteria..... 25
4.5	Interventions 25
4.5.1	Name and description of intervention arms..... 25
4.5.2	Legal status of drugs used in intervention arms..... 25
4.5.3	Summary of Product Characteristics..... 25
4.5.4	Drug Storage and Supply 26
4.5.5	Preparation and labelling of study drugs 26
4.5.6	Known drug reactions (adverse events)..... 26
4.5.7	Concomitant medication and interaction with other therapies 26
4.5.8	Trial restrictions 26

4.5.9	Assessment of compliance	26
4.5.10	Withdraw of interventions	27
4.6	Statistical approach.....	27
4.6.1	Primary outcome	27
4.6.2	Secondary outcomes.....	30
4.6.3	Exploratory outcome.....	30
4.6.4	Planned subgroup analyses.....	30
4.7	Sample size and power	31
4.7.1	Primary outcome 1: specificity of trial-of-antibiotics versus mycobacteriology.....	31
4.7.2	Primary outcome 2: Incidence of adverse clinical outcome at Day-29.....	31
4.7.3	Secondary outcomes.....	32
4.7.4	Exploratory outcomes.....	32
5	Pilot study	33
5.1	Specific objectives of the pilot study.....	33
5.2	Population for the pilot study	34
5.3	Pilot study procedures.....	34
5.4	Data analysis.....	35
6	Study procedures	37
6.1	Screening.....	37
6.2	Informed consent.....	37
6.3	Baseline procedures	37
6.4	Assignment of interventions	38
6.5	Blinding.....	40
6.6	Participant follow up	40
6.6.1	Day-8 activities	41
6.6.2	Day-29 activities	41
6.7	Laboratory methods	42
6.7.1	Tuberculosis mycobacteriology.....	42
6.7.2	Urine antigen testing for lipoarabamannan and other MTB antigens.....	42
6.7.3	Antimicrobial resistance testing	42
6.8	Loss to follow-up.....	43

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

6.9 Trial closure 43

6.10 Summary schedule for study procedures.....43

7 Safety reporting 45

7.1 Definitions 45

7.2 DMID grading for AEs.....46

7.3 Grading for expected events.....46

7.4 Causality 48

7.5 Reporting Procedures 49

7.5.1 Non-serious Adverse Events (AEs).....49

7.5.2 Serious Adverse Events (SAEs) 49

8 Economic evaluation..... 50

8.1 Objective 50

8.2 Outcomes 50

8.3 Data collection 50

8.4 Data analysis.....51

8.5 Missing data.....51

9 Data management..... 52

9.1 Source Data.....52

9.2 Data collection methods 52

9.3 Data management.....52

9.4 Quality control and quality assurance 53

9.5 Access to data 53

10 Data monitoring and quality assurance 54

10.1 Data monitoring 54

10.2 Audits and Inspections 54

10.3 Data Safety and Monitoring Board (DSMB).....54

10.4 Trial Management Group (TMG) 54

10.5 Trial Investigational Team.....55

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

11	Ethics and dissemination	56
11.1	Risk assessment	56
11.2	Research ethics approval	56
11.3	Indemnity	57
11.4	Sponsor	57
11.5	Declaration of interests	57
11.6	Cost of participation, ancillary and post-trial care	57
11.7	Dissemination policy	57
12	References	58
13	Appendix 1: Informed consent	61
14	Appendix 2: Division of Microbiology and Infectious Diseases (DMID) adult toxicity table	62
15	Appendix 3: Package insert for Azithromycin and amoxicillin	74

1 Abbreviations

ACASI	Audio Computer Assisted Self-Interview
AE	Adverse Event
AMR	Antimicrobial Resistance
AR	Adverse Reaction
ART	Antiretroviral Therapy
CD4	Cluster of Differentiation 4
CEACs	Cost-Effectiveness Acceptability Curves
COMREC	University of Malawi College of Medicine Research and Ethics Committee
CXR	Chest X-Ray
DMID	Division of Microbiology and Infectious Diseases
DSMB	Data Safety and Monitoring Board
GLM	Generalised Linear Model
HIV	Human Immunodeficiency Virus
HRQoL	Health Quality of Life
LAM	Urine Lipoarabinomannan Assay
LJ	Lowenstein-Jensen
LSHTM	London School of Hygiene & Tropical Medicine
MDA	Mass Drug Administration
MGIT	Mycobacteria Growth Indicator Tube

MTB or M.tb	<i>Mycobacterium tuberculosis</i>
NMBs	Net Monetary Benefits
NTM	Non-Tuberculous Mycobacteria
NTP	National Tuberculosis Control Program
NTS	Non-Typhoidal Salmonellae
PCP	Pneumocystis Jiroveci
PLHIV	People Living With HIV
PTB	Pulmonary Tuberculosis
QALY	Quality-Adjusted Life Year
RCT	Randomized Controlled Trial
SAE	Serious Adverse Event
SAR	Serious Adverse Reaction
SOC	Standard of Care
STGG	Skim Milk Tryptone Glucose Glycerol
SUSAR	Suspected Unexpected Serious Adverse Reaction
TB	Tuberculosis
TMG	Trial Management Group
WHO	World Health Organization
WTP	Willingness to Pay

2 Study Summary

Title	Randomised controlled clinical trial investigating benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis (TB) in primary care adult patients versus risk of antimicrobial resistance (AMR)	
Design	Three arm (625 per arm) individually randomised (1:1:1), open-label controlled clinical trial investigating standard care diagnostic approach for tuberculosis. The trial will not use any unlicensed products.	
Objective	Outcomes	
Primary		
1. To establish the diagnostic value of trial-of-antibiotics for excluding pulmonary tuberculosis (PTB) in adults with prolonged cough at primary care level in Malawi.	Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 (i.e. after a trial-of-antibiotics if in azithromycin or amoxicillin arms, or without antibiotics if in standard of care arm) against a mycobacteriology reference standard, among participants submitting at least one sputum specimen	
2. To determine the overall clinical benefit of giving empirical antibiotic treatment in primary care participants with chronic cough.	Proportion of participants experiencing at least one of the following adverse outcomes by Day 29: 1) death 2) hospitalisation 3) missed TB diagnosis 4) HIV care loss to follow up 5) TB care loss to follow up	
Secondary		
3. To evaluate using nasopharyngeal Streptococcus pneumonia, the effect of a trial-of-antibiotics on selection for antimicrobial resistance.	Risk of acquiring nasopharyngeal Streptococcus pneumonia isolates resistant to any of the commonly used groups of antimicrobials by Day-29.	
4. To establish the diagnostic value of trial-of-antibiotics for excluding pulmonary tuberculosis (PTB) in adults with prolonged cough at primary care level in Malawi.	Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 (i.e. after a trial-of-antibiotics if in azithromycin or amoxicillin arms, or without antibiotics if in standard of care arm) against a mycobacteriology reference standard, among all	

	randomised participants, with those who could not provide sputum classified as mycobacteriologically negative.
5. To estimate the incremental cost-effectiveness of trial-of-antibiotics using azithromycin and trial-of-antibiotics using amoxicillin in comparison to standard of care, and to each other.	• Incremental cost per quality adjusted life year gained • Total direct medical costs per participant over 56 days • Eq-5D utility score
Exploratory	
Our exploratory analyses will be comparisons between the azithromycin and amoxicillin arms for all our primary and secondary outcomes.	
Population	Adults presenting to primary care centres in Malawi reporting cough.
	Inclusion criteria: • Ambulatory clinic attendees presenting with cough for ≥ 14 days • Aged at least 18 years • Reside in Blantyre and willing to return to the same clinic for follow up visits over the entire study period. Exclusion criteria: • Self-reported allergy to study medications • Acute danger signs defined in national TB treatment guidelines • Tuberculosis treatment or isoniazid preventive therapy in the last 6 months • Treated with antibiotics, other than co-trimoxazole prophylaxis, for the current illness or within the past 14 days
Treatment	Arm 1: Azithromycin 500mg once daily for 3 days commencing on randomization day. Arm 2: Amoxicillin 1 g 3 times daily for 5 days commencing on randomization day. Arm 3: Standard of care in current national guidelines for patients presenting with cough and without danger signs (No treatment until re-evaluation with sputum TB test results)
Duration	We will give treatments on the randomisation day (Day-1) and perform follow up activities on days 8, and 29.




Figure 1: Flow diagram for the planned clinical trial in Blantyre, Malawi

3 Introduction

3.1 Background

Antimicrobial resistance is a growing crisis, becoming in 2016 one of only four health topics ever to be discussed at the United Nations General Assembly.¹⁻⁴ Tuberculosis is the leading global infectious cause of death in adults,⁵ with approximately 10.4 million cases and 1.8 million deaths in 2015.⁶ The high case-fatality rate in part reflects suboptimal diagnostics (Figure 2).⁷⁻¹⁰




Figure 2: method of diagnosis for TB notifications globally (A) and in Blantyre, Malawi (B)

To complement the suboptimal diagnostics, standard diagnostic algorithms in resource-limited settings include a “trial-of-antibiotics” (Figure 3). This is a course of broad-spectrum antibiotics, with negligible *Mycobacterium tuberculosis* activity, given to patients with symptoms such as cough in order to “rule-out” or “rule in” tuberculosis.¹¹⁻¹³ Patients with negative sputum mycobacteriology and responded to antibiotic treatment are considered tuberculosis negative while those who remain symptomatic are deemed likely to have tuberculosis and undergo further evaluations leading on to receiving tuberculosis treatment.




Figure 3: Implementation of trial-of-antibiotics (marked with red boxes) in Malawi TB diagnostic algorithm, National TB control program (NTP)

Approximately 26.5 million course of antibiotics are prescribed in the diagnosis of the 5.3 million smear negative tuberculosis registrations per annum (Figure 4).⁶ This estimate is based on an average of 5 antibiotic courses per sputum-negative treatment initiation, with 2 courses given to the patients before tuberculosis treatment,⁸ and the other 3 courses accounting for patients whose symptoms resolved and tuberculosis was ruled out.¹⁴

Wilkinson et al ¹⁴ prescribed 120 + 74 courses of trial-of-antibiotics to diagnose 40 smear-negative TB patients (a typical ratio of ~1:5). ⁸ If generalizable, then for 5.3 million annual smear-negative TB registrations globally ~5 x 5.3 million trial-of-antibiotics courses (26.5 million) will have been prescribed.	Enrolled	280
	TB smear microscopy positive	160
	Given trial-of-antibiotics (amoxicillin)	120
	Improved, declared TB negative	46
	Given trial-of-antibiotics (erythromycin)	74
	Improved, declared TB negative	34
	Treated for smear negative TB	40
<i>Wilkinson et.al Int J Tuberc Lung Dis. 2000</i>		
Figure 4: Quantifying number of trial-of-antibiotics courses prescribed per year using data from Wilkinson et.al and WHO TB Report 2016		

Despite this widespread use, there is no randomised controlled trial evidence supporting the diagnostic accuracy of trial-of-antibiotics. There is also a dearth of evidence on their impact on antimicrobial resistance or patient clinical outcomes.

3.2 Systematic literature review

We performed a systematic literature review to determine the sensitivity and specificity of using a trial-of-antibiotics compared to sputum mycobacteriology for diagnosis of PTB. We also wanted to describe how trial-of-antibiotics fits into TB diagnostic algorithms: timing of prescription; type, duration, and number of antibiotic prescriptions; and how response to treatment is measured. We searched MEDLINE, Embase, and Global Health using the Ovid platform to identify studies meeting the following criteria:

Population	Adult patients with symptoms suggestive of pulmonary tuberculosis
Intervention	Routinely prescribed broad-spectrum oral antibiotics without MTB activity, and given as part of evaluation of pulmonary TB
Outcome	sensitivity and specificity of the intervention in comparison with any mycobacteriology test
Study design	Any design with prospective component allows evaluation of the outcome of the intervention
Time frame	Studies published after WHO declaration of TB as a 'global emergency' (1993)
Language	English, lack of translation capacity

We identified 7,064 articles from a systematic search on MEDLINE, Embase, and Global Health using the Ovid platform. Of these studies, 12 were eligible for narrative synthesis and seven had suitable data for meta-analysis. None of the studies was an RCT and all the observational studies were small and not primarily designed to address the benefits and consequences of trial-of-antibiotics. Unlike our proposed RCT, most of the published work was from hospital setting or in specialised clinics. Most studies used amoxicillin and some studies prescribed a subsequent course of antimicrobials either before or after assessing for improvement. The definition of improvement from baseline clinical state was largely subjective: it was based on self-report, clinical examination, radiological assessment or a combination.

There is no consensus on the sensitivity and specificity of trial-of-antibiotics across studies with estimates ranging from 43% to 91% for sensitivity and 41% to 82% for specificity (shown below).

Population, Study		Sensitivity, 95% CI			Specificity, 95% CI		
237	Wilkinson et al 1997	0.5	0.37	0.64	0.82	0.76	0.87
120	Wilkinson et al 2000	0.83	0.71	0.91	0.56	0.44	0.67
204	Kudjawu et al 2006	0.91	0.83	0.96	0.65	0.56	0.73
1000	Kamran et al 2006	0.72	0.62	0.8	0.41	0.38	0.44
264	Soto et al 2011	0.43	0.32	0.55	0.68	0.63	0.72
439	Soto et al 2013	0.46	0.34	0.58	0.6	0.53	0.66
440	Padmapriyadarsini et al 2	0.7	0.55	0.8	0.69	0.64	0.73

We could not identify any RCT, the current literature only has small studies, with trial-of-antibiotics not being the primary focus of investigation in most cases. There is limited data for primary care settings as most of the work was in hospital setting. None of the studies addressed AMR. Therefore, despite widespread use, the approach, the value and consequences of having trial-of-antibiotics in TB diagnostic algorithms, remains to be established.

3.3 Planned study

To address the evidence gaps related to a) accuracy, b) antimicrobial resistance, and c) impact on clinical outcomes), we propose to conduct a randomised controlled clinical trial recruiting adult patients presenting to primary care centres in Blantyre, Malawi with history of cough for at least 2 weeks. After excluding those with danger signs we will randomise participants to receiving or not receiving trial-of-antibiotics (azithromycin or amoxicillin) from Day-1 to determine diagnostic accuracy (specificity) against mycobacteriology reference standard (smear microscopy, Xpert/MTB/RIF and culture).

For secondary outcomes, we will also compare between arms differences in antimicrobial resistance and clinical outcomes (risk of death, hospitalisation, TB misdiagnosis, and loss to HIV or TB care follow up) at Day-29. To our knowledge this will be the first randomised controlled trial to address these questions in over 20 years of systematic use of trial-of-antibiotics without strong evidence base.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3.4 Rationale for current study

3.4.1 Accuracy of trial-of-antibiotics

As an approach that is being used on such a large scale, trial-of-antibiotics should ideally have a strong evidence-base (supported by reference mycobacteriology) of how much diagnostic and/or clinical improvement it brings to the TB diagnostic algorithm.^{15,16} This will be among the most important considerations when deciding whether it is worth the trade-off with potential for AMR. Such evidence could come from an RCT or a well-designed prospective study.¹⁵⁻¹⁷ However, despite being in use for more than 20 years, we have not identified any such clinical trial, and even the observational evidence is highly limited and of insufficient quality and quantity to definitively address the question.

There is also no guidance on antibiotic choice beyond a recommendation to avoid those with anti-tuberculosis activity (like fluoroquinolones). Another key area that lacks clarity is lack of a clear definition for clinical resolution when determining the outcome of trial-of-antibiotics. Clinical resolution is the basis for decisions that follow (i.e. discontinue follow up or proceed Antimicrobial resistance and trial-of-antibiotics

Antimicrobial resistance can be either intrinsic or acquired. The risk of acquired resistance relating to antibiotic use during evaluation for suspected tuberculosis has not been previously investigated, although previous work has shown that empirical antibiotics can drive rapid emergence of AMR.^{18,19} For example, co-trimoxazole prophylaxis for HIV-positive patients, introduced in 2005, was followed by near-universal resistance in bloodstream infections by 2010.²⁰ Mass drug administration of azithromycin for trachoma control initially reduces nasopharyngeal carriage of *Streptococcus pneumoniae*, but with increased macrolide-resistance 6 months later.^{21,22}

In our study, the AMR risks of empirical antibiotic prescriptions (azithromycin and amoxicillin arms of the RCT) are justified because of the widespread use of this approach for amoxicillin, and the low potential clinical impact and short-lived effects of use of azithromycin on AMR, given the limited use of macrolides in Malawi. Mathematical modelling work suggests that macrolide resistance can successfully be eliminated by intra-species competition alone (fitness cost) within 5 years of last use.²³

3.4.2 Antimicrobial resistance and trial-of-antibiotics

Antimicrobial resistance relating to antibiotic use during evaluation for suspected tuberculosis has not been investigated before. Previous work has shown that empirical antibiotics can drive rapid emergence of antimicrobial resistance.^{18,19} Co-trimoxazole prophylaxis for HIV-positive patients, introduced in 2005, was followed by near-universal resistance in bloodstream infections by 2010²⁰ also shown in Table 1. Mass drug administration of azithromycin for trachoma control initially

reduces nasopharyngeal carriage of *Streptococcus pneumoniae*, but with increased macrolide-resistance 6 months later.^{21,22}

We will investigate antimicrobial resistance in nasopharyngeal *S. pneumonia* by randomisation arm and cumulative antibiotic exposure to assess the extent to which brief exposure drives antimicrobial resistance during diagnostic work-up for tuberculosis. An ecological niche for many bacterial species, the upper respiratory tract also presents a convenient window for investigating antimicrobial resistance.²⁴ *S. pneumonia* is the organism of choice not only for being an important cause of respiratory tract infections but also because it often colonises the upper respiratory tract and has well documented laboratory investigation procedures in place.²⁵ As exploratory analyses, we will also assess nasopharyngeal colonization and antimicrobial resistance in relation to tuberculosis treatment and HIV status.

Table 1 Resistance patterns of common aetiologies of pneumonia to commonly used antimicrobials in Blantyre, Malawi

Organism		Gram positive		Gram negative			
		Streptococcus pneumoniae	Staphylococcus aureus	Haemophilus influenzae	Klebsiella pneumoniae	Escherichia coli	Pseudomonas aeruginosa
Prevalence		15.6%	6.6%	0.9%	4.4%	0.1%	1.5%
Resistance percentage	amoxicillin	*	*	58%	100%	94%	100%
	penicillin	21%	*	*	*	*	*
	co-trimoxazole	98%	40%	100%	92%	94%	75%
	chloramphenicol	21%	2%	92%	48%	61%	100%
	Erythromycin	2%	30%	*	*	*	*
	tetracycline	38%	35%	*	*	*	*
	Ceftriaxone	*	*	0%	90%	30%	100%
	Ciprofloxacin	*	*	NA	705	31%	24%
*not routinely tested							
2016 data from hospitalised febrile patients at Queen Elizabeth central hospital (Blantyre, Malawi) as reported by the MLW Clinical research laboratory (unpublished).							

3.4.3 Potential benefits of antibiotics

In areas with high HIV prevalence, empirical antibiotics during tuberculosis investigations could be life-saving: mortality immediately before and after tuberculosis diagnosis is high,^{7,26} and is often secondary to severe bacterial infections.²⁶⁻²⁸ The leading aetiologies of infection and death on tuberculosis treatment as well as among outpatients with tuberculosis-like symptoms are *Streptococcus pneumoniae* and non-typhoidal salmonellae (NTS): both can present with cough (primary cause) or as co-morbidities (super-infections) in patients presenting with active *Mycobacterium tuberculosis* (*M.tb*) disease.²⁶⁻²⁸ If effective treatment of this type of life-threatening primary/super-infections reduces mortality during the diagnostic work-up of suspected TB in people living with HIV (PLHIV), then empirical use of broad-spectrum antibiotics would be indicated for this purpose alone, irrespective of any diagnostic contribution to TB treatment decisions. In this context,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

azithromycin may be the most effective arm, as Salmonella infections are highly sensitive to azithromycin, but not to amoxicillin.²⁹

3.4.3.1 Measures of clinical benefit of trial-of-antibiotics

In this study, we will investigate the overall clinical benefit of trial-of-antibiotics by comparing the risk of any of death, hospitalisation, missed TB diagnosis, and loss to HIV or TB care follow up by Day 29. Although all these events are potential consequences of trial-of-antibiotics, grouping them as a single composite endpoint may only appropriately represent the effect of the intervention 1) there are similarities in the importance patients would attach to each of its components and 2) the components occur with similar frequencies in the patient population.³⁰

The impact of antibiotics on hospitalisation and mortality causing illnesses is as described above. Both these outcomes are important with their similarity hinged on the fact that hospitalisation event predicts mortality. In patients with chronic cough, frequencies of mortality and that of hospitalization over a two months period are similar, ranging from 2 to 6%.³¹

TB misdiagnosis becomes a concern because of the potential for misclassification in either direction –false positive or false negative. False positive diagnosis in the context of trial-of-antibiotics would occur when the underlying pathology for the respiratory symptoms is not responding to the antibiotic, which can be secondary to either AMR or the illness not being of bacterial origin. On the other hand, patients would be prone to a false negative result had both TB and a susceptible bacterial infection. If the symptoms were largely driven by the susceptible bacterial infection, their symptoms will improve and would be declared TB negative. TB is a life-threatening illness, missing its diagnosis can therefore lead to death which is more important to an individual patient than taking TB chemotherapy with a false positive TB diagnosis. We will therefore include only missed TB diagnoses in the composite clinical outcome. Unpublished data from Blantyre shows that the frequency of missed TB diagnosis under routine care settings is approximately 5% which is similar to that of death and hospitalisation.

Experiencing respiratory symptoms prompts care seeking which often leads to TB and HIV diagnosis and respective long-term treatment and follow up going way beyond resolution of initial symptoms. We hypothesize that giving antibiotics and curing the respiratory illness that prompted them to seek diagnosis, reduces care-seeking motivation. Care seeking is often driven by having symptoms and perceivable benefits of care often fade away as symptoms shed off. We will estimate the frequency of HIV and TB care loss to follow up at 1 month during the pilot study. The pilot study will also assess the combined risk of all the five components of the clinical benefit outcome.

3.4.4 Important subgroups

Response to trial-of-antibiotic- in patients with bacteriologically confirmed tuberculosis (i.e. false-negatives/low sensitivity from the perspective of TB diagnosis) may relate to multiple super-infections and so this phenomenon may vary by HIV status, since multiple concurrent infections are a hallmark of advanced HIV immunosuppression, and commonly identified in patients with suspected TB in the pre-ART era.^{8,27} More recently, in Malawi, 45% of adults who presented to primary care with prolonged cough (≥ 2 weeks) were HIV-positive, of whom only ~20% started TB treatment on the basis of positive mycobacteriology.³¹ As such, the benefits and consequences of trial-of-antibiotics may vary by HIV status and by subsequent TB treatment decisions. We will, therefore, include a pre-specified sub-analysis of trial outcomes stratified by HIV and ART status.

3.5 Choice of study interventions

Our trial will compare azithromycin and amoxicillin to standard of care. We propose 2 different antibiotic arms for the following reasons: -

- a) Macrolides, including azithromycin, are rarely used in Malawi because of their higher manufacturing costs. However, they do provide a more effective treatment of community-acquired pneumonia than the standard antibiotic by Ministry of Health for trial-of-antibiotic (amoxicillin), because of low levels of acquired macrolide-resistance in bacterial isolates in Malawi,²⁹ reflecting low rates of past exposure to this class of drugs, and also better intrinsic coverage of “bacterial cause of pneumonia including “atypical” intracellular organisms such as *mycoplasma* species.

Although viral pneumonias, *Pneumocystis jiroveci* (PCP) and non-infectious causes of cough will still not be expected to respond to azithromycin, this arm should then provide the highest possible diagnostic discrimination for bacterial vs mycobacterial causes of cough. The starting point of low pre-existing (acquired) resistance will also facilitate investigation of AMR acquired during trial-of-antibiotics. However, the trial will have limited national relevance in Malawi without comparison to an antibiotic in programmatic use.

- b) Amoxicillin is low cost option that is still a recommended treatment for community-acquired pneumonia in most settings, including UK, despite potential treatment failure from bacterial pneumonia due to organisms with intrinsic (“atypicals”) or acquired (common in gram-negative organisms, and *Staphylococcus aureus*) penicillin resistance.²⁹ This arm reflects the true standard of care (SOC) currently in widespread use in Malawi and many other low-income countries, and so provides data of immediate programmatic relevance and also a starting point to investigate exacerbation of pre-existing AMR pressure. If there is a marked difference between

the azithromycin and amoxicillin arms, then there will also be important health economic considerations of relevance to many national TB programmes beyond Malawi.

Azithromycin provides effective treatment for community-acquired pneumonia³²⁻³⁴ and has negligible activity against *M.tb*.^{35,36} As discussed above, macrolides are not commonly used in Malawi. Azithromycin has an excellent safety profile and is used for mass drug administration (MDA) in communities prone to trachoma. Azithromycin used for MDA in Ethiopia reduced inter-current infections^{21,37} and death in children,^{38,39} supporting the safety of using this drug for our trial.⁷

Amoxicillin is the first line treatment for outpatient management of pneumonia in Malawi and is commonly used for trial-of-antibiotics. We anticipate higher specificity for azithromycin than amoxicillin, due to broader coverage of “atypical pneumonia” organisms, and salmonella species, but with the 2 antibiotics arms having “equipoise” due to lack of previous head-to-head comparison.²⁷

3.6 Nasopharyngeal pneumococcus for AMR

Streptococcus pneumonia is a major cause of morbidity and mortality in children and adults.^{20,29,40,41} Asymptomatic nasopharyngeal carriage of *S. pneumoniae* is common and a prerequisite for the occurrence and transmission of invasive pneumococcal disease.^{42,43} Since carriage is more common than the invasive *S. pneumoniae* disease it forms a basis for establishing circulating serotypes, resistance patterns, and evaluation of vaccine effectiveness.

The other key advantage is the existence of globally accepted laboratory procedures for assessing and interpreting pneumococcal resistance. Our laboratory (in Malawi-Liverpool Wellcome Trust) has carried out pneumococcal work for decades with outstanding quality assurance reputation.

3.7 Objectives and outcomes

In Table 2 below, we present study objectives together with corresponding outcomes. We have clarified the outcomes with detailed definitions and planned analyses under “statistical approach” section.

Table 2: study objectives and outcomes

Objective	Outcome
Primary	
1. To establish the diagnostic value of trial-of-antibiotics for excluding pulmonary tuberculosis (PTB) in adults	Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 (i.e. after a trial-of-

with prolonged cough at primary care level in Malawi.	antibiotics if in azithromycin or amoxicillin arms, or without antibiotics if in standard of care arm) against a mycobacteriology reference standard, among participants submitting at least one sputum specimen
2. To determine the overall clinical benefit of giving empirical antibiotic treatment in primary care participants with chronic cough.	Proportion of participants experiencing at least one of the following adverse outcomes by Day 29: 1) death 2) hospitalisation 3) missed TB diagnosis 4) HIV care loss to follow up 5) TB care loss to follow up
Secondary	
3. To evaluate using nasopharyngeal Streptococcus pneumonia, the effect of a trial-of-antibiotics on selection for antimicrobial resistance.	Risk of acquiring nasopharyngeal Streptococcus pneumonia isolates resistant to any of the commonly used groups of antimicrobials by Day-29.
4. To establish the diagnostic value of trial-of-antibiotics for excluding pulmonary tuberculosis (PTB) in adults with prolonged cough at primary care level in Malawi.	Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 (i.e. after a trial-of-antibiotics if in azithromycin or amoxicillin arms, or without antibiotics if in standard of care arm) against a mycobacteriology reference standard, among all randomised participants, with those who could not provide sputum classified as mycobacteriologically negative.
5. To estimate the incremental cost-effectiveness of trial-of-antibiotics using azithromycin and trial-of-antibiotics using amoxicillin in comparison to standard of care, and to each other.	• Incremental cost per quality adjusted life year gained • Total direct medical costs per participant over 56 days • Eq-5D utility score
Exploratory	
Our exploratory analyses will be comparisons between the azithromycin and amoxicillin arms for all our primary and secondary outcomes.	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

4 Study design, participants, and statistical approach

4.1 Study design

This is a three arm (625 per arm) individually randomised (1:1:1), open-label controlled clinical trial investigating accuracy and broader clinical, and antimicrobial resistance impact of using trial-of-antibiotics to “rule out” tuberculosis among adults presenting with cough at primary care centres in Malawi.


4.2 Study setting

We will screen adults aged at least 18 presenting to primary care centres in Blantyre, Malawi. Blantyre has an estimated adult HIV prevalence of 12.7% (95% CI: 11.9 to 13.6) and an estimated tuberculosis prevalence of 1,014 per 100,000 (95% CI: 486 to 1,542).⁴⁴

4.3 Standard of care

The standard of care in national guidelines from the NTP for primary care patients presenting with cough and are otherwise well (no danger signs) is to take sputum x 2 for smear microscopy or Xpert and ask them to return for results, typically 3 days - 1 week later (Figure 3 and 5). The Malawi tuberculosis diagnostic algorithm recommends use of broad-spectrum antibiotics as trial-of-antibiotics after negative sputum tests are provided to the patient, if they remain symptomatic.

However, more commonly this algorithm is adapted in the outpatient setting to combine prescription of antibiotics (usually amoxicillin) with sputum collection at the first visit, to save the patient from making separate visits: thus, our amoxicillin arm is the most common standard-of-care in Malawi, while the no-antibiotic arm is the NTP recommended standard-of-care.



4.4 Eligibility criteria

We will offer enrolment to patients who satisfy the following inclusion and exclusion criteria.

4.4.1 Inclusion Criteria

- Ambulatory clinic attendees presenting with cough for at least 14 days
- No previous formal consultation for current illness (initial presentation)
- Aged at least 18 years
- Reside in Blantyre and willing to return to the same clinic for follow up visits over the entire study period.

4.4.2 Exclusion Criteria

- Self-reported allergy to study medications
- Danger signs (WHO/Malawi NTP): respiratory rate > 30/min, temperature >39°C, Heart rate >120/minute, confused/agitated, respiratory distress, systolic blood pressure <90 mmHg, inability to walk unassisted
- Treated with antibiotics other than co-trimoxazole prophylaxis within the past 14 days
- TB treatment or Isoniazid preventive therapy within the last 6 months

4.5 Interventions

We will have two active study arms receiving trial-of-antibiotics at enrolment (azithromycin and amoxicillin) and a standard of care arm of no trial-of-antibiotics. In this study, the goal is to investigate the role of these antibiotics as they are used in TB diagnostic algorithms, as “trial-of-antibiotics,” to exclude TB in symptomatic patients. The study is likely to be underpowered to detect differences between the 2 antibiotic arms will only be compared for exploratory outcomes.

4.5.1 Name and description of intervention arms

The study will have three arms as follows:

- Arm 1: Immediate trial-of-antibiotics with Azithromycin 500mg once daily for 3 days.
- Arm 2: Immediate trial-of-antibiotics with Amoxicillin 500 mg 3 times daily for 5 days.
- Arm 3: Standard of care

4.5.2 Legal status of drugs used in intervention arms

Both azithromycin and amoxicillin are registered for use in Malawi and United Kingdom, with both Arms 1 and 2 regimens being UK-recommended community-acquired pneumonia treatment.

4.5.3 Summary of Product Characteristics

Appendix 3 includes current versions of package inserts for azithromycin and amoxicillin. We will review and update (when applicable) the package inserts annually with each ethics continuing review.

4.5.4 Drug Storage and Supply

We will procure study products from Durbin PLC (DURBIN PLC 180 Northolt Road South Harrow Middlesex HA2 0LT). Azithromycin will be manufactured by Sandoz limited or other pharmaceutical companies recognised in United Kingdom where Durbin is based. Amoxicillin will be manufactured by Medopharm private limited or other pharmaceutical companies recognised in United Kingdom where Durbin is based. Both azithromycin and amoxicillin are stable at room temperature. We will therefore ship and store in ambient conditions.

4.5.5 Preparation and labelling of study drugs

Study products will be stored at Malawi Liverpool Wellcome Trust Pharmacy. The pharmacy team will be responsible for packing and labelling.

4.5.6 Known drug reactions (adverse events)

Azithromycin and amoxicillin are already widely used in Malawi and are well tolerated. Rare side effects for azithromycin include nervousness, dermatologic reactions including Stevens–Johnson syndrome, anaphylaxis and prolonged QT interval. Rare side-effects for amoxicillin are mental state changes, light-headedness, photosensitivity and severe allergic reactions.

4.5.7 Concomitant medication and interaction with other therapies

We do not have any restrictions with respect to concomitant medications apart from those listed in the exclusion criteria. We expect some participants to be on HIV antiretroviral drugs and some may subsequently start tuberculosis therapy. Important interactions therefore would be those with HIV antiretroviral drugs and tuberculosis therapy. There is no moderate or major interaction between either azithromycin or amoxicillin with the classes of HIV antiretroviral drugs, tuberculosis therapy, and antimalarial drugs used in Malawi.

4.5.8 Trial restrictions

We do not require participants to have any dietary restrictions. We will also accept co-administration with contraception. Our trial interventions can safely be used in pregnancy, so we will include pregnant women should they be eligible.

4.5.9 Assessment of compliance

On Day-8, we will document self-reported compliance adherence of study products.

4.5.10 Withdraw of interventions

The investigator may also terminate a participant from study product if indicated by an adverse reaction. If a participant stops taking study product either voluntarily or by investigator decision, they will be encouraged to remain in follow up and their data will form part of intention to treat analyses.

4.6 Statistical approach

We will summarise the processes of recruitment including non-eligibility and reasons of exclusion in a CONSORT flow chart. We will describe the study participants by their baseline characteristics which we will report for each arm. We will perform analyses of all our outcomes based on an intention to treat analysis (using the arm patient was randomised to), adjusting for centre. We will make the following comparisons:

- i) azithromycin or amoxicillin versus standard of care
- ii) azithromycin versus standard of care
- iii) amoxicillin versus standard of care

We will perform data cleaning and analysis using Stata release 15 (Stata Corp, College station, Texas, USA).

The following are descriptions of each outcome and corresponding statistical approach. The statistical approach will be expanded in a detailed statistical analysis plan, separate to the protocol, which will be finalised before unblinding the study data.

4.6.1 Primary outcome

4.6.1.1 Primary outcome 1: Specificity of trial-of-antibiotics versus mycobacteriology

Outcome definition

Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 ACASI against a mycobacteriology reference standard (b+d in Figure 6).

To minimise ascertainment bias in ascertaining this endpoint, the evaluation of improvement of baseline symptoms will be captured using a self-interview platform: Audio Computer Assisted Self-Interview (ACASI). After orientation, the participant will be left alone in the room to interact with the computer. ACASI on Day-8 will precede all other interaction with research staff and clinical assessment/decision making.

Mycobacteriology reference standard will be defined in participants with at least one specimen with a valid result on days 1 and 8 as:

- **TUBERCULOSIS-POSITIVE:** if at least one positive smear microscopy, Xpert/MTB/RIF, or MTB culture on sputum samples taken.
- **TUBERCULOSIS-NEGATIVE:** none of the day 1 and day 8 sputum samples are positive on smear microscopy, GeneXpert MTB/RIF, or MTB culture.

To minimise bias, the mycobacteriology will be performed by a high-quality research laboratory in the University of Malawi College of Medicine by staff with no access to participant treatment allocation information or ACASI results.

ACASI Response interpretation

The responses of participants during the ACASI interview will be classified as:

- **TUBERCULOSIS-POSITIVE:** participant reports lack of improvement of symptoms they had on Day 1.
- **TUBERCULOSIS-NEGATIVE:** participant reports improvement of symptoms they had on Day 1.




Figure 6: Ascertainment of diagnostic value of trial-of-antibiotics

Estimation of measures of effect

We will use a generalised linear model (GLM) with identity link to estimate risks differences and the GLM with log link to estimate risk ratios for the three comparisons, adjusting for center. For each comparison, we will report 95% Confidence Intervals and Chi-square p-values. In pre-specified

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).

subgroup analysis, we will estimate the treatment effects stratifying by baseline HIV status. If the GLM model does not converge, we will use logistic regression to estimate the treatment effect using an odds ratio.

Participants without mycobacteriology

Primary analyses will be limited to participants who have at least one valid sputum sample result from all samples collected on visits Day-1 and Day-8. However, in real-life, ~15% fail to produce sputum, we will as a secondary outcome, perform all the analyses described for primary outcome with these participants defined as mycobacteriology negative. Further sensitivity analyses with urine lipoarabamannan antigen (LAM) results will include them in mycobacteriology definition.

4.6.1.2 Primary outcome 2: Clinical benefit of trial-of-antibiotics

Outcome definition

Proportion of participants experiencing at least one of the following adverse outcomes: death, hospitalisation, TB misdiagnosis, HIV care loss to follow up, TB care loss to follow up. The definitions of the components of this composite clinical outcome are defined in the table below:

Outcome component	Definition
death	Proportion of deaths by Day 29
hospitalisation	Proportion hospitalised for any cause by Day 29
missed TB diagnosis	Day 29 proportion of participants meeting standard mycobacteriological and radiological TB definitions but incorrectly classified as TB negative and not yet on TB treatment by Day 29.
HIV care loss to follow up	Proportion of newly identified (Day 1) HIV positive participants not continuing with care by Day 29
TB care loss to follow up	Proportion of newly identified (Day 1/Day 8) TB positive participants who were put on treatment but were not continuing with treatment and follow up by Day 29

Estimation of measures of effect

We will use a generalised linear model (GLM) with identity link to estimate risks differences and the GLM with log link to estimate risk ratios for the three comparisons, adjusting for primary care center. For each comparison, we will report 95% Confidence Intervals and Chi-square p-values. If the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

outcome is rare or if GLM does not converge, we will use logistic regression to model odds and report odds ratios for the following comparisons and their associated report 95% CIs and p-values.

4.6.2 Secondary outcomes

Outcome definitions

- 1) Risk of acquiring nasopharyngeal Streptococcus pneumonia isolates resistant to any of the commonly used groups of antimicrobials by Day-29. We will exclude those with resistant isolates on both Day-1 and Day-29 from the numerator, as they may not truly represent incident resistance. In the denominator, we will include all randomised participants and perform analysis as intention to treat.
- 2) Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 (i.e. after a trial-of-antibiotics if in azithromycin or amoxicillin arms, or without antibiotics if in standard of care arm) against a mycobacteriology reference standard, among all randomised participants, with those who could not provide sputum classified as mycobacteriologically negative.

Estimation of measures of effect

Our secondary outcomes are anticipated to be rare, we will therefore use logistic regression to model odds and report odds ratios for the following comparisons and their associated report 95% CIs and p-values.

4.6.3 Exploratory outcome

Our exploratory analyses will be comparisons between the **azithromycin** and **amoxicillin** arms for all our primary and secondary outcomes.

4.6.4 Planned subgroup analyses

We will perform subgroup analysis for the primary outcome. The important subgroups based on rationale detailed under section 2.4.4, include HIV status, ART status, and PTB treatment. HIV and ART status will be as documented on Day-1 while PTB treatment will be either as:

- TB treatment commenced based on positive baseline (Day-1 and Day-8) mycobacteriology, or
- TB treatment commenced within 29 days of enrolment in patients with negative Day1 and Day-8 bacteriology.

The 29 days cut off for clinical decision to treat is to ensure that we only capture TB disease that was present at baseline. 29 days is a reasonable because: TB is a slowly progressing disease

which if positive at Day-29, must have been incident on Day-1; and in routine care setting it can take over a month from presentation to diagnosis of TB.⁸

4.7 Sample size and power

4.7.1 Primary outcome 1: specificity of trial-of-antibiotics versus mycobacteriology

We assume that trial-of-antibiotics (in azithromycin arm or in amoxicillin arm) will correctly classify 60% of mycobacteriology negative participants.¹⁴ We have determined that 400 mycobacteriologically negative (true negatives) participants per arm will provide 80% power to detect a 10% difference in proportion of participants correctly classified as negative by amoxicillin arm or by azithromycin arm (60%) versus standard of care arm (50%). See table 3. We assume that 80% of participants randomised will have negative mycobacteriology,³¹ requiring 500 participants to yield the 400 per arm. Assuming that 15% will not be able to produce sputum, and that 5% will not return for Day-8 visit, the sample size is increased to 625 per arm or 1,875 for the whole study.

Table 3: Power and sample size estimation for primary outcome 1

True negatives (mycobacteriology tests negative participants) b+d	¹ p (negatives correctly classified) d/(b+d)	² effect size	² power (X ² difference between independent proportions)
320	0.60	0.10	69%
400	0.60	0.10	80%
480	0.60	0.10	86%

¹ specificity with either azithromycin or amoxicillin trial-of-antibiotics arms
² risk difference (azithromycin arm- standard of care arm)

4.7.2 Primary outcome 2: Incidence of adverse clinical outcome at Day-29

We will use a pilot study to determine the standard of care risk of at least one of death, hospitalisation, missed TB diagnosis, HIV care loss to follow up, and TB care loss to follow up. The pilot study is described in section 5.0.

For now, we will assume that there is a 10% risk of experiencing this composite adverse outcome in the standard of care arm, and that loss to follow up by Day-29 will be 10%. With the sample size of 625 participants per arm (based on the primary outcome 1 sample size calculation), and alpha of 0.05, we will be able to detect the difference between intervention and standard of care with 80% power, if the risk in intervention arm is 6% or lower (Table 4).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 4: Sample size estimation for clinical benefit outcome

Participants per arm based on primary	625
10% loss to follow up by Day-29	562
Outcome risk in standard of care arm	0.10
Desired power	0.80
Alpha	0.05
Required intervention arm risk	0.06

4.7.3 Secondary outcomes

1) Incidence of resistant *S. pneumonia* on Day-29

We assume 10% loss to follow up by Day-29, and the rate of *S. pneumonia* isolation from nasopharyngeal swabs in this population is expected to be ~45% at Day-29. The sample size based on the primary outcome (625 per arm) will provides ~253 *S. pneumonia* isolates/arm. In the standard of care arm, with 10% risk of resistant isolates, this translates into 25 cases. For the intention to treat population (the randomised 625 participants/arm) in the standard of care arm the 21 cases of resistant isolates translate into 4% (25/625) risk. With 4% risk in the standard of care group, alpha of 0.05, and using Pearson's Chi-squared test we will be able to detect the impact of the intervention with 85% power if it leads to an increase of risk of resistant isolates from 4% to 8% (or RR of 2, risk difference of 4%) (Table 5).

Table 5: Sample size estimation for AMR outcome

Participants per arm based on primary	625
10% loss to follow up by Day-29	563
45% isolation rate for <i>S. pneumonia</i>	253
Resistance: 10% of all isolates	25
Overall proportion in standard of care (25/625)	0.04
Effect size (RR =2, or RD=4%)	0.04 to 0.08
Power	0.85

4.7.4 Exploratory outcomes

We anticipate that our sample size will be enough for hypothesis generation around our exploratory objectives but may not be enough to provide discriminatory power for comparison of outcomes between arms.

5 Pilot study

This area of research has limited evidence to guide the precise determination of sample size and the practical aspects of the clinical trial making a pilot study an invaluable tool. We have identified the following as key knowledge gaps which require exploration using a pilot study:

- 1) Among the adult patients presenting to primary care centres with cough for at least 2 weeks what proportion gets antibiotics:
 - a. before clinic presentation?
 - b. on first clinic visit?
 - c. on follow up clinic visit after mycobacteriology results?
- 2) Following antibiotic treatment, how do patients report their clinical response? What are the best questions to ask patients post-antibiotic treatment to determine if they have improved or not? How best can we deliver these questions via Audio Computer Assisted Self-Interview (ACASI)? How well do these responses correlate with mycobacteriology and radiology?
- 3) What is the best timing for nasopharyngeal swabs for evaluating AMR in patients who receive a course of antibiotics during TB investigations?
- 4) In the standard of care setting, what proportion of adult patients presenting to primary care centres with cough for at least 2 weeks experience the following adverse outcomes (as defined under the clinical benefit composite endpoint)?
 - a. death
 - b. hospitalisation
 - c. missed TB diagnosis
 - d. HIV care loss to follow up
 - e. TB care loss to follow up

5.1 Specific objectives of the pilot study

- 1) To determine the proportion of adults with prolonged cough who
 - a. present to primary care having already had antibiotics for the index clinical complaints.
 - b. receive antibiotics before sputum mycobacteriology results at first presentation
 - c. receive antibiotics after negative mycobacteriology

- 2) To establish an objective way of documenting response to antibiotic treatment using Audio Computer Assisted Self Interview (ACASI). Assessing ACASI responses against clinical signs, outcomes of TB mycobacteriology and chest radiography.
- 3) To determine:
- a. the prevalence of *Streptococcus pneumoniae*;
 - b. the prevalence of resistant *Streptococcus pneumoniae* isolates;
 - c. the optimal specimen collection timing for evaluating impact of antibiotic use on prevalence of *Streptococcus pneumoniae* isolates resistant to common antibiotics
- 4) To establish standard of care rates of the following adverse clinical outcomes:
- a. death
 - b. hospitalisation
 - c. missed TB diagnosis
 - d. HIV care loss to follow up
 - e. TB care loss to follow up

5.2 Population for the pilot study

This exploratory study will include up to 400 adult (≥18 years old) patients presenting to primary care centres with cough for at least 14 days. We will exclude patients not meeting the eligibility criteria of the clinical trial.


5.3 Pilot study procedures

The pilot study procedures are outlined in the flow chart below. Following pilot study informed consent, we will use a baseline assessment questionnaire to collect clinical history, and antibiotic use for the index illness prior to the clinic visit. Throughout follow up, we will record all antibiotic use from any source. We will collect sputum samples for mycobacteriology from all participants on Day1 and Day 8.

We will establish HIV and TB diagnosis throughout the study, link participants to care services, and follow their adherence to follow up. For TB we will use a combination of Xpert, smear and culture on Day 1, 8 and whenever symptomatic suggestions of TB arise. We will also perform a chest x-ray on Day 8 and a follow up film on Day 29.

We will collect nasopharyngeal swab samples, for antimicrobial resistance assessment using *Streptococcus pneumoniae* culture and sensitivity, on Day 1, Day 8, and Day 29. We will assess change in symptoms and well-being from Day 1 to Day 8, by using various combinations of questions and answers delivered via Audio Computer Assisted Self Interview (ACASI) on Day 8. We

will ask participants which sets of questions they found easy to understand. We will also collect clinical information on all study visits including illness events, hospitalisations and vital status.



Pilot study flow diagram, summarizing the study procedures at each visit.

5.4 Data analysis

We will report the proportions of participants who used any antibiotics prior to primary care and during work-up for Tuberculosis. We will determine the best ACASI question and response combinations by participant reported ease of use, and by assessing correlation with clinical findings,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

mycobacteriology and radiological outcomes. The optimal time for assessing AMR will be determined by comparing incidence of resistant *Streptococcus pneumonia* isolates at days 8 and 29.

We will comparing participants exposed to antibiotics to those not exposed to antibiotics by estimating and reporting relative risk and 95% confidence intervals for:

- 1) Day 8 and Day 29 of resistant Streptococcus pneumonia
- 2) Composite adverse outcome of experiencing any of: death, hospitalisation, missed TB diagnosis, HIV care loss to follow up, and TB care loss to follow up

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

6 Study procedures

6.1 Screening

At the designated primary health care centres, study staff will approach patients with symptoms of pulmonary tuberculosis (including cough of any duration, fever, weight loss, and night sweats) with information about the study. Those willing to be screened for eligibility will be assessed against the study inclusion and exclusion criteria.

6.2 Informed consent

We will seek written informed consent (Appendix 1) from all patients who meet eligibility criteria before any trial-specific procedures. Screening for tuberculosis symptoms will not be considered as part of the study procedures, as it is already a fundamental component of the routine clinical assessment and history taking. A member of the study team will hand an informed consent form to a potential participant in their preferred language (Chichewa or English) detailing background, procedures, risks, benefits and participant expectations should they choose to join the study. The consent form will also state that the participant is free to withdraw from the trial at any time for any reason without prejudice to future care, and no obligation to give reason for the withdrawal.

If they choose to join as a study participant, we will then request them to sign two copies of informed consent form. If a potential participant does not know how to read or write, we will perform the informed consent process in the presence of a witness. In such cases, if they agree to participate in the study, we will ask them to sign using a thumb-print in the presence of their witness and a study team member. We will keep one copy of the signed informed consent forms and hand the participant the other copy.

6.3 Baseline procedures

After consenting, we will on the same visit request participants to provide 2 on the spot sputum samples for smear microscopy, Xpert and culture collected at least one hour apart. Those unable to spontaneously produce sputum will be instructed in the physiotherapy manoeuvre of "huffing" (forced expiration technique) for inducing mucus clearance from the airways.

Patients still unable to provide at least one mucoid sputum sample of >1 ml will initially will be given a sputum container and asked to return it the next day. If they do not manage to produce sputum at home, their mycobacteriology results will be treated as missing. We expect ~15% of participants to fall in this category³¹ and have accounted for them in the sample size estimation. For participants who produce less than the needed quantity of sputum, we will process them for the planned tests in the following priority order: 1) Xpert MTB/RIF, 2) MTB culture, 3) smear microscopy. The Xpert MTB/RIF

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

is the single most important guide for immediate clinical diagnosis and the MTB culture is the single most accurate reference diagnostic.

We will also collect a urine sample which we will store for subsequent lipoarabamannan antigen detection (LAM); and a nasopharyngeal swab for pneumococcal culture and sensitivity testing to estimate prevalent antimicrobial resistance. We will also perform HIV tests according to the national algorithm, and if positive we will do HIV viral load. After completing all Day-1 visit procedures, we will link the newly tested positive participants to routine HIV care and will document when they start ART (Malawi National Program provides same-Day-ART initiation to all newly-diagnosed or untreated HIV-positive patients). After the sample collections, we will collect the following information:

- Demographic data, including precise geographic locator information using ePAL geolocation software (to aid follow-up). The locator information will also include phone numbers for the participant and for up to 3 family, or friends they nominate as alternative contacts.
- Clinical history including information on tuberculosis symptoms and health care seeking for HIV and tuberculosis care services including ART, cotrimoxazole, isoniazid preventive therapy, and past TB treatment.
- Vital signs including height and weight

After completing all these baseline procedures, we will randomise the participants to the three study arms.

6.4 Assignment of interventions

Step 1: An independent statistician based at LSHTM and without contact with participants or the study staff that see participants, will use the ralloc command in Stata (StataCorp LLC, College Station, Texas USA. Release 15.0) to prepare a random allocation sequence in advance of study recruitment efforts. Randomisation will be 1:1:1 to the three arms of the trial, block-randomised with variable block sizes, and stratified by primary care centre.

Step 2: Each treatment allocation will be printed alongside a randomisation number onto a pdf document.

Step 3: The statistician will email the pdf document to an independent designee within university of Malawi who will print and place the randomisation assignments in envelopes labelled with randomisation numbers. The independent designee will hand the envelopes directly to the study pharmacist who will also receive a shipment of study medications. The pharmacist will store the envelopes in a secure location within the pharmacy.

Step 5: The pharmacist will pre-pack 625 each of protocol doses of azithromycin and amoxycillin without any reference to the allocation sequence. There is no need to refer to the allocation sequence for this step because the dosage for both treatments is the same and the total number of allocation for each treatment is known.

Step 6: At the beginning of each working week and upon request from study site, the study pharmacist will hand to site coordinators of each primary care center, a recruitment-rate-driven daily working stock of 1) the sequentially numbered sealed opaque envelopes containing randomization numbers and corresponding treatment allocations, and 2) study drugs.

Step 7: Study staff from each site will conduct patient eligibility assessments. Patients meeting the quick criteria of age and cough for ≥ 14 days, will be assigned screening IDs before being taken through the full eligibility criteria and consenting process. Participants will be considered eligible and ready for randomisation after they meet all criteria and sign consent.

Step 8: Upon signing consent, the participant will be taken to the site-coordinators (nurse or clinical officer) who will assign them the next available study ID number and document it on their paper and electronic eligibility checklist and enrolment CRF. The study ID number will be the number on the treatment allocation envelope plus a site-specific code. They will then open the envelope, document the treatment assignment, to the participant's enrolment paper and electronic case report forms as well as on a study card that will be pasted in the participant personal health profile book.

Step 9: The coordinator will double-check to ensure that the enrolment number and the treatment assignment are recorded correctly. They will then record screening date, screening ID, randomisation date, study ID, and randomisation arm on an enrolment log. They will then administer the allocated treatment. Administering study medications will not be considered as prescribing considering that prescription to all eligible participants will have already been done by the study protocol.

Step 10: When the stock of either envelopes or study drugs runs out,, the nurse-coordinators will reorder a from the study pharmacist.

Additional details

All steps of receipt, and utilization of the allocations and study drugs are elaborated in a detailed SOP. The SOP guides implementation of the above plan as far as possible and in line with site conditions.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The study drugs will be pre-packed blindly without any reference to treatment allocations ensuring that neither the pharmacist nor the nurse-coordinator know the treatment allocations until just before assigning to a participant.

6.5 Blinding

We will mask the treatments as far as possible. The study pharmacist will remain blinded as they will use the randomly- allocated label numbers to prepare and pack the correctly dosed study medications in opaque packaging. Study outcome assessment will occur without reference to study treatment allocation. All laboratory forms for mycobacteriology and nasopharyngeal pneumococcal work will have no reference to participant treatment allocation. On Day-8, assessment of improvement from baseline symptoms will utilize audio computer-assisted self-interview (ACASI) to minimise potential for social-mediated reporting and ascertainment biases (see Procedures Section of the protocol). All clinical endpoints assessment case report forms will bear no reference to treatment arm. However, we will keep participants, research coordinators, and routine care staff unmasked to ensure safety of the participants and allow appropriate patient management decision-making which may be related to the trial interventions.

6.6 Participant follow up

Following enrolment and completion of baseline procedures we will ask participants to return for follow up visits on days 8, and 29. They will be given 1 sputum collection bottle when leaving the clinic on Day-1 to bring with them sputum for mycobacteriology planned for Day-8 (“morning” specimen) followed by collection of one further “spot” sputum on Day-8, 2 sputum samples in total). We will also collect a second urine sample for storage for subsequent LAM antigen testing. Patients unable to produce at least one mucoid sputum sample of >1ml on Day-8 will be assumed for purposes of analysis to be mycobacterially negative for the Day-8 sputum samples. We are performing two sets of sputum examinations (Day-1 and Day-8) for each participant to strengthen the accuracy of the reference standard. Considering that TB progresses very slowly, making a diagnosis on Day-8 is not different from that made on Day-1.

We will advise participants that their sputum TB test results will start becoming available from 48 working hours after collection, but with the last test (MTB culture) taking up to 4 weeks. Patients will be advised that they will not be routinely contacted if positive TB test results become available before their Day-8 appointment (as is standard for outpatient management without danger signs in Malawi), and so will be advised to report promptly back to the clinic (with refund of transportation given) if they experience any clinical deterioration during Days 2 to 7.

In the circumstances where TB treatment is commenced before completion of antibiotics prescribed for trial-of-antibiotics (amoxicillin and azithromycin), we will ask them to carry on with their allocated intervention together with the TB treatment.

6.6.1 Day-8 activities

On Day-8, the first activity before the participants undergo all other evaluations will be documentation of self-reported improvement of baseline (Day 1) TB symptoms using a pilot-validated set of questions and answer options delivered via Audio Computer Assisted Self Interview (ACASI). We will use ACASI with the goal of eliminating inter-observer variability and patient/interviewer reporting or ascertainment biases. After a “how to use” orientation and testing session, the participant will be left alone in the room to interact with the computer. A pre-recorded interviewer will ask the participant questions related to how their symptoms have changed on that day compared to how they were on Day-1 and will offer categorised voice-recorded responses with touch screen response buttons. The ACASI questionnaire will also include questions about adherence to study arm drugs and any other medical care (including traditional medicine) sought during the previous week.

Other activities for all participants on Day-8 include:

- collection of a second sputum sample for mycobacteriology tests.
- providing participants with Day 1 smear and Xpert results linking those with positive tests, ongoing symptoms and other illnesses with routine care for appropriate management.
- clinical history detailing clinical events since enrolment.
- documentation of any medications including antimicrobials and traditional medicine outside the study
- providing a study Day-29 appointment card

For participants with negative Day-1 mycobacteriology results we will perform clinical evaluation after ACASI and will inform the patient that any positive Day-8 sputum mycobacteriology results will be reported actively (via telephone or house visit) as soon as quality-assured results become available (within 48 working hours for microscopy and Xpert). Patients who have not had complete resolution of symptoms will be referred with all available results to routine primary care management.

6.6.2 Day-29 activities

Day-29 will be the final study visit. We will on this visit, collect data on clinical impact of antibiotic treatment and risk of AMR. In line with the second primary endpoint (composite clinical impact), we will document:

- 1) vital status
- 2) hospitalisations
- 3) identify missed TB diagnosis by using culture results from Day 1 and Day 8 sputum, any chest X-rays performed in follow up, and repeat mycobacteriology if symptomatic
- 4) perform HIV tests for those with unknown status and eligible for routine HIV test.
- 5) establish the status of HIV care and follow up
- 6) establish the status of TB care and follow up

We will first collect information on clinical events prior to and at the visit and communicate all available sputum culture results and the final reported CXR results.

After collecting the clinical information, we will collect nasopharyngeal swab sample for assessing antimicrobial resistance. To collect the sample, a trained study staff will swab the participants' nasopharynx and place the swab in a tube containing skim milk tryptone glucose glycerol (STGG).

6.7 Laboratory methods

6.7.1 Tuberculosis mycobacteriology

We will process mycobacteriology tests at the Malawi College of Medicine TB laboratory, a reference laboratory located in Blantyre. For sputum samples collected on Day-1, we will perform smear microscopy, Xpert MTB/RIF and MTB culture. For sputum samples collected on Day-8, we will perform smear microscopy and MTB culture. We will use Mycobacteria Growth Indicator Tube (MGIT) and Lowenstein-Jensen (LJ) culture methods for TB culture. Once isolated, we will perform speciation as *Mycobacteria tuberculosis* (MTB) or non-tuberculous mycobacteria (NTM) using MBP84 antigen testing, microscopic cording and, if necessary, morphology and growth characteristics at different temperatures and on solid (LJ) media containing p-nitrobenzoic acid (PNB).

6.7.2 Urine antigen testing for lipoarabamannan and other MTB antigens

Urine will be collected and stored as two 1 ml aliquots at -20°C from each participant on both Day-1 and Day-8 for subsequent mycobacterial antigen testing. No appropriate product is available for immediate use, but we anticipate that a commercial product with sufficiently high analytic accuracy for use in ambulant outpatients (sensitivity and specificity) may become available during the course of, or soon after, the study. If ongoing evaluations of the FIND-sponsored FujiFilm product⁴⁵ meet or exceed pre-specified requirements for clinical utility in the outpatient context, then point-of-care LAM testing at Day-1 and Day-8 will be added to the mycobacteriological definition of TB and patient management as soon as kits have been obtained and evaluated in Malawi.

6.7.3 Antimicrobial resistance testing

We will store swabs in STGG at minus 80°C. At a later stage we will thaw them in batches, and plate them onto selective media and culture colonies consistent with *S. pneumoniae*. We will determine Minimal inhibitory concentrations (MICs) using E-test strips (azithromycin and amoxicillin), and Kirby Bauer Disc diffusion testing (azithromycin, rifampicin, tetracycline, ceftriaxone, chloramphenicol, cotrimoxazole, erythromycin and penicillin) and define resistance by EUCAST breakpoints.

We will store isolates and remaining STGG at minus 80°C to allow genotypic characterization, isolation and susceptibility testing of other key respiratory pathogens, FTD 33 respiratory pathogen diagnostic panel, metagenomics analysis, and microarrays to detect multiple carriage and macrolide resistance genes in a broader range of pathogens at a later stage.

6.8 Loss to follow-up

To minimise loss to follow up, we will at enrolment record geolocation information of participants' place of residence using ePAL android app, a high-resolution mapping system validated in Blantyre. We will also record up to 3 contact phone numbers of the participant and their nominated friends and relatives. Should a participant miss a study visit, we will contact them by phone or by visiting them at home to encourage them to attend the study visit before expiry of prescribed visit window.

We anticipate a loss to follow-up of 5% by Day-8, and 10% by Day-29. We have accounted for these assumptions in the sample size calculation. We will not replace participants who discontinue study participation or study treatment regardless of reason for withdrawal or discontinuation or the time either of these occurs.

6.9 Trial closure

We will consider the trial closed after completing follow up of the last enrolled participant, and upon recording all mycobacteriology laboratory reports. Antimicrobial resistance lab work will continue beyond trial closure. The trial may be terminated early by the trial steering committee upon recommendation of the DSMB. The halting rule for a trial arm is an unacceptable high level of deaths assessed using an alpha determined at the first DSMB meeting.

6.10 Summary schedule for study procedures

In Table 6 below, we have summarised all key study procedures over the study period.

Table 6: key study procedures over the study period

TIMEPOINT**	STUDY PERIOD			
	Enrolment	Follow up		
	Day-1	Day-8		Day-29
ENROLMENT:				
Eligibility screen	X			
Informed consent	X			
Allocation	X			
INTERVENTIONS:				
Azithromycin	X			
Amoxicillin	X			
Standard of care	X			
ASSESSMENTS:				
Demographics	X			
History of antibiotic use	X	X		X
*History & examination	X	X		X
**Sputum collection	X	X		
Urine for TB LAM test	X	X		
Nasopharyngeal swab	X			X
HIV test and CD4 count	X			X
Linking to routine care	X	X		X
¹ ACASI		X		
***Clinical events		X		X
		X		X
Update contact & address				
*For symptomatic participants, Day-8 sputum mycobacteriology should be fast-tracked to inform care before they leave the clinic. Chest X-ray should be performed and interpreted in real-time. **Give sputum bottles at end of Day-1 visit for submission on Day-8. Also collect sputum and perform mycobacteriology at any time of the study when clinically indicated ***Illnesses, clinic visits, radiological outcomes, new HIV diagnosis, new TB diagnosis, death, hospitalisation, missed TB diagnosis, HIV care loss to follow up, and TB care loss to follow up ¹Audio Computer Assisted Self-Interview for documenting change of symptoms on Day- 8 versus Day-1				

7 Safety reporting

7.1 Definitions

Term	Definition
Adverse Event (AE)	Any untoward medical occurrence in a participant to whom a medicinal product has been administered, including occurrences which are not necessarily caused by or related to that product. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational medicinal product (IMP), whether or not considered related to the IMP.
Adverse Reaction (AR)	Any untoward and unintended response in a participant to an investigational medicinal product which is related to any dose administered to that participant. The phrase “response to an investigational medicinal product” means that a causal relationship between a trial medication and an AE is at least a reasonable possibility, i.e. the relationship cannot be ruled out. All cases judged by either the reporting medically qualified professional or the Sponsor as having a reasonable suspected causal relationship to the trial medication qualify as adverse reactions.
Serious Adverse Event (SAE)	A serious adverse event is any untoward medical occurrence that: • Results in death • Is life-threatening • Requires inpatient hospitalisation or prolongation of existing hospitalisation • Results in persistent or significant disability/incapacity • Consists of a congenital anomaly or birth defect Other ‘important medical events’ may also be considered serious if they jeopardise the participant or require an intervention to prevent one of the above consequences.
Serious Adverse Reaction (SAR)	An adverse event that is both serious and, in the opinion of the reporting investigator, believed with reasonable probability to be due to one of the trial treatments, based on the information provided.
Suspected Unexpected Serious Adverse Reaction (SUSAR)	A serious adverse reaction, the nature and severity of which is not consistent with the information about the medicinal product in question set out: • In the case of a product with a marketing authorisation, in the summary of product characteristics (SmPC) for that product.

1

2

3

4

7.2 DMID grading for AEs

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

We will adopt the events grading criteria prepared by the Division of Microbiology and Infectious Diseases (DMID) of the USA National Institutes of Health as shown in the table below.

1 MILD	2 MODERATE	3 SEVERE	4 LIFE-THREATENING
Transient or mild discomfort (< 48 hours); no medical intervention required	Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention required	Marked limitation in activity, some assistance usually required; medical intervention required, hospitalizations possible	Extreme limitation in activity, significant assistance required; significant medical intervention required, hospitalization probable

20

21

22

23

24

25

26

27

7.3 Grading for expected events

The following table provides guidance for grading known important or frequent side effects of azithromycin (based on the AE grading criteria provided in the BREATHE Trial Protocol, also investigating azithromycin) and amoxicillin graded on the DMID scale. All events not mentioned here or in Appendix 2, will be graded using the DMID grading for AEs table presented above.

	1 MILD	2 MODERATE	3 SEVERE	4 LIFE-THREATENING
Side-effects	1	2	3	4
Acute Allergic Reaction	Localized urticaria (wheals) with no medical intervention indicated	Localized urticaria with intervention indicated OR Mild angioedema with no intervention indicated	Generalized urticaria OR Angioedema with intervention indicated OR Symptoms of mild bronchospasm	Acute anaphylaxis OR Life-threatening bronchospasm OR Laryngeal oedema
Rash <i>Specify type, if applicable</i>	Localized rash	Diffuse rash OR Target lesions	Diffuse rash AND Vesicles or limited number of bullae or superficial ulcerations of mucous membrane limited to one site	Extensive or generalized bullous lesions OR Ulceration of mucous membrane involving two or more distinct mucosal sites OR Stevens-Johnson syndrome OR Toxic epidermal necrolysis
Mental state changes	mild anxiety or depression	moderate anxiety or depression; therapy required;	severe mood changes requiring therapy; or suicidal ideation;	acute psychosis requiring hospitalization; or suicidal gesture/attempt or hallucinations

	1 MILD	2 MODERATE	3 SEVERE	4 LIFE-THREATENING
		change in normal routine	or aggressive ideation	
Photosensitivity	Painless erythema covering <10% body surface area	Tender Erythema covering 10 - 30% body surface area	Erythema covering >30% body surface area and erythema with blistering, requiring intervention	Life-threatening consequences; urgent intervention indicated
Arrhythmia (by ECG or physical examination) <i>Specify type, if applicable</i>	No symptoms AND No intervention indicated	No symptoms AND Non-urgent intervention indicated	Non-life-threatening symptoms AND Non-urgent intervention indicated	Life-threatening arrhythmia OR Urgent intervention indicated
Prolonged QTc Interval	0.45 to 0.47 seconds	> 0.47 to 0.50 seconds	> 0.50 seconds OR ≥ 0.06 seconds above baseline	Life-threatening consequences (e.g., Torsade de pointes, other associated serious ventricular dysrhythmia)
Diarrhea ≥ 1 year of age	Transient or intermittent episodes of unformed stools OR Increase of ≤ 3 stools over baseline per 24-hour period	Persistent episodes of unformed to watery stools OR Increase of 4 to 6 stools over baseline per 24-hour period	Increase of ≥ 7 stools per 24-hour period OR IV fluid replacement indicated	Life-threatening consequences (e.g., hypotensive shock)
Tinnitus	Symptoms causing no or minimal interference with usual social & functional activities with intervention not indicated	Symptoms causing greater than minimal interference with usual social & functional activities with intervention indicated	Symptoms causing inability to perform usual social & functional activities	NA
Nausea	Transient (< 24 hours) or intermittent AND No or minimal	Persistent nausea resulting in decreased oral intake for 24 to 48 hours	Persistent nausea resulting in minimal oral intake for > 48 hours OR Rehydration	Life-threatening consequences (e.g., hypotensive shock)

	1 MILD	2 MODERATE	3 SEVERE	4 LIFE-THREATENING
	interference with oral intake		indicated (e.g., IV fluids)	
Vomiting	Transient or intermittent AND No or minimal interference with oral intake	Frequent episodes with no or mild dehydration	Persistent vomiting resulting in orthostatic hypotension OR Aggressive rehydration indicated (e.g., IV fluids)	Life-threatening consequences (e.g., hypotensive shock)
Laboratory	1	2	3	4
ALT or SGPT, High <i>Report only one</i>	1.25 to < 2.5 x ULN	2.5 to < 5.0 x ULN	5.0 to < 10.0 x ULN	≥ 10.0 x ULN
Creatinine Clearance or eGFR, Low <i>Report only one</i>	NA	< 90 to 60 ml/min or ml/min/1.73 m ² OR 10 to < 30% decrease from baseline	< 60 to 30 ml/min or ml/min/1.73 m ² OR ≥ 30 to < 50% decrease from baseline	< 30 ml/min or ml/min/1.73 m ² OR ≥ 50% decrease from baseline or dialysis needed

7.4 Causality

When reporting on serious adverse events, the trial investigator will state whether they believe that the event is causally associated with any of the trial treatments and the strength of the causal relationship. They will also state whether the adverse event was expected and what if any action was taken.

Relationship	Description
Unrelated	There is no evidence of any causal relationship
Unlikely	There is little evidence to suggest there is a causal relationship (e.g. the event did not occur within a reasonable time after administration of the trial medication). There is another reasonable explanation for the event (e.g. the participant's clinical condition, other concomitant treatment).
Possible	There is some evidence to suggest a causal relationship (e.g. because the event occurs within a reasonable time after administration of the trial medication). However, the influence of other factors may have contributed to the event (e.g. the participant's clinical condition, other concomitant treatments).
Probable	There is evidence to suggest a causal relationship and the influence of other factors is unlikely.

Definitely	There is clear evidence to suggest a causal relationship and other possible contributing factors can be ruled out.
Not assessable	There is insufficient or incomplete evidence to make a clinical judgement of the causal relationship.

7.5 Reporting Procedures

7.5.1 Non-serious Adverse Events (AEs)

Adverse events will be ascertained from patient follow-up visits or reports from relatives or guardian if patient cannot be contacted for follow-up. Study clinicians will be responsible for recording of details of the event including a description of the event, date of onset, severity, assessment of relatedness to trial interventions. Adverse events will be recorded in case report forms and uploaded into the study database.

7.5.2 Serious Adverse Events (SAEs)

All serious adverse events (SAEs) will be recorded on the relevant study CRFs and reported immediately to the Principal Investigator who will ensure that they are compiled in aggregate form and reported to COMREC and the DSMB once every 6 months. The DSMB will review SAE reports at their 6 monthly meetings and issue recommendations which will be shared with ethics committees. Events relating to a pre-existing condition or any planned hospitalisations for elective treatment of a pre-existing condition will not be reported as SAEs.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

8 Economic evaluation

8.1 Objective

The objective of the economic evaluation is to undertake a cost-utility analysis to estimate the incremental cost-effectiveness of trial-of-antibiotics using azithromycin and trial-of-antibiotics using amoxicillin in comparison to standard of care, and to each other. We will systematically compare costs and consequences associated with the interventions.

8.2 Outcomes

We will perform a within trial comparison of the three treatment arms to estimate the incremental cost per quality-adjusted life year (QALY) gained for the azithromycin or amoxicillin arm in comparison to standard of care. Costs will be estimated from the Malawian Ministry of Health perspective. Health outcomes will be quantified in QALYs, estimated from participants' responses to the Chichewa version of the EQ-5D-3L, a Health quality of life (HRQoL) measure.^{46,47} We will adopt a time horizon matching the length of participant follow-up to achieve the within trial evaluation.

8.3 Data collection

The health economic data collection will be undertaken alongside planned clinical data collections. We will administer the Chichewa version of the EQ-5D-3L to all trial participants at baseline (Day1), Day 8 and Day 29. The Chichewa EQ-5D-3L was prepared in accordance with international and EuroQoL guidelines. The EQ-5D uses a descriptive system and a visual analogue scale (VAS). HRQoL on the day of response is defined using the descriptive system in terms of the following dimensions: 1) mobility, 2)self care, 3)usual activities, 4)pain/discomfort, and 5) anxiety or depression. The responses are then split into the following ordinal levels: 1) no problems; 2) some or moderate problems; and 3) severe or extreme problems.

The EQ-5D has 243 health states to which each response is allocated and converted to an EQ-5D utility score using a tariff. Tariff sets are derived from national surveys and currently no Malawian EQ-5D tariff exists. Zimbabwe, a setting similar to Malawi, has EQ-5D tariff set. In this study, we will use the Zimbabwean set to derive EQ-5D utility scores⁴⁸ an acceptable practice considering the similarities in how the two populations value health.⁴⁹ The EQ-5D utility scores in the Zimbabwean tariff, range from 1.0 (which means no problems in the five dimensions) to -0.29 (defined as severe problems in all five dimension).

We will capture all healthcare resources used by trial participants from recruitment into the trial till Day 29. This will be undertaken on Day 1, Day 8 and Day 29. Healthcare resources will be translated into direct medical costs using previously estimated costs^{47,50,51} and the wider literature.

Drug prices will be based on International market prices.⁵² The health resource use questionnaire will at a minimum capture:

- Outpatient clinic visits
- Days of inpatient hospital care
- Medications
- Investigations and procedures

8.4 Data analysis

Our primary analysis will focus on direct intervention and the broader healthcare costs. We will define direct intervention costs as the costs associated with the application of the interventions. We will plot health state values measured by the EQ-5D-3L against time assuming that the health states reported at each time point are linearly connected. We will estimate QALYs associated with participant health profile by area under the plotted curve as calculated using the trapezium rule.

We will use a range of analytical methods depending on whether baseline covariates (EQ-5D utility values) are balanced between the trial arms or not. If they are balanced, we can obtain unbiased cost-effectiveness estimates by using non-parametric bootstrap approaches; if imbalance exists regression methods will be the approach of choice.

We will explore a range of estimators and undertake model diagnostics to determine the optimal model because the distributions of costs and QALYs are commonly skewed, often bimodal, or truncated. We will estimate mean costs and outcomes for each intervention together with respective mean incremental cost-effectiveness ratio. We will for each estimate report respective measures of uncertainty (standard errors and confidence intervals). We will also estimate the net monetary benefits (NMBs) for a range of different willingness to pay (WTP) thresholds. To identify the optimal intervention at different WTP thresholds, we will construct cost-effectiveness acceptability curves (CEACs) based on the NMB framework.

8.5 Missing data

For each participant we will collect complete data as far as possible but in cases of missing values, a common occurrence in trials, we will perform additional analyses to explore the impact of and account for the missingness.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

9 Data management

9.1 Source Data

We will consider a document as source if it is where data were first recorded, and from which we obtained participants' case report forms (CRF) data. These will include hospital records, health center records, participant health passport, laboratory and pharmacy records, diaries, radiographs, and correspondence. We will consider CRF entries as source data if the CRF is the site of the original recording.

We will on all study-specific documents, other than study ID code list, the signed consent forms household locator form and, refer to the participant by their trial participant identification number, not by name. We will keep study ID code list, consent and locator forms separate from the rest of the participant file to avoid linkage between participant name and the study ID.

9.2 Data collection methods

We will collect data using standardised, pre-tested CRFs in two forms:

- programmed into android tablets using Open Data Kit (ODK) platform (opendatakit.org) with paper back-ups.
- optical mark recognition readable forms read and extracted using TELEFORM system (Cardiff Software, Inc., Vista, CA), an optical-character-recognition software.

9.3 Data management

Any participants' identifiable data collected by the Study Coordination Centre will be stored securely and their confidentiality protected in accordance with the Data Protection Act 1998.

To ensure data security and maintenance of participant confidentiality, we will take several strict measures. All the study data collection tablets and computers will be encrypted, password protected and stored in a fireproof lockable cabinet inside a locked room. The principal investigator, study coordinator and data manager will be responsible for the maintenance of the tablets as well as all other computers, and their security from viruses and theft. All users will check in with the study coordinator and sign for data entry tablets every time they are taken out to for data entry and upon return. Whenever not in use, the devices will be kept in their locked cabinet.

We will keep all paper records in a locked space only be accessible to the principal investigator, co-investigators and delegated study staff. Study databases will be encrypted, password protected and will be stored on dedicated servers within the University of Malawi College of Medicine. We will keep all electronic and paper records securely for up to 10 years after the end of the trial in accordance with LSHTM Records Retention & Disposal Schedule guidelines.

9.4 Quality control and quality assurance

We will apply quality control at each stage of data handling in accordance with GCP requirements to ensure that all data are reliable and have been processed correctly. We will manual review all paper CRFs for completeness, accuracy and legibility before scanning. Our ODK data entry system will include automatic pre-programmed real-time data validation. The TELEFORM system will also have pre-programmed automatic data validation capabilities. We will perform data quality assurance (QA) on a random 10% of all participant files. The QA process will involve examining database entries and for paper source documents, verification of database entries and source.

9.5 Access to data

We will upon request, provide direct access to authorised representatives from the Sponsor, host institution and the regulatory authorities to allow smooth running of trial-related monitoring, audits and inspections.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

10 Data monitoring and quality assurance

10.1 Data monitoring

Site monitoring for safety will be conducted to ensure human subject protection. The study will be monitored just before commencing enrolment, then once every 6 months by a monitoring team from the University of Malawi College of Medicine. The objective will be to ensure that study procedures, study products administration, and data collection processes are of high quality and meet ethical and regulatory guidelines. The regular monitoring will focus on the following areas: 1) protocol adherence, 2) informed consent documentation, 3) trial endpoints, 4) treatment discontinuation, 5) regulatory documents, 6) compare source documents and case report forms for accuracy, and 7) documentation practices in general.

10.2 Audits and Inspections

The study will be subject audit by the London School of Hygiene & Tropical Medicine under their remit as sponsor, the Study Coordination Centre and other regulatory bodies to ensure adherence to GCP.

10.3 Data Safety and Monitoring Board (DSMB)

We will set up a DSMB before commencing trial activities. The DSMB will provide independent review of the study conduct, progress and findings. It will comprise 3 members including a chairperson who will be responsible for collating and communicating the views of the DSMB. The DSMB will consist of an independent statistician and two clinicians, at least one of them a physician, with research experience and expertise in the management of tuberculosis and HIV in Africa. The proposed data safety monitoring plan will be discussed in a teleconference including the DSMB members and the key investigators prior to the study starting.

The proposed meeting schedule is 6 monthly. Two weeks before a 6 monthly DSMB meeting, the study team will prepare a report covering study progress, study approvals, any obstacles, and recruitment statistics, adverse events, withdrawals and trial outcome measures. The DSMB will, through its chairperson, provide written feedback to the principal investigator who will be responsible for passing it on to ethics committees.

10.4 Trial Management Group (TMG)

A Trial Management Group (TMG) will be appointed and will be responsible for overseeing the progress of the trial. The day-to-Day-management of the trial will be co-ordinated through the University of Malawi College of Medicine.

10.5 Trial Investigational Team

Our investigational team includes expertise in diagnosis and management of TB; clinical evaluation of TB diagnostics; design and conduct of large randomised controlled trials; laboratory TB and AMR diagnostics; data management and analysis.

Chief investigator

Dr Titus H Divala: the chief investigator and PhD student will be responsible for protocol development, coordination and conduct of the trial, governance, data management, data analysis and results dissemination. Dr Divala is a clinician with a career interest in clinical trials. Apart from medical training, he holds MPH and Masters of Science in epidemiology and preventive medicine. He has managed two large GCP, US-NIH-funded clinical trials, one of which was IND as the local PI supervising over 40 study staff at two sites in different cities. He has worked as a clinician for over 8 years in Malawi, a period when identifying TB cases and putting them on treatment was a daily job. This topic therefore falls in area of great personal interest above and beyond the potential benefit it has towards improving patient care in Malawi and all low and middle-income countries where 95% of the TB burden lies, where this approach is the standard.

Co-investigators and members of PhD supervisory team

Prof Katherine L Fielding: a seasoned TB statistician and clinical trialist, and PhD supervisor for the CI, will be responsible for protocol development, conduct of the study, and data dissemination.

Prof Elizabeth L Corbett: a seasoned TB clinical epidemiologist and PhD co-supervisor for the CI, will be responsible for protocol development, conduct of the study, and data dissemination.

Co-investigators and members of PhD advisory committee

Dr Derek J Sloan: clinician with detailed local clinical and research experience, will be responsible for protocol development, trial implementation and data dissemination.

Prof Neil French: a seasoned pneumococcal expert, will be responsible for protocol development, oversee all aspects of AMR work, and data dissemination.

Collaborators

Dr Marriott Nliwasa: clinician, with experience conducting studies in the study setting. He will be support the conduct of the study, linkage with the national program, and data dissemination.

Mr Augustine Choko: statistician, with expertise and experience in using ACASI. He will support ACASI development, data management and development of analysis plan.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Dr Ankur Gupta-Wright: clinician, will provide clinical input in protocol development and clinical consultation support to research coordinators during study implementation..

Dr Jennifer Cornick: microbiologist, will be support protocol development, and AMR laboratory methods and analysis, and data dissemination.

Prof Jon Øyvind Odland: Epidemiologist and honorary professor at University of Malawi College of Medicine, responsible for seeking ethical approvals from the funder appointed ethics committee.

11 Ethics and dissemination

We will ensure that this trial is conducted in accordance with the principles of the Declaration of Helsinki and in full conformity with relevant regulations and with the ICH Guidelines for Good Clinical Practice E6 (R2) of November 2016.

11.1 Risk assessment

This is a low risk study as it is using already licensed antibiotics with good safety profile in a population defined by national clinical guidelines as clinically stable and not requiring other intervention but TB investigations. Our work complements standard of care by bringing in detailed TB diagnostics. In our study, the standard of care equivalent of the antibiotics we will prescribed on Day-1 to those randomised to either azithromycin or amoxicillin arms, are in standard of care prescribed on Day-8 only to mycobacteriology negative symptomatic patients (similar to the no antibiotic or standard of care arm of our trial). So, participants randomised to no antibiotic at Day-1 will not be receiving inadequate care but the recommended standard management of withholding antibiotics until after the TB results are available (Figure 1). To maintain participant safety and continuity of their care while on study interventions, we will not blind routine care clinical team and they will be free to manage the participants on their clinical judgement and national guidelines.

11.2 Research ethics approval

We will seek ethical approval for the trial protocol, informed consent forms, participant information sheet, any advertising material, and amendments to any of these documents, from the University of Malawi College of Medicine Research and Ethics Committee (COMREC), the LSHTM Research Ethics Committee, and Regional Committee for Health and Research Ethics, NTNU-Midt, Norway (on behalf of the funder). We will seek regulatory approval from the Malawi Pharmacy, Medicines, and Poisons Board (PMPB). Every year when the trial is active, we will seek continuous ethical review and approval before expiry of previous year's approval. In the event of an amendment, the changes will only be implemented upon ethical and regulatory approval.

11.3 Indemnity

London School of Hygiene & Tropical Medicine holds Public Liability ("negligent harm") and Clinical Trial ("non-negligent harm") insurance policies which apply to this trial.

11.4 Sponsor

London School of Hygiene & Tropical Medicine will act as the main sponsor for this study. Delegated responsibilities will be assigned locally.

11.5 Declaration of interests

The study team declares that they have no conflict of interest in conducting this clinical trial.

11.6 Cost of participation, ancillary and post-trial care

During the study, participant will benefit from frequent interaction with clinical study staff and associated optimised management of illnesses. There are minimal risks including discomfort associated with collection of nasopharyngeal samples, and side-effects of study interventions. We will reimburse participant transport for attending study visits.

11.7 Dissemination policy

This work will form part of a PhD thesis for Titus Divala, which he will submit to the London School of Hygiene & Tropical Medicine (LSHTM). All publications and presentations relating to the study will be authorised by the Trial Management Group. The first publication of the trial results will be in the name of the Trial Management Group, if this does not conflict with the journal's policy. If there are named authors, these will include at least the trial's Chief Investigator, Statistician and Trial Coordinator.

Members of the TMG and the DSMB will be listed and contributors will be cited by name if published in a journal where this does not conflict with the journal's policy

12 References

1. Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, Guerin PJ, Piddock LJ. Understanding the mechanisms and drivers of antimicrobial resistance. *The Lancet* 2016; **387**(10014): 176-87.
2. World Health Organization. The evolving threat of antimicrobial resistance: options for action: Geneva: World Health Organization; 2012.
3. World Health Organization. Antimicrobial resistance: global report on surveillance: World Health Organization; 2014.
4. Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen J-A, Klugman K, Davies S. Access to effective antimicrobials: a worldwide challenge. *The Lancet* 2016; **387**(10014): 168-75.
5. Raviglione M, Sulis G. Tuberculosis 2015: burden, challenges and strategy for control and elimination. *Infectious disease reports* 2016; **8**(2): 6570.
6. World Health Organization. Global tuberculosis report 2016. 2016.
7. Nliwasa M, MacPherson P, Mukaka M, Mdolo A, Mwapasa M, Kaswaswa K, Msefula C, Chipungu G, Mwandumba H, Corbett E. High mortality and prevalence of HIV and tuberculosis in adults with chronic cough in Malawi: a cohort study. *The international journal of tuberculosis and lung disease* 2016; **20**(2): 202-10.
8. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. *The Lancet* 2007; **369**(9578): 2042-9.
9. Corbett E, MacPherson P. Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality [State of the art series. Active case finding/screening. Number 5 in the series]. *The international journal of tuberculosis and lung disease* 2013; **17**(9): 1125-38.
10. Siddiqi K, Lambert M-L, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. *The Lancet infectious diseases* 2003; **3**(5): 288-96.
11. Ghana Health Service. Guidelines for the Clinical Management of TB and HIV Co-infection in Ghana. In: Department DCaP, editor. Accra; 2007.
12. Ministry of Health. Malawi National TB Programme Manual. . In: Programme NT, editor. 8 ed. Lilongwe; 2016.
13. National Department of Health. South Africa National Tuberculosis Management Guidelines 2014. In: Coordination TDS, editor. Pretoria; 2014.
14. Wilkinson D, Newman W, Reid A, Squire S, Sturm A, Gilks C. Trial-of-antibiotic algorithm for the diagnosis of tuberculosis in a district hospital in a developing country with high HIV prevalence. *The International Journal of Tuberculosis and Lung Disease* 2000; **4**(6): 513-8.
15. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Annals of internal medicine* 2011; **155**(8): 529-36.
16. Rychetnik L, Frommer M, Hawe P, Shiell A. Criteria for evaluating evidence on public health interventions. *Journal of Epidemiology & Community Health* 2002; **56**(2): 119-27.
17. Schunemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, Williams JW, Jr., Kunz R, Craig J, Montori VM, Bossuyt P, Guyatt GH, Group GW. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. *BMJ* 2008; **336**(7653): 1106-10.
18. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. *Nature medicine* 2004; **10**(12s): S122.
19. Goossens H, Ferech M, Vander Stichele R, Elseviers M, Group EP. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. *The Lancet* 2005; **365**(9459): 579-87.
20. Everett DB, Mukaka M, Denis B, Gordon SB, Carrol ED, van Oosterhout JJ, Molyneux EM, Molyneux M, French N, Heyderman RS. Ten years of surveillance for invasive

- Streptococcus pneumoniae* during the era of antiretroviral scale-up and cotrimoxazole prophylaxis in Malawi. *PLoS one* 2011; **6**(3): e17765.
21. Coles CL, Mabula K, Seidman JC, Levens J, Mkocho H, Munoz B, Mfinanga SG, West S. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant *Streptococcus pneumoniae* carriage in young children 6 months after treatment. *Clinical Infectious Diseases* 2013; **56**(11): 1519-26.
 22. Mitjà O, Houinei W, Moses P, Kapa A, Paru R, Hays R, Lukehart S, Godornes C, Bieb SV, Grice T. Mass treatment with single-dose azithromycin for yaws. *New England Journal of Medicine* 2015; **372**(8): 703-10.
 23. Maher MC, Alemayehu W, Lakew T, Gaynor BD, Haug S, Cevallos V, Keenan JD, Lietman TM, Porco TC. The fitness cost of antibiotic resistance in *Streptococcus pneumoniae*: insight from the field. *PLoS One* 2012; **7**(1): e29407.
 24. Man WH, de Steenhuijsen Piters W, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. *Nat Rev Microbiol* 2017; **15**(5): 259-70.
 25. Satzke C, Turner P, Virolainen-Julkunen A, Adrian PV, Antonio M, Hare KM, Henao-Restrepo AM, Leach AJ, Klugman KP, Porter BD. Standard method for detecting upper respiratory carriage of *Streptococcus pneumoniae*: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group. *Vaccine* 2013; **32**(1): 165-79.
 26. Cain KP, Anekthananon T, Burapat C, Akksilp S, Mankhatitham W, Srinak C, Nateniyom S, Sattayawuthipong W, Tasaneeyapan T, Varma JK. Causes of death in HIV-infected persons who have tuberculosis, Thailand. *Emerging infectious diseases* 2009; **15**(2): 258.
 27. Bedell RA, Anderson ST, Van Lettow M, Åkesson A, Corbett EL, Kumwenda M, Chan AK, Heyderman RS, Zachariah R, Harries AD. High prevalence of tuberculosis and serious bloodstream infections in ambulatory individuals presenting for antiretroviral therapy in Malawi. *PLoS One* 2012; **7**(6): e39347.
 28. Schleicher G, Feldman C. Dual infection with *Streptococcus pneumoniae* and *Mycobacterium tuberculosis* in HIV-seropositive patients with community acquired pneumonia. *The International Journal of Tuberculosis and Lung Disease* 2003; **7**(12): 1207-8.
 29. Musicha P, Cornick JE, Bar-Zeev N, French N, Masesa C, Denis B, Kennedy N, Mallewa J, Gordon MA, Msefula CL, Heyderman RS, Everett DB, Feasey NA. Trends in antimicrobial resistance in bloodstream infection isolates at a large urban hospital in Malawi (1998–2016): a surveillance study. *The Lancet Infectious Diseases* 2017; **17**(10): 1042-52.
 30. Montori VM, Permanyer-Miranda G, Ferreira-González I, Busse JW, Pacheco-Huergo V, Bryant D, Alonso J, Akl EA, Domingo-Salvany A, Mills E. Validity of composite end points in clinical trials. *Bmj* 2005; **330**(7491): 594-6.
 31. Nliwasa M, MacPherson P, Chisala P, Kamdolozi M, Khundi M, Kaswaswa K, Mwapasa M, Msefula C, Sohn H, Flach C. The sensitivity and specificity of Loop-Mediated Isothermal Amplification (LAMP) assay for Tuberculosis diagnosis in adults with chronic cough in Malawi. *PLoS one* 2016; **11**(5): e0155101.
 32. Lubell Y, Turner P, Ashley EA, White NJ. Susceptibility of bacterial isolates from community-acquired infections in sub-Saharan Africa and Asia to macrolide antibiotics. *Tropical Medicine & International Health* 2011; **16**(10): 1192-205.
 33. Phua J, Dean NC, Guo Q, Kuan WS, Lim HF, Lim TK. Severe community-acquired pneumonia: timely management measures in the first 24 hours. *Critical Care* 2016; **20**(1): 237.
 34. Lim W, Smith D, Wise M, Welham S. British Thoracic Society community acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together. *Thorax* 2015: thoraxjnl-2015-206881.
 35. van der Paardt A-F, Wilffert B, Akkerman OW, de Lange WC, van Soolingen D, Sinha B, van der Werf TS, Kosterink JG, Alffenaar J-WC. Evaluation of macrolides for possible use against multidrug-resistant *Mycobacterium tuberculosis*. *European Respiratory Journal* 2015; **46**(2): 444-55.

36. Falzari K, Zhu Z, Pan D, Liu H, Hongmanee P, Franzblau SG. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. *Antimicrob Agents Chemother* 2005; **49**(4): 1447-54.
37. Fry A, Jha H, Lietman T, Chaudhary JP, Bhatta R, Elliott J, Hyde T, Schuchat A, Gaynor B, Dowell S. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. *Clinical infectious diseases* 2002; **35**(4): 395-402.
38. Porco TC, Gebre T, Ayele B, House J, Keenan J, Zhou Z, Hong KC, Stoller N, Ray KJ, Emerson P. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. *Jama* 2009; **302**(9): 962-8.
39. Keenan JD, Ayele B, Gebre T, Zerihun M, Zhou Z, House JI, Gaynor BD, Porco TC, Emerson PM, Lietman TM. Childhood mortality in a cohort treated with mass azithromycin for trachoma. *Clin Infect Dis* 2011; **52**(7): 883-8.
40. Musher DM, Thorner AR. Community-acquired pneumonia. *N Engl J Med* 2014; **371**(17): 1619-28.
41. Gordon SB, Chaponda M, Walsh AL, Whitty CJ, Gordon MA, Machili CE, Gilks CF, Boeree MJ, Kampondeni S, Read RC, Molyneux ME. Pneumococcal disease in HIV-infected Malawian adults: acute mortality and long-term survival. *AIDS* 2002; **16**(10): 1409-17.
42. Jochems SP, Weiser JN, Malley R, Ferreira DM. The immunological mechanisms that control pneumococcal carriage. *PLoS pathogens* 2017; **13**(12): e1006665.
43. Goldblatt D, Hussain M, Andrews N, Ashton L, Virta C, Melegaro A, Pebody R, George R, Soininen A, Edmunds J, Gay N, Kayhty H, Miller E. Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. *J Infect Dis* 2005; **192**(3): 387-93.
44. National Tuberculosis Control programme. Malawi Nationwide Tuberculosis Prevalence Survey. 45th Union World Conference on Lung Health. Barcelona, Spain, 2014.
45. Global Health Innovative Technology Fund. Highly Sensitive POC TB-LAM Rapid Diagnostic Test. 2017. <https://www.ghitfund.org/impact/portfolio/awpdetail/detail/78> (accessed 28 Feb 2018).
46. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. *Health policy (Amsterdam, Netherlands)* 1990; **16**(3): 199.
47. Maheswaran H, Petrou S, MacPherson P, Choko AT, Kumwenda F, Lalloo DG, Clarke A, Corbett EL. Cost and quality of life analysis of HIV self-testing and facility-based HIV testing and counselling in Blantyre, Malawi. *BMC medicine* 2016; **14**(1): 34.
48. Jelsma J, Hansen K, De Weerd W, De Cock P, Kind P. How do Zimbabweans value health states? *Population health metrics* 2003; **1**(1): 11.
49. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes: Oxford university press; 2015.
50. Maheswaran H, Petrou S, MacPherson P, Kumwenda F, Lalloo DG, Corbett EL, Clarke A. Economic costs and health-related quality of life outcomes of HIV treatment after self-and facility-based HIV testing in a cluster randomized trial. *Journal of acquired immune deficiency syndromes (1999)* 2017; **75**(3): 280.
51. Maheswaran H, Petrou S, Cohen D, MacPherson P, Kumwenda F, Lalloo DG, Corbett EL, Clarke A. Economic costs and health-related quality of life outcomes of hospitalised patients with high HIV prevalence: A prospective hospital cohort study in Malawi. *PLOS ONE* 2018; **13**(3): e0192991.
52. Frye JE. International Medical Products price indicator guide: Management Sciences for Health, 2015.

13 Appendix 1: Informed consent

Included as a separate document on headed pages.

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

14 Appendix 2: Division of Microbiology and Infectious Diseases (DMID) adult toxicity table

TABLE VERSION: November 2007

ABBREVIATIONS: Abbreviations utilized in the Table:

ULN = Upper Limit of Normal LLN = Lower Limit of Normal R_x = Therapy Req = Required

Mod = Moderate IV = Intravenous ADL = Activities of Daily Living Dec = Decreased

• **ESTIMATING SEVERITY GRADE**

For abnormalities NOT found elsewhere in the Toxicity Tables use the scale below to estimate grade of severity:

GRADE 1 Mild Transient or mild discomfort

(< 48 hours); no medical intervention/therapy required

GRADE 2 Moderate Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required

GRADE 3 Severe Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalizations possible

GRADE 4 Life-threatening Extreme limitation in activity, significant assistance required; significant medical intervention/therapy required, hospitalization or hospice care probable

SERIOUS OR LIFE-THREATENING AEs

ANY clinical event deemed by the clinician to be serious or life-threatening should be considered a grade 4 event. Clinical events considered to be serious or life-threatening include, but are not limited to: seizures, coma, tetany, diabetic ketoacidosis, disseminated intravascular coagulation, diffuse petechiae, paralysis, acute psychosis, severe depression.

COMMENTS REGARDING THE USE OF THIS TABLE

- Standardized and commonly used toxicity tables (Division of AIDS, NCI’s Common Toxicity Criteria (CTC), and World Health Organization (WHO)) have been adapted for use by the Division of Microbiology and Infectious Diseases (DMID) and modified to better meet the needs of participants in DMID trials.
- For parameters not included in the following Toxicity Tables, sites should refer to the “Guide for Estimating Severity Grade” located above.

- Criteria are generally grouped by body system.
- Some protocols may have additional protocol specific grading criteria, which will supersede the use of these tables for specified criteria.

HEMATOLOGY				
	Grade 1	Grade 2	Grade 3	Grade 4
Hemoglobin	9.5 - 10.5 gm/d L	8.0 - 9.4gm/dL	6.5 - 7.9 gm/d L	< 6.5 gm/dL
Absolute Neutrophil Count	1000-1500/ mm ³	750-999/ mm ³	500-749/ mm ³	<500/ mm ³
Platelets	75,000- 99,999/ mm ³	50,000- 74,999/ mm ³	20,000-49,999/ mm ³	<20,000/ mm ³
WBCs	11,000-13,000/ mm ³	13,000- 15,000 / mm ³	15,000- 30,000/ mm ³	>30,000 or <1,000 / mm ³
% Polymorphonuclear Leucocytes + Band Cells	> 80%	90 – 95%	>95%	-----
Abnormal Fibrinogen	Low: 100-200 mg/dL High: 400-600 mg/dL	Low: <100 mg/dL High: >600 mg/dL	Low: < 50 mg/dL -----	Fibrinogen associated with gross bleeding or with disseminated coagulation
Fibrin Split Product	20-40 mcg/ ml	41-50 mcg/ ml	51-60 mcg/ ml	> 60 mcg/ ml
Prothrombin Time (PT)	1.01 - 1.25 x ULN	1.26-1.5 x ULN	1.51 -3.0 x ULN	>3 x ULN
Activated Partial Thromboplastin (APPT)	1.01 -1.66 x ULN	1.67 - 2.33 x ULN	2.34 - 3 x ULN	> 3 x ULN
Methemoglobin	5.0 - 9.9 %	10.0 - 14.9 %	15.0 - 19.9%	> 20.0 %

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES).

CHEMISTRIES				
	Grade 1	Grade 2	Grade 3	Grade 4
Hyponatremia	130-135 mEq/ L	123-129 mEq/ L	116-122 mEq/ L	< 116 mEq/ L or abnormal sodium <i>with</i> mental status changes or seizures
Hypernatremia	146-150 mEq/ L	151-157 mEq/ L	158-165 mEq/ L	> 165 mEq/ L or abnormal sodium <i>with</i> mental status changes or seizures
Hypokalemia	3.0 - 3.4 mEq/ L	2.5 - 2.9 mEq/ L	2.0 - 2.4 mEq/ L or intensive replacement therapy or hospitalization required	< 2.0 mEq/ L or abnormal potassium <i>with</i> paresis, ileus or life-threatening arrhythmia
Hyperkalemia	5.6 - 6.0 mEq/ L	6.1 - 6.5 mEq/ L	6.6 - 7.0 mEq/ L	> 7.0 mEq/ L or abnormal potassium <i>with</i> life-threatening arrhythmia
Hypoglycemia	55-64 mg/dL	40-54 mg/dL	30-39 mg/dL	<30 mg/d L or abnormal glucose <i>with</i> mental

				status changes or coma
Hyperglycemia (nonfasting and no prior diabetes)	116 - 160 mg/dL	161- 250 mg/d L	251 - 500 mg/dL	> 500 mg/d L or abnormal glucose <i>with</i> ketoacidosis or seizures
Hypocalcemia (corrected for albumin)	8.4 - 7.8 mg/dL	7.7 - 7.0 mg/dL	6.9 - 6.1 mg/dL	< 6.1 mg/dL or abnormal calcium <i>with</i> life threatening arrhythmia or tetany
Hypercalcemia (correct for albumin)	10.6 - 11.5 mg/d L	11.6 - 12.5 mg/d L	12.6 - 13.5 mg/d L	> 13.5 mg/dL or abnormal calcium <i>with</i> life threatening arrhythmia
Hypomagnesemia	1.4 - 1.2 mEq/ L	1.1 - 0.9 mEq/ L	0.8 - 0.6 mEq/ L	< 0.6 mEq/ L or abnormal magnesium <i>with</i> life-threatening arrhythmia
Hypophosphatemia	2.0 - 2.4 mg/dL	1.5 -1.9 mg/dL or replacement Rx required	1.0 -1.4 mg/dL intensive therapy or hospitalization required	< 1.0 mg/dL or abnormal phosphate <i>with</i> life-threatening arrhythmia
Hyperbilirubinemia (when accompanied by any	1.1 - <1.25 x ULN	1.25 - <1.5 x ULN	1.5 – 1.75 x ULN	> 1.75 x ULN

increase in other liver function test)				
Hyperbilirubinemia (when other liver function are in the normal range)	1.1 - <1.5 x ULN	1.5 - <2.0 x ULN	2.0 – 3.0 x ULN	> 3.0 x ULN
BUN	1.25 - 2.5 x ULN	2.6 - 5 x ULN	5.1 - 10 x ULN	> 10 x ULN
Hyperuricemia (uric acid)	7.5 – 10.0 mg/dL	10.1 – 12.0 mg/d L	12.1 – 15.0 mg/d L	>15.0 mg/d L
Creatinine	1.1 - 1.5 x ULN	1.6 - 3.0 x ULN	3.1 - 6 x ULN	> 6 x ULN or dialysis required
EN ZYMES				
	Grade 1	Grade 2	Grade 3	Grade 4
AST (SGOT)	1.1 - <2.0 x ULN	2.0 – <3.0 x ULN	3.0 – 8.0 x ULN	> 8 x ULN
ALT (SGPT)	1.1 - <2.0 x ULN	2.0 – <3.0 x ULN	3.0 – 8.0 x ULN	> 8 x ULN
GGT	1.1 - <2.0 x ULN	2.0 – <3.0 x ULN	3.0 – 8.0 x ULN	> 8 x ULN
Alkaline Phosphatase	1.1 - <2.0 x ULN	2.0 – <3.0 x ULN	3.0 – 8.0 x ULN	> 8 x ULN
Amylase	1.1 - 1.5 x ULN	1.6 - 2.0 x ULN	2.1 - 5.0 x ULN	> 5.1 x ULN
Lipase	1.1 - 1.5 x ULN	1.6 - 2.0 x ULN	2.1 - 5.0 x ULN	> 5.1 x ULN
URINALYSIS				
	Grade 1	Grade 2	Grade 3	Grade 4
Proteinuria	1+ or 200 mg - 1 gm loss/day	2-3+ or 1- 2 gm loss/day	4+ or 2-3.5 gm loss/day	nephrotic syndrome or > 3.5 gm loss/day

Hematuria	microscopic only <10 rbc/hpf	gross, no clots >10 rbc/hpf	gross, with or without clots, OR red blood cell casts	obstructive or required transfusion
CARDIOVASCULAR				
	Grade 1	Grade 2	Grade 3	Grade 4
Cardiac Rhythm		asymptomatic, transient signs, no Rx required	recurrent/persiste nt; symptomatic Rx required	unstable dysrhythmia; hospitalization and treatment required
Hypertension	transient increase > 20 mm/ Hg; no treatment	recurrent, chronic increase > 20mm/ Hg. /treatment required	acute treatment required; outpatient treatment or hospitalization possible	end organ damage or hospitalization required
Hypotension	transient orthostatic hypotension with heart rate increased by <20 beat/min or decreased by <10 mm Hg systolic BP, No treatment required	symptoms due to orthostatic hypotension or BP decreased by <20 mm Hg systolic; correctable with oral flu id treatment	requires IV fluids; no hospitalization required	mean arterial pressure <60mm/ Hg or end organ damage or shock; requires hospitalization and vasopressor treatment

Pericarditis	minimal effusion	mild/ moderate asymptomatic effusion, no treatment	symptomatic effusion; pain; EKG changes	tamponade; pericardiocentes is or surgery required
Hemorrhage, Blood Loss	microscopic/occult	mild, no transfusion	gross blood loss; 1-2 units transfused	massive blood loss; > 3 units transfused
RESPIRATORY				
	Grade 1	Grade 2	Grade 3	Grade 4
Cough	transient- no treatment	persistent cough; treatment responsive	Paroxysmal cough; uncontrolled with treatment	-----
Bronchospasm, Acute	transient; no treatment; 70% - 80% FEV ₁ of peak flow	requires treatment; normalizes with bronchodilator; FEV ₁ 50% - 70% (of peak flow)	no normalization with bronchodilator; FEV ₁ 25% - 50% of peak flow; or retractions present	cyanosis: FEV ₁ < 25% of peak flow or intubation necessary
Dyspnea	dyspnea on exertion	dyspnea with normal activity	dyspnea at rest	dyspnea requiring Oxygen therapy
GASTROINTESTINAL				
	Grade 1	Grade 2	Grade 3	Grade 4

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Ensignment Supérieur (ABES)

Nausea	mild or transient; maintains reasonable intake	moderate discomfort; intake decreased significantly; some activity limited	no significant intake; requires IV fluids	hospitalization required;
Vomiting	1 episode in 24 hours	2-5 episodes in 24 hours	>6 episodes in 24 hours or needing IV fluids	physiologic consequences requiring hospitalization or requiring parenteral nutrition
Constipation	requiring stool softener or dietary modification	requiring laxatives	obstipation requiring manual evacuation or enema	obstruction or toxic megacolon
Diarrhea	mild or transient; 3-4 loose stools/Day-or mild diarrhea last < 1 week	moderate or persistent; 5-7 loose stools/Day-or diarrhea lasting >1 week	>7 loose stools/day or bloody diarrhea; or orthostatic hypotension or electrolyte imbalance or >2L IV fluids required	hypotensive shock or physiologic consequences requiring hospitalization
Oral Discomfort/Dysphagia	mild discomfort; no difficulty swallowing	some limits on eating/drinking	eating/talking very limited; unable to swallow solid foods	unable to drink fluids; requires IV fluids
NEUROLOGICAL				

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Grade 1	Grade 2	Grade 3	Grade 4
Neuro-Cerebellar	slight incoordination dysdiadochokines is	intention tremor, dysmetria, slurred speech; nystagmus	locomotor ataxia	incapacitated
Psychiatric	mild anxiety or depression	moderate anxiety or depression; therapy required; change in normal routine	severe mood changes requiring therapy; or suicidal ideation; or aggressive ideation	acute psychosis requiring hospitalization; or suicidal gesture/attempt or hallucinations
Muscle Strength	subjective weakness no objective symptoms/ signs	mild objective signs/symptoms no decrease in function	objective weakness function limited	paralysis
Paresthesia (burning, tingling, etc.)	mild discomfort; no treatment required	moderate discomfort; non-narcotic analgesia required	severe discomfort; or narcotic analgesia required with symptomatic improvement	incapacitating; or not responsive to narcotic analgesia
Neuro-sensory	mild impairment in sensation (decreased sensation, e.g., vibratory, pinprick, hot/cold in great toes) in	moderate impairment (mod decreased sensation, e.g., vibratory, pinprick, hot/cold to	severe impairment (decreased or loss of sensation to knees or wrists) or loss of sensation of at	sensory loss involves limbs and trunk; paralysis; or seizures

	focal area or symmetrical distribution; or change in taste, smell, vision and/or hearing	ankles) and/or joint position or mild impairment that is not symmetrical	least mod degree in multiple different body areas (i.e., upper and lower extremities)	
MUSCULOSKELETAL				
	Grade 1	Grade 2	Grade 3	Grade 4
Arthralgia (joint pain)	mild pain not interfering with function	moderate pain, analgesics and/or pain interfering with function but not with activities of daily living	severe pain; pain and/or analgesics interfering with activities of daily living	disabling pain
Arthritis	mild pain with inflammation, erythema or joint swelling – but not interfering with function	moderate pain with inflammation, erythema or joint swelling – interfering with function, but not with activities of daily living	severe pain with inflammation, erythema or joint swelling –and interfering with activities of daily living	permanent and/or disabling joint destruction
Myalgia	myalgia with no	muscle	severe muscle	frank

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES) .

	limitation of activity	tenderness (at other than injection site) or with moderate impairment of activity	tenderness with marked impairment of activity	myonecrosis
SKIN				
	Grade 1	Grade 2	Grade 3	Grade 4
Mucocutaneous	erythema; pruritus	diffuse, maculo-papular rash, dry desquamation	vesiculation or moist desquamation or ulceration	exfoliative dermatitis, mucous membrane involvement or erythema, multiforme or suspected Stevens-Johnson or necrosis requiring surgery
Induration	< 15mm	15-30 mm	>30mm	
Erythema	< 15mm	15-30 mm	>30mm	
Edema	< 15mm	15-30 mm	>30mm	

Rash at Injection Site	< 15mm	15-30 mm	>30mm	
Pruritus	slight itching at injection site	moderate itching at injection extremity	itching over entire body	
SYSTEMIC				
	Grade 1	Grade 2	Grade 3	Grade 4
Allergic Reaction	pruritus without rash	localized urticaria	generalized urticaria; angioedema	anaphylaxis
Headache	mild, no treatment required	transient, moderate; treatment required	severe; responds to initial narcotic therapy	intractable; requires repeated narcotic therapy
Fever: oral	37.7 - 38.5 C or 100.0 - 101.5 F	38.6 - 39.5 C or 101.6 - 102.9 F	39.6 - 40.5 C or 103 - 105 F	> 40 C or > 105 F
Fatigue	normal activity reduced < 48 hours	normal activity decreased 25-50% > 48 hours	normal activity decreased > 50% can't work	unable to care for self

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

15 Appendix 3: Package insert for Azithromycin and amoxicillin

Included as separate attachments.

For peer review only

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.



PARTICIPANT INFORMATION SHEET

Participant information sheet

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE

What is the benefit and unintended consequences of using antibiotic treatment as a way of excluding tuberculosis disease in patients with cough?

Introduction

We would like to invite you to take part in a research study. Joining the study is entirely up to you. Before you decide, you need to understand why the research is being done and what it would involve. One of our team will go through this information sheet with you, and answer any questions you may have. Ask questions if anything you read is not clear or you would like more information. Please feel free to talk to others about the study if you wish. Take time to decide whether or not to take part.

What is the purpose of the study?

Tuberculosis (TB) is a disease that causes a long illness and cough with sputum. Although curable TB is difficult to detect. When they fail to detect TB after testing sputum, clinicians give antibiotic treatment that can cure all other causes of TB symptoms but not TB. In this approach, TB is considered ruled out if patient gets better and it is considered likely if they do not get better. The goal of this research study is to develop understanding of how well the antibiotics help distinguish TB patients from those who do not have it, whether giving antibiotics carries other health benefits, and whether it leads to development of disease causing organisms which are resistant to drugs.

We will learn about this by comparing a group of patients given antibiotics on the first day of the study to another group not given antibiotics. There will be two groups receiving antibiotics as follows: 1) Azithromycin taken as one tablet once a day for 3 days, and 2) Amoxicillin 4 capsules taken three times a day for 5 days. The group you will go into, out of the three, will be decided by chance so you can fall into any group.

What will be involved if I accept to participate in the study?

We are considering you for participation in this study because you told us that you have a cough. Any patient who has been coughing for at least 2 weeks, is at least 18 years, and lives within Blantyre, is eligible to participate in this study if they do not have signs consistent with serious illness. Apart from you, we will recruit 1,874 other individuals.

Study activities will be performed the first day, at 1 week (Day 8), and at one month (Day 29). At each of these study visits, we will ask you questions about your contact details, your health, use of medications, and any illnesses or hospitalisations you may have had in between study visits. We will also document relevant details from your health passport and other clinical documentation you may have.

On Day 1 and at 1 week, we will ask you to submit sputum and urine samples for TB tests. If you are not able to give sputum on Day 1, we will give you containers so that you can bring them the following morning. Some of the sputum TB tests results will become available after 7 days and we will pass them to health center clinicians who will make a plan for your care, the other results may take up to 4 weeks so you will get them at the 1 month visit. Urine TB test results will not be available for your clinical care.

21-May-2019

A copy of this informed consent document to be offered to the participant

Study title: Randomised controlled clinical trial of diagnostic value, clinical benefits and unintended consequences of using trial-of-antibiotics to evaluate ambulatory adults with prolonged cough for tuberculosis in Malawi


Version & Date: 3.0/28 Feb 2019

Principal Investigator: Dr Titus H Divala

Participant Information Sheet For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml> Page 1 of 4

We will also do an HIV test. If the results are confirmed to be HIV positive we will do a viral load test, and at the end of the study activities on Day 1, we will link you to HIV management team here at the health center who will start you on treatment. Should we make a diagnosis of TB or HIV at any other point during the study, we will link you with the responsible health center team for treatment services.

On day 1 and at 1-month visit, we will swab the back of the inside of your nose as shown in this picture to collect germs that live there. We will test the germs for drug resistance. Results of this test are not relevant to your care.



On 1-week visit, we will ask you to report how your health has changed in comparison to how you were on day 1. These questions will be read to you by a computer and you will answer them by choosing various options which it will display during the interview.

The 1 month visit will be the final study visit where we will also provide you with results for TB culture and ask if you have TB symptoms. If you are in HIV or TB care, we will ask how your follow up is going. The appointment with you at 1 months is very important because it will help you to know the results of the TB tests and it will also help us know the status of your health.

The number of clinic visits you will make for this study is at least three. Here we count Day 1, one visit after one week, and another visit at one month. If you have not been able to come here for any of the visits, we will remind you by phone call or we will use the permission and information you will give us to visit you at your home. The first visit will take about 60 minutes and the later visits will take about 30 minutes each.

Will there be any risks involved in this study?

This study is a low risk study. There are no risks involved in submitting sputum or urine for the study. You may feel some discomfort during swabbing of the back of the nose and during blood collection for HIV and viral load tests. Azithromycin and amoxicillin are already widely used in Malawi and rarely cause problems. Rare side effects for azithromycin include feeling nervousness, skin reactions and disturbance of heart function. Rare side-effects for amoxicillin are mental state changes, feeling light-headed, and reactions to sunlight.

The London School of Hygiene and Tropical Medicine holds insurance policies which apply to this study. If you experience harm or injury as a result of taking part in this study, you may be eligible to claim compensation.

Will there be any benefits in this study?

The key benefit of this study is that you will have access to a more detailed TB evaluation process than usual. This will help you know if you have TB and to have the opportunity to start TB treatment. The study is also beneficial to health care providers because it will address important questions about use of antibiotics during the TB diagnostic process.

Will the findings in the study be confidential?

A copy of this informed consent document to be offered to the participant

Study title: Randomised controlled clinical trial of diagnostic value, clinical benefits and unintended consequences of using trial-of-antibiotics to evaluate ambulatory adults with prolonged cough for tuberculosis in Malawi

Version & Date: 3.0/28 Feb2019

Principal Investigator: Dr Titus H Divala

Participant Information Sheet For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml> Page 2 of 4

REC ref: LSHTM 15232; COMREC P.04/18/2381



Your identity in this study will be treated as confidential. The results of the study, including laboratory or any other data, may be published for scientific purposes but will not give your name or include any identifiable references to you. Information about TB test result and HIV test results will be recorded using an identification number. However, any records or data obtained as a result of your participation in this study may be used by LSHTM who are sponsoring this study, regulators of health research (COMREC), or by members of the research team. These records will be kept in a locked space in the University of Malawi College of Medicine. Information and samples collected in this study will be retained for up to 10 years after the end of the trial, according to our institution recommendations. These collected samples and other information may also be used for future studies if you give us that consent.

Can I withdraw from the study anytime and will this affect my treatment?

You are free to choose whether or not to participate in this study. While we would like you to participate in the study to the very end, withdrawing at any point is an option that is freely available to you without any penalty or loss of any entitled benefits. You will be provided with any significant new findings developed during the course of this study that may relate to or influence your willingness to continue participation.

What are the financial benefits of participating in this study?

There will be no payment given to you for participating in the study. The study will provide at least MK8,000 as compensation for your costs of attending the study visits. We will give this money in instalments on scheduled study visits.

Is this study approved by an ethics committee?

The study has been approved by the London School of Hygiene & Tropical Medicine Research Ethics Committee, and the College of Medicine Research Ethics Committee (COMREC).

Who do you ask if you have questions regarding the study?

If you have any questions concerning participation in this study, please feel free to ask me. Alternatively, you can contact the following people by phone or post:

	Name	Telephone	Postal address
Study investigators	Dr Titus Divala	0999478376	Helse Nord Tuberculosis Initiative
	Dr Marriott	0888681948	University of Malawi College of Medicine
	Nliwasa		Private Bag 360, Chichiri, Blantyre 3, Malawi
COMREC			
	Administrative officer, COMREC Secretariat	01 877 245 01 877 291	University of Malawi College of Medicine Private Bag 360, Chichiri, Blantyre 3, Malawi

21-May-2019

A copy of this informed consent document to be offered to the participant

Study title: Randomised controlled clinical trial of diagnostic value, clinical benefits and unintended consequences of using trial-of-antibiotics to evaluate ambulatory adults with prolonged cough for tuberculosis in Malawi

Version & Date: 3.0/28 Feb 2019

Principal Investigator: Dr Titus H Divala

Participant Information Sheet For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml> Page 3 of 4

What is the benefit and unintended consequences of using antibiotics treatments as a way of excluding tuberculosis disease in patients with cough?

Patient declaration

Statement	Initial or thumbprint each box	
I confirm that I have read the above information sheet for the above named study. I have had the opportunity to consider the information, ask questions and have these answered satisfactorily. OR I have had the information explained to by study personnel in a language that I understand. I have had the opportunity to consider the information, ask questions and have these answered satisfactorily.		
I understand that my participation is voluntary and that I am free to withdraw at any time without giving any reason, without my medical care or legal rights being affected.		
I understand that relevant sections of my medical notes and data collected during the study may be looked at by authorised individuals from LSHTM, University of Malawi College of Medicine, and COMREC, where it is relevant to my taking part in this research. I give permission for these individuals to have access to my records.		
I understand that data about me may be shared via a public data repository or by sharing directly with other researchers, and that I will not be identifiable from this information		
I understand that the tissue sample collected from me will be used to support other research in the future, and may be shared anonymously with other researchers, for their ethically-approved projects		
I agree to take part in the above named study		
Printed name of participant	Signature/thumb print of participant	Date
Printed name of impartial witness*	Signature of impartial witness*	Date
I attest that I have explained the study information accurately to _____, and was understood to the best of my knowledge by, the participant and that he/she has freely given their consent to participate* in the presence of the above named impartial witness (where applicable).		
Printed name of staff obtaining consent	Signature of staff obtaining consent	Date

*Impartial witness should be someone the participant trusts. The impartial witness can write the participant name but cannot sign for them. Instead, illiterate participants should use thumbprint in place of signature and the impartial witness should go ahead and sign in designated space.



PARTICIPANT INFORMATION SHEET

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



Chikalata chofotokozera ofuna kutenga nawo mbali

Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Chiyambi

Tikukukupemphani kuti mutenge nawo mbali mu kafukufuku. Ndi chifuniro chanu kulowa mu kafukufukuyu. Musanapange chiganizo, mukuyenera kumvetsa chifukwa chimene kafukufukuyu akuchitikira komanso zimene zitadzachitike. M'modzi mwa anthu a gulu logwira ntchito mu kafukufuku awerenga chikalatachi pamodzi ndi inu, ndipo ayankha mafunso ena aliwonse amene mungakhale nawo. Funsani mafunso ngati simukumvetsa zomwe mwawerenga kapena ngati mukufuna uthenga owonjezera. Muli omasuka kulankhula ndi ena zokhudza kafukufukuyu ngati mukufuna. Ganizani mofatsa musanavomereze kutenga nawo mbali kapena ayi.

Kodi cholinga cha kafukufukuyu ndi chiyani?

Chifuwa chachikulu (TB) ndi matenda amene munthu amkhala chidwalire kwa nthawi yaitali. Odwalayo, amapanga makhololo. Ngakhale chili chochizika, chifuwa chachikulu ndi chovuta kuchipeza. Pamene njira zoyeza makholoro zalephera kupeza chifuwa chachikulu, achipatala amapereka mankhwala opha tizirombo toyambitsa matenda amene angathane ndi zonse zimene zimayambitsa zizindikiro za matenda ofanana ndi chifuwa chachikulu. Ngati odwala apeza bwino ndi njira imeneyi amaganiziridwa kuti alibe matenda a chifuwa chachikulu koma ngati sanapeze bwino amaganiziridwa kuti ali ndi chifuwa chachikulu. Cholinga cha kafukufuku ameneyu ndi kufuna kumvetsa za m'mene mankhwala amenewa amathandizira kusiyanyitsa odwala matenda a chifuwa chachikulu ndi amene alibe matendawa, ngati mankhwalawa ali ndi phindu lina kwa odwala, komanso ngati kupereka mankhwalawa kukubweretsa tizirombo tosamva makhwala.

Tiphunzira zimenezi pakusiyanyitsa gulu la anthu odwala amene apatsidwa mankhwala opha tizirombo toyambitsa matenda patsiku loyamba la kafukufukuyu ndi gulu lina limene silinapatsidwe mankhwalawa. Pakhala magulu awiri olandira mankhwala opha tizirombo motere: 1) Azitromycin omwedwa pilisi imodzi kamodzi patsiku kwa masiku atatu, komanso 2) Amoxicillin makapusolo anayi omwedwa katatu patsiku kwa masiku asanu. Gulu limene mulowe, mwa magulu atatuwa, lisankhidwa mwa mayere choncho mukhoza kupezeka mu gulu lina lirilonse.

Kodi chidzachitike ndi chiyani ngati ndingavomereze kutenga nawo mbali mu kafukufukuyu?

Tikukupemphani kuti mutenge nawo mbali mu kafukufukuyu chifukwa mwatiuza kuti muli ndi chifuwa. Odwala wina aliyense amene wakhala akukhosomola kwa masabata osachepera awiri, ali ndi zaka zosachepera 18, ndipo amakhala mu Blantyre muno, atha kutenga nawo mbali mu kafukufukuyu ngati alibe zizindikiro zosonyeza kudwalika kwambiri. Kupatula inu, tilemba anthu ena okwanira 1,874.

Zochitika za kafukufukuyu zidzapangidwa patsiku loyamba, pa sabata imodzi (Tsiku 8), ndi pamwezi umodzi (Tsiku 29). Pa masiku a kafukufuku onsewa, tidzakufunsani mafunso okhudzana ndi m'mene tingalumikizirane nanu, thanzi lanu, kagwiritsidwe ntchito ka mankhwala, ndi matenda ena aliwonse kapena kugonekedwa mu chipatala komwe kungakuchitikireni. Tidzalembanso zinthu zofunika

Mpateni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?


Version & Date: 3.0/28 Feb 2019

Mkulu wakafukufuku: Dr Titus H Divala

Chikalata chofotokozera ofuna kutenga nawo mbali

BEC ref: LSHTM 152321, COMREC P.04/18/2381

Page 1 of 5




kuchokera mu bukhu lanu la kuchipatala komanso zolembedwa zina za chipatala zimene mungakhale nazo.

Patsiku loyamba ndi pakutha pasabata yoyamba, tidzakufunsani kuti mupereke makhololo komanso mkodzo pofuna kuyeza matenda a chifuwa chachikulu. Ngati simungakwanitse kupereka makhololo patsiku loyamba, tidzakupatsani mabotolo kuti mudzawabweretse m'mawa wa tsiku lotsatira. Zotsatira zina za makhololo zidzatuluka pakutha pa masiku asanu ndi awiri ndipo tidzazipereka kwa matodolo a chipatala chino kuti akuthandizeni, zotsatira zina zidzatenga pafupi-fupi masabata anayi choncho mudzazilandira pa ulendo wa pamwezi umodzi. Zotsatira zanu zoyesa mikodzo ku matenda a chifuwa chachikulu sizidzakhalapo ku nkhani ya chisamaliro chanu cha kuchipatala.

Tidzayezanso kachiombo ka HIV. Ngati zotsatirazi zasonyeza kuti muli ndi kachiombo ka HIV tidzayeza kuchuluka kwa tizirombo ta HIV, komanso kukutumizani kolandilira chithandizo chamatendawa. Ngati tingakupezeni kuti muli ndi matenda a chifuwa chachikulu kapena kachiombo ka HIV panthawi ina iliyonse mkati mwa kafukufukuyu, tidzakutumizani kolandilira zithandizo zamatendawa pompano pachipatala.

Patsiku loyamba komanso pa ulendo wa mwezi woyamba, tidzapukuta kumbuyo kwa mkati mwa mphuno mwanu ngati m'mene zikuonekera pachithunzichi kuti titenge tizirombo timene timakhala m'menemo. Tidzayeza tizirombo timeneti kuti tione ngati tikumva mankhwala. Zotsatira zimenezi sizidzagwiritsidwa ntchito kuchisamaliro chanu chaku chipatala.



Pa ulendo wa sabata yoyamba, tidzakupemphani kuti mutiuze m'mene thanzi lanu lasinthira kuyerekeza ndi m'mene munaliri patsiku loyamba. Mafunso amenewa adzawerengedwa kwa inu kudzera pa makina a kompyuta ndipo mudzawayankha pakusankha mayankho angapo amene makinawa adzawonetse panthawi yomwe azidzafunsa.

Ulendo wa pa mwezi umodzi udzakhala wotsiriza umene tidzakupatsenins zotsatira za zoyesa za matenda a chifuwa chachikulu komanso tidzakufunsani ngati muli ndi zizindikiro za matenda a chifuwa chachikulu. Ngati panthawiyi mudzakhale kuti mukulandira Thandizo la HIV kapena TB, tidzakufuna kudziwa kuti zikuyenda bwanji. Kukumana ndi inu patatha mwezi umodzi ndikofunikira kwambiri chifukwa zidzakuthandizirani kuti mudziwe zotsatira za zoyeza za matenda a chifuwa chachikulu ndipo zidzatithandiziranso kudziwa zam'mene thanzi lanu liliri.

Maulendo a kuchipatala amene mudzayende a kafukufukuyu ndiwosachepera atatu. Pamenepa tikuwerenga tsiku loyamba, ulendo umodzi pakutha pa sabata imodzi, ndi ulendo umodzi pa mwezi umodzi. Ngati simunakwanitse kubwera kuno pa ulendo wina uliwonse tidzakukumbutsani pokuyimbirani lamya kapena tidzagwiritsa ntchito chilorezo ndi uthenga umene mudzatipitse kuti tikuyendereni kunyumba kwanu. Patsiku loyamba tidzakhala nanu kwa mphindi makumi asanu ndi imodzi, pamene paasiku ena onse, tidzakhala nanu kwa mphindi makumi atatu.

Kodi padzakhala ziopsezo zina zilizonse zochitika mu kafukufukuyu?

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Version & Date: 3.0/28 Feb 2019

Mkulu wakafukufuku: Dr Titus H Divala

Chikalata chofotokozera ofuna kutenga nawo mbali

REC ref: LSHTM 15232; COMREC P.04/18/2381

Page 2 of 5



Kupanga nawo kafukufukuyu sikuika moyo wanu pa chiopsyeyo chochuluka. Palibe chiopsezo pa kupereka makhololo kapena mikozo mu kafukufukuyu. Mukhoza kusamva bwino panthawi yopukuta kumbuyo kwa mphuno komanso panthawi yotenga magazi oyeza za kachiroombo ka HIV ndi kuchuluka kwa tiziombo toyambitsa matendawa. Azithromycin ndi amoxicillin ndi mankhwala oti akhala akugwiritsidwa ntchito kwa nthawi yayitali m'Malawi ndipo sikweni-kweni kuyambitsa mavuto. Patali-patali azithromycin amapangitsa kumva nthumazi, ziwengo, komanso kusokonekera kwa kagwiridwe ntchito ka mtima. Patali-patali amoxicillin amapangitsa kusakhazikika mmanganizo, kumva chizungulire, komanso kutuluka ziwengo munthu akakhala padzuwa.

A London School of Hygiene ndi Tropical Medicine ali ndi thumba landalama zachipukuta misozi lokhudzana ndi kafukufukuyu. Ngati mwapweteka kapena kuvulala chifukwa chotenga nawo mbali mu kafukufukuyu, mudzakhale omasuka kupempha chipukuta misonzi.

Kodi padzakhala zopindula zina zilizonse mu kafukufukuyu?

Chopindulitsa chodziwika cha kafukufukuyu ndi chakuti mudzakhala ndi mwayi oyezedwa matenda a chifuwa chachikulu mozama kuposa m'mene zimakhallira nthawi zonse. Zimenezi zidzakuthandizirani kudziwa ngati muli ndi matenda a chifuwa chachikulu komanso kukhala ndi mwayi oyamba kulandira thandizo la mankhwala a chifuwa chachikulu. Kafukufukuyu ndi opindindulitsanso kwa opereka chisamaliro cha kuchipatala chifukwa adzayankha mafunso ofunikira okhudzana ndi kagwiritsidwe ntchito ka mankhwala opha tiziombo toyambitsa matenda panthawi ya ndondomeko yoyeza matenda a chifuwa chachikulu.

Kodi zotsatira za mukafukufukuyu zidzakhala za chinsinsi?

Chizindikiritso chanu mu kafukufukuyu chidzatengedwa kukhala cha chinsinsi. Zotsatira za kafukufukuyu, zikhoza kudzasindikizidwa ndi cholinga cha sayansi koma dzina lanu kapena chizindikiritso chilichonse chokhudzana ndi inu chidzabisidwa. Uthenga okhudza zotsatira zoyesa matenda achifuwa chachikulu kapena HIV zidzalembedwa pogwiritsa ntchito nambala yanu yakafukufuku. Komabe, zina zomwe mungatifotokozere zitha kudzagwiritsidwa ntchito ndi amene ali oyang'anira za kafukufuku wa zaumoyo (COMREC) komanso LSHTM. kapena ndi mamembala a gulu la kafukufukuyu. Zolembedwazi zidasungidwa mumalo otsekedwa bwino ku sukulu ya ukachenjede ya Malawi College of Medicine. Uthenga ndi zoyesa zotengedwa mu kafukufukuyu zidzassungidwa kwa zaka pafupi-fupi khumi (10) pakutha pakuyesaku, malingana ndi ndondomeko ya bungwe lathu. Zoyesa zotengedwazi ndi mauthenga ena zikhoza kugwiritsidwanso ntchito pa kafukufuku wamtsogolo ngati mutatipatsa chilolezo chimenecho.

Kodi ndikhoza kusiya kafukufukuyu nthawi ina iliyonse ndipo zimenezi zingadzakhudze thandizo langa la mankhwala?

Muli ndi ufulu kusankha kutenga nawo mbali kapena kusatenga nawo mbali mu kafukufukuyu. Ngakhale tingakonde kuti mutenge nawo mbali mu kafukufukuyu mpaka ku mapeto, kutuluka nthawi iliyonse mukafukufuku ndi chisankho chanu popanda chilango chilli chonse kapena kuluza kulandira thandizo lililonse lomwe mukuyenera kulandira. Munthawi yakafukufukuyu, tidzakudziwitsani patati

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tiziombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Version & Date: 3.0/28 Feb 2019

Mkulu wakafukufuku: Dr Titus H Divala

Chikalata chofotokozera ofuna kutenga nawo mbali

REC ref: LSHTM 15232; COMREC P.04/18/2381

Page 3 of 5



patuluka mauthenga ena a sayansi ofotokoza zinthu zimene zingakupangitseni kuti mulingalirenso zachisamkho chanu chotenga nawo mbali.

Kodi pali phindu la ndalama lotani pakutenga nawo mbali mu kafukufukuyu?

Sipadzakhala kupatsidwa malipiro chifukwa chotenga nawo mbali mukafukufukuyu. Ndalama yomwe tidzakupatseni ndi yokwana MK8,000. Ndalamayi tizikupatsani pangonopango pamasiku anu akafukufuku..

Kodi kafukufukuyu ndiwovomerezeka ndi komiti yowona za ufulu wa anthu mukafukufuku?

Kafukufukuyu wavomerezedwa ndi London School of Hygiene & Tropical Medicine Research Ethics Committee, ndi College of Medicine Research Ethics Committee (COMREC).

Kodi mungafunse ndani ngati muli ndi mafunso okhudzana ndi kafukufukuyu?

Ngati muli ndi mafunso ena aliwonse okhudza kutenga nawo mbali mukafukufukuyu, chonde khalani omasuka kundifunsa. Munjira ina, mukhoza kulumikizana ndi anthu otsatirawa pa lanya kapena polemba kalata kumakeyala awa:

	Name Dzina	Telephone Lamya	Postal address Adilesi
Study investigators Akulu-akulu akafukufuku	Dr Titus Divala	0999478376	Helse Nord Tuberculosis Initiative University of Malawi College of Medicine
	Dr Marriott Nliwasa	0888681948	Private Bag 360, Chichiri, Blantyre 3, Malawi
COMREC	Administrative officer, COMREC Secretariat	01 877 245 01 877 291	University of Malawi College of Medicine Private Bag 360, Chichiri, Blantyre 3, Malawi

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake
Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?



Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)
BMJ Open: first published as 10.1136/bmjopen-2019-033999 on 25 March 2020. Downloaded from <http://bmjopen.bmj.com/> on June 9, 2025 at Agence Bibliographique de l



Kodi pali phindu lotani komanso zotsatira zosayembekezereka zotani pogwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ngati njira yothana ndi matenda a chifuwa chachikulu mu anthu amene ali ndi chifuwa?

Chitsimikizo cha odwala

Lembani mubokosi liri kumanjali mawu oyamba adzina lanu kapena dindani ndi chala ngati mukuvomereza

Mfundo yachitsimikizo	
Ndikutsimikiza kuti ndawerenga chikalata cha uthenga wa kafukufuku amene watchulidwa m'mwambamu. Ndakhala ndi mwayi woganizira za uthengawu, kufunsa mafunso komanso ndayankhidwa mokhutira.	
KAPENA	
Ndafotokozeredwa uthengawu ndi akafukufuku mu chilankhulo chimene ndikuchimvetsa. Ndakhala ndi mwayi woganizira za uthengawu, kufunsa mafunso komanso ndayankhidwa mokhutira.	
Ndikumvetsa kuti kutenga nawo mbali kwanga ndikosakakamizidwa ndipo ndili ndi ufulu kusiya panthawi ina iliyonse popanda kupereka chifukwa china chilichonse, popanda kukhudza chisamaliro cha kuchipatala kapena ufulu wanga.	
Ndikumvetsa kuti magawo ofunikira a zolembedwa zanga za ku chipatala komanso mu kafukufukuyu kuwonedwa ndi anthu ovomerezeka aku LSHTM, University of Malawi College of Medicine komanso COMREC, pamene kuli kofunika kutenga nawo mbali mukafukufukuyu. Ndikupereka chilolezo kwa anthu amenewa kuti athe kuwona za zolembedwa zanga.	
Ndikumvetsa kuti zomwe atolere akafukufuku zokhudza ine zikhoza kugawilidwa kwa anthu ena opanga kakafukufuku, ndipo kuti sipadzakhala chizindikiro chilichonse chosonyeza kuti zinachokera kwa ine.	
Ndikumvetsa kuti zoyeza za mthupi mwanga zimene zidzatengedwe kwa ine zidzagwiritsidwa ntchito kuthandizira kafukufuku wina mtsogolo, ndipo zikhoza kudzagawidwa mwachinsinsi ndi akafukufuku ena, pa ntchito yawo yovomerezeka ndi malamulo aowona zakafukufuku.	
Ndikuvomereza kutenga nawo mbali mu kafukufuku amene watchulidwa pamwambayu.	

Dzina la wotenga nawo mbali **Sayini/chidindo cha chala cha wotenga mbali** **Tsiku**

Dzina la mboni yopanda mbali* **Sayini ya mboni yopanda mbali** **Tsiku**

Ndikutsimikiza kuti ndafotokoza za uthenga wa kafukufukuyu molondola kwa _____, ndipo zinamveka monga mwakudziwa kwanga ndi, wotenga nawo mbali komanso kuti apereka chilolezo chawo kuti atenge nawo mbali* pamaso pa mboni yopanda mbali imene yatchulidwa pamwambapa (ngati kuli koyenera).

Dzina la wotenga chilolezo **Sayini ya wotenga chilolezo** **Tsiku**

*Mboni yopanda mbali ikuyenekera kukhala yokhulupiridwa ndi munthu ofuna kutenga nawo mukafukufukuyo. Mboni ikhoza kulemba dzina la munthu ofuna kutenga nawo mukafukufukuyo koma siingasayine mmalo mwake. Munthu ofuna kutenga nawo mukafukufuku, ngati samatha kuwerenga ndi kulemba, asayine ndi chidindo cha chala chake ndipo mboni isayine dzina ndi sayini, pamalo ambone.

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200-207

Reporting Item			Page Number
Administrative information			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	30
Protocol version	#3	Date and version identifier	1
Funding	#4	Sources and types of financial, material, and other support	26

1	Roles and	#5a	Names, affiliations, and roles of protocol contributors	26
2	responsibilities:			
3	contributorship			
4				
5				
6	Roles and	#5b	Name and contact information for the trial sponsor	26
7	responsibilities:			
8	sponsor contact			
9	information			
10				
11				
12				
13	Roles and	#5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	26
14	responsibilities:			
15	sponsor and funder			
16				
17				
18				
19				
20				
21				
22				
23	Roles and	#5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	21
24	responsibilities:			
25	committees			
26				
27				
28				
29				
30				
31				
32				
33	Introduction			
34				
35	Background and	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4
36	rationale			
37				
38				
39				
40				
41				
42				
43	Background and	#6b	Explanation for choice of comparators	4, 8, 22
44	rationale: choice of			
45	comparators			
46				
47				
48	Objectives	#7	Specific objectives or hypotheses	5, 10
49				
50				
51	Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	5, 6
52				
53				
54				
55				
56				
57				
58				
59				
60				

1 **Methods:**
2 **Participants,**
3 **interventions, and**
4 **outcomes**

5	Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
6	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
7	Interventions: description	#11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
8	Interventions: modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)
9	Interventions: adherence	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)
10	Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
11	Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended

Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	17
Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	18
Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size	15
Methods:			
Assignment of interventions (for controlled trials)			
Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	15
Allocation concealment mechanism	#16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	15
Allocation: implementation	#16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	15
Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, trial participants, care	15

1		providers, outcome assessors, data analysts),	
2		and how	
3			
4	Blinding (masking):	#17b	15
5	emergency	If blinded, circumstances under which	
6	unblinding	unblinding is permissible, and procedure for	
7		revealing a participant’s allocated intervention	
8		during the trial	
9			
10			
11	Methods: Data		
12	collection,		
13	management, and		
14	analysis		
15			
16			
17	Data collection plan	#18a	15
18		Plans for assessment and collection of	
19		outcome, baseline, and other trial data,	
20		including any related processes to promote	
21		data quality (eg, duplicate measurements,	
22		training of assessors) and a description of study	
23		instruments (eg, questionnaires, laboratory	
24		tests) along with their reliability and validity, if	
25		known. Reference to where data collection	
26		forms can be found, if not in the protocol	
27			
28			
29			
30			
31			
32	Data collection plan:	#18b	16
33	retention	Plans to promote participant retention and	
34		complete follow-up, including list of any	
35		outcome data to be collected for participants	
36		who discontinue or deviate from intervention	
37		protocols	
38			
39			
40	Data management	#19	16
41		Plans for data entry, coding, security, and	
42		storage, including any related processes to	
43		promote data quality (eg, double data entry;	
44		range checks for data values). Reference to	
45		where details of data management procedures	
46		can be found, if not in the protocol	
47			
48			
49			
50	Statistics: outcomes	#20a	10
51		Statistical methods for analysing primary and	
52		secondary outcomes. Reference to where other	
53		details of the statistical analysis plan can be	
54		found, if not in the protocol	
55			
56			
57	Statistics: additional	#20b	18
58	analyses	Methods for any additional analyses (eg,	
59		subgroup and adjusted analyses)	
60			

1	Statistics: analysis	#20c	Definition of analysis population relating to	19
2	population and		protocol non-adherence (eg, as randomised	
3	missing data		analysis), and any statistical methods to handle	
4			missing data (eg, multiple imputation)	
5				
6				
7				
8	Methods:			
9	Monitoring			
10				
11	Data monitoring:	#21a	Composition of data monitoring committee	21
12	formal committee		(DMC); summary of its role and reporting	
13			structure; statement of whether it is	
14			independent from the sponsor and competing	
15			interests; and reference to where further details	
16			about its charter can be found, if not in the	
17			protocol. Alternatively, an explanation of why a	
18			DMC is not needed	
19				
20	Data monitoring:	#21b	Description of any interim analyses and	P30, appendix
21	interim analysis		stopping guidelines, including who will have	(protocol)
22			access to these interim results and make the	
23			final decision to terminate the trial	
24				
25	Harms	#22	Plans for collecting, assessing, reporting, and	P30, appendix
26			managing solicited and spontaneously reported	(protocol)
27			adverse events and other unintended effects of	
28			trial interventions or trial conduct	
29				
30	Auditing	#23	Frequency and procedures for auditing trial	P30, appendix
31			conduct, if any, and whether the process will be	(protocol)
32			independent from investigators and the sponsor	
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43	Ethics and			
44	dissemination			
45				
46				
47	Research ethics	#24	Plans for seeking research ethics committee /	22
48	approval		institutional review board (REC / IRB) approval	
49				
50				
51	Protocol	#25	Plans for communicating important protocol	22
52	amendments		modifications (eg, changes to eligibility criteria,	
53			outcomes, analyses) to relevant parties (eg,	
54			investigators, REC / IRBs, trial participants, trial	
55			registries, journals, regulators)	
56				
57				
58				
59				
60				

1	Consent or assent	#26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	30 appendix (consent)
2				
3				
4				
5				
6	Consent or assent:	#26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	30 appendix (consent)
7	ancillary studies			
8				
9				
10				
11	Confidentiality	#27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	30 appendix (consent)
12				
13				
14				
15				
16				
17				
18	Declaration of	#28	Financial and other competing interests for principal investigators for the overall trial and each study site	23
19	interests			
20				
21				
22				
23	Data access	#29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	30, appendix (protocol)
24				
25				
26				
27				
28				
29				
30	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	30, appendix (protocol)
31	trial care			
32				
33				
34				
35				
36	Dissemination	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	22
37	policy: trial results			
38				
39				
40				
41				
42				
43				
44				
45				
46				
47	Dissemination	#31b	Authorship eligibility guidelines and any intended use of professional writers	25, and 28 appendix (protocol)
48	policy: authorship			
49				
50				
51	Dissemination	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	25, and 28 appendix (protocol)
52	policy: reproducible			
53	research			
54				
55				

56 Appendices

57
58
59
60

BMJ Open: first published as 10.1136/bmjopen-2019-033999 on 25 March 2020. Downloaded from <http://bmjopen.bmj.com/> on June 9, 2025 at Agence Bibliographique de l'Enseignement Supérieur (ABES).
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	30 appendix (consent)
Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	30 appendix (consent/protocol)

Notes:

- The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist was completed on 01. September 2019 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Accuracy and Consequences of using Trial-of-antibiotics for TB diagnosis (ACT-TB Study): protocol for a randomised controlled clinical trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-033999.R2
Article Type:	Protocol
Date Submitted by the Author:	20-Feb-2020
Complete List of Authors:	Divala, Titus; London School of Hygiene and Tropical Medicine, TB Centre; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative Fielding, Katherine; London School of Hygiene & Tropical Medicine, TB Centre; University of the Witwatersrand, School of Public Health Sloan, Derek; University of Saint Andrews, School of Medicine French, Neil; University of Liverpool Faculty of Health and Life Sciences, Centre for Global Vaccine Research, Institute of Infection and Global Health Nliwasa, Marriott; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; London School of Hygiene and Tropical Medicine, TB Centre MacPherson, Peter ; Liverpool School of Tropical Medicine; Malawi Liverpool Wellcome Trust Clinical Research Programme Kandulu, Chikondi; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; Malawi Liverpool Wellcome Trust Clinical Research Programme Chiume, Lingstone ; Malawi Liverpool Wellcome Trust Clinical Research Programme; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative Chilanga, Sanderson ; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; Malawi Liverpool Wellcome Trust Clinical Research Programme Ndaferankhande, Masiye; Malawi Liverpool Wellcome Trust Clinical Research Programme Corbett, Elizabeth ; London School of Hygiene and Tropical Medicine; Malawi Liverpool Wellcome Trust Clinical Research Programme
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	Diagnostics, Epidemiology, Evidence based practice, General practice / Family practice, HIV/AIDS
Keywords:	trial-of-antibiotics, Tuberculosis < INFECTIOUS DISEASES, TB, antimicrobial resistance, diagnostic performance, antibiotics





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

TITLE

Accuracy and Consequences of using *Trial-of-antibiotics* for TB diagnosis (ACT-TB Study): protocol for a randomised controlled clinical trial

Authors

Titus H Divala^{1,2,3}, Katherine L Fielding^{1,4}, Derek J Sloan⁵, Neil French⁶, Marriott Nliwasa^{1,2,3}, Peter MacPherson^{3,7}, Chikondi Kandulu^{2,3}, Lingstone Chiume^{2,3}, Sanderson Chilanga^{2,3}, Masiye Ndaferankhande³, Elizabeth L Corbett^{1,2,3}

Author affiliations

1. TB Centre, London School of Hygiene & Tropical Medicine, Keppel Street, Bloomsbury, London, United Kingdom
2. Helse Nord Tuberculosis Initiative, University of Malawi College of Medicine, Blantyre, Malawi
3. Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi
4. School of Public Health, University of the Witwatersrand, Johannesburg, South Africa
5. School of Medicine, University of St Andrews (Derek J Sloan PhD)
6. Institute of Infection & Global Health, University of Liverpool, Liverpool, United Kingdom
7. Liverpool School of Tropical Medicine, Liverpool, United Kingdom

Correspondence to:

Dr Titus H Divala
TB Centre, London School of Hygiene & Tropical Medicine, Keppel Street, Bloomsbury, London WC1E 7HT
titus.divala@lshtm.ac.uk

KEY WORDS

trial-of-antibiotics, tuberculosis, TB, antimicrobial resistance, AMR, antibiotics, diagnostic performance, sensitivity, specificity, randomised controlled clinical trial, randomised, RCT

Protocol version 4.0, 27 Jan 2020

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

31 ABSTRACT:

32 Introduction

33 Over 40% of global tuberculosis case notifications are diagnosed clinically without
34 mycobacteriological confirmation. Standard diagnostic algorithms include “trial-of-antibiotics”
35 –empirical antibiotic treatment given to mycobacteriology-negative individuals to treat
36 infectious causes of symptoms other than tuberculosis, as a “rule-out” diagnostic test for
37 tuberculosis. Potentially 26.5 million such antibiotic courses/year are prescribed globally for
38 the 5.3 million/year mycobacteriology-negative patients, making trial-of-antibiotics the most
39 common tuberculosis diagnostic, and a global-scale risk for antimicrobial resistance (AMR).
40 Our systematic review found no randomised controlled trial (RCT) to support use of trial-of-
41 antibiotic. The RCT aims to determine the diagnostic and clinical value and AMR
42 consequences of trial-of-antibiotics.

43 Methods and analysis

44 A three-arm, open-label, RCT randomising (1:1:1) Malawian adults (≥ 18 years) seeking
45 primary care for cough into: a) azithromycin 500mg once daily for 3 days, or b) amoxicillin 1g
46 three times/day for 5 days, or c) standard-of-care (no immediate antibiotic). We will perform
47 Mycobacteriology tests (microscopy, Xpert/MTB/RIF and Mycobacterium-Tuberculosis
48 culture) at baseline. We will use Audio-Computer-Assisted-Self-Interview (ACASI) to assess
49 clinical improvement at day eight. First primary outcome will be proportion of patients
50 reporting day-eight improvement out of those with negative mycobacteriology (specificity).
51 Second primary outcome will be day 29 incidence of a composite endpoint of either death or;
52 hospitalisation or; missed tuberculosis diagnosis. To determine AMR impact we compare
53 proportion of resistant nasopharyngeal *Streptococcus pneumoniae* isolates on day 29. 400
54 mycobacteriology-negative participants/arm will be required to detect a $\geq 10\%$ absolute

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

55 difference in diagnostic specificity with 80% power. We will estimate measures of effect by
56 comparing outcomes in antibiotic arms (combined and individually) to standard-of-care.

57 **Ethics and dissemination**

58 The study has been reviewed and approved by Malawi College of Medicine Research and
59 Ethics Committee, London School of Hygiene & Tropical Medicine (LSHTM) Research Ethics
60 Committee, and Regional Committee for Health and Research Ethics –Norway, and Malawi
61 Pharmacy, Medicines, and Poisons Board (Appendix 1). We will present abstracts at
62 relevant conferences, and prepare a manuscript for publication in a peer-reviewed journal.

63 **Registration**

64 Clinicaltrials.gov, NCT03545373

65 **Strengths and limitations**

- 66 • To our knowledge this is the first randomised controlled trial to address benefits and
67 consequences of using antibiotics as an exclusion diagnostic for tuberculosis, a
68 widely used practice that results in millions of antibiotic prescriptions/year.
- 69 • We will also contribute evidence on AMR affecting common antimicrobials used for
70 managing respiratory infections.
- 71 • The use of ACASI for assessing clinical response and adherence to antibiotic
72 treatment which can be used in future studies.
- 73 • Acknowledged weaknesses include limited power to evaluate safety of deferred
74 antibiotic treatment; conduct subgroup analysis by HIV status; and the possibility that
75 participants randomised to the standard-of-care arm may find alternative access to
76 antibiotics therefore misclassifying exposure/intervention status.

57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

79 INTRODUCTION

80 The high case-fatality rate for tuberculosis, the leading global infectious cause of death in
81 adults¹ with approximately 10 million cases and 1.6 million deaths in 2017,² in part reflects
82 suboptimal diagnostics.³⁻⁶ To complement this diagnostic gap, standard algorithms
83 throughout the world include a “trial-of-antibiotics” (Figure 1). This is a course of broad-
84 spectrum antibiotics, with negligible *Mycobacterium tuberculosis* activity, given to patients
85 with symptoms such as cough in order to “rule-out” or “rule in” tuberculosis.⁷⁻⁹ In clinical
86 practice and most national guidelines (summarised in figure 1), patients who have negative
87 sputum mycobacteriology and have responded to antibiotic treatment are considered
88 tuberculosis-negative while those who remain symptomatic are deemed likely to have
89 tuberculosis and undergo further evaluations potentially leading on to receiving tuberculosis
90 treatment.⁷⁻⁹

91
92
93 We estimate that 26.5 million courses of antibiotics are prescribed in the diagnosis of the 5.3
94 million smear negative tuberculosis registrations recorded annually,¹⁰ making antibiotics the
95 most common diagnostic for tuberculosis.¹¹ Our 26.5 million estimate assumes that for every
96 one smear-negative tuberculosis case detected, five antibiotics courses are used: the first
97 two courses being given to patients are ultimately registered as smear-negative tuberculosis,
98 while the other three courses represent patients whose symptoms resolved without starting
99 anti-tuberculosis treatment.^{4 12} This high frequency of prescription of important broad-
100 spectrum antibiotics raises a global-scale risk for antimicrobial resistance (AMR) which like
101 tuberculosis, is a major crisis, becoming in 2016 one of only four health topics ever to be
102 discussed at the United Nations General Assembly.¹³⁻¹⁶

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

104 We performed a systematic literature review¹⁷ which demonstrated that, despite being in
105 global and national guidelines for decades, trial-of-antibiotics has a limited supporting
106 evidence base but with the available evidence suggesting poor diagnostic performance.¹⁸
107 None of the identified studies was an RCT and most of the observational studies were very
108 small and not primarily designed to assess the benefits and consequences of trial-of-
109 antibiotics. Pooled sensitivity and specificity of trial-of-antibiotics versus mycobacteriology
110 tests were below internationally defined minimum performance profiles for tuberculosis
111 diagnostics.¹⁹
112 We hypothesise that use of antibiotics in the course of evaluating patients for tuberculosis
113 has both benefits and risks that need to be weighed carefully to optimise patient and public
114 health outcomes. We will address evidence gaps related to a) accuracy, b) antimicrobial
115 resistance, and c) impact on clinical outcomes of trial-of-antibiotics by conducting an RCT
116 (ACT-TB Study) recruiting adult patients with cough presenting to health centres in Blantyre,
117 Malawi. To our knowledge this is the first randomised controlled trial to rigorously address
118 these questions.
119

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

METHODS AND ANALYSIS

Study design

This is a three-arm individually randomised (1:1:1), open-label controlled clinical trial (RCT) investigating accuracy and broader clinical, and antimicrobial resistance impact of using trial-of-antibiotics to rule-out tuberculosis among adults presenting with cough at primary care centres in Malawi (Figure 2). The trial is registered with Clinicaltrials.gov (NCT03545373) (Appendix 2). The full trial protocol is provided as Appendix 3.

Study setting

We will screen adults aged at least 18 years presenting to Limbe and Ndirande health centres in Blantyre, Malawi. Blantyre has an estimated tuberculosis prevalence of 1,014 per 100,000 (95% CI: 486 to 1,542), and an estimated adult HIV prevalence of 12.7% (95% CI: 11.9 to 13.6).²⁰

Eligibility criteria

We will offer enrolment to patients who satisfy the following inclusion and exclusion criteria.

Inclusion Criteria

- Ambulatory clinic attendees presenting with cough
- Unwell for at least 14 days
- Aged at least 18 years
- Reside in Blantyre and willing to return to the same clinic for follow up visits over the entire study period.

Exclusion Criteria

- Self-reported allergy to study medications

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 142 • WHO/Malawi National tuberculosis Program (NTP) danger signs: respiratory rate >
143 30/min, temperature >39°C, Heart rate >120/minute, confused/agitated, respiratory
144 distress, systolic blood pressure <90 mmHg, inability to walk unassisted
- 145 • Treated with antibiotics other than co-trimoxazole prophylaxis within the past 14 days
- 146 • Tuberculosis treatment or isoniazid preventive therapy within the last 6 months

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES).

Interventions

We will randomise participants, in a ratio of 1:1:1, to the following arms:

- **Arm 1** (Azithromycin): Azithromycin 500mg taken once daily for 3 days from enrolment day
- **Arm 2** (Amoxicillin): Amoxicillin 1g taken three times daily for 5 days from enrolment day.
- **Arm 3** (Standard of care): No study antibiotic prescription.

Rationale for interventions

Amoxicillin was chosen because it is the standard antibiotic used as first line treatment and for trial-of-antibiotics in Malawi. However, amoxicillin may not demonstrate the best performance for trial-of-antibiotics because of increasing resistance, and a narrow coverage for aetiology of community acquired pneumonia and “atypical” organisms. We chose azithromycin to represent the optimal biological specificity of an oral regimen due to more complete coverage of atypical organisms that cause community acquired pneumonia (e.g mycoplasma and chlamydia), and also the low resistance rates in Malawi where macrolides are rarely used. The dose for Azithromycin is as recommended in the British National Formulary (BNF) as treatment for community acquired pneumonia.²¹ The dose for amoxicillin is the BNF recommendation for severe infections but it is the recommended first line established by the Department of Medicine at Queen Elizabeth Central Hospital (Blantyre, Malawi) based on local microbiology.

Timing of interventions

The standard of care in Malawi defined by National Tuberculosis Programme guidelines for primary care patients presenting with cough who are otherwise well (no danger signs) is to take two sputum specimens for smear microscopy or Xpert and ask patients to return for

results, typically 3 days - 1 week later (Figure 1). The Malawi tuberculosis diagnostic algorithm recommends use of broad-spectrum antibiotics as trial-of-antibiotics after negative sputum tests are provided to patients who remain symptomatic. Therefore, the ideal population for randomisation for this study are patients on who already have negative results for smear microscopy or Xpert. However, that may have ethical challenges considering the implications of withholding treatment (if randomised to reference arm) from a symptomatic patient who, according to guidelines, should be given antibiotics. The first visit therefore was the most ideal time for randomisation and is in line with recommendations for test interval in investigations evaluating diagnostic tests with respect to the time interval between the index test (trial-of-antibiotics) and the reference test (mycobacteriology sputum sample collection). The timing also conforms to common clinical practice of prescribing trial-of-antibiotics at the same time as sputum collection to reduce diagnostic delay. The design was discussed with the District Health Office and the national tuberculosis programme ahead of ethics submission.

Known drug reactions

Azithromycin and amoxicillin have a long registration history, have been widely used globally and are well tolerated. Rare side effects for azithromycin include nervousness, dermatologic reactions including Stevens–Johnson syndrome, anaphylaxis and prolonged QT interval. Rare side-effects for amoxicillin are mental state changes, light-headedness, photosensitivity and severe allergic reactions.

Concomitant medication and interaction with other therapies

We do not have any restrictions with respect to concomitant medications apart from those listed in the exclusion criteria. We expect some participants to be on HIV antiretroviral drugs and some to subsequently start tuberculosis therapy. Important interactions therefore would be those those between the product and HIV antiretroviral drugs. There is no moderate or

198 major interaction between either azithromycin or amoxicillin with the classes of HIV
199 antiretroviral drugs currently used in Malawi.

200 **Trial restrictions**

201 We do not require participants to have any dietary restrictions. We will also accept co-
202 administration with contraception. Azithromycin and amoxicillin are both considered safe in
203 pregnancy, so we will include pregnant women should they be eligible.

204 **Assessment of compliance**

205 On Day-8, we will document self-reported compliance adherence of study products.

206 **Withdraw of interventions**

207 The investigator may also terminate a participant from study product if indicated by an
208 adverse reaction. If a participant stops taking study product either voluntarily or by
209 investigator decision, they will be encouraged to remain in follow up and their data will form
210 part of intention to treat analyses.

211 **Study outcomes**

212 The clinical trial has two separately powered, and distinctly assessed primary outcomes, one
213 for diagnostic evaluation (Primary outcome 1: Day 8) and the other for clinical impact
214 (Primary outcome 2: Day 29) of the intervention. The following are descriptions of all study
215 outcomes:

216 ***Primary outcome 1: Specificity of day 8 symptom change versus mycobacteriology***

217 The first primary outcome is the proportion of patients without tuberculosis (by sputum tests)
218 who report improvement of their baseline illness when asked 7 days after randomisation
219 (Day 8 study visit). This outcome can be thought of as diagnostic specificity if you take
220 sputum test results as a reference standard and *change in symptoms at Day 8* as the

221 investigational test (Figure 3). In this case the possible results of the investigational test are
222 improvement and no improvement (no change or worsened) in response to the question: *on*
223 *day 1, you reported that you were unwell; compared to that day, has your illness worsened,*
224 *remained the same, or improved?*

225 As with all self-rated outcomes, social desirability bias (tendency of participants to answer
226 questions in a manner that will be viewed favourably by healthcare worker), and interviewer
227 bias (interviewers' subconscious or conscious influencing subject response) may affect the
228 outcome. To minimise these biases in evaluation of improvement of baseline symptoms the
229 interview will be conducted using Audio Computer Assisted Self-Interview (ACASI), a
230 platform that allows patients to report their health state in private and directly into a database
231 via an audio questionnaire administered by a tablet. The lack of human-to-human interaction
232 will minimize interviewer, ascertainment, and social desirability biases. Another concern with
233 open-label design is placebo-effect favouring those randomised to antibiotics over the
234 standard of care arm that is however not addressed in our design.

235 We developed, piloted, and optimised the ACASI questionnaire in the study target population
236 and arrived at the question: *on day 1, you reported that you were unwell; compared to that*
237 *day, has your illness worsened, remained the same, or improved?* Before proceeding to the
238 self-interview, participants will be oriented using test questions until study staff are sure that
239 they will be able to go through the interview on their own. We will term ACASI interview
240 outcome as **ACASI-test-negative** if the participant reports improvement or **ACASI-test-**
241 **positive** if the participant reports no change or worsening (Figure 3).

242 The mycobacteriology reference standard will be defined in participants with at least one
243 valid sputum test result on days 1 and 8 as **sputum-test-positive** if there is at least one
244 positive of smear microscopy, Xpert/MTB/RIF, or MTB culture; and as **sputum-test-**
245 **negative** if none of the tests is positive. To minimise bias, the sputum tests will be performed
246 by a high-quality research laboratory in the University of Malawi College of Medicine by staff
247 with no access to participant treatment allocation information or symptom results.

248 The specificity of day 8 symptom change (the index test measured using ACASI) against
249 mycobacteriology tests (reference test) is defined as: **proportion of sputum-test-negative**
250 **who are ACASI-test-negative.**

251

252 ***Primary outcome 2: Clinical impact of trial-of-antibiotics***

253 We will investigate the overall clinical impact of trial-of-antibiotics by comparing the day 29
254 risk of any of death, hospitalisation, and “missed tuberculosis” (untreated
255 mycobacteriological or radiological tuberculosis). All these events can lead to mortality and
256 are potential consequences of trial-of-antibiotics; therefore, grouping them as a composite
257 endpoint appropriately represents the effect of the intervention because: 1) there are
258 similarities in the importance of each of the components, 2) the components occur with
259 similar frequencies in the patient population, and 3) the direction of effect is anticipated to be
260 the same for all.²²

261 The connection between trial-of-antibiotics and risk of hospitalisation and death assumes a
262 protective effect of antibiotics. In patients presenting with chronic cough at primary care in
263 high HIV prevalence settings, frequencies of mortality and hospitalization over a two months
264 period are similar, ranging from 2 to 6%.²³

265 We have included missed tuberculosis diagnosis in our composite clinical outcome because
266 this too can lead to death. We are defining “missed tuberculosis” as participants who meet
267 standard mycobacteriological and radiological tuberculosis definitions but are incorrectly
268 classified as tuberculosis-negative and not yet on tuberculosis treatment by Day 29. Clinical,
269 radiological, and microbiological evaluation for tuberculosis will be done at Day 8, Day 29, as
270 well as day between these two for patients who report worsening symptoms.

271 ***Secondary outcome 1: impact of trial-of-antibiotics on antimicrobial resistance***

272 We will use *Streptococcus pneumoniae* isolated from swabs of the nasopharynx as the
273 indicator pathogen for AMR evaluation. An ecological niche for many bacterial species, the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

upper respiratory tract also presents a convenient window for investigating antimicrobial resistance. *Streptococcus pneumoniae* is the organism of choice not only for being an important cause of respiratory tract infections but also because it often colonises the upper respiratory tract, acquires resistance readily, and has well documented laboratory investigation procedures in place.²⁴

We will define **AMR positive** as having nasopharyngeal isolates of *Streptococcus pneumoniae* that are resistant to any of the following commonly used antibiotics: ceftriaxone, amoxycillin, cefoxitin, azithromycin, and erythromycin as determined using disc diffusion technique; and **AMR negative** as either (1) not isolating any *Streptococcus pneumoniae* or (2) isolating any *Streptococcus pneumoniae* that is not resistant to any of the assessed antibiotics. For each arm, and at both baseline and day 29, we will report proportion of AMR positive participants. The study outcome will be the proportion of AMR positive participants at day 29.

Secondary outcome 2: diagnostic value of trial-of-antibiotics in all patients including those without a valid sputum result

In this analysis, all will remain as described for primary outcome 1 except for the denominator, which will now include those without a valid sputum test result. The mycobacteriology reference standard for secondary outcome 2 will be defined as sputum test positive if at least one positive of smear microscopy, Xpert/MTB/RIF, or MTB culture from samples collected on days 1 and 8. The reference test will be sputum-test-negative if none of the tests is positive and where there is no valid sputum test result available. The most likely reason for not having a valid sputum result will be inability to produce sputum, but other explanations will be: lost sample before laboratory analysis, an invalid laboratory reading, or contamination. We have opted to analyse this population because in symptomatic adults of the study setting, failure to produce sputum can be as high as 13%.²³

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

299 **Secondary outcome 3: Economic evaluation**

300 The objective of the economic evaluation is to undertake a cost-utility analysis to estimate
301 the incremental cost-effectiveness of trial-of-antibiotics using azithromycin and trial-of-
302 antibiotics using amoxicillin in comparison to standard of care, and to each other. We will
303 systematically compare costs and consequences associated with the interventions. We will
304 perform a within trial comparison of the three treatment arms to estimate the incremental
305 cost per quality-adjusted life year (QALY) gained for the azithromycin or amoxicillin arm in
306 comparison to standard of care. Costs will be estimated from the Malawian Ministry of Health
307 perspective. Health outcomes will be quantified in QALYs, estimated from participants'
308 responses to the Chichewa version of the EQ-5D-3L, a Health quality of life (HRQoL)
309 measure.^{25 26} We will adopt a time horizon matching the length of participant follow-up to
310 achieve the within trial evaluation.

311 **Exploratory outcomes**

312 Our exploratory analyses will be comparisons between the **azithromycin** and **amoxicillin**
313 arms for all our primary and secondary outcomes.

314 **Planned subgroup analyses**

315 We will perform analysis of primary outcomes stratified by HIV status and by ART status as
316 documented on enrolment day. This is important because the study site has high prevalence
317 of HIV and associated bacterial infections which may be amenable to antibiotics used for
318 trial-of-antibiotics.

319 **Study procedures**

320 Figure 2 and Table 1 presents the study time schedule including a summary of patient
321 identification, baseline procedures and outcome ascertainment at day 8 and day 29 follow up
322 visits.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Screening

Study staff will approach patients with symptoms of pulmonary tuberculosis (including cough of any duration, fever, weight loss, and night sweats) with information about the study and seek written informed consent (Appendix 4) from all patients who meet eligibility criteria. After consenting, a participant will be given a unique study identification number confirming enrolment.

Randomisation

Randomisation will be in the ratio 1:1:1 to the three arms of the trial, using block-randomisation with variable block sizes, and stratified by study site. An independent statistician will prepare the randomisation list using Ralloc command in Stata software, then print each allocation alongside a randomisation number, and seal in opaque envelopes. Upon confirming eligibility and consenting status a designated site staff will open the next available of sequentially numbered randomisation envelopes and administer the allocated study arm.

Blinding

The study is not placebo controlled because of funding limitations, and so will not use blinding due to the nature of the study design. However, study team masking will be maintained with all study outcome assessment occurring without reference to randomisation arm.

Baseline procedures

At baseline, we will collect demographic data, clinical history, record vital signs, height and weight. Participants will be requested to provide two sputum samples for Xpert/MTB/RIF and two more sputum samples the following morning for smear microscopy and MTB culture. We will also collect a urine sample for lipoarabamannan antigen detection (TB LAM); and a nasopharyngeal swab for pneumococcal culture and sensitivity testing. We will offer and perform HIV testing according to the national algorithm, and link all who test positive to care.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

349 To minimise loss to follow up, we will collect contact phone numbers, a physical address and
350 geolocation information.

351 ***Participant follow up***

352 On day 8, the first activity (ahead of any other interaction with study staff) will be the ACASI.
353 Other activities include providing results for day 1 tuberculosis tests and linking those who
354 test positive to care; collection of another sputum sample for smear microscopy and
355 *Mycobacterium tuberculosis* (MTB) culture; and management of ongoing symptoms and
356 other illnesses. On visit day 29, the final study visit, we will document participant vital status,
357 hospitalisations, and establish adherence to HIV and tuberculosis treatment. We will also
358 collect nasopharyngeal swab samples from all participants, and sputum from those with
359 tuberculosis symptoms.

360 ***Participant retention***

361 To minimise loss to follow up, we will record geolocation information of participants' place of
362 residence using ePAL android app, a high-resolution mapping system validated in Blantyre.
363 We will also record up to 3 contact phone numbers of the participant and their nominated
364 friends and relatives. We will not replace participants who discontinue study participation or
365 study treatment regardless of reason for withdrawal or discontinuation or the time either of
366 these occurs.

367 ***Data management***

368 We will collect data using TeleForm (paper based system that uses optical character
369 recognition) and Open Data Kit systems (ODK, an electronic data capture system installed
370 on android devices). Data will be committed to a secure database located at Malawi-
371 Liverpool Wellcome Trust (MLW) within 2 days for TeleForm, and 7 days for ODK.

372

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

373 **Table 1:** key study procedures over the study period

	STUDY PERIOD			
	Enrolment	Follow up		
TIMEPOINT	Day-1	Day-8		Day-29
ENROLMENT:				
Eligibility screen	x			
Informed consent	x			
Allocation	x			
INTERVENTIONS:				
Azithromycin	x			
Amoxicillin	x			
Standard of care	x			
ASSESSMENTS:				
Demographics	x			
History of antibiotic use	x	x		x
History & examination ¹	x	x		x
Sputum collection ²	x	x		
Urine for TB LAM test ³	x	x		
Nasopharyngeal swab for AMR ⁴	x			x
HIV test	x			
Linking to routine care	x	x		x
ACASI ⁵		x		
Clinical events ⁶				x
Update contact & address		x		x
1. For symptomatic participants, Day-8 sputum mycobacteriology should be fast-tracked to inform care before they leave the clinic. 2. Give sputum bottles at end of Day-1 visit for submission on Day-8. Also collect sputum and perform mycobacteriology at any time of the study when clinically indicated 3. Urine Lipoarabinomannan for Tuberculosis Diagnosis (TB LAM) 4. Nasopharyngeal swab for Streptococcus pneumoniae culture and sensitivity as a way of determining risk of antimicrobial resistance (AMR) 5. Audio Computer Assisted Self-Interview (ACASI) for documenting change of symptoms on Day- 8 versus Day-1 6. Illnesses, clinic visits, radiological outcomes, new HIV diagnosis, new tuberculosis diagnosis, death, hospitalisation, missed tuberculosis diagnosis, HIV care loss to follow up, and tuberculosis care loss to follow up				

374

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

375 Statistical approach

376 We will summarise the processes of recruitment including non-eligibility and reasons of
377 exclusion in a CONSORT (Consolidated Standards of Reporting Trials) flow chart. We will
378 describe the study participants by their baseline characteristics, by arm. We will perform
379 analyses of all our outcomes based on an intention to treat analysis (using the arm patient
380 was randomised to). Analysis for primary outcome 1 will be restricted to participants with a
381 valid sputum test result. We will report measures of effect from the following comparisons:

- 382 i) Azithromycin or amoxicillin (combined) versus standard of care
- 383 ii) azithromycin versus standard of care
- 384 iii) amoxicillin versus standard of care

385 We will use a generalised linear model (GLM) with identity link to estimate risks differences
386 and the GLM with log link to estimate risk ratios for the three comparisons, adjusting for
387 study site. For each comparison, we will report 95% confidence intervals (CIs) and p-values
388 from the likelihood test. If outcomes are rare, or the GLM model does not converge, we will
389 use logistic regression to estimate the treatment effect using an odds ratio. We will not
390 perform adjustments for multiple comparisons but will report all effect sizes with their 95%
391 CIs and p-values to facilitate appropriate interpretation of our results.

392 We will perform data cleaning and analysis using Stata release 15 (Stata Corp, College
393 station, Texas, USA). The statistical approach will be expanded in a detailed statistical
394 analysis plan, which will be finalised before unblinding the study data.

395 Sample size and power

396 We performed power and sample size estimations for the diagnostic impact, clinical impact,
397 and AMR impact outcomes as described below. Our sample size estimations are based on
398 planned analysis that will use Chi-squared test for comparing two independent proportions.

1
2
3 399 **Diagnostic impact outcome**

4
5 400 We assume that at Day 8, change in well-being from baseline state in trial-of-antibiotics
6
7 401 (azithromycin or amoxicillin) arms will correctly classify 60% of all mycobacteriology negative
8
9 402 participants (i.e 60%specificity of day 8 symptom change in trial-of-antibiotics arms).¹² We
10
11 403 wanted to estimate a sample size that would provide a discriminatory power of 80% at a two-
12
13 404 sided significance level of 5%, to detect at least 10% difference in specificity (i.e ≤50%
14
15 405 specificity of day 8 symptom change in standard of care arm).

16
17
18 406 **Sample size for a combination of 2 antibiotic arms against standard of care arm**

19
20
21 407 The sample size estimates along with assumptions for this comparison are shown in the
22
23 408 Table 2A. To achieve the desired 80% discriminatory power, we will need to recruit at least
24
25 409 290 sputum-test-negative participants per arm. Accounting for TB prevalence, ability to
26
27 410 produce and submit sputum, and loss-to-follow up increases the sample to 453 per arm or
28
29 411 1,359 for the whole study.

30
31
32 412 **Table 2A:** Sample size estimation for the *diagnostic impact outcome* comparing a
33
34 413 combination of two antibiotic arms to standard of care arm (2:1 comparison)

POWER (X2 difference between independent proportions)	Effect size (50% SoC vs 60% amoxycillin or azithromycin)	Effective sample per arm (Sputum negative participants needed)
0.80	0.10	290
0.85	0.10	332
0.90	0.10	388

Target power and respective sample size estimates based on knowledge of TB risk, ability to produce and submit sputum, and loss-to-follow up.

Stata code: `power twoproportions .5 .6, test(chi2) power(0.80) nratio(2)`

35
36
37 414
38
39 415 **Sample size for one antibiotic arm against standard of care arm**

40
41
42 416 The sample size estimates along with assumptions for this comparison are shown in the
43
44 417 Table 2B. To achieve the desired 80% discriminatory power, we will need to recruit at least

388 sputum-test-negative participants per arm. Accounting for TB prevalence, ability to produce and submit sputum, and loss-to-follow up increases the sample to 606 per arm or 1,819 for the whole study (The ethics approved protocol uses an older calculation that yields 625 per arm, and 1875 for whole study).

Table 2B: Sample size estimation for the *diagnostic impact outcome* one antibiotic arm to standard of care arm (pairwise comparison)

POWER (X2 difference between independent proportions)	Effect size (50% SoC vs 60% amoxycillin or azithromycin)	Effective sample per arm (Sputum negative participants needed)
0.80	0.10	388
0.85	0.10	443
0.90	0.10	519

Target power and respective sample size estimates based on knowledge of TB risk, ability to produce and submit sputum, and loss-to-follow up.

Stata code: `power twoproportions .5 .6, test(chi2) power(0.80) nratio(1)`

Power for clinical impact outcome

For the clinical impact of trial-of-antibiotics outcome, we assume a 4% baseline risk of composite outcome, and a loss to follow up of 10% by Day 29. Using the sample size of 625 participants per arm (obtained in Table 2B), and a type I alpha of 5%, we will be able to detect the difference between arms with 80% power, if the risk in the intervention arm is twice that of the standard of care arm. This estimate is applicable to all comparisons shown in section 3.

Power for AMR outcome

Study arms will be compared based proportion of participants with resistant *Streptococcus pneumoniae* on day 29. We assume that 45% of Day-29 nasopharyngeal swabs will successfully grow *Streptococcus pneumoniae*, and that 10% of the isolates will meet the definition of resistance (described earlier under outcomes), and that 10% will be lost to follow up by Day 29. Therefore, on day 29, the standard of care arm (of 625 participants) will have

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

253 *Streptococcus pneumoniae* isolates, 25 of which would meet the definition of resistance. This translates into a 4% (25/625) risk of AMR positive cases in the standard of care arm. To detect a twofold change in odds of day 29 AMR risk with at least 80% power, using Pearson's Chi-squared test, at 0.05 alpha, we will need at least 431 and 553 participants per arm for the 2:1 and pairwise comparisons respectively.

Monitoring and oversight

The trial will be monitored by the Research Support Centre Clinical Trials Unit of the University of Malawi College of Medicine. An independent Data and Safety Monitoring Board (DSMB), and a Trial Steering Committee (TSC) have been set up and meet bi-annually.

Trial closure

We will consider the trial closed after completing follow up of the last enrolled participant, and upon recording all mycobacteriology laboratory reports. Antimicrobial resistance lab work will continue beyond trial closure. The trial may be terminated early by the trial steering committee upon recommendation of the DSMB. The halting rule for a trial arm is an unacceptable high level of deaths assessed using an alpha determined at the first DSMB meeting.

PATIENT AND PUBLIC INVOLVEMENT

Patients were involved in the design of the study especially the audio-computer-assisted interview (ACASI) used for collecting primary outcome data. Health workers were involved in the design of study visits and patient flow.

DISCUSSION

The ACT-TB study will investigate the benefits and consequences of “trial-of-antibiotics,” a widely promoted approach to many patients with suspected tuberculosis in low- and middle-

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

income countries without solid evidence base. To our knowledge, ACT-TB Study is the first RCT of this kind. Results of our trial will add to the evidence-base regarding routine diagnosis of tuberculosis in low and middle-income countries and strengthen our fight against AMR. Both tuberculosis and AMR are diseases of major importance globally, with tuberculosis causing an estimated 1.6 million deaths in 2017 and AMR projected to cause 10 million deaths per year by 2050.^{2 27}

Choice of study interventions

We have chosen amoxicillin because it is the first line treatment for outpatient management of pneumonia in Malawi and is commonly used for trial-of-antibiotics. It also provides data of immediate programmatic relevance and a starting point to investigate exacerbation of pre-existing AMR pressure. However, amoxicillin may not demonstrate the full benefits for trial-of-antibiotics because of organisms with intrinsic (“atypicals”) or acquired (common in gram-negative organisms, and *Staphylococcus aureus*) penicillin resistance.²⁸ Oral antibiotics that may provide the better diagnostic discrimination for bacterial versus mycobacterial causes of cough are macrolides, such as azithromycin, because of better intrinsic coverage of “atypical” intracellular organisms such as *mycoplasma* species that cause community acquired pneumonia,²⁹⁻³¹ and low levels of acquired macrolide-resistance in bacterial isolates in Malawi.²⁸

ACASI for post-treatment improvement assessment

Our systematic review¹⁸ did not identify a consistent definition of tuberculosis or no tuberculosis based on trial-of-antibiotics. A definition of clinical change following antibiotic treatment is necessary for the trial-of-antibiotics as this determines who get categorised as well or tuberculosis-positive. Approaches that ranged from self-reported improvement to a combination of clinical and radiological assessments are likely to be highly subjective and prone to bias, as well as being a potentially avoidable source of heterogeneity between

studies. In this study, we hope to address these biases (particularly, inter-observer variability, and patient/interviewer reporting or ascertainment biases) by using self-rated change of illness (on day 8) recorded using a self-completed questionnaire, the ACASI (described under outcomes). The ACASI questionnaire, the delivery platform, and the resulting data management can all be replicated in future studies, creating potential for more standardisation in assessment of clinical response to treatment.

Potential clinical impact of antibiotics

In areas with high HIV prevalence, empirical antibiotics during tuberculosis investigations could be life-saving: mortality immediately before and after tuberculosis diagnosis is high,^{3 32} and is often secondary to severe bacterial infections.³²⁻³⁴ The leading aetiologies of infection and death on tuberculosis treatment as well as among outpatients with tuberculosis-like symptoms are *Streptococcus pneumoniae* and non-typhoidal salmonellae: both can present with cough (primary cause) or as co-morbidities (super-infections) in patients presenting with active *Mycobacterium tuberculosis* disease.³²⁻³⁴ If effective treatment of this type of life-threatening primary/super-infections reduces mortality during the diagnostic work-up of suspected tuberculosis in people living with HIV, then empirical use of broad-spectrum antibiotics would be indicated for this purpose alone, irrespective of any diagnostic contribution to tuberculosis treatment decisions. In this context, azithromycin may be the most effective arm, as salmonella infections are highly sensitive to azithromycin, but not to amoxicillin.²⁸

AMR and trial-of-antibiotics

Antimicrobial resistance relating to antibiotic use during evaluation for suspected tuberculosis has not been investigated before. Previous work has shown that empirical antibiotics can drive rapid emergence of antimicrobial resistance.^{35 36} Co-trimoxazole prophylaxis for HIV-positive patients, introduced in 2005, was followed by near-universal

resistance in bloodstream infections by 2010³⁷. Mass drug administration of azithromycin for trachoma control initially reduces nasopharyngeal carriage of *Streptococcus pneumoniae*, but with increased macrolide-resistance 6 months later.^{38 39}

In this study we have the opportunity to assess the extent to which brief exposure drives antimicrobial resistance during diagnostic work-up for tuberculosis. An ecological niche for many bacterial species, the upper respiratory tract also presents a convenient sampling opportunity for investigating antimicrobial resistance.⁴⁰ *Streptococcus pneumoniae* is the organism of choice not only for being an important cause of respiratory tract infections but also because it often colonises the upper respiratory tract, acquires resistance readily, and has well documented laboratory investigation procedures in place.²⁴ As exploratory analyses, we will also assess nasopharyngeal colonization and antimicrobial resistance in relation to tuberculosis treatment and HIV status.

Important subgroups

Clinical response to trial-of-antibiotics is possible and indeed well-described in patients with bacteriologically confirmed tuberculosis (i.e. false-negatives/low sensitivity from the perspective of tuberculosis diagnosis) may relate to multiple super-infections.^{4 33} As such, this phenomenon may vary by HIV status, since multiple concurrent infections are a hallmark of advanced HIV immunosuppression, and are most commonly reported in patients with suspected tuberculosis in the pre-ART era. In 2015, in Malawi, 45% of adults who presented to primary care with prolonged cough (≥ 2 weeks) were HIV-positive, of whom only ~20% started tuberculosis treatment on the basis of positive mycobacteriology.²³ As such, the benefits and consequences of trial-of-antibiotics may vary by HIV status and ART coverage, and by subsequent tuberculosis treatment decisions. We will, therefore, include a pre-specified sub-analysis of trial outcomes stratified by HIV and ART status.

Limitations

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The study has several limitations. Firstly, we did not use a placebo-control arm. Secondly, the study is not adequately powered to evaluate safety of deferred antibiotic treatment or conduct subgroup analyses of outcomes by HIV status, both which are important evidence gaps. Other limitations include the possibility that participants randomised to the standard-of-care arm may find alternative access to antibiotics therefore misclassifying exposure/intervention status. There is also a possibility of misclassifying active tuberculosis status because of the suboptimal nature of the available tests.

ETHICS AND DISSEMINATION

The study has been reviewed and approved by the University of Malawi College of Medicine Research and Ethics Committee (COMREC; registration number P.04/18/2381), the London School of Hygiene & Tropical Medicine Research Ethics Committee (LSHTM EC; registration number 15232), and Regional Committee for Health and Research Ethics, NTNU-Midt, Norway (REK nord; registration number 208/1964). Regulatory approval has been granted by the Malawi Pharmacy, Medicines, and Poisons Board (PMPB; registration number CTRC/III/14062018102). We will present any future protocol modifications to these bodies before implementing. We will submit results for publication in a peer-reviewed journal. We will submit abstracts to relevant national and international conferences. This work will also form part of a PhD thesis for TD, which he will submit to the LSHTM. This study will follow the standards set by CONSORT guidelines.

AUTHORS' CONTRIBUTIONS

THD, KF and ELC are the main contributors to the conception, and design of the study. DS, MN and PM contributed to the general study planning and clinical design. NF contributed to the general study planning and antimicrobial resistance design. CK, LC, SC, and MJN contributed to the design, piloting, and refining of study and clinical procedures. THD developed the first draft of the manuscript. All authors carefully reviewed and substantially

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

contributed to the development of the trial protocol and this manuscript. All authors read and approved the final manuscript. THD is the guarantor for this work.

FUNDING AND SPONSORSHIP STATEMENT

The clinical trial is funded by the Commonwealth Scholarship Commission and the Helse Nord RHF grant awarded to THD. This work is part of THD's PhD work at London School of Hygiene & Tropical Medicine (LSHTM). LSHTM is the sponsor of this clinical trial (sponsor address: Keppel Street, Bloomsbury, London WC1E 7HT). ELC is funded by a Wellcome Trust Senior Research Fellowship in Clinical Science: WT200901. The funding agencies and the sponsor had no role in the preparation of the protocol or the intention to submit this manuscript for publication.

COMPETING INTERESTS STATEMENT

We have no conflicts of interest to declare.

BODY WORD COUNT: 4,034

REFERENCES

1. Raviglione M, Sulis G. Tuberculosis 2015: burden, challenges and strategy for control and elimination. *Infectious disease reports* 2016;8(2):6570. doi: 10.4081/idr.2016.6570
2. World Health Organization. Global tuberculosis report 2018: World Health Organization 2018.
3. Nliwasa M, MacPherson P, Mukaka M, et al. High mortality and prevalence of HIV and tuberculosis in adults with chronic cough in Malawi: a cohort study. *The international journal of tuberculosis and lung disease* 2016;20(2):202-10. doi: 10.5588/ijtld.15.0388
4. Getahun H, Harrington M, O'Brien R, et al. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. *The Lancet* 2007;369(9578):2042-49. doi: 10.1016/S0140-6736(07)60284-0
5. Corbett E, MacPherson P. Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality [State of the art series. Active case

1
2
3 587 finding/screening. Number 5 in the series]. *The international journal of tuberculosis and*
4 588 *lung disease* 2013;17(9):1125-38.
5
6 589 6. Siddiqi K, Lambert M-L, Walley J. Clinical diagnosis of smear-negative pulmonary
7 590 tuberculosis in low-income countries: the current evidence. *The Lancet infectious*
8 591 *diseases* 2003;3(5):288-96.
9
10 592 7. Ghana Health Service. Guidelines for the Clinical Management of TB and HIV Co-
11 593 infection in Ghana. In: Department DCaP, ed. Accra, 2007.
12
13 594 8. Ministry of Health. Malawi National TB Programme Manual. . In: Programme NT, ed. 8 ed.
14 595 Lilongwe, 2016.
15
16 596 9. National Department of Health. South Africa National Tuberculosis Management
17 597 Guidelines 2014. In: Coordination TDS, ed. Pretoria, 2014.
18
19 598 10. World Health Organization. Global tuberculosis report 2016. 2016
20
21 599 11. McDowell A, Pai M. Treatment as diagnosis and diagnosis as treatment: empirical
22 600 management of presumptive tuberculosis in India. *The International Journal of*
23 601 *Tuberculosis and Lung Disease* 2016;20(4):536-43.
24
25 602 12. Wilkinson D, Newman W, Reid A, et al. Trial-of-antibiotic algorithm for the diagnosis of
26 603 tuberculosis in a district hospital in a developing country with high HIV prevalence. *The*
27 604 *International Journal of Tuberculosis and Lung Disease* 2000;4(6):513-18. [published
28 605 Online First: 2000/06/23]
29
30 606 13. Holmes AH, Moore LS, Sundsfjord A, et al. Understanding the mechanisms and drivers
31 607 of antimicrobial resistance. *The Lancet* 2016;387(10014):176-87. doi: 10.1016/S0140-
32 608 6736(15)00473-0
33
34 609 14. World Health Organization. The evolving threat of antimicrobial resistance: options for
35 610 action: Geneva: World Health Organization 2012.
36
37 611 15. World Health Organization. Antimicrobial resistance: global report on surveillance: World
38 612 Health Organization 2014.
39
40 613 16. Laxminarayan R, Matsoso P, Pant S, et al. Access to effective antimicrobials: a
41 614 worldwide challenge. *The Lancet* 2016;387(10014):168-75. doi: 10.1016/S0140-
42 615 6736(15)00474-2
43
44 616 17. Divala TH, Fielding KL, Nliwasa M, et al. Sensitivity and specificity of using trial-of-
45 617 antibiotics versus sputum mycobacteriology for diagnosis of tuberculosis: protocol for a
46 618 systematic literature review. *Systematic reviews* 2018;7(1):141.
47
48 619 18. Divala TH, Nliwasa M, Gupta-Wrigh A, et al. Is the current practice of using response to
49 620 empirical broad-spectrum antibiotic treatment as an exclusion diagnostic for tuberculosis
50 621 supported by evidence? Systematic review and meta-analysis. 49th World Conference on
51 622 Lung Health of the International Union Against Tuberculosis and Lung Disease (The
52 623 Union): Int J Tuberc Lung Dis, 2018.
53
54 624 19. World Health Organization. High priority target product profiles for new tuberculosis
55 625 diagnostics: report of a consensus meeting, 28-29 April 2014, Geneva, Switzerland:
56 626 World Health Organization, 2014.
57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

- 627 20. National Tuberculosis Control programme. Malawi Nationwide Tuberculosis Prevalence
628 Survey. 45th Union World Conference on Lung Health. Barcelona, Spain, 2014.
- 629 21. Joint Formulary Committee. British national formulary (BNF) 78: Pharmaceutical Press
630 2019.
- 631 22. Montori VM, Permyer-Miralda G, Ferreira-González I, et al. Validity of composite end
632 points in clinical trials. *Bmj* 2005;330(7491):594-96.
- 633 23. Nliwasa M, MacPherson P, Chisala P, et al. The sensitivity and specificity of Loop-
634 Mediated Isothermal Amplification (LAMP) assay for Tuberculosis diagnosis in adults with
635 chronic cough in Malawi. *PloS one* 2016;11(5):e0155101. doi:
636 10.1371/journal.pone.0155101 [published Online First: 2016/05/14]
- 637 24. Satzke C, Turner P, Virolainen-Julkunen A, et al. Standard method for detecting upper
638 respiratory carriage of *Streptococcus pneumoniae*: updated recommendations from the
639 World Health Organization Pneumococcal Carriage Working Group. *Vaccine*
640 2013;32(1):165-79. doi: 10.1016/j.vaccine.2013.08.062
- 641 25. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life.
642 *Health policy (Amsterdam, Netherlands)* 1990;16(3):199.
- 643 26. Maheswaran H, Petrou S, MacPherson P, et al. Cost and quality of life analysis of HIV
644 self-testing and facility-based HIV testing and counselling in Blantyre, Malawi. *BMC*
645 *medicine* 2016;14(1):34.
- 646 27. O'Neill J. Tackling drug-resistant infections globally: Final report and recommendations.
647 2016. *HM Government and Wellcome Trust: UK* 2018
- 648 28. Musicha P, Cornick JE, Bar-Zeev N, et al. Trends in antimicrobial resistance in
649 bloodstream infection isolates at a large urban hospital in Malawi (1998–2016): a
650 surveillance study. *The Lancet Infectious Diseases* 2017;17(10):1042-52. doi:
651 10.1016/s1473-3099(17)30394-8
- 652 29. Lubell Y, Turner P, Ashley EA, et al. Susceptibility of bacterial isolates from community-
653 acquired infections in sub-Saharan Africa and Asia to macrolide antibiotics
654 Sensibilité aux macrolides des isolats bactériens provenant des infections acquises dans la
655 communauté en Afrique subsaharienne et en Asie
656 Susceptibilidad a macrólidos de aislados bacterianos provenientes de infecciones adquiridas
657 en la comunidad. *Tropical Medicine & International Health* 2011;16(10):1192-205. doi:
658 10.1111/j.1365-3156.2011.02837.x
- 659 30. Phua J, Dean NC, Guo Q, et al. Severe community-acquired pneumonia: timely
660 management measures in the first 24 hours. *Critical Care* 2016;20(1):237. doi:
661 10.1186/s13054-016-1414-2
- 662 31. Lim W, Smith D, Wise M, et al. British Thoracic Society community acquired pneumonia
663 guideline and the NICE pneumonia guideline: how they fit together. *Thorax*
664 2015;thoraxjnl-2015-206881.
- 665 32. Cain KP, Anekthananon T, Burapat C, et al. Causes of death in HIV-infected persons
666 who have tuberculosis, Thailand. *Emerging infectious diseases* 2009;15(2):258.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

33. Bedell RA, Anderson ST, Van Lettow M, et al. High prevalence of tuberculosis and serious bloodstream infections in ambulatory individuals presenting for antiretroviral therapy in Malawi. *PLoS One* 2012;7(6):e39347. doi: 10.1371/journal.pone.0039347

34. Schleicher G, Feldman C. Dual infection with *Streptococcus pneumoniae* and *Mycobacterium tuberculosis* in HIV-seropositive patients with community acquired pneumonia. *The International Journal of Tuberculosis and Lung Disease* 2003;7(12):1207-08.

35. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. *Nature medicine* 2004;10(12s):S122. doi: 10.1038/nm1145

36. Goossens H, Ferech M, Vander Stichele R, et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. *The Lancet* 2005;365(9459):579-87.

37. Everett DB, Mukaka M, Denis B, et al. Ten years of surveillance for invasive *Streptococcus pneumoniae* during the era of antiretroviral scale-up and cotrimoxazole prophylaxis in Malawi. *PloS one* 2011;6(3):e17765. doi: 10.1371/journal.pone.0017765

38. Coles CL, Mabula K, Seidman JC, et al. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant *Streptococcus pneumoniae* carriage in young children 6 months after treatment. *Clinical Infectious Diseases* 2013;56(11):1519-26.

39. Mitjà O, Houinei W, Moses P, et al. Mass treatment with single-dose azithromycin for yaws. *New England Journal of Medicine* 2015;372(8):703-10. doi: 10.1056/NEJMoa1408586

40. Man WH, de Steenhuijsen Piters W, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. *Nat Rev Microbiol* 2017;15(5):259-70. doi: 10.1038/nrmicro.2017.14

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Ensignment Supérieur (ABES)

LEGENDS FOR FIGURES

1. Legend for figure 1

*The common clinical practice is that outpatients start antibiotics at the time of submitting sputum, to avoid the need for a third clinic visit to complete the algorithm.

Figure 1: The position of trial-of-antibiotics in standard algorithms for diagnosis of tuberculosis in low and middle income countries (based on the 2018 WHO GLI model guidelines and as implemented in national guidelines e.g Ghana, Malawi and South Africa.)

2. Legend for figure 2

ART = antiretroviral treatment for HIV

NTP = Malawi National Tuberculosis Program

TB LAM = Urine Lipoarabinomannan for Tuberculosis Diagnosis

VL = HIV Viral load

Figure 2: Flow diagram for the clinical trial in Blantyre, Malawi

3. Legend for figure 3

Figure 3: Assessing the diagnostic value of a change in symptoms from baseline to day 8

APPENDIX 1: ETHICS AND REGULATORY APPROVALS

(attached separately)

APPENDIX 2: TRIAL REGISTRATION—DATA SET

(attached separately)


APPENDIX 3: FULL TRIAL PROTOCOL

1
2
3 719 (attached separately)
4 720
5
6 721
7
8 722
9
10 723 (attached separately)
11 724
12 725
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

**APPENDIX 4: PATIENT INFORMATION SHEET AND INFORMED
CONSENT**


For peer review only

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.



*The common clinical practice is that outpatients start antibiotics at the time of submitting sputum, to avoid the need for a third clinic visit to complete the algorithm.

Figure 1: The position of trial-of-antibiotics in standard algorithms for diagnosis of tuberculosis in low and middle income countries (based on the 2018 WHO GLI model guidelines and as implemented in national guidelines e.g Ghana, Malawi and South Africa.)



ART = antiretroviral treatment for HIV
 NTP = Malawi National Tuberculosis Program
 TB LAM = Urine Lipoarabinomannan for Tuberculosis Diagnosis
 VL = HIV Viral load
 Figure 2: Flow diagram for the clinical trial in Blantyre, Malawi

Reference Result: any positive *smear microscopy*, *Xpert/MTB/RIF*, or *MTB Culture* from sputum samples collected on Day 1 and Day 8 visit defines tuberculosis-test-positive

	Sputum-test-positive	Sputum-test-negative
ACASI* Response on Day 8 <i>ACASI test is defined by response to the following question asked using ACASI on Day 8: on day 1, you reported that you were unwell; compared to that day, has your illness <u>worsened</u>, <u>remained the same</u>, or <u>improved</u>?</i>	ACASI-test-positive (worse or no change) a	b
	ACASI-test negative (Improved) c	d

Primary outcome: specificity, calculated by $d / (b+d)$

*Audio Computer Assisted Self-Interview (ACASI) in which the participant, after a how-to-use test session, responds to the prescribed question on a database-linked android tablet, without any human interaction, and in private.

Figure 3: Assessing the diagnostic value of a change in symptoms from baseline to day 8

366x222mm (96 x 96 DPI)



CERTIFICATE OF ETHICS APPROVAL

This is to certify that the College of Medicine Research and Ethics Committee (COMREC) has reviewed and approved a study entitled:

P.04/18/2381 - Accuracy and Consequences of using Trial-of-antibiotics for TB diagnosis (ACT-TB Study) by Titus H Divala

On 03-Jul-18

As you proceed with the implementation of your study, we would like you to adhere to international ethical guidelines, national guidelines and all requirements by COMREC as indicated on the next page

03-Jul-18

Dr. YB. Mlombe - Chairperson (COMREC)

Date

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

REQUIREMENTS FOR ALL COMREC APPROVED RESEARCH PROTOCOLS

1. Pay the research overhead fees as required by the College of Medicine for all approved studies.
2. You should note that the COMREC Sub-Committee on Research Participants' Safety will monitor the conduct of the approved protocol and any deviation from the approved protocol may result in your study being stopped.
3. You will provide an interim report in the course of the study and an end of study report.
4. All COMREC approvals of new applications and progress reports are valid for one year only. Therefore all approved studies running for more than one year are subject to continuing review annually. You are required to submit a progress report to COMREC within 90-30 days before the expiration date. Your current expiration date is 03-Jul-19. Studies shall be considered lapsed and inactive if continuing review application is not received one month after the expiry of the previous approval. In that case, all study related operations should cease immediately except those that are necessary for the welfare of subjects.
5. All investigators who are Medical Practitioners must be fully registered with the Medical Council of Malawi.



PHARMACY, MEDICINES & POISONS BOARD

Mission: To promote and improve the health of the population of Malawi through the regulation of Pharmacy Personnel, Pharmacy Businesses, Medicines and Allied Substances

ALL CORRESPONDENCE SHOULD BE ADDRESSED TO THE REGISTRAR

Head Office:

Off Paul Kagame/
Chilambula Road
P.O.Box 30241
Capital City
LILONGWE 3, MALAWI

Phone: (+265) 01 755 165
Fax : (+265) 01 755 204
Email: info@pmpb.mw
Web: www.pmpb.mw

PMPB/CTRC/III/14062018102
DATE: 4th July, 2018

Department of Infectious Disease Epidemiology
London School of Hygiene and Tropical Medicine
Keppel St
London

Attn.: Dr. Titus Divala

**RE: ACCURACY AND CONSEQUENCES OF USING TRIAL-OF-ANTIBIOTICS FOR TB
DIAGNOSIS (ACT-TB STUDY).**

Refer to your application to register the above mentioned clinical trial with the Pharmacy, Medicines and Poisons Board (PMPB).

The Clinical Trial Review Committee (CTRC), at its meeting held on 22nd June, 2018, issued a **No Objection** to the implementation of the trial after members agreed that the nature of the trial was seen to be outside the scope of trials that should be regulated by PMPB through the CTCR.

Please contact the undersigned if there are any issues that need further clarification.

Yours faithfully,

M. Kawaye
ACTING REGISTRAR





Region:	Saksbehandler:	Telefon:	Vår dato:	Vår referanse:
REK nord			06.11.2018	2018/1964/REK nord
			Deres dato:	Deres referanse:
			25.09.2018	
			Vår referanse må oppgis ved alle henvendelser	

Jon Øyvind Odland
Institutt for samfunnsmedisin

2018/1964 En kontrollert klinisk studie for å undersøke responsen til bredspekret antibiotika som en eksklusjonsdiagnose i allmen praksis mot risiko for antibiotika resistens

Forskningsansvarlig institusjon: UiT Norges arktiske universitet

Prosjektleder: Jon Øyvind Odland

Vi viser til søknad om forhåndsgodkjenning av ovennevnte forskningsprosjekt. Søknaden ble behandlet av Regional komité for medisinsk og helsefaglig forskningsetikk (REK nord) i møtet 25.10.2018. Vurderingen er gjort med hjemmel i helseforskningsloven (hforsknl) § 10.

Prosjektleders prosjekttale

Det skal undersøkes, ved hjelp av en randomisert, kontrollert studie om respons til bredspekret antibiotika kan brukes som eksklusjonsdiagnose for tuberkulose. Dette skal vurderes opp mot risiko for resistensutvikling knyttet til behandlingen. Tre grupper (625 per gruppe) individuelt randomisert (1:1:1), med åpen informasjon undersøkes med standard diagnostisk tilnærming. Kun voksne deltakere, med full brukermedvirkning og informert samtykke. Studien kan forenkle diagnostikk og klinikk for en utsatt gruppe mennesker. Studien skal i sin helhet foregå i Malawi. Alle etiske godkjenninger fra Malawi og London er vedlagt.

Komiteen vurderte at Hanne Husom Haukland var inhabil og hun fratrådte møtet da saken ble behandlet, jf. fvl. § 6.

Om prosjektet

Prosjektet er en del av en PhD. Studenten skal avlegge sin PhD i London.

Dette er et samarbeidsprosjekt mellom Universitetet i Malawi, London School of Hygiene and Tropical Medicine, og Universitetet i Tromsø.

Prosjektet skal gjennomføres i Malawi og er et «Tuberkulose initiativ» fra Helse Nord.

Det foreligger godkjenning fra London School of Hygiene and Tropical Medicine, og University of Malawi.

Data

Det skal hentes data fra pasientjournal og fra lokale poliklinikker. Data er standard medisinske opplysninger knyttet til infeksjoner og sykehistorie.

Nye helseopplysninger er respons på behandling av infeksjoner.

Data aidentifiseres med koblingsnøkkel. Database oppbevares i 5 år i Malawi.

Deltakere/rekruttering

Voksne deltakere fordeles i tre grupper voksne deltakere (625 per gruppe), individuelt randomisert. Deltakere rekrutteres gjennom behandling på poliklinikkene.

REK har ingen innvendinger til prosjektet

Vedtak

REK har gjort en helhetlig forskningsetisk vurdering av alle prosjektets sider og godkjenner det med hjemmel i helseforskningsloven § 10. REK forutsetter at prosjektet også har godkjenning fra Malawi.

Sluttmelding og søknad om prosjektendring

Prosjektleder skal sende sluttmelding til REK nord på eget skjema senest 21.03.2022, jf. hfl. § 12. Prosjektleder skal sende søknad om prosjektendring til REK nord dersom det skal gjøres vesentlige endringer i forhold til de opplysninger som er gitt i søknaden, jf. hfl. § 11.

Klageadgang

Du kan klage på komiteens vedtak, jf. forvaltningsloven § 28 flg. Klagen sendes til REK nord. Klagefristen er tre uker fra du mottar dette brevet. Dersom vedtaket opprettholdes av REK nord, sendes klagen videre til Den nasjonale forskningsetiske komité for medisin og helsefag for endelig vurdering.

Med vennlig hilsen

May Britt Rossvoll
sekretariatsleder

Kopi til: jon.oyvind.odland@uit.no

London School of Hygiene & Tropical Medicine

Keppel Street, London WC1E 7HT
 United Kingdom
 Switchboard: +44 (0)20 7636 8636
www.lshtm.ac.uk

LONDON
 SCHOOL of
 HYGIENE
 & TROPICAL
 MEDICINE

**Observational / Interventions Research Ethics Committee**

Dr Titus Divala
 LSHTM

9 May 2018

Dear Titus ,

Study Title: RCT investigating if benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis in primary care adult patients outweigh the risk of antimicrobial resistance

LSHTM ethics ref: 15232

Thank you for your application for the above research, which has now been considered by the Interventions Committee.

Confirmation of ethical opinion

On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation, subject to the conditions specified below.

Conditions of the favourable opinion

Approval is dependent on local ethical approval having been received, where relevant.

Approved documents

The final list of documents reviewed and approved by the Committee is as follows:

Document Type	File Name	Date	Version
Safety Information	ACT_PackageInsertAzithromycin	14/03/2013	JUNE 2013
Safety Information	ACT_PackageInsertAmoxicillin	21/12/2015	DEC 2015
Sponsor Letter	2018-KEP-077_Sponsor Confirmation_13.03.18	13/03/2018	1
Other	GCP Cert_LSHTM_TDivala_21.03.18	21/03/2018	1
Investigator CV	ACT-CV1_TitusDivala	30/03/2018	1
Investigator CV	ACT-CV2_KatherineFielding	30/03/2018	1
Investigator CV	ACT-CV3_LizCorbett	30/03/2018	1
Information Sheet	ACT-20180330InformedConsentEnglish	30/03/2018	1.0
Information Sheet	ACT-20180330InformedConsentChichewa	30/03/2018	1.0
Protocol / Proposal	ACT-20180330Protocol	30/03/2018	1.0

After ethical review

The Chief Investigator (CI) or delegate is responsible for informing the ethics committee of any subsequent changes to the application. These must be submitted to the Committee for review using an Amendment form. Amendments must not be initiated before receipt of written favourable opinion from the committee.

The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reactions (SUSARs) which occur during the project by submitting a Serious Adverse Event form.

An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study.

At the end of the study, the CI or delegate must notify the committee using an End of Study form.

All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at: <http://leo.lshtm.ac.uk>

Additional information is available at: www.lshtm.ac.uk/ethics

Yours sincerely,

1 ethics@lshtm.ac.uk
2 <http://www.lshtm.ac.uk/ethics/>
3
4
5

6 **Improving health worldwide**
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

London School of Hygiene & Tropical Medicine

Keppel Street, London WC1E 7HT
 United Kingdom
 Switchboard: +44 (0)20 7636 8636
www.lshtm.ac.uk

LONDON
 SCHOOL of
 HYGIENE
 & TROPICAL
 MEDICINE

**Observational / Interventions Research Ethics Committee**

Dr Titus Divala
 LSHTM

12/04/2019

Dear Titus,

Project Title: RCT investigating if benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis in primary care adult patients outweigh the risk of antimicrobial resistance

Project ID: 15232

Thank you for your annual report application for the continuation of your research dated 09/04/2019 12:01 , which has now been considered by the Chair on behalf of the Ethics Committee.

Confirmation of ethical opinion

This application is approved by the committee for a further year.

Conditions of the favourable opinion

Approval is dependent on local ethical approval having been received, where relevant.

After ethical review

Any changes to the application must be submitted to the committee via an Amendment form.

The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reaction (SUSARs) which occur during the project by submitting a SUSAR and Protocol Violation form.

An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study.

At the end of the study, the CI or delegate must notify the committee using an End of Study form.

All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at <http://leo.lshtm.ac.uk>.

Additional information is available at: www.lshtm.ac.uk/ethics.

Yours sincerely,


Professor John DH Porter
 Chair

ethics@lshtm.ac.uk
<http://www.lshtm.ac.uk/ethics/>

Improving health worldwide

APPENDIX 2: TRIAL REGISTRATION—DATA SET

NCT Number	NCT03545373
Title	Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis (ACT-TB Study)
Acronym	ACT-TB
Status	Recruiting
Study Results	No Results Available
Conditions	Tuberculosis Respiratory Tract Infections Pneumonia
Interventions	Drug: Azithromycin Drug: Amoxicillin
Outcome Measures	Diagnostic accuracy of trial-of-antibiotics: Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 against a mycobacteriology reference standard. Overall clinical benefit of empirical antibiotic treatment in primary care participants with chronic cough: proportion of participants experiencing adverse clinical outcomes Impact of trial-of-antibiotics on antimicrobial resistance Diagnostic accuracy of trial-of-antibiotics including participants who did not produce sputum Economic analysis of use of trial-of-antibiotics
Sponsor/Collaborators	London School of Hygiene and Tropical Medicine University of Malawi College of Medicine
Gender	All
Age	18 Years and older Å (Adult, Older Adult)
Phases	Phase 3
Enrollment	1875
Funded Bys	Other
Study Type	Interventional
Study Designs	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Outcomes Assessor) Primary Purpose: Diagnostic
Other IDs	15232
Start Date	February 25, 2019
Primary Completion Date	Jun-20
Completion Date	Jun-20
First Posted	June 4, 2018
Results First Posted	
Last Update Posted	August 15, 2019
Locations	University of Malawi College of Medicine, Blantyre, Southern, Malawi
Study Documents	
URL	https://ClinicalTrials.gov/show/NCT03545373



Randomised controlled clinical trial investigating benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis (TB) in primary care adult patients versus risk of antimicrobial resistance (AMR)

Short title: Accuracy and Consequences of using Trial-of-antibiotics for TB diagnosis

Acronym: ACT-TB Study

Trial registration:

Protocol version: 4.0, 27 Jan 2020

Chief Investigator: Titus H Divala
London School of Hygiene & Tropical Medicine
Keppel Street, London WC1E 7HT
Tel: +44 740 523 1847
Email: titus.divala@lshtm.ac.uk

Co-Investigators: Katherine L Fielding, Neil French, Derek J Sloan, Elizabeth L Corbett

Collaborators: Marriott Nliwasa, Augustine Choko, Ankur Gupta-Wright, Jennifer Cornic, Jon Øyvind Odland, Chisomo Msefula, Hendramoorthy Maheswaran

Sponsor: London School of Hygiene & Tropical Medicine is the main research sponsor for this study. For further information regarding the sponsorship conditions, please contact the Research Governance and Integrity Office:
London School of Hygiene & Tropical Medicine
Keppel Street, London WC1E 7HT
Tel: +44 207 927 2626
Email: RGIO@lshtm.ac.uk

Funding: Helse Nord RHF
Tromsø, Norway; Tel: +47 97065144
Email: Hanne.Husom.Haukland@helse-nord.no

Study Coordination Centre: University of Malawi College of Medicine
Private Bag 360
Chichiri, Blantyre, Malawi
Tel: +2651871911
Email: rscdirector@medcol.mw

This trial will adhere to the principles outlined in the International Council for Harmonisation Good Clinical Practice (ICH GCP) guidelines, protocol and all applicable local regulations.

Table of contents		
1	Abbreviations	6
2	Study Summary	8
3	Introduction.....	11
3.1	Background.....	11
3.2	Systematic literature review	13
3.3	Planned study	15
3.4	Rationale for current study.....	15
3.4.1	Accuracy of trial-of-antibiotics	15
3.4.2	Antimicrobial resistance and trial-of-antibiotics	16
3.4.3	Potential benefits of antibiotics.....	17
3.4.4	Important subgroups	18
3.5	Choice of study interventions.....	19
3.6	Nasopharyngeal pneumococcus for AMR	20
3.7	Objectives and outcomes	20
4	Study design, participants, and statistical approach	22
4.1	Study design	22
4.2	Study setting.....	22
4.3	Standard of care	22
4.4	Eligibility criteria.....	24
4.4.1	Inclusion Criteria.....	24
4.4.2	Exclusion Criteria	24
4.5	Interventions	24
4.5.1	Name and description of intervention arms.....	24
4.5.2	Legal status of drugs used in intervention arms.....	24
4.5.3	Summary of Product Characteristics.....	24
4.5.4	Drug Storage and Supply.....	25
4.5.5	Preparation and labelling of study drugs.....	25
4.5.6	Known drug reactions (adverse events).....	25
4.5.7	Concomitant medication and interaction with other therapies.....	25
4.5.8	Trial restrictions.....	25

4.5.9	Assessment of compliance.....	25
4.5.10	Withdraw of interventions.....	26
4.6	Statistical approach	26
4.6.1	Primary outcome	26
4.6.2	Secondary outcomes.....	29
4.6.3	Exploratory outcome	30
4.6.4	Planned subgroup analyses.....	30
4.7	Sample size and power	30
4.7.1	Primary outcome 1: specificity of trial-of-antibiotics versus mycobacteriology.....	30
4.7.2	Primary outcome 2: Incidence of adverse clinical outcome at Day-29.....	31
4.7.3	Secondary outcomes.....	32
4.7.4	Exploratory outcomes.....	32
5	Pilot study	33
5.1	Specific objectives of the pilot study	33
5.2	Population for the pilot study.....	34
5.3	Pilot study procedures.....	34
5.4	Data analysis.....	35
6	Study procedures	37
6.1	Screening	37
6.2	Informed consent	37
6.3	Baseline procedures	37
6.4	Assignment of interventions	38
6.5	Blinding	40
6.6	Participant follow up	40
6.6.1	Day-8 activities.....	41
6.6.2	Day-29 activities.....	41
6.7	Laboratory methods.....	42
6.7.1	Tuberculosis mycobacteriology.....	42
6.7.2	Urine antigen testing for lipoarabamannan and other MTB antigens.....	42
6.7.3	Antimicrobial resistance testing.....	42
6.8	Loss to follow-up.....	43

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

6.9	Trial closure	43
6.10	Summary schedule for study procedures.....	43
7	Safety reporting	45
7.1	Definitions	45
7.2	DMID grading for AEs	46
7.3	Grading for expected events	46
7.4	Causality.....	48
7.5	Reporting Procedures	49
7.5.1	Non-serious Adverse Events (AEs).....	49
7.5.2	Serious Adverse Events (SAEs).....	49
8	Economic evaluation.....	50
8.1	Objective	50
8.2	Outcomes	50
8.3	Data collection	50
8.4	Data analysis.....	51
8.5	Missing data.....	51
9	Data management.....	52
9.1	Source Data.....	52
9.2	Data collection methods	52
9.3	Data management.....	52
9.4	Quality control and quality assurance	53
9.5	Access to data	53
10	Data monitoring and quality assurance	54
10.1	Data monitoring	54
10.2	Audits and Inspections	54
10.3	Data Safety and Monitoring Board (DSMB).....	54
10.4	Trial Management Group (TMG).....	54
10.5	Trial Investigational Team	55

11	Ethics and dissemination	56
11.1	Risk assessment	56
11.2	Research ethics approval	56
11.3	Indemnity.....	57
11.4	Sponsor.....	57
11.5	Declaration of interests.....	57
11.6	Cost of participation, ancillary and post-trial care.....	57
11.7	Dissemination policy.....	57
12	References	58
13	Appendix 1: Informed consent.....	61
14	Appendix 2: Division of Microbiology and Infectious Diseases (DMID) adult toxicity table	62
15	Appendix 3: Package insert for Azithromycin and amoxicillin.....	74

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Abbreviations

ACASI	Audio Computer Assisted Self-Interview
AE	Adverse Event
AMR	Antimicrobial Resistance
AR	Adverse Reaction
ART	Antiretroviral Therapy
CD4	Cluster of Differentiation 4
CEACs	Cost-Effectiveness Acceptability Curves
COMREC	University of Malawi College of Medicine Research and Ethics Committee
CXR	Chest X-Ray
DMID	Division of Microbiology and Infectious Diseases
DSMB	Data Safety and Monitoring Board
GLM	Generalised Linear Model
HIV	Human Immunodeficiency Virus
HRQoL	Health Quality of Life
LAM	Urine Lipoarabinomannan Assay
LJ	Lowenstein-Jensen
LSHTM	London School of Hygiene & Tropical Medicine
MDA	Mass Drug Administration
MGIT	Mycobacteria Growth Indicator Tube

MTB or M.tb	<i>Mycobacterium tuberculosis</i>
NMBs	Net Monetary Benefits
NTM	Non-Tuberculous Mycobacteria
NTP	National Tuberculosis Control Program
NTS	Non-Typhoidal Salmonellae
PCP	Pneumocystis Jiroveci
PLHIV	People Living With HIV
PTB	Pulmonary Tuberculosis
QALY	Quality-Adjusted Life Year
RCT	Randomized Controlled Trial
SAE	Serious Adverse Event
SAR	Serious Adverse Reaction
SOC	Standard of Care
STGG	Skim Milk Tryptone Glucose Glycerol
SUSAR	Suspected Unexpected Serious Adverse Reaction
TB	Tuberculosis
TMG	Trial Management Group
WHO	World Health Organization
WTP	Willingness to Pay

2 Study Summary

Title	Randomised controlled clinical trial investigating benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis (TB) in primary care adult patients versus risk of antimicrobial resistance (AMR)	
Design	Three arm (625 per arm) individually randomised (1:1:1), open-label controlled clinical trial investigating standard care diagnostic approach for tuberculosis. The trial will not use any unlicensed products.	
Objective	Outcomes	
Primary		
1. To establish the diagnostic value of trial-of-antibiotics for excluding pulmonary tuberculosis (PTB) in adults with prolonged cough (and have a valid sputum test result) at primary care level in Malawi.	Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 (i.e. after a trial-of-antibiotics if in azithromycin or amoxicillin arms, or without antibiotics if in standard of care arm) against a mycobacteriology reference standard, among participants with a valid result from at least one sputum TB test	
2. To determine the overall clinical benefit of giving empirical antibiotic treatment in primary care participants with chronic cough.	Proportion of participants experiencing at least one of the following adverse outcomes by Day 29: 1) death 2) hospitalisation 3) missed TB diagnosis	
Secondary		
3. To evaluate using nasopharyngeal <i>Streptococcus pneumoniae</i> , the effect of a trial-of-antibiotics on selection for antimicrobial resistance.	Proportion of Day 29 nasopharyngeal <i>Streptococcus pneumoniae</i> isolates resistant to commonly used antimicrobials.	
4. To establish the diagnostic value of trial-of-antibiotics for excluding pulmonary tuberculosis (PTB) in primary care presenting Malawian adults with prolonged cough including those without a successful sputum	Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 (i.e. after a trial-of-antibiotics if in azithromycin or amoxicillin arms, or without antibiotics if in standard of care arm) against a mycobacteriology reference standard, among all	

test (unable to submit sputum and those with invalid sputum results).	randomised participants, with those who could not provide sputum or had an invalid sputum result classified as mycobacteriologically negative.
5. To estimate the incremental cost-effectiveness of trial-of-antibiotics using azithromycin and trial-of-antibiotics using amoxicillin in comparison to standard of care, and to each other.	• Incremental cost per quality adjusted life year gained • Total direct medical costs per participant over 56 days • Eq-5D utility score
Exploratory	
Our exploratory analyses will be comparisons between the azithromycin and amoxicillin arms for all our primary and secondary outcomes.	
Population	Adults presenting to primary care centres in Malawi reporting cough.
	Inclusion criteria: • Ambulatory clinic attendees presenting with cough • Should have been ill for ≥ 14 days • Aged at least 18 years • Reside in Blantyre and willing to return to the same clinic for follow up visits over the entire study period. Exclusion criteria: • Self-reported allergy to study medications • Acute danger signs defined in national TB treatment guidelines • Tuberculosis treatment or isoniazid preventive therapy in the last 6 months • Treated with antibiotics, other than co-trimoxazole prophylaxis, for the current illness or within the past 14 days
Treatment	Arm 1: Azithromycin 500mg once daily for 3 days commencing on randomization day. Arm 2: Amoxicillin 1 g 3 times daily for 5 days commencing on randomization day. Arm 3: Standard of care in current national guidelines for patients presenting with cough and without danger signs (No treatment until re-evaluation with sputum TB test results)
Duration	We will give treatments on the randomisation day (Day-1) and perform follow up activities on days 8, and 29.




Figure 1: Flow diagram for the planned clinical trial in Blantyre, Malawi

3 Introduction

3.1 Background

Antimicrobial resistance is a growing crisis, becoming in 2016 one of only four health topics ever to be discussed at the United Nations General Assembly.¹⁻⁴ Tuberculosis is the leading global infectious cause of death in adults,⁵ with approximately 10.4 million cases and 1.8 million deaths in 2015.⁶ The high case-fatality rate in part reflects suboptimal diagnostics (Figure 2).⁷⁻¹⁰




Figure 2: method of diagnosis for TB notifications globally (A) and in Blantyre, Malawi (B)

To complement the suboptimal diagnostics, standard diagnostic algorithms in resource-limited settings include a “trial-of-antibiotics” (Figure 3). This is a course of broad-spectrum antibiotics, with negligible *Mycobacterium tuberculosis* activity, given to patients with symptoms such as cough in order to “rule-out” or “rule in” tuberculosis.¹¹⁻¹³ Patients with negative sputum mycobacteriology and responded to antibiotic treatment are considered tuberculosis negative while those who remain symptomatic are deemed likely to have tuberculosis and undergo further evaluations leading on to receiving tuberculosis treatment.




Figure 3: Implementation of trial-of-antibiotics (marked with red boxes) in Malawi TB diagnostic algorithm, National TB control program (NTP)

Approximately 26.5 million course of antibiotics are prescribed in the diagnosis of the 5.3 million smear negative tuberculosis registrations per annum (Figure 4).⁶ This estimate is based on an average of 5 antibiotic courses per sputum-negative treatment initiation, with 2 courses given to the patients before tuberculosis treatment,⁸ and the other 3 courses accounting for patients whose symptoms resolved and tuberculosis was ruled out.¹⁴

Wilkinson et al ¹⁴ prescribed 120 + 74 courses of trial-of-antibiotics to diagnose 40 smear-negative TB patients (a typical ratio of ~1:5). ⁸ If generalizable, then for 5.3 million annual smear-negative TB registrations globally ~5 x 5.3 million trial-of-antibiotics courses (26.5 million) will have been prescribed.	Enrolled	280
	TB smear microscopy positive	160
	Given trial-of-antibiotics (amoxicillin)	120
	Improved, declared TB negative	46
	Given trial-of-antibiotics (erythromycin)	74
	Improved, declared TB negative	34
	Treated for smear negative TB	40
<i>Wilkinson et.al Int J Tuberc Lung Dis. 2000</i>		
Figure 4: Quantifying number of trial-of-antibiotics courses prescribed per year using data from Wilkinson et.al and WHO TB Report 2016		

Despite this widespread use, there is no randomised controlled trial evidence supporting the diagnostic accuracy of trial-of-antibiotics. There is also a dearth of evidence on their impact on antimicrobial resistance or patient clinical outcomes.

3.2 Systematic literature review

We performed a systematic literature review to determine the sensitivity and specificity of using a trial-of-antibiotics compared to sputum mycobacteriology for diagnosis of PTB. We also wanted to describe how trial-of-antibiotics fits into TB diagnostic algorithms: timing of prescription; type, duration, and number of antibiotic prescriptions; and how response to treatment is measured. We searched MEDLINE, Embase, and Global Health using the Ovid platform to identify studies meeting the following criteria:

Population	Adult patients with symptoms suggestive of pulmonary tuberculosis
Intervention	Routinely prescribed broad-spectrum oral antibiotics without MTB activity, and given as part of evaluation of pulmonary TB
Outcome	sensitivity and specificity of the intervention in comparison with any mycobacteriology test
Study design	Any design with prospective component allows evaluation of the outcome of the intervention
Time frame	Studies published after WHO declaration of TB as a 'global emergency' (1993)
Language	English, lack of translation capacity

We identified 7,064 articles from a systematic search on MEDLINE, Embase, and Global Health using the Ovid platform. Of these studies, 12 were eligible for narrative synthesis and seven had suitable data for meta-analysis. None of the studies was an RCT and all the observational studies were small and not primarily designed to address the benefits and consequences of trial-of-antibiotics. Unlike our proposed RCT, most of the published work was from hospital setting or in specialised clinics. Most studies used amoxicillin and some studies prescribed a subsequent course of antimicrobials either before or after assessing for improvement. The definition of improvement from baseline clinical state was largely subjective: it was based on self-report, clinical examination, radiological assessment or a combination.

There is no consensus on the sensitivity and specificity of trial-of-antibiotics across studies with estimates ranging from 43% to 91% for sensitivity and 41% to 82% for specificity (shown below).

Population, Study		Sensitivity, 95% CI			Specificity, 95% CI		
237	Wilkinson et al 1997	0.5	0.37	0.64	0.82	0.76	0.87
120	Wilkinson et al 2000	0.83	0.71	0.91	0.56	0.44	0.67
204	Kudjawu et al 2006	0.91	0.83	0.96	0.65	0.56	0.73
1000	Kamran et al 2006	0.72	0.62	0.8	0.41	0.38	0.44
264	Soto et al 2011	0.43	0.32	0.55	0.68	0.63	0.72
439	Soto et al 2013	0.46	0.34	0.58	0.6	0.53	0.66
440	Padmapriyadarsini et al 2	0.7	0.55	0.8	0.69	0.64	0.73

We could not identify any RCT, the current literature only has small studies, with trial-of-antibiotics not being the primary focus of investigation in most cases. There is limited data for primary care settings as most of the work was in hospital setting. None of the studies addressed AMR. Therefore, despite widespread use, the approach, the value and consequences of having trial-of-antibiotics in TB diagnostic algorithms, remains to be established.

3.3 Planned study

To address the evidence gaps related to a) accuracy, b) antimicrobial resistance, and c) impact on clinical outcomes), we propose to conduct a randomised controlled clinical trial recruiting adult patients presenting to primary care centres in Blantyre, Malawi with history of cough for at least 2 weeks. After excluding those with danger signs we will randomise participants to receiving or not receiving trial-of-antibiotics (azithromycin or amoxicillin) from Day-1 to determine diagnostic accuracy (specificity) against mycobacteriology reference standard (smear microscopy, Xpert/MTB/RIF and culture).

For secondary outcomes, we will also compare between arms differences in antimicrobial resistance and clinical outcomes (risk of death, hospitalisation, and missed TB diagnosis) at Day-29. To our knowledge this will be the first randomised controlled trial to address these questions in over 20 years of systematic use of trial-of-antibiotics without strong evidence base.

3.4 Rationale for current study

3.4.1 Accuracy of trial-of-antibiotics

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

As an approach that is being used on such a large scale, trial-of-antibiotics should ideally have a strong evidence-base (supported by reference mycobacteriology) of how much diagnostic and/or clinical improvement it brings to the TB diagnostic algorithm.^{15,16} This will be among the most important considerations when deciding whether it is worth the trade-off with potential for AMR. Such evidence could come from an RCT or a well-designed prospective study.¹⁵⁻¹⁷ However, despite being in use for more than 20 years, we have not identified any such clinical trial, and even the observational evidence is highly limited and of insufficient quality and quantity to definitively address the question.

There is also no guidance on antibiotic choice beyond a recommendation to avoid those with anti-tuberculosis activity (like fluoroquinolones). Another key area that lacks clarity is lack of a clear definition for clinical resolution when determining the outcome of trial-of-antibiotics. Clinical resolution is the basis for decisions that follow (i.e. discontinue follow up or proceed Antimicrobial resistance and trial-of-antibiotics

Antimicrobial resistance can be either intrinsic or acquired. The risk of acquired resistance relating to antibiotic use during evaluation for suspected tuberculosis has not been previously investigated, although previous work has shown that empirical antibiotics can drive rapid emergence of AMR.^{18,19} For example, co-trimoxazole prophylaxis for HIV-positive patients, introduced in 2005, was followed by near-universal resistance in bloodstream infections by 2010.²⁰ Mass drug administration of azithromycin for trachoma control initially reduces nasopharyngeal carriage of *Streptococcus pneumoniae*, but with increased macrolide-resistance 6 months later.^{21,22}

In our study, the AMR risks of empirical antibiotic prescriptions (azithromycin and amoxicillin arms of the RCT) are justified because of the widespread use of this approach for amoxicillin, and the low potential clinical impact and short-lived effects of use of azithromycin on AMR, given the limited use of macrolides in Malawi. Mathematical modelling work suggests that macrolide resistance can successfully be eliminated by intra-species competition alone (fitness cost) within 5 years of last use.²³

3.4.2 Antimicrobial resistance and trial-of-antibiotics

Antimicrobial resistance relating to antibiotic use during evaluation for suspected tuberculosis has not been investigated before. Previous work has shown that empirical antibiotics can drive rapid emergence of antimicrobial resistance.^{18,19} Co-trimoxazole prophylaxis for HIV-positive patients, introduced in 2005, was followed by near-universal resistance in bloodstream infections by 2010²⁰ also shown in Table 1. Mass drug administration of azithromycin for trachoma control initially reduces nasopharyngeal carriage of *Streptococcus pneumoniae*, but with increased macrolide-resistance 6 months later.^{21,22}

We will investigate antimicrobial resistance in nasopharyngeal *S. pneumonia* by randomisation arm and cumulative antibiotic exposure to assess the extent to which brief exposure drives antimicrobial resistance during diagnostic work-up for tuberculosis. An ecological niche for many bacterial species, the upper respiratory tract also presents a convenient window for investigating antimicrobial resistance.²⁴ *S. pneumonia* is the organism of choice not only for being an important cause of respiratory tract infections but also because it often colonises the upper respiratory tract and has well documented laboratory investigation procedures in place.²⁵ As exploratory analyses, we will also assess nasopharyngeal colonization and antimicrobial resistance in relation to tuberculosis treatment and HIV status.

Table 1 Resistance patterns of common aetiologies of pneumonia to commonly used antimicrobials in Blantyre, Malawi

Organism		Gram positive		Gram negative			
		Streptococcus pneumoniae	Staphylococcus aureus	Haemophilus influenzae	Klebsiella pneumoniae	Escherichia coli	Pseudomonas aeruginosa
Prevalence		15.6%	6.6%	0.9%	4.4%	0.1%	1.5%
Resistance percentage	amoxicillin	*	*	58%	100%	94%	100%
	penicillin	21%	*	*	*	*	*
	co-trimoxazole	98%	40%	100%	92%	94%	75%
	chloramphenicol	21%	2%	92%	48%	61%	100%
	Erythromycin	2%	30%	*	*	*	*
	tetracycline	38%	35%	*	*	*	*
	Ceftriaxone	*	*	0%	90%	30%	100%
	Ciprofloxacin	*	*	NA	705	31%	24%
*not routinely tested							
2016 data from hospitalised febrile patients at Queen Elizabeth central hospital (Blantyre, Malawi) as reported by the MLW Clinical research laboratory (unpublished).							

3.4.3 Potential benefits of antibiotics

In areas with high HIV prevalence, empirical antibiotics during tuberculosis investigations could be life-saving: mortality immediately before and after tuberculosis diagnosis is high,^{7,26} and is often secondary to severe bacterial infections.²⁶⁻²⁸ The leading aetiologies of infection and death on tuberculosis treatment as well as among outpatients with tuberculosis-like symptoms are *Streptococcus pneumoniae* and non-typhoidal salmonellae (NTS): both can present with cough (primary cause) or as co-morbidities (super-infections) in patients presenting with active *Mycobacterium tuberculosis* (*M.tb*) disease.²⁶⁻²⁸ If effective treatment of this type of life-threatening primary/super-infections reduces mortality during the diagnostic work-up of suspected TB in people living with HIV (PLHIV), then empirical use of broad-spectrum antibiotics would be indicated for this purpose alone, irrespective of any diagnostic contribution to TB treatment decisions. In this context, azithromycin may be the most effective arm, as Salmonella infections are highly sensitive to azithromycin, but not to amoxicillin.²⁹

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3.4.3.1 Measures of clinical benefit of trial-of-antibiotics

In this study, we will investigate the overall clinical benefit of trial-of-antibiotics by comparing the risk of any of death, hospitalisation, and missed TB diagnosis by Day 29. Although all these events are potential consequences of trial-of-antibiotics, grouping them as a single composite endpoint may only appropriately represent the effect of the intervention 1) there are similarities in the importance patients would attach to each of its components and 2) the components occur with similar frequencies in the patient population.³⁰

The impact of antibiotics on hospitalisation and mortality causing illnesses is as described above. Both these outcomes are important with their similarity hinged on the fact that hospitalisation event predicts mortality. In patients with chronic cough, frequencies of mortality and that of hospitalization over a two months period are similar, ranging from 2 to 6%.³¹

TB misdiagnosis becomes a concern because of the potential for misclassification in either direction –false positive or false negative. False positive diagnosis in the context of trial-of-antibiotics would occur when the underlying pathology for the respiratory symptoms is not responding to the antibiotic, which can be secondary to either AMR or the illness not being of bacterial origin. On the other hand, patients would be prone to a false negative result had both TB and a susceptible bacterial infection. If the symptoms were largely driven by the susceptible bacterial infection, their symptoms will improve and would be declared TB negative. TB is a life-threatening illness, missing its diagnosis can therefore lead to death which is more important to an individual patient than taking TB chemotherapy with a false positive TB diagnosis. We will therefore include only missed TB diagnoses in the composite clinical outcome. Unpublished data from Blantyre shows that the frequency of missed TB diagnosis under routine care settings is approximately 5% which is similar to that of death and hospitalisation.

3.4.4 Important subgroups

Response to trial-of-antibiotic- in patients with bacteriologically confirmed tuberculosis (i.e. false-negatives/low sensitivity from the perspective of TB diagnosis) may relate to multiple super-infections and so this phenomenon may vary by HIV status, since multiple concurrent infections are a hallmark of advanced HIV immunosuppression, and commonly identified in patients with suspected TB in the pre-ART era.^{8,27} More recently, in Malawi, 45% of adults who presented to primary care with prolonged cough (≥2 weeks) were HIV-positive, of whom only ~20% started TB treatment on the basis of positive mycobacteriology.³¹ As such, the benefits and consequences of trial-of-antibiotics may vary by HIV status and by subsequent TB treatment decisions. We will, therefore, include a pre-specified sub-analysis of trial outcomes stratified by HIV and ART status.

3.5 Choice of study interventions

Our trial will compare azithromycin and amoxicillin to standard of care. We propose 2 different antibiotic arms for the following reasons: -

- a) Macrolides, including azithromycin, are rarely used in Malawi because of their higher manufacturing costs. However, they do provide a more effective treatment of community-acquired pneumonia than the standard antibiotic by Ministry of Health for trial-of-antibiotic (amoxicillin), because of low levels of acquired macrolide-resistance in bacterial isolates in Malawi,²⁹ reflecting low rates of past exposure to this class of drugs, and also better intrinsic coverage of “bacterial cause of pneumonia including “atypical” intracellular organisms such as *mycoplasma* species.

Although viral pneumonias, *Pneumocystis jiroveci* (PCP) and non-infectious causes of cough will still not be expected to respond to azithromycin, this arm should then provide the highest possible diagnostic discrimination for bacterial vs mycobacterial causes of cough. The starting point of low pre-existing (acquired) resistance will also facilitate investigation of AMR acquired during trial-of-antibiotics. However, the trial will have limited national relevance in Malawi without comparison to an antibiotic in programmatic use.

- b) Amoxicillin is low cost option that is still a recommended treatment for community-acquired pneumonia in most settings, including UK, despite potential treatment failure from bacterial pneumonia due to organisms with intrinsic (“atypicals”) or acquired (common in gram-negative organisms, and *Staphylococcus aureus*) penicillin resistance.²⁹ This arm reflects the true standard of care (SOC) currently in widespread use in Malawi and many other low-income countries, and so provides data of immediate programmatic relevance and also a starting point to investigate exacerbation of pre-existing AMR pressure. If there is a marked difference between the azithromycin and amoxicillin arms, then there will also be important health economic considerations of relevance to many national TB programmes beyond Malawi.

Azithromycin provides effective treatment for community-acquired pneumonia³²⁻³⁴ and has negligible activity against *M.tb*.^{35,36} As discussed above, macrolides are not commonly used in Malawi. Azithromycin has an excellent safety profile and is used for mass drug administration (MDA) in communities prone to trachoma. Azithromycin used for MDA in Ethiopia reduced inter-current infections^{21,37} and death in children,^{38,39} supporting the safety of using this drug for our trial.⁷

Amoxicillin is the first line treatment for outpatient management of pneumonia in Malawi and is commonly used for trial-of-antibiotics. We anticipate higher specificity for azithromycin than amoxicillin, due to broader coverage of “atypical pneumonia” organisms, and salmonella species,

but with the 2 antibiotics arms having “equipoise” due to lack of previous head-to-head comparison.²⁷

3.6 Nasopharyngeal pneumococcus for AMR

Streptococcus pneumonia is a major cause of morbidity and mortality in children and adults.^{20,29,40,41} Asymptomatic nasopharyngeal carriage of *S. pneumoniae* is common and a prerequisite for the occurrence and transmission of invasive pneumococcal disease.^{42,43} Since carriage is more common than the invasive *S. pneumoniae* disease it forms a basis for establishing circulating serotypes, resistance patterns, and evaluation of vaccine effectiveness.

The other key advantage is the existence of globally accepted laboratory procedures for assessing and interpreting pneumococcal resistance. Our laboratory (in Malawi-Liverpool Wellcome Trust) has carried out pneumococcal work for decades with outstanding quality assurance reputation.

3.7 Objectives and outcomes

In Table 2 below, we present study objectives together with corresponding outcomes. We have clarified the outcomes with detailed definitions and planned analyses under “statistical approach” section.

Table 2: study objectives and outcomes

Objective	Outcome
Primary	
1. To establish the diagnostic value of trial-of-antibiotics for excluding pulmonary tuberculosis (PTB) in adults with prolonged cough (and have a valid sputum test result) at primary care level in Malawi.	Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 (i.e. after a trial-of-antibiotics if in azithromycin or amoxicillin arms, or without antibiotics if in standard of care arm) against a mycobacteriology reference standard, among participants with a valid result from at least one sputum test
2. To determine the overall clinical benefit of giving empirical antibiotic treatment in primary care participants with chronic cough.	Proportion of participants experiencing at least one of the following adverse outcomes by Day 29: 1) death 2) hospitalisation 3) missed TB diagnosis

Secondary	
3. To evaluate using nasopharyngeal <i>Streptococcus pneumoniae</i> , the effect of a trial-of-antibiotics on selection for antimicrobial resistance.	Proportion of Day 29 nasopharyngeal <i>Streptococcus pneumoniae</i> isolates resistant to any of commonly used antimicrobials.
4. To establish the diagnostic value of trial-of-antibiotics for excluding pulmonary tuberculosis (PTB) in primary care presenting Malawian adults with prolonged cough including those without a successful sputum test (unable to submit sputum and those with invalid sputum results).	Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 (i.e. after a trial-of-antibiotics if in azithromycin or amoxicillin arms, or without antibiotics if in standard of care arm) against a mycobacteriology reference standard, among all randomised participants, with those who could not provide sputum or had an invalid sputum result classified as mycobacteriologically negative.
5. To estimate the incremental cost-effectiveness of trial-of-antibiotics using azithromycin and trial-of-antibiotics using amoxicillin in comparison to standard of care, and to each other.	• Incremental cost per quality adjusted life year gained • Total direct medical costs per participant over 56 days • Eq-5D utility score
Exploratory	
Our exploratory analyses will be comparisons between the azithromycin and amoxicillin arms for all our primary and secondary outcomes.	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

4 Study design, participants, and statistical approach

4.1 Study design

This is a three arm (625 per arm) individually randomised (1:1:1), open-label controlled clinical trial investigating accuracy and broader clinical, and antimicrobial resistance impact of using trial-of-antibiotics to “rule out” tuberculosis among adults presenting with cough at primary care centres in Malawi.

4.2 Study setting

We will screen adults aged at least 18 presenting to primary care centres in Blantyre, Malawi. Blantyre has an estimated adult HIV prevalence of 12.7% (95% CI: 11.9 to 13.6) and an estimated tuberculosis prevalence of 1,014 per 100,000 (95% CI: 486 to 1,542).⁴⁴

4.3 Standard of care

The standard of care in national guidelines from the NTP for primary care patients presenting with cough and are otherwise well (no danger signs) is to take sputum x 2 for smear microscopy or Xpert and ask them to return for results, typically 3 days - 1 week later (Figure 3 and 5). The Malawi tuberculosis diagnostic algorithm recommends use of broad-spectrum antibiotics as trial-of-antibiotics after negative sputum tests are provided to the patient, if they remain symptomatic. However, more commonly this algorithm is adapted in the outpatient setting to combine prescription of antibiotics (usually amoxicillin) with sputum collection at the first visit, to save the patient from making separate visits: thus, our amoxicillin arm is the most common standard-of-care in Malawi, while the no-antibiotic arm is the NTP recommended standard-of-care.




Figure 5: A comparison of standard of care (Malawi NTP guidelines) and the RCT design with respect to timing of trial-of-antibiotics and study procedures

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

4.4 Eligibility criteria

We will offer enrolment to patients who satisfy the following inclusion and exclusion criteria.

4.4.1 Inclusion Criteria

- Ambulatory clinic attendees presenting with cough for at least 14 days
- No previous formal consultation for current illness (initial presentation)
- Aged at least 18 years
- Reside in Blantyre and willing to return to the same clinic for follow up visits over the entire study period.

4.4.2 Exclusion Criteria

- Self-reported allergy to study medications
- Danger signs (WHO/Malawi NTP): respiratory rate > 30/min, temperature >39°C, Heart rate >120/minute, confused/agitated, respiratory distress, systolic blood pressure <90 mmHg, inability to walk unassisted
- Treated with antibiotics other than co-trimoxazole prophylaxis within the past 14 days
- TB treatment or Isoniazid preventive therapy within the last 6 months

4.5 Interventions

We will have two active study arms receiving trial-of-antibiotics at enrolment (azithromycin and amoxicillin) and a standard of care arm of no trial-of-antibiotics. In this study, the goal is to investigate the role of these antibiotics as they are used in TB diagnostic algorithms, as “trial-of-antibiotics,” to exclude TB in symptomatic patients. The study is likely to be underpowered to detect differences between the 2 antibiotic arms will only be compared for exploratory outcomes.

4.5.1 Name and description of intervention arms

The study will have three arms as follows:

- Arm 1: Immediate trial-of-antibiotics with Azithromycin 500mg once daily for 3 days.
- Arm 2: Immediate trial-of-antibiotics with Amoxicillin 500 mg 3 times daily for 5 days.
- Arm 3: Standard of care

4.5.2 Legal status of drugs used in intervention arms

Both azithromycin and amoxicillin are registered for use in Malawi and United Kingdom, with both Arms 1 and 2 regimens being UK-recommended community-acquired pneumonia treatment.

4.5.3 Summary of Product Characteristics

Appendix 3 includes current versions of package inserts for azithromycin and amoxicillin. We will review and update (when applicable) the package inserts annually with each ethics continuing review.

4.5.4 Drug Storage and Supply

We will procure study products from Durbin PLC (DURBIN PLC 180 Northolt Road South Harrow Middlesex HA2 0LT). Azithromycin will be manufactured by Sandoz limited or other pharmaceutical companies recognised in United Kingdom where Durbin is based. Amoxicillin will be manufactured by Medopharm private limited or other pharmaceutical companies recognised in United Kingdom where Durbin is based. Both azithromycin and amoxicillin are stable at room temperature. We will therefore ship and store in ambient conditions.

4.5.5 Preparation and labelling of study drugs

Study products will be stored at Malawi Liverpool Wellcome Trust Pharmacy. The pharmacy team will be responsible for packing and labelling.

4.5.6 Known drug reactions (adverse events)

Azithromycin and amoxicillin are already widely used in Malawi and are well tolerated. Rare side effects for azithromycin include nervousness, dermatologic reactions including Stevens–Johnson syndrome, anaphylaxis and prolonged QT interval. Rare side-effects for amoxicillin are mental state changes, light-headedness, photosensitivity and severe allergic reactions.

4.5.7 Concomitant medication and interaction with other therapies

We do not have any restrictions with respect to concomitant medications apart from those listed in the exclusion criteria. We expect some participants to be on HIV antiretroviral drugs and some may subsequently start tuberculosis therapy. Important interactions therefore would be those with HIV antiretroviral drugs and tuberculosis therapy. There is no moderate or major interaction between either azithromycin or amoxicillin with the classes of HIV antiretroviral drugs, tuberculosis therapy, and antimalarial drugs used in Malawi.

4.5.8 Trial restrictions

We do not require participants to have any dietary restrictions. We will also accept co-administration with contraception. Our trial interventions can safely be used in pregnancy, so we will include pregnant women should they be eligible.

4.5.9 Assessment of compliance

On Day-8, we will document self-reported compliance adherence of study products.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

4.5.10 Withdraw of interventions

The investigator may also terminate a participant from study product if indicated by an adverse reaction. If a participant stops taking study product either voluntarily or by investigator decision, they will be encouraged to remain in follow up and their data will form part of intention to treat analyses.

4.6 Statistical approach

We will summarise the processes of recruitment including non-eligibility and reasons of exclusion in a CONSORT flow chart. We will describe the study participants by their baseline characteristics which we will report for each arm. We will perform analyses of all our outcomes based on an intention to treat analysis (using the arm patient was randomised to), adjusting for centre. We will make the following comparisons:

- i) azithromycin or amoxicillin versus standard of care
- ii) azithromycin versus standard of care
- iii) amoxicillin versus standard of care

We will perform data cleaning and analysis using Stata release 15 (Stata Corp, College station, Texas, USA).

The following are descriptions of each outcome and corresponding statistical approach. The statistical approach will be expanded in a detailed statistical analysis plan, separate to the protocol, which will be finalised before unblinding the study data.

4.6.1 Primary outcome

The clinical trial has two separately powered, and distinctly assessed primary outcomes, one for diagnostic evaluation (Primary outcome 1: Day 8) and the other for clinical impact (Primary outcome 2: Day 29) of the intervention.

4.6.1.1 Primary outcome 1: Specificity of day 8 symptom change versus mycobacteriology

Investigational test

The investigational test is change in symptoms at Day 8 categorised as: improved or not improved (no change plus worsened) in response to the following question: *on day 1, you reported that you were unwell; compared to that day, has your illness worsened, remained the same, or improved?*

To minimise ascertainment bias in ascertaining this endpoint, the evaluation of improvement of baseline symptoms will be captured using a self-interview platform: Audio Computer Assisted Self-Interview (ACASI). After orientation, the participant will be left alone in the room to interact with the

computer. ACASI on Day-8 will precede all other interaction with research staff and clinical assessment/decision making. We will report ACASI interview outcome as:

- **ACASI-test-negative** if the participant reports improvement
- **ACASI-test-positive** if the participant reports no change or worsening.

Reference test

Mycobacteriology reference standard will be defined in participants with at least one specimen with a valid result on days 1 and 8 as:

- **Sputum-test-positive**: if at least one positive smear microscopy, Xpert/MTB/RIF, or MTB culture on sputum samples taken.
- **Sputum-test-negative**: none of the day 1 and day 8 sputum samples are positive on smear microscopy, GeneXpert MTB/RIF, or MTB culture.

To minimise bias, the mycobacteriology will be performed by a high-quality research laboratory in the University of Malawi College of Medicine by staff with no access to participant treatment allocation information or ACASI results.

The diagnostic assessment outcome

- Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 ACASI against a mycobacteriology reference standard (b+d in Figure 6). Using the investigational test and reference test described above, this can be rewritten as: proportion of sputum-test-negative participants who are ACASI-test-negative.




Figure 6: Ascertainment of diagnostic value of trial-of-antibiotics

Estimation of measures of effect

We will use a generalised linear model (GLM) with identity link to estimate risks differences and the GLM with log link to estimate risk ratios for the three comparisons, adjusting for center. For each comparison, we will report 95% Confidence Intervals and Chi-square p-values. In pre-specified subgroup analysis, we will estimate the treatment effects stratifying by baseline HIV status. If the GLM model does not converge, we will use logistic regression to estimate the treatment effect using an odds ratio.

Participants without valid sputum mycobacteriology results

Primary analyses will be limited to participants who have at least one valid sputum sample result from all samples collected on visits Day-1 and Day-8. However, in real-life, ~15% fail to produce sputum, we will as a secondary outcome, perform all the analyses described for primary outcome with these participants defined as mycobacteriology negative. Further sensitivity analyses with urine lipoarabamannan antigen (LAM) results will include them in mycobacteriology definition.

4.6.1.2 Primary outcome 2: Clinical benefit of trial-of-antibiotics

Outcome definition

Proportion of participants experiencing at least one of the following adverse outcomes: death, hospitalisation, and missed TB diagnosis. The definitions of the components of this composite clinical outcome are defined in the table below:

Outcome component	Definition
death	Proportion of deaths by Day 29
hospitalisation	Proportion hospitalised for any cause by Day 29
missed TB diagnosis	Day 29 proportion of participants meeting standard mycobacteriological and radiological TB definitions but incorrectly classified as TB negative and not yet on TB treatment by Day 29.

Estimation of measures of effect

We will use a generalised linear model (GLM) with identity link to estimate risks differences and the GLM with log link to estimate risk ratios for the three comparisons, adjusting for primary care center. For each comparison, we will report 95% Confidence Intervals and Chi-square p-values. If the outcome is rare or if GLM does not converge, we will use logistic regression to model odds and report odds ratios for the following comparisons and their associated report 95% CIs and p-values.

4.6.2 Secondary outcomes

Outcome definitions

- 1) Proportion of day 29 nasopharyngeal *Streptococcus pneumoniae* isolates resistant to any of the commonly used antimicrobials.

We will define **AMR positive** as having nasopharyngeal isolates of *Streptococcus pneumoniae* that are resistant to any of the following commonly used antibiotics: ceftriaxone, amoxycillin, cefoxitin, azithromycin, and erythromycin as determined using disc diffusion technique; and **AMR negative** as either (1) not isolating any *Streptococcus pneumoniae* or (2) isolating any *Streptococcus pneumoniae* that is not resistant to any of the assessed antibiotics. For each arm, and at both baseline and day 29, we will report proportion of AMR positive participants. The study outcome will be the proportion of AMR positive participants at day 29.

- 2) Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 (i.e. after a trial-of-antibiotics if in azithromycin or amoxicillin arms, or without antibiotics if in standard of care arm) against a mycobacteriology

reference standard, among all randomised participants, with those who do not have a valid sputum test result classified as mycobacteriologically negative.

Estimation of measures of effect

Our secondary outcomes are anticipated to be rare, we will therefore use logistic regression to model odds and report odds ratios for the following comparisons and their associated report 95% CIs and p-values.

4.6.3 Exploratory outcome

Our exploratory analyses will be comparisons between the **azithromycin** and **amoxicillin** arms for all our primary and secondary outcomes.

4.6.4 Planned subgroup analyses

We will perform subgroup analysis for the primary outcome. The important subgroups based on rationale detailed under section 2.4.4, include HIV status, ART status, and PTB treatment. HIV and ART status will be as documented on Day-1 while PTB treatment will be either as:

- TB treatment commenced based on positive baseline (Day-1 and Day-8) mycobacteriology, or
- TB treatment commenced within 29 days of enrolment in patients with negative Day1 and Day-8 bacteriology.

The 29 days cut off for clinical decision to treat is to ensure that we only capture TB disease that was present at baseline. 29 days is a reasonable because: TB is a slowly progressing disease which if positive at Day-29, must have been incident on Day-1; and in routine care setting it can take over a month from presentation to diagnosis of TB.⁸

4.7 Sample size and power

4.7.1 Primary outcome 1: specificity of day 8 symptom change versus mycobacteriology

We assume that trial-of-antibiotics (in azithromycin arm or in amoxicillin arm) will correctly classify 60% of mycobacteriology negative participants.¹⁴ We have determined that 400 mycobacteriologically negative (true negatives) participants per arm will provide 80% power to detect a 10% difference in proportion of participants correctly classified as negative by amoxicillin arm or by azithromycin arm (60%) versus standard of care arm (50%). See table 3. We assume that 80% of participants randomised will have negative mycobacteriology,³¹ requiring 500 participants to yield the 400 per arm. Assuming that 15% will not be able to produce sputum, and that 5% will not return for Day-8 visit, the sample size is increased to 625 per arm or 1,875 for the whole study.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

For a 2:1 comparison (combining the two antibiotic arms versus the standard of care arm), 305 sputum-test-negative participants per arm will be needed to achieve 80% discriminatory power to detect a 10% difference in specificity. Accounting for TB prevalence, ability to produce and submit sputum, and loss-to-follow up increases the sample size requirement to 472 per arm or 1,416 for the whole study.

Table 3: Power and sample size estimation for primary outcome 1

True negatives (mycobacteriology tests negative participants) b+d	¹ p (negatives correctly classified) d/(b+d)	² effect size	² power (X difference between independent proportions)
320	0.60	0.10	69%
400	0.60	0.10	80%
480	0.60	0.10	86%

¹ specificity with either azithromycin or amoxicillin trial-of-antibiotics arms
² risk difference (azithromycin arm- standard of care arm)

4.7.2 Primary outcome 2: Incidence of adverse clinical outcome at Day-29

We will use a pilot study to determine the standard of care risk of at least one of death, hospitalisation, and missed TB diagnosis. The pilot study is described in section 5.0.

For now, we will assume that there is a 10% risk of experiencing this composite adverse outcome in the standard of care arm, and that loss to follow up by Day-29 will be 10%. With the sample size of 625 participants per arm (based on the primary outcome 1 sample size calculation), and alpha of 0.05, we will be able to detect the difference between intervention and standard of care with 80% power, if the risk in intervention arm is 6% or lower (Table 4). This estimate is applicable to the 2:1 comparison of the study arms.

Table 4: Sample size estimation for clinical benefit outcome

Participants per arm based on primary	625
10% loss to follow up by Day-29	562
Outcome risk in standard of care arm	0.10
Desired power	0.80
Alpha	0.05
Required intervention arm risk	0.06

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

4.7.3 Secondary outcomes

1) Incidence of resistant *S. pneumonia* on Day-29

Study arms will be compared based proportion of participants with resistant *Streptococcus pneumoniae* on day 29. We assume 10% loss to follow up by Day-29, and the rate of *S. pneumonia* isolation from nasopharyngeal swabs in this population is expected to be ~45% at Day-29. The sample size based on the primary outcome (625 per arm) will provides ~253 *S. pneumonia* isolates/arm. In the standard of care arm, with 10% risk of resistant isolates, this translates into 25 cases. For the intention to treat population (the randomised 625 participants/arm) in the standard of care arm the 21 cases of resistant isolates translate into 4% (25/625) risk. To detect a twofold change in odds of day 29 AMR risk with at least 80% power, alpha of 0.05, and using Pearson's Chi-squared test, we will need at least 431 and 553 participants per arm for the 2:1 and pairwise comparisons respectively.

4.7.4 Exploratory outcomes

We anticipate that our sample size will be enough for hypothesis generation around our exploratory objectives but may not be enough to provide discriminatory power for comparison of outcomes between arms.

5 Pilot study

This area of research has limited evidence to guide the precise determination of sample size and the practical aspects of the clinical trial making a pilot study an invaluable tool. We have identified the following as key knowledge gaps which require exploration using a pilot study:

- 1) Among the adult patients presenting to primary care centres with cough for at least 2 weeks what proportion gets antibiotics:
 - a. before clinic presentation?
 - b. on first clinic visit?
 - c. on follow up clinic visit after mycobacteriology results?
- 2) Following antibiotic treatment, how do patients report their clinical response? What are the best questions to ask patients post-antibiotic treatment to determine if they have improved or not? How best can we deliver these questions via Audio Computer Assisted Self-Interview (ACASI)? How well do these responses correlate with mycobacteriology and radiology?
- 3) What is the best timing for nasopharyngeal swabs for evaluating AMR in patients who receive a course of antibiotics during TB investigations?
- 4) In the standard of care setting, what proportion of adult patients presenting to primary care centres with cough for at least 2 weeks experience the following adverse outcomes (as defined under the clinical benefit composite endpoint)?
 - a. death
 - b. hospitalisation
 - c. missed TB diagnosis
 - d. HIV care loss to follow up
 - e. TB care loss to follow up

5.1 Specific objectives of the pilot study

- 1) To determine the proportion of adults with prolonged cough who
 - a. present to primary care having already had antibiotics for the index clinical complaints.
 - b. receive antibiotics before sputum mycobacteriology results at first presentation
 - c. receive antibiotics after negative mycobacteriology

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
- 2) To establish an objective way of documenting response to antibiotic treatment using Audio Computer Assisted Self Interview (ACASI). Assessing ACASI responses against clinical signs, outcomes of TB mycobacteriology and chest radiography.
 - 3) To determine:
 - a. the prevalence of *Streptococcus pneumoniae*;
 - b. the prevalence of resistant *Streptococcus pneumoniae* isolates;
 - c. the optimal specimen collection timing for evaluating impact of antibiotic use on prevalence of *Streptococcus pneumoniae* isolates resistant to common antibiotics
 - 4) To establish standard of care rates of the following adverse clinical outcomes:
 - a. death
 - b. hospitalisation
 - c. missed TB diagnosis
 - d. HIV care loss to follow up
 - e. TB care loss to follow up

32
33
34
35
36
37
38
39

5.2 Population for the pilot study

This exploratory study will include up to 400 adult (≥ 18 years old) patients presenting to primary care centres with cough for at least 14 days. We will exclude patients not meeting the eligibility criteria of the clinical trial.

40
41
42
43
44
45
46
47


5.3 Pilot study procedures

The pilot study procedures are outlined in the flow chart below. Following pilot study informed consent, we will use a baseline assessment questionnaire to collect clinical history, and antibiotic use for the index illness prior to the clinic visit. Throughout follow up, we will record all antibiotic use from any source. We will collect sputum samples for mycobacteriology from all participants on Day 1 and Day 8.

We will establish HIV and TB diagnosis throughout the study, link participants to care services, and follow their adherence to follow up. For TB we will use a combination of Xpert, smear and culture on Day 1, 8 and whenever symptomatic suggestions of TB arise. We will also perform a chest x-ray on Day 8 and a follow up film on Day 29.

We will collect nasopharyngeal swab samples, for antimicrobial resistance assessment using *Streptococcus pneumoniae* culture and sensitivity, on Day 1, Day 8, and Day 29. We will assess change in symptoms and well-being from Day 1 to Day 8, by using various combinations of questions and answers delivered via Audio Computer Assisted Self Interview (ACASI) on Day 8. We

will ask participants which sets of questions they found easy to understand. We will also collect clinical information on all study visits including illness events, hospitalisations and vital status.



Pilot study flow diagram, summarizing the study procedures at each visit.

5.4 Data analysis

We will report the proportions of participants who used any antibiotics prior to primary care and during work-up for Tuberculosis. We will determine the best ACASI question and response combinations by participant reported ease of use, and by assessing correlation with clinical findings,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

mycobacteriology and radiological outcomes. The optimal time for assessing AMR will be determined by comparing incidence of resistant *Streptococcus pneumonia* isolates at days 8 and 29.

We will comparing participants exposed to antibiotics to those not exposed to antibiotics by estimating and reporting relative risk and 95% confidence intervals for:

- 1) Day 8 and Day 29 of resistant Streptococcus pneumonia
- 2) Composite adverse outcome of experiencing any of: death, hospitalisation, missed TB diagnosis, HIV care loss to follow up, and TB care loss to follow up

6 Study procedures

6.1 Screening

At the designated primary health care centres, study staff will approach patients with symptoms of pulmonary tuberculosis (including cough of any duration, fever, weight loss, and night sweats) with information about the study. Those willing to be screened for eligibility will be assessed against the study inclusion and exclusion criteria.

6.2 Informed consent

We will seek written informed consent (Appendix 1) from all patients who meet eligibility criteria before any trial-specific procedures. Screening for tuberculosis symptoms will not be considered as part of the study procedures, as it is already a fundamental component of the routine clinical assessment and history taking. A member of the study team will hand an informed consent form to a potential participant in their preferred language (Chichewa or English) detailing background, procedures, risks, benefits and participant expectations should they choose to join the study. The consent form will also state that the participant is free to withdraw from the trial at any time for any reason without prejudice to future care, and no obligation to give reason for the withdrawal.

If they choose to join as a study participant, we will then request them to sign two copies of informed consent form. If a potential participant does not know how to read or write, we will perform the informed consent process in the presence of a witness. In such cases, if they agree to participate in the study, we will ask them to sign using a thumb-print in the presence of their witness and a study team member. We will keep one copy of the signed informed consent forms and hand the participant the other copy.

6.3 Baseline procedures

After consenting, we will on the same visit request participants to provide 2 on the spot sputum samples for smear microscopy, Xpert and culture collected at least one hour apart. Those unable to spontaneously produce sputum will be instructed in the physiotherapy manoeuvre of “huffing” (forced expiration technique) for inducing mucus clearance from the airways.

Patients still unable to provide at least one mucoid sputum sample of >1 ml will initially will be given a sputum container and asked to return it the next day. If they do not manage to produce sputum at home, their mycobacteriology results will be treated as missing. We expect ~15% of participants to fall in this category³¹ and have accounted for them in the sample size estimation. For participants who produce less than the needed quantity of sputum, we will process them for the planned tests in the following priority order: 1) Xpert MTB/RIF, 2) MTB culture, 3) smear microscopy. The Xpert MTB/RIF

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

is the single most important guide for immediate clinical diagnosis and the MTB culture is the single most accurate reference diagnostic.

We will also collect a urine sample which we will store for subsequent lipoarabamannan antigen detection (LAM); and a nasopharyngeal swab for pneumococcal culture and sensitivity testing to estimate prevalent antimicrobial resistance. We will also perform HIV tests according to the national algorithm, and if positive we will do HIV viral load. After completing all Day-1 visit procedures, we will link the newly tested positive participants to routine HIV care and will document when they start ART (Malawi National Program provides same-Day-ART initiation to all newly-diagnosed or untreated HIV-positive patients). After the sample collections, we will collect the following information:

- Demographic data, including precise geographic locator information using ePAL geolocation software (to aid follow-up). The locator information will also include phone numbers for the participant and for up to 3 family, or friends they nominate as alternative contacts.
- Clinical history including information on tuberculosis symptoms and health care seeking for HIV and tuberculosis care services including ART, cotrimoxazole, isoniazid preventive therapy, and past TB treatment.
- Vital signs including height and weight

After completing all these baseline procedures, we will randomise the participants to the three study arms.

6.4 Assignment of interventions

Step 1: An independent statistician based at LSHTM and without contact with participants or the study staff that see participants, will use the ralloc command in Stata (StataCorp LLC, College Station, Texas USA. Release 15.0) to prepare a random allocation sequence in advance of study recruitment efforts. Randomisation will be 1:1:1 to the three arms of the trial, block-randomised with variable block sizes, and stratified by primary care centre.

Step 2: Each treatment allocation will be printed alongside a randomisation number onto a pdf document.

Step 3: The statistician will email the pdf document to an independent designee within university of Malawi who will print and place the randomisation assignments in envelopes labelled with randomisation numbers. The independent designee will hand the envelopes directly to the study pharmacist who will also receive a shipment of study medications. The pharmacist will store the envelopes in a secure location within the pharmacy.

Step 5: The pharmacist will pre-pack 625 each of protocol doses of azithromycin and amoxycillin without any reference to the allocation sequence. There is no need to refer to the allocation sequence for this step because the dosage for both treatments is the same and the total number of allocation for each treatment is known.

Step 6: At the beginning of each working week and upon request from study site, the study pharmacist will hand to site coordinators of each primary care center, a recruitment-rate-driven daily working stock of 1) the sequentially numbered sealed opaque envelopes containing randomization numbers and corresponding treatment allocations, and 2) study drugs.

Step 7: Study staff from each site will conduct patient eligibility assessments. Patients meeting the quick criteria of age and cough for ≥ 14 days, will be assigned screening IDs before being taken through the full eligibility criteria and consenting process. Participants will be considered eligible and ready for randomisation after they meet all criteria and sign consent.

Step 8: Upon signing consent, the participant will be taken to the site-coordinators (nurse or clinical officer) who will assign them the next available study ID number and document it on their paper and electronic eligibility checklist and enrolment CRF. The study ID number will be the number on the treatment allocation envelope plus a site-specific code. They will then open the envelope, document the treatment assignment, to the participant's enrolment paper and electronic case report forms as well as on a study card that will be pasted in the participant personal health profile book.

Step 9: The coordinator will double-check to ensure that the enrolment number and the treatment assignment are recorded correctly. They will then record screening date, screening ID, randomisation date, study ID, and randomisation arm on an enrolment log. They will then administer the allocated treatment. Administering study medications will not be considered as prescribing considering that prescription to all eligible participants will have already been done by the study protocol.

Step 10: When the stock of either envelopes or study drugs runs out,, the nurse-coordinators will reorder a from the study pharmacist.

Additional details

All steps of receipt, and utilization of the allocations and study drugs are elaborated in a detailed SOP. The SOP guides implementation of the above plan as far as possible and in line with site conditions.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The study drugs will be pre-packed blindly without any reference to treatment allocations ensuring that neither the pharmacist nor the nurse-coordinator know the treatment allocations until just before assigning to a participant.

6.5 Blinding

We will mask the treatments as far as possible. The study pharmacist will remain blinded as they will use the randomly- allocated label numbers to prepare and pack the correctly dosed study medications in opaque packaging. Study outcome assessment will occur without reference to study treatment allocation. All laboratory forms for mycobacteriology and nasopharyngeal pneumococcal work will have no reference to participant treatment allocation. On Day-8, assessment of improvement from baseline symptoms will utilize audio computer-assisted self-interview (ACASI) to minimise potential for social-mediated reporting and ascertainment biases (see Procedures Section of the protocol). All clinical endpoints assessment case report forms will bear no reference to treatment arm. However, we will keep participants, research coordinators, and routine care staff unmasked to ensure safety of the participants and allow appropriate patient management decision-making which may be related to the trial interventions.

6.6 Participant follow up

Following enrolment and completion of baseline procedures we will ask participants to return for follow up visits on days 8, and 29. They will be given 1 sputum collection bottle when leaving the clinic on Day-1 to bring with them sputum for mycobacteriology planned for Day-8 (“morning” specimen) followed by collection of one further “spot” sputum on Day-8, 2 sputum samples in total). We will also collect a second urine sample for storage for subsequent LAM antigen testing. Patients unable to produce at least one mucoid sputum sample of >1ml on Day-8 will be assumed for purposes of analysis to be mycobacterially negative for the Day-8 sputum samples. We are performing two sets of sputum examinations (Day-1 and Day-8) for each participant to strengthen the accuracy of the reference standard. Considering that TB progresses very slowly, making a diagnosis on Day-8 is not different from that made on Day-1.

We will advise participants that their sputum TB test results will start becoming available from 48 working hours after collection, but with the last test (MTB culture) taking up to 4 weeks. Patients will be advised that they will not be routinely contacted if positive TB test results become available before their Day-8 appointment (as is standard for outpatient management without danger signs in Malawi), and so will be advised to report promptly back to the clinic (with refund of transportation given) if they experience any clinical deterioration during Days 2 to 7.

In the circumstances where TB treatment is commenced before completion of antibiotics prescribed for trial-of-antibiotics (amoxicillin and azithromycin), we will ask them to carry on with their allocated intervention together with the TB treatment.

6.6.1 Day-8 activities

On Day-8, the first activity before the participants undergo all other evaluations will be documentation of self-reported improvement of baseline (Day 1) TB symptoms using a pilot-validated set of questions and answer options delivered via Audio Computer Assisted Self Interview (ACASI). We will use ACASI with the goal of eliminating inter-observer variability and patient/interviewer reporting or ascertainment biases. After a “how to use” orientation and testing session, the participant will be left alone in the room to interact with the computer. A pre-recorded interviewer will ask the participant questions related to how their symptoms have changed on that day compared to how they were on Day-1 and will offer categorised voice-recorded responses with touch screen response buttons. The ACASI questionnaire will also include questions about adherence to study arm drugs and any other medical care (including traditional medicine) sought during the previous week.

Other activities for all participants on Day-8 include:

- collection of a second sputum sample for mycobacteriology tests.
- providing participants with Day 1 smear and Xpert results linking those with positive tests, ongoing symptoms and other illnesses with routine care for appropriate management.
- clinical history detailing clinical events since enrolment.
- documentation of any medications including antimicrobials and traditional medicine outside the study
- providing a study Day-29 appointment card

For participants with negative Day-1 mycobacteriology results we will perform clinical evaluation after ACASI and will inform the patient that any positive Day-8 sputum mycobacteriology results will be reported actively (via telephone or house visit) as soon as quality-assured results become available (within 48 working hours for microscopy and Xpert). Patients who have not had complete resolution of symptoms will be referred with all available results to routine primary care management.

6.6.2 Day-29 activities

Day-29 will be the final study visit. We will on this visit, collect data on clinical impact of antibiotic treatment and risk of AMR. In line with the second primary endpoint (composite clinical impact), we will document:

- 1) vital status
- 2) hospitalisations
- 3) identify missed TB diagnosis by using culture results from Day 1 and Day 8 sputum, any chest X-rays performed in follow up, and repeat mycobacteriology if symptomatic
- 4) perform HIV tests for those with unknown status and eligible for routine HIV test.

We will first collect information on clinical events prior to and at the visit and communicate all available sputum culture results and the final reported CXR results.

After collecting the clinical information, we will collect nasopharyngeal swab sample for assessing antimicrobial resistance. To collect the sample, a trained study staff will swab the participants' nasopharynx and place the swab in a tube containing skim milk tryptone glucose glycerol (STGG).

6.7 Laboratory methods

6.7.1 Tuberculosis mycobacteriology

We will process mycobacteriology tests at the Malawi College of Medicine TB laboratory, a reference laboratory located in Blantyre. For sputum samples collected on Day-1, we will perform smear microscopy, Xpert MTB/RIF and MTB culture. For sputum samples collected on Day-8, we will perform smear microscopy and MTB culture. We will use Mycobacteria Growth Indicator Tube (MGIT) and Lowenstein-Jensen (LJ) culture methods for TB culture. Once isolated, we will perform speciation as *Mycobacterium tuberculosis* (MTB) or non-tuberculous mycobacteria (NTM) using MBP84 antigen testing, microscopic cording and, if necessary, morphology and growth characteristics at different temperatures and on solid (LJ) media containing p-nitrobenzoic acid (PNB).

6.7.2 Urine antigen testing for lipoarabamannan and other MTB antigens

Urine will be collected and stored as two 1 ml aliquots at -20°C from each participant on both Day-1 and Day-8 for subsequent mycobacterial antigen testing. No appropriate product is available for immediate use, but we anticipate that a commercial product with sufficiently high analytic accuracy for use in ambulant outpatients (sensitivity and specificity) may become available during the course of, or soon after, the study. If ongoing evaluations of the FIND-sponsored FujiFilm product⁴⁵ meet or exceed pre-specified requirements for clinical utility in the outpatient context, then point-of-care LAM testing at Day-1 and Day-8 will be added to the mycobacteriological definition of TB and patient management as soon as kits have been obtained and evaluated in Malawi.

6.7.3 Antimicrobial resistance testing

We will store swabs in STGG at minus 80°C. At a later stage we will thaw them in batches, and plate them onto selective media and culture colonies consistent with *S. pneumoniae*. We will determine

Minimal inhibitory concentrations (MICs) using E-test strips (azithromycin and amoxicillin), and Kirby Bauer Disc diffusion testing (azithromycin, rifampicin, tetracycline, ceftriaxone, chloramphenicol, cotrimoxazole, erythromycin and penicillin) and define resistance by EUCAST breakpoints.

We will store isolates and remaining STGG at minus 80°C to allow genotypic characterization, isolation and susceptibility testing of other key respiratory pathogens, FTD 33 respiratory pathogen diagnostic panel, metagenomics analysis, and microarrays to detect multiple carriage and macrolide resistance genes in a broader range of pathogens at a later stage.

6.8 Loss to follow-up

To minimise loss to follow up, we will at enrolment record geolocation information of participants' place of residence using ePAL android app, a high-resolution mapping system validated in Blantyre. We will also record up to 3 contact phone numbers of the participant and their nominated friends and relatives. Should a participant miss a study visit, we will contact them by phone or by visiting them at home to encourage them to attend the study visit before expiry of prescribed visit window.

We anticipate a loss to follow-up of 5% by Day-8, and 10% by Day-29. We have accounted for these assumptions in the sample size calculation. We will not replace participants who discontinue study participation or study treatment regardless of reason for withdrawal or discontinuation or the time either of these occurs.

6.9 Trial closure

We will consider the trial closed after completing follow up of the last enrolled participant, and upon recording all mycobacteriology laboratory reports. Antimicrobial resistance lab work will continue beyond trial closure. The trial may be terminated early by the trial steering committee upon recommendation of the DSMB. The halting rule for a trial arm is an unacceptable high level of deaths assessed using an alpha determined at the first DSMB meeting.

6.10 Summary schedule for study procedures

In Table 5 below, we have summarised all key study procedures over the study period.

Table 5: key study procedures over the study period

TIMEPOINT**	STUDY PERIOD			
	Enrolment	Follow up		
	Day-1	Day-8		Day-29
ENROLMENT:				
Eligibility screen	X			
Informed consent	X			
Allocation	X			
INTERVENTIONS:				
Azithromycin	X			
Amoxicillin	X			
Standard of care	X			
ASSESSMENTS:				
Demographics	X			
History of antibiotic use	X	X		X
*History & examination	X	X		X
**Sputum collection	X	X		
Urine for TB LAM test	X	X		
Nasopharyngeal swab	X			X
HIV test and CD4 count	X			X
Linking to routine care	X	X		X
¹ ACASI		X		
***Clinical events		X		X
		X		X
Update contact & address				
*For symptomatic participants, Day-8 sputum mycobacteriology should be fast-tracked to inform care before they leave the clinic. Chest X-ray should be performed and interpreted in real-time. **Give sputum bottles at end of Day-1 visit for submission on Day-8. Also collect sputum and perform mycobacteriology at any time of the study when clinically indicated ***Illnesses, clinic visits, radiological outcomes, new HIV diagnosis, new TB diagnosis, death, hospitalisation, missed TB diagnosis, HIV care loss to follow up, and TB care loss to follow up ¹Audio Computer Assisted Self-Interview for documenting change of symptoms on Day- 8 versus Day-1				

7 Safety reporting

7.1 Definitions

Term	Definition
Adverse Event (AE)	Any untoward medical occurrence in a participant to whom a medicinal product has been administered, including occurrences which are not necessarily caused by or related to that product. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational medicinal product (IMP), whether or not considered related to the IMP.
Adverse Reaction (AR)	Any untoward and unintended response in a participant to an investigational medicinal product which is related to any dose administered to that participant. The phrase “response to an investigational medicinal product” means that a causal relationship between a trial medication and an AE is at least a reasonable possibility, i.e. the relationship cannot be ruled out. All cases judged by either the reporting medically qualified professional or the Sponsor as having a reasonable suspected causal relationship to the trial medication qualify as adverse reactions.
Serious Adverse Event (SAE)	A serious adverse event is any untoward medical occurrence that: • Results in death • Is life-threatening • Requires inpatient hospitalisation or prolongation of existing hospitalisation • Results in persistent or significant disability/incapacity • Consists of a congenital anomaly or birth defect Other ‘important medical events’ may also be considered serious if they jeopardise the participant or require an intervention to prevent one of the above consequences.
Serious Adverse Reaction (SAR)	An adverse event that is both serious and, in the opinion of the reporting investigator, believed with reasonable probability to be due to one of the trial treatments, based on the information provided.
Suspected Unexpected Serious Adverse Reaction (SUSAR)	A serious adverse reaction, the nature and severity of which is not consistent with the information about the medicinal product in question set out: • In the case of a product with a marketing authorisation, in the summary of product characteristics (SmPC) for that product.

7.2 DMID grading for AEs

We will adopt the events grading criteria prepared by the Division of Microbiology and Infectious Diseases (DMID) of the USA National Institutes of Health as shown in the table below.

1 MILD	2 MODERATE	3 SEVERE	4 LIFE-THREATENING
Transient or mild discomfort (< 48 hours); no medical intervention required	Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention required	Marked limitation in activity, some assistance usually required; medical intervention required, hospitalizations possible	Extreme limitation in activity, significant assistance required; significant medical intervention required, hospitalization probable

7.3 Grading for expected events

The following table provides guidance for grading known important or frequent side effects of azithromycin (based on the AE grading criteria provided in the BREATHE Trial Protocol, also investigating azithromycin) and amoxicillin graded on the DMID scale. All events not mentioned here or in Appendix 2, will be graded using the DMID grading for AEs table presented above.

	1 MILD	2 MODERATE	3 SEVERE	4 LIFE-THREATENING
Side-effects	1	2	3	4
Acute Allergic Reaction	Localized urticaria (wheals) with no medical intervention indicated	Localized urticaria with intervention indicated OR Mild angioedema with no intervention indicated	Generalized urticaria OR Angioedema with intervention indicated OR Symptoms of mild bronchospasm	Acute anaphylaxis OR Life-threatening bronchospasm OR Laryngeal oedema
Rash <i>Specify type, if applicable</i>	Localized rash	Diffuse rash OR Target lesions	Diffuse rash AND Vesicles or limited number of bullae or superficial ulcerations of mucous membrane limited to one site	Extensive or generalized bullous lesions OR Ulceration of mucous membrane involving two or more distinct mucosal sites OR Stevens-Johnson syndrome OR Toxic epidermal necrolysis
Mental state changes	mild anxiety or depression	moderate anxiety or depression; therapy required;	severe mood changes requiring therapy; or suicidal ideation;	acute psychosis requiring hospitalization; or suicidal gesture/attempt or hallucinations

	1 MILD	2 MODERATE	3 SEVERE	4 LIFE-THREATENING
		change in normal routine	or aggressive ideation	
Photosensitivity	Painless erythema covering <10% body surface area	Tender Erythema covering 10 - 30% body surface area	Erythema covering >30% body surface area and erythema with blistering, requiring intervention	Life-threatening consequences; urgent intervention indicated
Arrhythmia (by ECG or physical examination) <i>Specify type, if applicable</i>	No symptoms AND No intervention indicated	No symptoms AND Non-urgent intervention indicated	Non-life-threatening symptoms AND Non-urgent intervention indicated	Life-threatening arrhythmia OR Urgent intervention indicated
Prolonged QTc Interval	0.45 to 0.47 seconds	> 0.47 to 0.50 seconds	> 0.50 seconds OR ≥ 0.06 seconds above baseline	Life-threatening consequences (e.g., Torsade de pointes, other associated serious ventricular dysrhythmia)
Diarrhea ≥ 1 year of age	Transient or intermittent episodes of unformed stools OR Increase of ≤ 3 stools over baseline per 24-hour period	Persistent episodes of unformed to watery stools OR Increase of 4 to 6 stools over baseline per 24-hour period	Increase of ≥ 7 stools per 24-hour period OR IV fluid replacement indicated	Life-threatening consequences (e.g., hypotensive shock)
Tinnitus	Symptoms causing no or minimal interference with usual social & functional activities with intervention not indicated	Symptoms causing greater than minimal interference with usual social & functional activities with intervention indicated	Symptoms causing inability to perform usual social & functional activities	NA
Nausea	Transient (< 24 hours) or intermittent AND No or minimal	Persistent nausea resulting in decreased oral intake for 24 to 48 hours	Persistent nausea resulting in minimal oral intake for > 48 hours OR Rehydration	Life-threatening consequences (e.g., hypotensive shock)

	1 MILD	2 MODERATE	3 SEVERE	4 LIFE-THREATENING
	interference with oral intake		indicated (e.g., IV fluids)	
Vomiting	Transient or intermittent AND No or minimal interference with oral intake	Frequent episodes with no or mild dehydration	Persistent vomiting resulting in orthostatic hypotension OR Aggressive rehydration indicated (e.g., IV fluids)	Life-threatening consequences (e.g., hypotensive shock)
Laboratory	1	2	3	4
ALT or SGPT, High <i>Report only one</i>	1.25 to < 2.5 x ULN	2.5 to < 5.0 x ULN	5.0 to < 10.0 x ULN	≥ 10.0 x ULN
Creatinine Clearance or eGFR, Low <i>Report only one</i>	NA	< 90 to 60 ml/min or ml/min/1.73 m ² OR 10 to < 30% decrease from baseline	< 60 to 30 ml/min or ml/min/1.73 m ² OR ≥ 30 to < 50% decrease from baseline	< 30 ml/min or ml/min/1.73 m ² OR ≥ 50% decrease from baseline or dialysis needed

7.4 Causality

When reporting on serious adverse events, the trial investigator will state whether they believe that the event is causally associated with any of the trial treatments and the strength of the causal relationship. They will also state whether the adverse event was expected and what if any action was taken.

Relationship	Description
Unrelated	There is no evidence of any causal relationship
Unlikely	There is little evidence to suggest there is a causal relationship (e.g. the event did not occur within a reasonable time after administration of the trial medication). There is another reasonable explanation for the event (e.g. the participant's clinical condition, other concomitant treatment).
Possible	There is some evidence to suggest a causal relationship (e.g. because the event occurs within a reasonable time after administration of the trial medication). However, the influence of other factors may have contributed to the event (e.g. the participant's clinical condition, other concomitant treatments).
Probable	There is evidence to suggest a causal relationship and the influence of other factors is unlikely.

Definitely	There is clear evidence to suggest a causal relationship and other possible contributing factors can be ruled out.
Not assessable	There is insufficient or incomplete evidence to make a clinical judgement of the causal relationship.

7.5 Reporting Procedures

7.5.1 Non-serious Adverse Events (AEs)

Adverse events will be ascertained from patient follow-up visits or reports from relatives or guardian if patient cannot be contacted for follow-up. Study clinicians will be responsible for recording of details of the event including a description of the event, date of onset, severity, assessment of relatedness to trial interventions. Adverse events will be recorded in case report forms and uploaded into the study database.

7.5.2 Serious Adverse Events (SAEs)

All serious adverse events (SAEs) will be recorded on the relevant study CRFs and reported immediately to the Principal Investigator who will ensure that they are compiled in aggregate form and reported to COMREC and the DSMB once every 6 months. The DSMB will review SAE reports at their 6 monthly meetings and issue recommendations which will be shared with ethics committees. Events relating to a pre-existing condition or any planned hospitalisations for elective treatment of a pre-existing condition will not be reported as SAEs.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

8 Economic evaluation

8.1 Objective

The objective of the economic evaluation is to undertake a cost-utility analysis to estimate the incremental cost-effectiveness of trial-of-antibiotics using azithromycin and trial-of-antibiotics using amoxicillin in comparison to standard of care, and to each other. We will systematically compare costs and consequences associated with the interventions.

8.2 Outcomes

We will perform a within trial comparison of the three treatment arms to estimate the incremental cost per quality-adjusted life year (QALY) gained for the azithromycin or amoxicillin arm in comparison to standard of care. Costs will be estimated from the Malawian Ministry of Health perspective. Health outcomes will be quantified in QALYs, estimated from participants' responses to the Chichewa version of the EQ-5D-3L, a Health quality of life (HRQoL) measure.^{46,47} We will adopt a time horizon matching the length of participant follow-up to achieve the within trial evaluation.

8.3 Data collection

The health economic data collection will be undertaken alongside planned clinical data collections. We will administer the Chichewa version of the EQ-5D-3L to all trial participants at baseline (Day1), Day 8 and Day 29. The Chichewa EQ-5D-3L was prepared in accordance with international and EuroQoL guidelines. The EQ-5D uses a descriptive system and a visual analogue scale (VAS). HRQoL on the day of response is defined using the descriptive system in terms of the following dimensions: 1) mobility, 2)self care, 3)usual activities, 4)pain/discomfort, and 5) anxiety or depression. The responses are then split into the following ordinal levels: 1) no problems; 2) some or moderate problems; and 3) severe or extreme problems.

The EQ-5D has 243 health states to which each response is allocated and converted to an EQ-5D utility score using a tariff. Tariff sets are derived from national surveys and currently no Malawian EQ-5D tariff exists. Zimbabwe, a setting similar to Malawi, has EQ-5D tariff set. In this study, we will use the Zimbabwean set to derive EQ-5D utility scores⁴⁸ an acceptable practice considering the similarities in how the two populations value health.⁴⁹ The EQ-5D utility scores in the Zimbabwean tariff, range from 1.0 (which means no problems in the five dimensions) to -0.29 (defined as severe problems in all five dimension).

We will capture all healthcare resources used by trial participants from recruitment into the trial till Day 29. This will be undertaken on Day 1, Day 8 and Day 29. Healthcare resources will be translated into direct medical costs using previously estimated costs^{47,50,51} and the wider literature.

Drug prices will be based on International market prices.⁵² The health resource use questionnaire will at a minimum capture:

- Outpatient clinic visits
- Days of inpatient hospital care
- Medications
- Investigations and procedures

8.4 Data analysis

Our primary analysis will focus on direct intervention and the broader healthcare costs. We will define direct intervention costs as the costs associated with the application of the interventions. We will plot health state values measured by the EQ-5D-3L against time assuming that the health states reported at each time point are linearly connected. We will estimate QALYs associated with participant health profile by area under the plotted curve as calculated using the trapezium rule.

We will use a range of analytical methods depending on whether baseline covariates (EQ-5D utility values) are balanced between the trial arms or not. If they are balanced, we can obtain unbiased cost-effectiveness estimates by using non-parametric bootstrap approaches; if imbalance exists regression methods will be the approach of choice.

We will explore a range of estimators and undertake model diagnostics to determine the optimal model because the distributions of costs and QALYs are commonly skewed, often bimodal, or truncated. We will estimate mean costs and outcomes for each intervention together with respective mean incremental cost-effectiveness ratio. We will for each estimate report respective measures of uncertainty (standard errors and confidence intervals). We will also estimate the net monetary benefits (NMBs) for a range of different willingness to pay (WTP) thresholds. To identify the optimal intervention at different WTP thresholds, we will construct cost-effectiveness acceptability curves (CEACs) based on the NMB framework.

8.5 Missing data

For each participant we will collect complete data as far as possible but in cases of missing values, a common occurrence in trials, we will perform additional analyses to explore the impact of and account for the missingness.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

9 Data management

9.1 Source Data

We will consider a document as source if it is where data were first recorded, and from which we obtained participants' case report forms (CRF) data. These will include hospital records, health center records, participant health passport, laboratory and pharmacy records, diaries, radiographs, and correspondence. We will consider CRF entries as source data if the CRF is the site of the original recording.

We will on all study-specific documents, other than study ID code list, the signed consent forms household locator form and, refer to the participant by their trial participant identification number, not by name. We will keep study ID code list, consent and locator forms separate from the rest of the participant file to avoid linkage between participant name and the study ID.

9.2 Data collection methods

We will collect data using standardised, pre-tested CRFs in two forms:

- programmed into android tablets using Open Data Kit (ODK) platform (opendatakit.org) with paper back-ups.
- optical mark recognition readable forms read and extracted using TELEFORM system (Cardiff Software, Inc., Vista, CA), an optical-character-recognition software.

9.3 Data management

Any participants' identifiable data collected by the Study Coordination Centre will be stored securely and their confidentiality protected in accordance with the Data Protection Act 1998.

To ensure data security and maintenance of participant confidentiality, we will take several strict measures. All the study data collection tablets and computers will be encrypted, password protected and stored in a fireproof lockable cabinet inside a locked room. The principal investigator, study coordinator and data manager will be responsible for the maintenance of the tablets as well as all other computers, and their security from viruses and theft. All users will check in with the study coordinator and sign for data entry tablets every time they are taken out to for data entry and upon return. Whenever not in use, the devices will be kept in their locked cabinet.

We will keep all paper records in a locked space only be accessible to the principal investigator, co-investigators and delegated study staff. Study databases will be encrypted, password protected and will be stored on dedicated servers within the University of Malawi College of Medicine. We will keep all electronic and paper records securely for up to 10 years after the end of the trial in accordance with LSHTM Records Retention & Disposal Schedule guidelines.

9.4 Quality control and quality assurance

We will apply quality control at each stage of data handling in accordance with GCP requirements to ensure that all data are reliable and have been processed correctly. We will manual review all paper CRFs for completeness, accuracy and legibility before scanning. Our ODK data entry system will include automatic pre-programmed real-time data validation. The TELEFORM system will also have pre-programmed automatic data validation capabilities. We will perform data quality assurance (QA) on a random 10% of all participant files. The QA process will involve examining database entries and for paper source documents, verification of database entries and source.

9.5 Access to data

We will upon request, provide direct access to authorised representatives from the Sponsor, host institution and the regulatory authorities to allow smooth running of trial-related monitoring, audits and inspections.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

10 Data monitoring and quality assurance

10.1 Data monitoring

Site monitoring for safety will be conducted to ensure human subject protection. The study will be monitored just before commencing enrolment, then once every 6 months by a monitoring team from the University of Malawi College of Medicine. The objective will be to ensure that study procedures, study products administration, and data collection processes are of high quality and meet ethical and regulatory guidelines. The regular monitoring will focus on the following areas: 1) protocol adherence, 2) informed consent documentation, 3) trial endpoints, 4) treatment discontinuation, 5) regulatory documents, 6) compare source documents and case report forms for accuracy, and 7) documentation practices in general.

10.2 Audits and Inspections

The study will be subject audit by the London School of Hygiene & Tropical Medicine under their remit as sponsor, the Study Coordination Centre and other regulatory bodies to ensure adherence to GCP.

10.3 Data Safety and Monitoring Board (DSMB)

We will set up a DSMB before commencing trial activities. The DSMB will provide independent review of the study conduct, progress and findings. It will comprise 3 members including a chairperson who will be responsible for collating and communicating the views of the DSMB. The DSMB will consist of an independent statistician and two clinicians, at least one of them a physician, with research experience and expertise in the management of tuberculosis and HIV in Africa. The proposed data safety monitoring plan will be discussed in a teleconference including the DSMB members and the key investigators prior to the study starting.

The proposed meeting schedule is 6 monthly. Two weeks before a 6 monthly DSMB meeting, the study team will prepare a report covering study progress, study approvals, any obstacles, and recruitment statistics, adverse events, withdrawals and trial outcome measures. The DSMB will, through its chairperson, provide written feedback to the principal investigator who will be responsible for passing it on to ethics committees.

10.4 Trial Management Group (TMG)

A Trial Management Group (TMG) will be appointed and will be responsible for overseeing the progress of the trial. The day-to-Day-management of the trial will be co-ordinated through the University of Malawi College of Medicine.

10.5 Trial Investigational Team

Our investigational team includes expertise in diagnosis and management of TB; clinical evaluation of TB diagnostics; design and conduct of large randomised controlled trials; laboratory TB and AMR diagnostics; data management and analysis.

Chief investigator

Dr Titus H Divala: the chief investigator and PhD student will be responsible for protocol development, coordination and conduct of the trial, governance, data management, data analysis and results dissemination. Dr Divala is a clinician with a career interest in clinical trials. Apart from medical training, he holds MPH and Masters of Science in epidemiology and preventive medicine. He has managed two large GCP, US-NIH-funded clinical trials, one of which was IND as the local PI supervising over 40 study staff at two sites in different cities. He has worked as a clinician for over 8 years in Malawi, a period when identifying TB cases and putting them on treatment was a daily job. This topic therefore falls in area of great personal interest above and beyond the potential benefit it has towards improving patient care in Malawi and all low and middle-income countries where 95% of the TB burden lies, where this approach is the standard.

Co-investigators and members of PhD supervisory team

Prof Katherine L Fielding: a seasoned TB statistician and clinical trialist, and PhD supervisor for the CI, will be responsible for protocol development, conduct of the study, and data dissemination.

Prof Elizabeth L Corbett: a seasoned TB clinical epidemiologist and PhD co-supervisor for the CI, will be responsible for protocol development, conduct of the study, and data dissemination.

Co-investigators and members of PhD advisory committee

Dr Derek J Sloan: clinician with detailed local clinical and research experience, will be responsible for protocol development, trial implementation and data dissemination.

Prof Neil French: a seasoned pneumococcal expert, will be responsible for protocol development, oversee all aspects of AMR work, and data dissemination.

Collaborators

Dr Marriott Nliwasa: clinician, with experience conducting studies in the study setting. He will be support the conduct of the study, linkage with the national program, and data dissemination.

Mr Augustine Choko: statistician, with expertise and experience in using ACASI. He will support ACASI development, data management and development of analysis plan.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Dr Ankur Gupta-Wright: clinician, will provide clinical input in protocol development and clinical consultation support to research coordinators during study implementation..

Dr Jennifer Cornick: microbiologist, will be support protocol development, and AMR laboratory methods and analysis, and data dissemination.

Prof Jon Øyvind Odland: Epidemiologist and honorary professor at University of Malawi College of Medicine, responsible for seeking ethical approvals from the funder appointed ethics committee.

11 Ethics and dissemination

We will ensure that this trial is conducted in accordance with the principles of the Declaration of Helsinki and in full conformity with relevant regulations and with the ICH Guidelines for Good Clinical Practice E6 (R2) of November 2016.

11.1 Risk assessment

This is a low risk study as it is using already licensed antibiotics with good safety profile in a population defined by national clinical guidelines as clinically stable and not requiring other intervention but TB investigations. Our work complements standard of care by bringing in detailed TB diagnostics. In our study, the standard of care equivalent of the antibiotics we will prescribed on Day-1 to those randomised to either azithromycin or amoxicillin arms, are in standard of care prescribed on Day-8 only to mycobacteriology negative symptomatic patients (similar to the no antibiotic or standard of care arm of our trial). So, participants randomised to no antibiotic at Day-1 will not be receiving inadequate care but the recommended standard management of withholding antibiotics until after the TB results are available (Figure 1). To maintain participant safety and continuity of their care while on study interventions, we will not blind routine care clinical team and they will be free to manage the participants on their clinical judgement and national guidelines.

11.2 Research ethics approval

We will seek ethical approval for the trial protocol, informed consent forms, participant information sheet, any advertising material, and amendments to any of these documents, from the University of Malawi College of Medicine Research and Ethics Committee (COMREC), the LSHTM Research Ethics Committee, and Regional Committee for Health and Research Ethics, NTNU-Midt, Norway (on behalf of the funder). We will seek regulatory approval from the Malawi Pharmacy, Medicines, and Poisons Board (PMPB). Every year when the trial is active, we will seek continuous ethical review and approval before expiry of previous year's approval. In the event of an amendment, the changes will only be implemented upon ethical and regulatory approval.

11.3 Indemnity

London School of Hygiene & Tropical Medicine holds Public Liability ("negligent harm") and Clinical Trial ("non-negligent harm") insurance policies which apply to this trial.

11.4 Sponsor

London School of Hygiene & Tropical Medicine will act as the main sponsor for this study. Delegated responsibilities will be assigned locally.

11.5 Declaration of interests

The study team declares that they have no conflict of interest in conducting this clinical trial.

11.6 Cost of participation, ancillary and post-trial care

During the study, participant will benefit from frequent interaction with clinical study staff and associated optimised management of illnesses. There are minimal risks including discomfort associated with collection of nasopharyngeal samples, and side-effects of study interventions. We will reimburse participant transport for attending study visits.

11.7 Dissemination policy

This work will form part of a PhD thesis for Titus Divala, which he will submit to the London School of Hygiene & Tropical Medicine (LSHTM). All publications and presentations relating to the study will be authorised by the Trial Management Group. The first publication of the trial results will be in the name of the Trial Management Group, if this does not conflict with the journal's policy. If there are named authors, these will include at least the trial's Chief Investigator, Statistician and Trial Coordinator.

Members of the TMG and the DSMB will be listed and contributors will be cited by name if published in a journal where this does not conflict with the journal's policy

12 References

1. Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, Guerin PJ, Piddock LJ. Understanding the mechanisms and drivers of antimicrobial resistance. *The Lancet* 2016; **387**(10014): 176-87.

2. World Health Organization. The evolving threat of antimicrobial resistance: options for action: Geneva: World Health Organization; 2012.

3. World Health Organization. Antimicrobial resistance: global report on surveillance: World Health Organization; 2014.

4. Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen J-A, Klugman K, Davies S. Access to effective antimicrobials: a worldwide challenge. *The Lancet* 2016; **387**(10014): 168-75.

5. Raviglione M, Sulis G. Tuberculosis 2015: burden, challenges and strategy for control and elimination. *Infectious disease reports* 2016; **8**(2): 6570.

6. World Health Organization. Global tuberculosis report 2016. 2016.

7. Nliwasa M, MacPherson P, Mukaka M, Mdolo A, Mwapasa M, Kaswaswa K, Msefula C, Chipungu G, Mwandumba H, Corbett E. High mortality and prevalence of HIV and tuberculosis in adults with chronic cough in Malawi: a cohort study. *The international journal of tuberculosis and lung disease* 2016; **20**(2): 202-10.

8. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. *The Lancet* 2007; **369**(9578): 2042-9.

9. Corbett E, MacPherson P. Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality [State of the art series. Active case finding/screening. Number 5 in the series]. *The international journal of tuberculosis and lung disease* 2013; **17**(9): 1125-38.

10. Siddiqi K, Lambert M-L, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. *The Lancet infectious diseases* 2003; **3**(5): 288-96.

11. Ghana Health Service. Guidelines for the Clinical Management of TB and HIV Co-infection in Ghana. In: Department DCaP, editor. Accra; 2007.

12. Ministry of Health. Malawi National TB Programme Manual. . In: Programme NT, editor. 8 ed. Lilongwe; 2016.

13. National Department of Health. South Africa National Tuberculosis Management Guidelines 2014. In: Coordination TDS, editor. Pretoria; 2014.

14. Wilkinson D, Newman W, Reid A, Squire S, Sturm A, Gilks C. Trial-of-antibiotic algorithm for the diagnosis of tuberculosis in a district hospital in a developing country with high HIV prevalence. *The International Journal of Tuberculosis and Lung Disease* 2000; **4**(6): 513-8.

15. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Annals of internal medicine* 2011; **155**(8): 529-36.

16. Rychetnik L, Frommer M, Hawe P, Shiell A. Criteria for evaluating evidence on public health interventions. *Journal of Epidemiology & Community Health* 2002; **56**(2): 119-27.

17. Schunemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, Williams JW, Jr., Kunz R, Craig J, Montori VM, Bossuyt P, Guyatt GH, Group GW. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. *BMJ* 2008; **336**(7653): 1106-10.

18. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. *Nature medicine* 2004; **10**(12s): S122.

19. Goossens H, Ferech M, Vander Stichele R, Elseviers M, Group EP. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. *The Lancet* 2005; **365**(9459): 579-87.

20. Everett DB, Mukaka M, Denis B, Gordon SB, Carrol ED, van Oosterhout JJ, Molyneux EM, Molyneux M, French N, Heyderman RS. Ten years of surveillance for invasive

- Streptococcus pneumoniae during the era of antiretroviral scale-up and cotrimoxazole prophylaxis in Malawi. *PLoS one* 2011; **6**(3): e17765.
21. Coles CL, Mabula K, Seidman JC, Levens J, Mkocha H, Munoz B, Mfinanga SG, West S. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. *Clinical Infectious Diseases* 2013; **56**(11): 1519-26.
 22. Mitjà O, Houinei W, Moses P, Kapa A, Paru R, Hays R, Lukehart S, Godornes C, Bieb SV, Grice T. Mass treatment with single-dose azithromycin for yaws. *New England Journal of Medicine* 2015; **372**(8): 703-10.
 23. Maher MC, Alemayehu W, Lakew T, Gaynor BD, Haug S, Cevallos V, Keenan JD, Lietman TM, Porco TC. The fitness cost of antibiotic resistance in Streptococcus pneumoniae: insight from the field. *PLoS One* 2012; **7**(1): e29407.
 24. Man WH, de Steenhuijsen P, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. *Nat Rev Microbiol* 2017; **15**(5): 259-70.
 25. Satzke C, Turner P, Virolainen-Julkunen A, Adrian PV, Antonio M, Hare KM, Henao-Restrepo AM, Leach AJ, Klugman KP, Porter BD. Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group. *Vaccine* 2013; **32**(1): 165-79.
 26. Cain KP, Anekthananon T, Burapat C, Akksilp S, Mankhatitham W, Srinak C, Nateniyom S, Sattayawuthipong W, Tasaneeyapan T, Varma JK. Causes of death in HIV-infected persons who have tuberculosis, Thailand. *Emerging infectious diseases* 2009; **15**(2): 258.
 27. Bedell RA, Anderson ST, Van Lettow M, Åkesson A, Corbett EL, Kumwenda M, Chan AK, Heyderman RS, Zachariah R, Harries AD. High prevalence of tuberculosis and serious bloodstream infections in ambulatory individuals presenting for antiretroviral therapy in Malawi. *PLoS One* 2012; **7**(6): e39347.
 28. Schleicher G, Feldman C. Dual infection with Streptococcus pneumoniae and Mycobacterium tuberculosis in HIV-seropositive patients with community acquired pneumonia. *The International Journal of Tuberculosis and Lung Disease* 2003; **7**(12): 1207-8.
 29. Musicha P, Cornick JE, Bar-Zeev N, French N, Masesa C, Denis B, Kennedy N, Mallewa J, Gordon MA, Msefula CL, Heyderman RS, Everett DB, Feasey NA. Trends in antimicrobial resistance in bloodstream infection isolates at a large urban hospital in Malawi (1998–2016): a surveillance study. *The Lancet Infectious Diseases* 2017; **17**(10): 1042-52.
 30. Montori VM, Permyer-Miranda G, Ferreira-González I, Busse JW, Pacheco-Huergo V, Bryant D, Alonso J, Akl EA, Domingo-Salvany A, Mills E. Validity of composite end points in clinical trials. *Bmj* 2005; **330**(7491): 594-6.
 31. Nliwasa M, MacPherson P, Chisala P, Kamdolozi M, Khundi M, Kaswaswa K, Mwapasa M, Msefula C, Sohn H, Flach C. The sensitivity and specificity of Loop-Mediated Isothermal Amplification (LAMP) assay for Tuberculosis diagnosis in adults with chronic cough in Malawi. *PLoS one* 2016; **11**(5): e0155101.
 32. Lubell Y, Turner P, Ashley EA, White NJ. Susceptibility of bacterial isolates from community-acquired infections in sub-Saharan Africa and Asia to macrolide antibiotics. *Tropical Medicine & International Health* 2011; **16**(10): 1192-205.
 33. Phua J, Dean NC, Guo Q, Kuan WS, Lim HF, Lim TK. Severe community-acquired pneumonia: timely management measures in the first 24 hours. *Critical Care* 2016; **20**(1): 237.
 34. Lim W, Smith D, Wise M, Welham S. British Thoracic Society community acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together. *Thorax* 2015; thoraxjnl-2015-206881.
 35. van der Paardt A-F, Wilffert B, Akkerman OW, de Lange WC, van Soolingen D, Sinha B, van der Werf TS, Kosterink JG, Alffenaar J-WC. Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis. *European Respiratory Journal* 2015; **46**(2): 444-55.

36. Falzari K, Zhu Z, Pan D, Liu H, Hongmanee P, Franzblau SG. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. *Antimicrob Agents Chemother* 2005; **49**(4): 1447-54.
37. Fry A, Jha H, Lietman T, Chaudhary JP, Bhatta R, Elliott J, Hyde T, Schuchat A, Gaynor B, Dowell S. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. *Clinical infectious diseases* 2002; **35**(4): 395-402.
38. Porco TC, Gebre T, Ayele B, House J, Keenan J, Zhou Z, Hong KC, Stoller N, Ray KJ, Emerson P. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. *Jama* 2009; **302**(9): 962-8.
39. Keenan JD, Ayele B, Gebre T, Zerihun M, Zhou Z, House JI, Gaynor BD, Porco TC, Emerson PM, Lietman TM. Childhood mortality in a cohort treated with mass azithromycin for trachoma. *Clin Infect Dis* 2011; **52**(7): 883-8.
40. Musher DM, Thorner AR. Community-acquired pneumonia. *N Engl J Med* 2014; **371**(17): 1619-28.
41. Gordon SB, Chaponda M, Walsh AL, Whitty CJ, Gordon MA, Machili CE, Gilks CF, Boeree MJ, Kampondeni S, Read RC, Molyneux ME. Pneumococcal disease in HIV-infected Malawian adults: acute mortality and long-term survival. *AIDS* 2002; **16**(10): 1409-17.
42. Jochems SP, Weiser JN, Malley R, Ferreira DM. The immunological mechanisms that control pneumococcal carriage. *PLoS pathogens* 2017; **13**(12): e1006665.
43. Goldblatt D, Hussain M, Andrews N, Ashton L, Virta C, Melegaro A, Pebody R, George R, Soininen A, Edmunds J, Gay N, Kayhty H, Miller E. Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. *J Infect Dis* 2005; **192**(3): 387-93.
44. National Tuberculosis Control programme. Malawi Nationwide Tuberculosis Prevalence Survey. 45th Union World Conference on Lung Health. Barcelona, Spain, 2014.
45. Global Health Innovative Technology Fund. Highly Sensitive POC TB-LAM Rapid Diagnostic Test. 2017. <https://www.ghitfund.org/impact/portfolio/awpdetail/detail/78> (accessed 28 Feb 2018).
46. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. *Health policy (Amsterdam, Netherlands)* 1990; **16**(3): 199.
47. Maheswaran H, Petrou S, MacPherson P, Choko AT, Kumwenda F, Lalloo DG, Clarke A, Corbett EL. Cost and quality of life analysis of HIV self-testing and facility-based HIV testing and counselling in Blantyre, Malawi. *BMC medicine* 2016; **14**(1): 34.
48. Jelsma J, Hansen K, De Weerd W, De Cock P, Kind P. How do Zimbabweans value health states? *Population health metrics* 2003; **1**(1): 11.
49. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes: Oxford university press; 2015.
50. Maheswaran H, Petrou S, MacPherson P, Kumwenda F, Lalloo DG, Corbett EL, Clarke A. Economic costs and health-related quality of life outcomes of HIV treatment after self-and facility-based HIV testing in a cluster randomized trial. *Journal of acquired immune deficiency syndromes (1999)* 2017; **75**(3): 280.
51. Maheswaran H, Petrou S, Cohen D, MacPherson P, Kumwenda F, Lalloo DG, Corbett EL, Clarke A. Economic costs and health-related quality of life outcomes of hospitalised patients with high HIV prevalence: A prospective hospital cohort study in Malawi. *PLOS ONE* 2018; **13**(3): e0192991.
52. Frye JE. International Medical Products price indicator guide: Management Sciences for Health, 2015.

13 Appendix 1: Informed consent

Included as a separate document on headed pages.

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

14 Appendix 2: Division of Microbiology and Infectious Diseases (DMID) adult toxicity table

TABLE VERSION: November 2007

ABBREVIATIONS: Abbreviations utilized in the Table:

ULN = Upper Limit of Normal LLN = Lower Limit of Normal R_x = Therapy Req = Required

Mod = Moderate IV = Intravenous ADL = Activities of Daily Living Dec = Decreased

• **ESTIMATING SEVERITY GRADE**

For abnormalities NOT found elsewhere in the Toxicity Tables use the scale below to estimate grade of severity:

GRADE 1 Mild Transient or mild discomfort

(< 48 hours); no medical intervention/therapy required

GRADE 2 Moderate Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required

GRADE 3 Severe Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalizations possible

GRADE 4 Life-threatening Extreme limitation in activity, significant assistance required; significant medical intervention/therapy required, hospitalization or hospice care probable

SERIOUS OR LIFE-THREATENING AEs

ANY clinical event deemed by the clinician to be serious or life-threatening should be considered a grade 4 event. Clinical events considered to be serious or life-threatening include, but are not limited to: seizures, coma, tetany, diabetic ketoacidosis, disseminated intravascular coagulation, diffuse petechiae, paralysis, acute psychosis, severe depression.

COMMENTS REGARDING THE USE OF THIS TABLE

- Standardized and commonly used toxicity tables (Division of AIDS, NCI’s Common Toxicity Criteria (CTC), and World Health Organization (WHO)) have been adapted for use by the Division of Microbiology and Infectious Diseases (DMID) and modified to better meet the needs of participants in DMID trials.
- For parameters not included in the following Toxicity Tables, sites should refer to the “Guide for Estimating Severity Grade” located above.

- Criteria are generally grouped by body system.
- Some protocols may have additional protocol specific grading criteria, which will supersede the use of these tables for specified criteria.

HEMATOLOGY				
	Grade 1	Grade 2	Grade 3	Grade 4
Hemoglobin	9.5 - 10.5 gm/d L	8.0 - 9.4gm/dL	6.5 - 7.9 gm/d L	< 6.5 gm/dL
Absolute Neutrophil Count	1000-1500/ mm ³	750-999/ mm ³	500-749/ mm ³	<500/ mm ³
Platelets	75,000-99,999/ mm ³	50,000-74,999/ mm ³	20,000-49,999/ mm ³	<20,000/ mm ³
WBCs	11,000-13,000/ mm ³	13,000-15,000 / mm ³	15,000-30,000/ mm ³	>30,000 or <1,000 / mm ³
% Polymorphonuclear Leucocytes + Band Cells	> 80%	90 – 95%	>95%	-----
Abnormal Fibrinogen	Low: 100-200 mg/dL High: 400-600 mg/dL	Low: <100 mg/dL High: >600 mg/dL	Low: < 50 mg/dL -----	Fibrinogen associated with gross bleeding or with disseminated coagulation
Fibrin Split Product	20-40 mcg/ ml	41-50 mcg/ ml	51-60 mcg/ ml	> 60 mcg/ ml
Prothrombin Time (PT)	1.01 - 1.25 x ULN	1.26-1.5 x ULN	1.51 -3.0 x ULN	>3 x ULN
Activated Partial Thromboplastin (APPT)	1.01 -1.66 x ULN	1.67 - 2.33 x ULN	2.34 - 3 x ULN	> 3 x ULN
Methemoglobin	5.0 - 9.9 %	10.0 - 14.9 %	15.0 - 19.9%	> 20.0 %

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES).

CHEMISTRIES				
	Grade 1	Grade 2	Grade 3	Grade 4
Hyponatremia	130-135 mEq/ L	123-129 mEq/ L	116-122 mEq/ L	< 116 mEq/ L or abnormal sodium <i>with</i> mental status changes or seizures
Hypernatremia	146-150 mEq/ L	151-157 mEq/ L	158-165 mEq/ L	> 165 mEq/ L or abnormal sodium <i>with</i> mental status changes or seizures
Hypokalemia	3.0 - 3.4 mEq/ L	2.5 - 2.9 mEq/ L	2.0 - 2.4 mEq/ L or intensive replacement therapy or hospitalization required	< 2.0 mEq/ L or abnormal potassium <i>with</i> paresis, ileus or life-threatening arrhythmia
Hyperkalemia	5.6 - 6.0 mEq/ L	6.1 - 6.5 mEq/ L	6.6 - 7.0 mEq/ L	> 7.0 mEq/ L or abnormal potassium <i>with</i> life-threatening arrhythmia
Hypoglycemia	55-64 mg/dL	40-54 mg/dL	30-39 mg/dL	<30 mg/d L or abnormal glucose <i>with</i> mental

				status changes or coma
Hyperglycemia (nonfasting and no prior diabetes)	116 - 160 mg/dL	161- 250 mg/d L	251 - 500 mg/dL	> 500 mg/d L or abnormal glucose <i>with</i> ketoacidosis or seizures
Hypocalcemia (corrected for albumin)	8.4 - 7.8 mg/dL	7.7 - 7.0 mg/dL	6.9 - 6.1 mg/dL	< 6.1 mg/dL or abnormal calcium <i>with</i> life threatening arrhythmia or tetany
Hypercalcemia (correct for albumin)	10.6 - 11.5 mg/d L	11.6 - 12.5 mg/d L	12.6 - 13.5 mg/d L	> 13.5 mg/dL or abnormal calcium <i>with</i> life threatening arrhythmia
Hypomagnesemia	1.4 - 1.2 mEq/ L	1.1 - 0.9 mEq/ L	0.8 - 0.6 mEq/ L	< 0.6 mEq/ L or abnormal magnesium <i>with</i> life-threatening arrhythmia
Hypophosphatemia	2.0 - 2.4 mg/dL	1.5 -1.9 mg/dL or replacement Rx required	1.0 -1.4 mg/dL intensive therapy or hospitalization required	< 1.0 mg/dL or abnormal phosphate <i>with</i> life-threatening arrhythmia
Hyperbilirubinemia (when accompanied by any	1.1 - <1.25 x ULN	1.25 - <1.5 x ULN	1.5 – 1.75 x ULN	> 1.75 x ULN

increase in other liver function test)				
Hyperbilirubinemia (when other liver function are in the normal range)	1.1 - <1.5 x ULN	1.5 - <2.0 x ULN	2.0 – 3.0 x ULN	> 3.0 x ULN
BUN	1.25 - 2.5 x ULN	2.6 - 5 x ULN	5.1 - 10 x ULN	> 10 x ULN
Hyperuricemia (uric acid)	7.5 – 10.0 mg/dL	10.1 – 12.0 mg/d L	12.1 – 15.0 mg/d L	>15.0 mg/d L
Creatinine	1.1 - 1.5 x ULN	1.6 - 3.0 x ULN	3.1 - 6 x ULN	> 6 x ULN or dialysis required
EN ZYMES				
	Grade 1	Grade 2	Grade 3	Grade 4
AST (SGOT)	1.1 - <2.0 x ULN	2.0 – <3.0 x ULN	3.0 – 8.0 x ULN	> 8 x ULN
ALT (SGPT)	1.1 - <2.0 x ULN	2.0 – <3.0 x ULN	3.0 – 8.0 x ULN	> 8 x ULN
GGT	1.1 - <2.0 x ULN	2.0 – <3.0 x ULN	3.0 – 8.0 x ULN	> 8 x ULN
Alkaline Phosphatase	1.1 - <2.0 x ULN	2.0 – <3.0 x ULN	3.0 – 8.0 x ULN	> 8 x ULN
Amylase	1.1 - 1.5 x ULN	1.6 - 2.0 x ULN	2.1 - 5.0 x ULN	> 5.1 x ULN
Lipase	1.1 - 1.5 x ULN	1.6 - 2.0 x ULN	2.1 - 5.0 x ULN	> 5.1 x ULN
URINALYSIS				
	Grade 1	Grade 2	Grade 3	Grade 4
Proteinuria	1+ or 200 mg - 1 gm loss/day	2-3+ or 1- 2 gm loss/day	4+ or 2-3.5 gm loss/day	nephrotic syndrome or > 3.5 gm loss/day

Hematuria	microscopic only <10 rbc/hpf	gross, no clots >10 rbc/hpf	gross, with or without clots, OR red blood cell casts	obstructive or required transfusion
CARDIOVASCULAR				
	Grade 1	Grade 2	Grade 3	Grade 4
Cardiac Rhythm		asymptomatic, transient signs, no Rx required	recurrent/persiste nt; symptomatic Rx required	unstable dysrhythmia; hospitalization and treatment required
Hypertension	transient increase > 20 mm/ Hg; no treatment	recurrent, chronic increase > 20mm/ Hg. /treatment required	acute treatment required; outpatient treatment or hospitalization possible	end organ damage or hospitalization required
Hypotension	transient orthostatic hypotension with heart rate increased by <20 beat/min or decreased by <10 mm Hg systolic BP, No treatment required	symptoms due to orthostatic hypotension or BP decreased by <20 mm Hg systolic; correctable with oral flu id treatment	requires IV fluids; no hospitalization required	mean arterial pressure <60mm/ Hg or end organ damage or shock; requires hospitalization and vasopressor treatment

Pericarditis	minimal effusion	mild/ moderate asymptomatic effusion, no treatment	symptomatic effusion; pain; EKG changes	tamponade; pericardiocentes is or surgery required
Hemorrhage, Blood Loss	microscopic/occult	mild, no transfusion	gross blood loss; 1-2 units transfused	massive blood loss; > 3 units transfused
RESPIRATORY				
	Grade 1	Grade 2	Grade 3	Grade 4
Cough	transient- no treatment	persistent cough; treatment responsive	Paroxysmal cough; uncontrolled with treatment	-----
Bronchospasm, Acute	transient; no treatment; 70% - 80% FEV ₁ of peak flow	requires treatment; normalizes with bronchodilator; FEV ₁ 50% - 70% (of peak flow)	no normalization with bronchodilator; FEV ₁ 25% - 50% of peak flow; or retractions present	cyanosis: FEV ₁ < 25% of peak flow or intubation necessary
Dyspnea	dyspnea on exertion	dyspnea with normal activity	dyspnea at rest	dyspnea requiring Oxygen therapy
GASTROINTESTINAL				
	Grade 1	Grade 2	Grade 3	Grade 4

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

Nausea	mild or transient; maintains reasonable intake	moderate discomfort; intake decreased significantly; some activity limited	no significant intake; requires IV fluids	hospitalization required;
Vomiting	1 episode in 24 hours	2-5 episodes in 24 hours	>6 episodes in 24 hours or needing IV fluids	physiologic consequences requiring hospitalization or requiring parenteral nutrition
Constipation	requiring stool softener or dietary modification	requiring laxatives	obstipation requiring manual evacuation or enema	obstruction or toxic megacolon
Diarrhea	mild or transient; 3-4 loose stools/Day-or mild diarrhea last < 1 week	moderate or persistent; 5-7 loose stools/Day-or diarrhea lasting >1 week	>7 loose stools/day or bloody diarrhea; or orthostatic hypotension or electrolyte imbalance or >2L IV fluids required	hypotensive shock or physiologic consequences requiring hospitalization
Oral Discomfort/Dysphagia	mild discomfort; no difficulty swallowing	some limits on eating/drinking	eating/talking very limited; unable to swallow solid foods	unable to drink fluids; requires IV fluids
NEUROLOGICAL				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Grade 1	Grade 2	Grade 3	Grade 4
Neuro-Cerebellar	slight incoordination dysdiadochokines is	intention tremor, dysmetria, slurred speech; nystagmus	locomotor ataxia	incapacitated
Psychiatric	mild anxiety or depression	moderate anxiety or depression; therapy required; change in normal routine	severe mood changes requiring therapy; or suicidal ideation; or aggressive ideation	acute psychosis requiring hospitalization; or suicidal gesture/attempt or hallucinations
Muscle Strength	subjective weakness no objective symptoms/ signs	mild objective signs/symptoms no decrease in function	objective weakness function limited	paralysis
Paresthesia (burning, tingling, etc.)	mild discomfort; no treatment required	moderate discomfort; non-narcotic analgesia required	severe discomfort; or narcotic analgesia required with symptomatic improvement	incapacitating; or not responsive to narcotic analgesia
Neuro-sensory	mild impairment in sensation (decreased sensation, e.g., vibratory, pinprick, hot/cold in great toes) in	moderate impairment (mod decreased sensation, e.g., vibratory, pinprick, hot/cold to	severe impairment (decreased or loss of sensation to knees or wrists) or loss of sensation of at	sensory loss involves limbs and trunk; paralysis; or seizures

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

	focal area or symmetrical distribution; or change in taste, smell, vision and/or hearing	ankles) and/or joint position or mild impairment that is not symmetrical	least mod degree in multiple different body areas (i.e., upper and lower extremities)	
MUSCULOSKELETAL				
	Grade 1	Grade 2	Grade 3	Grade 4
Arthralgia (joint pain)	mild pain not interfering with function	moderate pain, analgesics and/or pain interfering with function but not with activities of daily living	severe pain; pain and/or analgesics interfering with activities of daily living	disabling pain
Arthritis	mild pain with inflammation, erythema or joint swelling – but not interfering with function	moderate pain with inflammation, erythema or joint swelling – interfering with function, but not with activities of daily living	severe pain with inflammation, erythema or joint swelling –and interfering with activities of daily living	permanent and/or disabling joint destruction
Myalgia	myalgia with no	muscle	severe muscle	frank

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES) .

	limitation of activity	tenderness (at other than injection site) or with moderate impairment of activity	tenderness with marked impairment of activity	myonecrosis
SKIN				
	Grade 1	Grade 2	Grade 3	Grade 4
Mucocutaneous	erythema; pruritus	diffuse, maculo-papular rash, dry desquamation	vesiculation or moist desquamation or ulceration	exfoliative dermatitis, mucous membrane involvement or erythema, multiforme or suspected Stevens-Johnson or necrosis requiring surgery
Induration	< 15mm	15-30 mm	>30mm	
Erythema	< 15mm	15-30 mm	>30mm	
Edema	< 15mm	15-30 mm	>30mm	

Rash at Injection Site	< 15mm	15-30 mm	>30mm	
Pruritus	slight itching at injection site	moderate itching at injection extremity	itching over entire body	
SYSTEMIC				
	Grade 1	Grade 2	Grade 3	Grade 4
Allergic Reaction	pruritus without rash	localized urticaria	generalized urticaria; angioedema	anaphylaxis
Headache	mild, no treatment required	transient, moderate; treatment required	severe; responds to initial narcotic therapy	intractable; requires repeated narcotic therapy
Fever: oral	37.7 - 38.5 C or 100.0 - 101.5 F	38.6 - 39.5 C or 101.6 - 102.9 F	39.6 - 40.5 C or 103 - 105 F	> 40 C or > 105 F
Fatigue	normal activity reduced < 48 hours	normal activity decreased 25-50% > 48 hours	normal activity decreased > 50% can't work	unable to care for self

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

15 Appendix 3: Package insert for Azithromycin and amoxicillin

Included as separate attachments.

For peer review only

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.



PARTICIPANT INFORMATION SHEET

Participant information sheet

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE

What is the benefit and unintended consequences of using antibiotic treatment as a way of excluding tuberculosis disease in patients with cough?

Introduction

We would like to invite you to take part in a research study. Joining the study is entirely up to you. Before you decide, you need to understand why the research is being done and what it would involve. One of our team will go through this information sheet with you, and answer any questions you may have. Ask questions if anything you read is not clear or you would like more information. Please feel free to talk to others about the study if you wish. Take time to decide whether or not to take part.

What is the purpose of the study?

Tuberculosis (TB) is a disease that causes a long illness and cough with sputum. Although curable TB is difficult to detect. When they fail to detect TB after testing sputum, clinicians give antibiotic treatment that can cure all other causes of TB symptoms but not TB. In this approach, TB is considered ruled out if patient gets better and it is considered likely if they do not get better. The goal of this research study is to develop understanding of how well the antibiotics help distinguish TB patients from those who do not have it, whether giving antibiotics carries other health benefits, and whether it leads to development of disease causing organisms which are resistant to drugs.

We will learn about this by comparing a group of patients given antibiotics on the first day of the study to another group not given antibiotics. There will be two groups receiving antibiotics as follows: 1) Azithromycin taken as one tablet once a day for 3 days, and 2) Amoxicillin 4 capsules taken three times a day for 5 days. The group you will go into, out of the three, will be decided by chance so you can fall into any group.

What will be involved if I accept to participate in the study?

We are considering you for participation in this study because you told us that you have a cough. Any patient who has been coughing for at least 2 weeks, is at least 18 years, and lives within Blantyre, is eligible to participate in this study if they do not have signs consistent with serious illness. Apart from you, we will recruit 1,874 other individuals.

Study activities will be performed the first day, at 1 week (Day 8), and at one month (Day 29). At each of these study visits, we will ask you questions about your contact details, your health, use of medications, and any illnesses or hospitalisations you may have had in between study visits. We will also document relevant details from your health passport and other clinical documentation you may have.

On Day 1 and at 1 week, we will ask you to submit sputum and urine samples for TB tests. If you are not able to give sputum on Day 1, we will give you containers so that you can bring them the following morning. Some of the sputum TB tests results will become available after 7 days and we will pass them to health center clinicians who will make a plan for your care, the other results may take up to 4 weeks so you will get them at the 1 month visit. Urine TB test results will not be available for your clinical care.

21-May-2019

A copy of this informed consent document to be offered to the participant

Study title: Randomised controlled clinical trial of diagnostic value, clinical benefits and unintended consequences of using trial-of-antibiotics to evaluate ambulatory adults with prolonged cough for tuberculosis in Malawi


Version & Date: 3.0/28 Feb 2019

Principal Investigator: Dr Titus H Divala

Participant Information Sheet For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml> Page 1 of 4

We will also do an HIV test. If the results are confirmed to be HIV positive we will do a viral load test, and at the end of the study activities on Day 1, we will link you to HIV management team here at the health center who will start you on treatment. Should we make a diagnosis of TB or HIV at any other point during the study, we will link you with the responsible health center team for treatment services.

On day 1 and at 1-month visit, we will swab the back of the inside of your nose as shown in this picture to collect germs that live there. We will test the germs for drug resistance. Results of this test are not relevant to your care.



On 1-week visit, we will ask you to report how your health has changed in comparison to how you were on day 1. These questions will be read to you by a computer and you will answer them by choosing various options which it will display during the interview.

The 1 month visit will be the final study visit where we will also provide you with results for TB culture and ask if you have TB symptoms. If you are in HIV or TB care, we will ask how your follow up is going. The appointment with you at 1 months is very important because it will help you to know the results of the TB tests and it will also help us know the status of your health.

The number of clinic visits you will make for this study is at least three. Here we count Day 1, one visit after one week, and another visit at one month. If you have not been able to come here for any of the visits, we will remind you by phone call or we will use the permission and information you will give us to visit you at your home. The first visit will take about 60 minutes and the later visits will take about 30 minutes each.

Will there be any risks involved in this study?

This study is a low risk study. There are no risks involved in submitting sputum or urine for the study. You may feel some discomfort during swabbing of the back of the nose and during blood collection for HIV and viral load tests. Azithromycin and amoxicillin are already widely used in Malawi and rarely cause problems. Rare side effects for azithromycin include feeling nervousness, skin reactions and disturbance of heart function. Rare side-effects for amoxicillin are mental state changes, feeling light-headed, and reactions to sunlight.

The London School of Hygiene and Tropical Medicine holds insurance policies which apply to this study. If you experience harm or injury as a result of taking part in this study, you may be eligible to claim compensation.

Will there be any benefits in this study?

The key benefit of this study is that you will have access to a more detailed TB evaluation process than usual. This will help you know if you have TB and to have the opportunity to start TB treatment. The study is also beneficial to health care providers because it will address important questions about use of antibiotics during the TB diagnostic process.

Will the findings in the study be confidential?

A copy of this informed consent document to be offered to the participant

Study title: Randomised controlled clinical trial of diagnostic value, clinical benefits and unintended consequences of using trial-of-antibiotics to evaluate ambulatory adults with prolonged cough for tuberculosis in Malawi

Version & Date: 3.0/28 Feb2019

Principal Investigator: Dr Titus H Divala

Participant Information Sheet For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml> Page 2 of 4

REC ref: LSHTM 15232; COMREC P.04/18/2381



Your identity in this study will be treated as confidential. The results of the study, including laboratory or any other data, may be published for scientific purposes but will not give your name or include any identifiable references to you. Information about TB test result and HIV test results will be recorded using an identification number. However, any records or data obtained as a result of your participation in this study may be used by LSHTM who are sponsoring this study, regulators of health research (COMREC), or by members of the research team. These records will be kept in a locked space in the University of Malawi College of Medicine. Information and samples collected in this study will be retained for up to 10 years after the end of the trial, according to our institution recommendations. These collected samples and other information may also be used for future studies if you give us that consent.

Can I withdraw from the study anytime and will this affect my treatment?

You are free to choose whether or not to participate in this study. While we would like you to participate in the study to the very end, withdrawing at any point is an option that is freely available to you without any penalty or loss of any entitled benefits. You will be provided with any significant new findings developed during the course of this study that may relate to or influence your willingness to continue participation.

What are the financial benefits of participating in this study?

There will be no payment given to you for participating in the study. The study will provide at least MK8,000 as compensation for your costs of attending the study visits. We will give this money in instalments on scheduled study visits.

Is this study approved by an ethics committee?

The study has been approved by the London School of Hygiene & Tropical Medicine Research Ethics Committee, and the College of Medicine Research Ethics Committee (COMREC).

Who do you ask if you have questions regarding the study?

If you have any questions concerning participation in this study, please feel free to ask me. Alternatively, you can contact the following people by phone or post:

	Name	Telephone	Postal address
Study investigators	Dr Titus Divala	0999478376	Helse Nord Tuberculosis Initiative
	Dr Marriott	0888681948	University of Malawi College of
	Nliwasa		Medicine Private Bag 360, Chichiri, Blantyre 3, Malawi
COMREC	Administrative	01 877 245	University of Malawi College of
	officer, COMREC Secretariat	01 877 291	Medicine Private Bag 360, Chichiri, Blantyre 3, Malawi

21-May-2019

A copy of this informed consent document to be offered to the participant

Study title: Randomised controlled clinical trial of diagnostic value, clinical benefits and unintended consequences of using trial-of-antibiotics to evaluate ambulatory adults with prolonged cough for tuberculosis in Malawi

Version & Date: 3.0/28 Feb 2019

Principal Investigator: Dr Titus H Divala

Participant Information Sheet For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml> Page 3 of 4

What is the benefit and unintended consequences of using antibiotics treatments as a way of excluding tuberculosis disease in patients with cough?

Patient declaration

Statement	Initial or thumbprint each box	
I confirm that I have read the above information sheet for the above named study. I have had the opportunity to consider the information, ask questions and have these answered satisfactorily. OR I have had the information explained to by study personnel in a language that I understand. I have had the opportunity to consider the information, ask questions and have these answered satisfactorily.		
I understand that my participation is voluntary and that I am free to withdraw at any time without giving any reason, without my medical care or legal rights being affected.		
I understand that relevant sections of my medical notes and data collected during the study may be looked at by authorised individuals from LSHTM, University of Malawi College of Medicine, and COMREC, where it is relevant to my taking part in this research. I give permission for these individuals to have access to my records.		
I understand that data about me may be shared via a public data repository or by sharing directly with other researchers, and that I will not be identifiable from this information		
I understand that the tissue sample collected from me will be used to support other research in the future, and may be shared anonymously with other researchers, for their ethically-approved projects		
I agree to take part in the above named study		
Printed name of participant	Signature/thumb print of participant	Date
Printed name of impartial witness*	Signature of impartial witness*	Date
I attest that I have explained the study information accurately to _____, and was understood to the best of my knowledge by, the participant and that he/she has freely given their consent to participate* in the presence of the above named impartial witness (where applicable).		
Printed name of staff obtaining consent	Signature of staff obtaining consent	Date

*Impartial witness should be someone the participant trusts. The impartial witness can write the participant name but cannot sign for them. Instead, illiterate participants should use thumbprint in place of signature and the impartial witness should go ahead and sign in designated space.

A copy of this informed consent document to be offered to the participant

Study title: Randomised controlled clinical trial of diagnostic value, clinical benefits and unintended consequences of using trial-of-antibiotics to evaluate ambulatory adults with prolonged cough for tuberculosis in Malawi

Version & Date: 3.0/28 Feb2019

Principal Investigator: Dr Titus H Divala

Participant Information Sheet For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml> Page 4 of 4

BMJ Open: first published as 10.1136/bmjopen-2019-033999 on 25 March 2020. Downloaded from <http://bmjopen.bmj.com/> on June 9, 2025 at Agence Bibliographique de l'Enseignement Supérieur (ABES).
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.



PARTICIPANT INFORMATION SHEET

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



Chikalata chofotokozera ofuna kutenga nawo mbali

Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Chiyambi

Tikukupemphani kuti mutenge nawo mbali mu kafukufuku. Ndi chifuniro chanu kulowa mu kafukufukuyu. Musanapange chiganizo, mukuyenera kumvetsa chifukwa chimene kafukufukuyu akuchitikira komanso zimene zitadzachitike. M'modzi mwa anthu a gulu logwira ntchito mu kafukufuku awerenga chikalatachi pamodzi ndi inu, ndipo ayankha mafunso ena aliwonse amene mungakhale nawo. Funsani mafunso ngati simukumvetsa zomwe mwawerenga kapena ngati mukufuna uthenga owonjezera. Muli omasuka kulankhula ndi ena zokhudza kafukufukuyu ngati mukufuna. Ganizani mofatsa musanavomereze kutenga nawo mbali kapena ayi.

Kodi cholinga cha kafukufukuyu ndi chiyani?

Chifuwa chachikulu (TB) ndi matenda amene munthu amkhala chidwalire kwa nthawi yaitali. Odwalayo, amapanga makhololo. Ngakhale chili chochizika, chifuwa chachikulu ndi chovuta kuchipeza. Pamene njira zoyeza makholoro zalephera kupeza chifuwa chachikulu, achipatala amapereka mankhwala opha tizirombo toyambitsa matenda amene angathane ndi zonse zimene zimayambitsa zizindikiro za matenda ofanana ndi chifuwa chachikulu. Ngati odwala apeza bwino ndi njira imeneyi amaganiziridwa kuti alibe matenda a chifuwa chachikulu koma ngati sanapeze bwino amaganiziridwa kuti ali ndi chifuwa chachikulu. Cholinga cha kafukufuku ameneyu ndi kufuna kumvetsa za m'mene mankhwala amenewa amathandizira kusiyantsa odwala matenda a chifuwa chachikulu ndi amene alibe matendawa, ngati mankhwalawa ali ndi phindu lina kwa odwala, komanso ngati kupereka mankhwalawa kukubweretsa tizirombo tosamva makhwala.

Tiphunzira zimenezi pakusiyantsa gulu la anthu odwala amene apatsidwa mankhwala opha tizirombo toyambitsa matenda patsiku loyamba la kafukufukuyu ndi gulu lina limene silinapatsidwe mankhwalawa. Pakhala magulu awiri olandira mankhwala opha tizirombo motere: 1) Azithromycin omwedwa pilisi imodzi kamodzi patsiku kwa masiku atatu, komanso 2) Amoxicillin makapusolo anayi omwedwa katatu patsiku kwa masiku asanu. Gulu limene mulowe, mwa magulu atatuwa, lisankhidwa mwa mayere choncho mukhoza kupezeka mu gulu lina lirilonse.

Kodi chidzachitike ndi chiyani ngati ndingavomereze kutenga nawo mbali mu kafukufukuyu?

Tikukupemphani kuti mutenge nawo mbali mu kafukufukuyu chifukwa mwatiuza kuti muli ndi chifuwa. Odwala wina aliyense amene wakhala akukhosomola kwa masabata osachepera awiri, ali ndi zaka zosachepera 18, ndipo amakhala mu Blantyre muno, atha kutenga nawo mbali mu kafukufukuyu ngati alibe zizindikiro zosonyeza kudwalika kwambiri. Kupatula inu, tilemba anthu ena okwanira 1,874.

Zochitika za kafukufukuyu zidzapangidwa patsiku loyamba, pa sabata imodzi (Tsiku 8), ndi pamwezi umodzi (Tsiku 29). Pa masiku a kafukufuku onsewa, tidzakufunsani mafunso okhudzana ndi m'mene tingalumikizirane nanu, thanzi lanu, kagwiritsidwe ntchito ka mankhwala, ndi matenda ena aliwonse kapena kugonekedwa mu chipatala komwe kungakuchitikireni. Tidzalembanso zinthu zofunika

Mpateni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?


Version & Date: 3.0/28 Feb 2019

Mkulu wakafukufuku: Dr Titus H Divala

Chikalata chofotokozera ofuna kutenga nawo mbali

BEC ref: LSHTM 152321, COMREC P.04/18/2381

Page 1 of 5




kuchokera mu bukhu lanu la kuchipatala komanso zolembedwa zina za chipatala zimene mungakhale nazo.

Patsiku loyamba ndi pakutha pasabata yoyamba, tidzakufunsani kuti mupereke makhololo komanso mkodzo pofuna kuyeza matenda a chifuwa chachikulu. Ngati simungakwanitse kupereka makhololo patsiku loyamba, tidzakupatsani mabotolo kuti mudzawabweretse m'mawa wa tsiku lotsatira. Zotsatira zina za makhololo zidzatuluka pakutha pa masiku asanu ndi awiri ndipo tidzazipereka kwa matodolo a chipatala chino kuti akuthandizeni, zotsatira zina zidzatenga pafupi-fupi masabata anayi choncho mudzazilandira pa ulendo wa pamwezi umodzi. Zotsatira zanu zoyesa mikodzo ku matenda a chifuwa chachikulu sizidzakhalapo ku nkhani ya chisamaliro chanu cha kuchipatala.

Tidzayezanso kachiombo ka HIV. Ngati zotsatirazi zasonyeza kuti muli ndi kachiombo ka HIV tidzayeza kuchuluka kwa tizirombo ta HIV, komanso kukutumizani kolandilira chithandizo chamatendawa. Ngati tingakupezeni kuti muli ndi matenda a chifuwa chachikulu kapena kachiombo ka HIV panthawi ina iliyonse mkati mwa kafukufukuyu, tidzakutumizani kolandilira zithandizo zamatendawa pompano pachipatala.

Patsiku loyamba komanso pa ulendo wa mwezi woyamba, tidzapukuta kumbuyo kwa mkati mwa mphuno mwanu ngati m'mene zikuonekera pachithunzichi kuti titenge tizirombo timene timakhala m'menemo. Tidzayeza tizirombo timeneti kuti tione ngati tikumva mankhwala. Zotsatira zimenezi sizidzagwiritsidwa ntchito kuchisamaliro chanu chaku chipatala.



Pa ulendo wa sabata yoyamba, tidzakupemphani kuti mutiuze m'mene thanzi lanu lasinthira kuyerekeza ndi m'mene munaliri patsiku loyamba. Mafunso amenewa adzawerengedwa kwa inu kudzera pa makina a kompyuta ndipo mudzawayankha pakusankha mayankho angapo amene makinawa adzawonetse panthawi yomwe azidzafunsa.

Ulendo wa pa mwezi umodzi udzakhala wotsiriza umene tidzakupatseninsu zotsatira za zoyesa za matenda a chifuwa chachikulu komanso tidzakufunsani ngati muli ndi zizindikiro za matenda a chifuwa chachikulu. Ngati panthawiyi mudzakhale kuti mukulandira Thandizo la HIV kapena TB, tidzakufuna kudziwa kuti zikuyenda bwanji. Kukumana ndi inu patatha mwezi umodzi ndikofunikira kwambiri chifukwa zidzakuthandizirani kuti mudziwe zotsatira za zoyeza za matenda a chifuwa chachikulu ndipo zidzatithandiziranso kudziwa zam'mene thanzi lanu liliri.

Maulendo a kuchipatala amene mudzayende a kafukufukuyu ndiwosachepera atatu. Pamenepa tikuwerenga tsiku loyamba, ulendo umodzi pakutha pa sabata imodzi, ndi ulendo umodzi pa mwezi umodzi. Ngati simunakwanitse kubwera kuno pa ulendo wina uliwonse tidzakukumbutsani pokuyimbirani lamya kapena tidzagwiritsa ntchito chilorezo ndi uthenga umene mudzatipitse kuti tikuyendereni kunyumba kwanu. Patsiku loyamba tidzakhala nanu kwa mphindi makumi asanu ndi imodzi, pamene paasiku ena onse, tidzakhala nanu kwa mphindi makumi atatu.

Kodi padzakhala ziopsezo zina zilizonse zochitika mu kafukufukuyu?

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Version & Date: 3.0/28 Feb 2019

Mkulu wakafukufuku: Dr Titus H Divala

Chikalata chofotokozera ofuna kutenga nawo mbali

REC ref: LSHTM 15232; COMREC P.04/18/2381

Page 2 of 5



Kupanga nawo kafukufukuyu sikuika moyo wanu pa chiopsyeyo chochuluka. Palibe chiopsezo pa kupereka makhololo kapena mikozo mu kafukufukuyu. Mukhoza kusamva bwino panthawi yopukuta kumbuyo kwa mphuno komanso panthawi yotenga magazi oyeza za kachiroombo ka HIV ndi kuchuluka kwa tizirombo toyambitsa matendawa. Azithromycin ndi amoxicillin ndi mankhwala oti akhala akugwiritsidwa ntchito kwa nthawi yayitali m'Malawi ndipo sikweni-kweni kuyambitsa mavuto. Patali-patali azithromycin amapangitsa kumva nthumazi, ziwengo, komanso kusokonekera kwa kagwiridwe ntchito ka mtima. Patali-patali amoxicillin amapangitsa kusakhazikika mmanganizo, kumva chizungulire, komanso kutuluka ziwengo munthu akakhala padzuwa.

A London School of Hygiene ndi Tropical Medicine ali ndi thumba landalama zachipukuta misozi lokhudzana ndi kafukufukuyu. Ngati mwapweteka kapena kuvulala chifukwa chotenga nawo mbali mu kafukufukuyu, mudzakhale omasuka kupempha chipukuta misonzi.

Kodi padzakhala zopindula zina zilizonse mu kafukufukuyu?

Chopindulitsa chodziwika cha kafukufukuyu ndi chakuti mudzakhala ndi mwayi oyezedwa matenda a chifuwa chachikulu mozama kuposa m'mene zimakhallira nthawi zonse. Zimenezi zidzakuthandizirani kudziwa ngati muli ndi matenda a chifuwa chachikulu komanso kukhala ndi mwayi oyamba kulandira thandizo la mankhwala a chifuwa chachikulu. Kafukufukuyu ndi opindindulitsanso kwa opereka chisamaliro cha kuchipatala chifukwa adzayankha mafunso ofunikira okhudzana ndi kagwiritsidwe ntchito ka mankhwala opha tizirombo toyambitsa matenda panthawi ya ndondomeko yoyeza matenda a chifuwa chachikulu.

Kodi zotsatira za mukafukufukuyu zidzakhala za chinsinsi?

Chizindikiritso chanu mu kafukufukuyu chidzatengedwa kukhala cha chinsinsi. Zotsatira za kafukufukuyu, zikhoza kudzasindikizidwa ndi cholinga cha sayansi koma dzina lanu kapena chizindikiritso chilichonse chokhudzana ndi inu chidzabisidwa. Uthenga okhudza zotsatira zoyesa matenda achifuwa chachikulu kapena HIV zidzalembedwa pogwiritsa ntchito nambala yanu yakafukufuku. Komabe, zina zomwe mungatifotokozere zitha kudzagwiritsidwa ntchito ndi amene ali oyang'anira za kafukufuku wa zaumoyo (COMREC) komanso LSHTM. kapena ndi mamembala a gulu la kafukufukuyu. Zolembedwazi zidasungidwa mumalo otsekedwa bwino ku sukulu ya ukachenjede ya Malawi College of Medicine. Uthenga ndi zoyesa zotengedwa mu kafukufukuyu zidzassungidwa kwa zaka pafupi-fupi khumi (10) pakutha pakuyesaku, malingana ndi ndondomeko ya bungwe lathu. Zoyesa zotengedwazi ndi mauthenga ena zikhoza kugwiritsidwanso ntchito pa kafukufuku wamtsogolo ngati mutatipatsa chilolezo chimenecho.

Kodi ndikhoza kusiya kafukufukuyu nthawi ina iliyonse ndipo zimenezi zingadzakhudze thandizo langa la mankhwala?

Muli ndi ufulu kusankha kutenga nawo mbali kapena kusatenga nawo mbali mu kafukufukuyu. Ngakhale tingakonde kuti mutenge nawo mbali mu kafukufukuyu mpaka ku mapeto, kutuluka nthawi iliyonse mukafukufuku ndi chisankho chanu popanda chilango chilli chonse kapena kuluza kulandira thandizo lililonse lomwe mukuyenera kulandira. Munthawi yakafukufukuyu, tidzakudziwitsani patati

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Version & Date: 3.0/28 Feb 2019

Mkulu wakafukufuku: Dr Titus H Divala

Chikalata chofotokozera ofuna kutenga nawo mbali

REC ref: LSHTM 15232; COMREC P.04/18/2381

Page 3 of 5



patuluka mauthenga ena a sayansi ofotokoza zinthu zimene zingakupangitseni kuti mulingalirenso zachisamkho chanu chotenga nawo mbali.

Kodi pali phindu la ndalama lotani pakutenga nawo mbali mu kafukufukuyu?

Sipadzakhala kupatsidwa malipiro chifukwa chotenga nawo mbali mukafukufukuyu. Ndalama yomwe tidzakupatseni ndi yokwana MK8,000. Ndalamayi tizikupatsani pangonopango pamasiku anu akafukufuku..

Kodi kafukufukuyu ndiwovomerezeka ndi komiti yowona za ufulu wa anthu mukafukufuku?

Kafukufukuyu wavomerezedwa ndi London School of Hygiene & Tropical Medicine Research Ethics Committee, ndi College of Medicine Research Ethics Committee (COMREC).

Kodi mungafunse ndani ngati muli ndi mafunso okhudzana ndi kafukufukuyu?

Ngati muli ndi mafunso ena aliwonse okhudza kutenga nawo mbali mukafukufukuyu, chonde khalani omasuka kundifunsa. Munjira ina, mukhoza kulumikizana ndi anthu otsatirawa pa lanya kapena polemba kalata kumakeyala awa:

	Name Dzina	Telephone Lamya	Postal address Adilesi
Study investigators Akulu-akulu akafukufuku	Dr Titus Divala	0999478376	Helse Nord Tuberculosis Initiative University of Malawi College of Medicine
	Dr Marriott Nliwasa	0888681948	Private Bag 360, Chichiri, Blantyre 3, Malawi
COMREC	Administrative officer, COMREC Secretariat	01 877 245 01 877 291	University of Malawi College of Medicine Private Bag 360, Chichiri, Blantyre 3, Malawi

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake
Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Mkulu wakafukufuku: Dr Titus H Divala
Chikalata chofotokozera ofuna kutenga nawo mbali

Version & Date: 3.0/28 Feb 2019

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

REC ref: LSHTM 15232; COMREC P.04/18/2381





Kodi pali phindu lotani komanso zotsatira zosayembekezereka zotani pogwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ngati njira yothana ndi matenda a chifuwa chachikulu mu anthu amene ali ndi chifuwa?

Chitsimikizo cha odwala

Lembani mubokosi liri kumanjali mawu oyamba adzina lanu kapena dindani ndi chala ngati mukuvomereza

Mfundo yachitsimikizo	
Ndikutsimikiza kuti ndawerenga chikalata cha uthenga wa kafukufuku amene watchulidwa m'mwambamu. Ndakhala ndi mwayi woganizira za uthengawu, kufunsa mafunso komanso ndayankhidwa mokhutira.	Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
KAPENA	
Ndafotokozeredwa uthengawu ndi akafukufuku mu chilankhulo chimene ndikuchimvetsa. Ndakhala ndi mwayi woganizira za uthengawu, kufunsa mafunso komanso ndayankhidwa mokhutira.	
Ndikumvetsa kuti kutenga nawo mbali kwanga ndikosakakamizidwa ndipo ndili ndi ufulu kusiya panthawi ina iliyonse popanda kupereka chifukwa china chilichonse, popanda kukhudza chisamaliro cha kuchipatala kapena ufulu wanga.	
Ndikumvetsa kuti magawo ofunikira a zolembedwa zanga za ku chipatala komanso mu kafukufukuyu kuwonedwa ndi anthu ovomerezeka aku LSHTM, University of Malawi College of Medicine komanso COMREC, pamene kuli kofunika kutenga nawo mbali mukafukufukuyu. Ndikupereka chilolezo kwa anthu amenewa kuti athe kuwona za zolembedwa zanga.	
Ndikumvetsa kuti zomwe atolere akafukufuku zokhudza ine zikhoza kugawilidwa kwa anthu ena opanga kakafukufuku, ndipo kuti sipadzakhala chizindikiro chilichonse chosonyeza kuti zinachokera kwa ine.	
Ndikumvetsa kuti zoyeza za mthupi mwanga zimene zidzatengedwe kwa ine zidzagwiritsidwa ntchito kuthandizira kafukufuku wina mtsogolo, ndipo zikhoza kudzagawidwa mwachinsinsi ndi akafukufuku ena, pa ntchito yawo yovomerezeka ndi malamulo aowona zakafukufuku.	
Ndikuvomereza kutenga nawo mbali mu kafukufuku amene watchulidwa pamwambayu.	

Dzina la wotenga nawo mbali Sayini/chidindo cha chala cha wotenga mbali **Tsiku**

Dzina la mboni yopanda mbali* Sayini ya mboni yopanda mbali **Tsiku**

Ndikutsimikiza kuti ndafotokoza za uthenga wa kafukufukuyu molondola kwa _____, ndipo zinamveka monga mwakudziwa kwanga ndi, wotenga nawo mbali komanso kuti apereka chilolezo chawo kuti atenge nawo mbali* pamaso pa mboni yopanda mbali imene yatchulidwa pamwambapa (ngati kuli koyenera).

Dzina la wotenga chilolezo Sayini ya wotenga chilolezo **Tsiku**

*Mboni yopanda mbali ikuyenekera kukhala yokhulupiridwa ndi munthu ofuna kutenga nawo mukafukufukuyo. Mboni ikhoza kulemba dzina la munthu ofuna kutenga nawo mukafukufukuyo koma siingasayine mmalo mwake. Munthu ofuna kutenga nawo mukafukufuku, ngati samatha kuwerenga ndi kulemba, asayine ndi chidindo cha chala chake ndipo mboni isayine dzina ndi sayini, pamalo ambone.

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Version & Date: 3.0/28 Feb 2019

Mkulu wakafukufuku: Dr Titus H Divala

Chikalata chofotokozeredwa ofuna kutenga nawo mbali

REC ref: LSHTM 15232; COMREC P.04/18/2381

Page 5 of 5

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200-207

Reporting Item			Page Number
Administrative information			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	30
Protocol version	#3	Date and version identifier	1
Funding	#4	Sources and types of financial, material, and other support	26

1	Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	26
6	Roles and responsibilities: sponsor contact information	#5b	Name and contact information for the trial sponsor	26
13	Roles and responsibilities: sponsor and funder	#5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	26
23	Roles and responsibilities: committees	#5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	21
32	Introduction			
35	Background and rationale	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4
43	Background and rationale: choice of comparators	#6b	Explanation for choice of comparators	4, 8, 22
49	Objectives	#7	Specific objectives or hypotheses	5, 10
51	Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	5, 6

1 **Methods:**
2 **Participants,**
3 **interventions, and**
4 **outcomes**

5	Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
6	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
7	Interventions: description	#11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
8	Interventions: modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)
9	Interventions: adherence	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)
10	Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
11	Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended

Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	17
Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	18
Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size	15
Methods:			
Assignment of interventions (for controlled trials)			
Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	15
Allocation concealment mechanism	#16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	15
Allocation: implementation	#16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	15
Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, trial participants, care	15

1		providers, outcome assessors, data analysts),	
2		and how	
3			
4	Blinding (masking):	#17b	15
5	emergency	If blinded, circumstances under which	
6	unblinding	unblinding is permissible, and procedure for	
7		revealing a participant's allocated intervention	
8		during the trial	
9			
10			
11	Methods: Data		
12	collection,		
13	management, and		
14	analysis		
15			
16			
17	Data collection plan	#18a	15
18		Plans for assessment and collection of	
19		outcome, baseline, and other trial data,	
20		including any related processes to promote	
21		data quality (eg, duplicate measurements,	
22		training of assessors) and a description of study	
23		instruments (eg, questionnaires, laboratory	
24		tests) along with their reliability and validity, if	
25		known. Reference to where data collection	
26		forms can be found, if not in the protocol	
27			
28	Data collection plan:	#18b	16
29	retention	Plans to promote participant retention and	
30		complete follow-up, including list of any	
31		outcome data to be collected for participants	
32		who discontinue or deviate from intervention	
33		protocols	
34			
35			
36			
37			
38			
39			
40	Data management	#19	16
41		Plans for data entry, coding, security, and	
42		storage, including any related processes to	
43		promote data quality (eg, double data entry;	
44		range checks for data values). Reference to	
45		where details of data management procedures	
46		can be found, if not in the protocol	
47			
48			
49			
50	Statistics: outcomes	#20a	10
51		Statistical methods for analysing primary and	
52		secondary outcomes. Reference to where other	
53		details of the statistical analysis plan can be	
54		found, if not in the protocol	
55			
56			
57	Statistics: additional	#20b	18
58	analyses	Methods for any additional analyses (eg,	
59		subgroup and adjusted analyses)	
60			

1	Statistics: analysis	#20c	Definition of analysis population relating to	19
2	population and		protocol non-adherence (eg, as randomised	
3	missing data		analysis), and any statistical methods to handle	
4			missing data (eg, multiple imputation)	
5				
6				
7				
8	Methods:			
9	Monitoring			
10				
11	Data monitoring:	#21a	Composition of data monitoring committee	21
12	formal committee		(DMC); summary of its role and reporting	
13			structure; statement of whether it is	
14			independent from the sponsor and competing	
15			interests; and reference to where further details	
16			about its charter can be found, if not in the	
17			protocol. Alternatively, an explanation of why a	
18			DMC is not needed	
19				
20				
21				
22				
23				
24	Data monitoring:	#21b	Description of any interim analyses and	P30, appendix
25	interim analysis		stopping guidelines, including who will have	(protocol)
26			access to these interim results and make the	
27			final decision to terminate the trial	
28				
29				
30				
31	Harms	#22	Plans for collecting, assessing, reporting, and	P30, appendix
32			managing solicited and spontaneously reported	(protocol)
33			adverse events and other unintended effects of	
34			trial interventions or trial conduct	
35				
36				
37				
38	Auditing	#23	Frequency and procedures for auditing trial	P30, appendix
39			conduct, if any, and whether the process will be	(protocol)
40			independent from investigators and the sponsor	
41				
42				
43	Ethics and			
44	dissemination			
45				
46				
47	Research ethics	#24	Plans for seeking research ethics committee /	22
48	approval		institutional review board (REC / IRB) approval	
49				
50				
51	Protocol	#25	Plans for communicating important protocol	22
52	amendments		modifications (eg, changes to eligibility criteria,	
53			outcomes, analyses) to relevant parties (eg,	
54			investigators, REC / IRBs, trial participants, trial	
55			registries, journals, regulators)	
56				
57				
58				
59				
60				

1	Consent or assent	#26a	Who will obtain informed consent or assent	30 appendix	Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
2			from potential trial participants or authorised	(consent)	
3			surrogates, and how (see Item 32)		
4					
5					
6	Consent or assent:	#26b	Additional consent provisions for collection and	30 appendix	
7	ancillary studies		use of participant data and biological	(consent)	
8			specimens in ancillary studies, if applicable		
9					
10					
11	Confidentiality	#27	How personal information about potential and	30 appendix	Enseignement Supérieur (ABES) . http://bmjopen.bmj.com/ on June 9, 2025 at Agence Bibliographique de l
12			enrolled participants will be collected, shared,	(consent)	
13			and maintained in order to protect		
14			confidentiality before, during, and after the trial		
15					
16					
17					
18	Declaration of	#28	Financial and other competing interests for	23	
19	interests		principal investigators for the overall trial and		
20			each study site		
21					Enseignement Supérieur (ABES) . http://bmjopen.bmj.com/ on June 9, 2025 at Agence Bibliographique de l
22					
23	Data access	#29	Statement of who will have access to the final	30, appendix	
24			trial dataset, and disclosure of contractual	(protocol)	
25			agreements that limit such access for		
26			investigators		
27					
28					
29					
30	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial	30, appendix	
31	trial care		care, and for compensation to those who suffer	(protocol)	Enseignement Supérieur (ABES) . http://bmjopen.bmj.com/ on June 9, 2025 at Agence Bibliographique de l
32			harm from trial participation		
33					
34					
35					
36	Dissemination	#31a	Plans for investigators and sponsor to	22	
37	policy: trial results		communicate trial results to participants,		
38			healthcare professionals, the public, and other		
39			relevant groups (eg, via publication, reporting in		
40			results databases, or other data sharing		
41			arrangements), including any publication		Enseignement Supérieur (ABES) . http://bmjopen.bmj.com/ on June 9, 2025 at Agence Bibliographique de l
42			restrictions		
43					
44					
45					
46					
47	Dissemination	#31b	Authorship eligibility guidelines and any	25, and 28	
48	policy: authorship		intended use of professional writers	appendix (protocol)	
49					
50					
51	Dissemination	#31c	Plans, if any, for granting public access to the	25, and 28	Enseignement Supérieur (ABES) . http://bmjopen.bmj.com/ on June 9, 2025 at Agence Bibliographique de l
52	policy: reproducible		full protocol, participant-level dataset, and	appendix (protocol)	
53	research		statistical code		
54					
55					
56	Appendices				
57					
58					
59					
60					

Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	30 appendix (consent)
Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	30 appendix (consent/protocol)

Notes:

- The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist was completed on 01. September 2019 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)